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Colorectal cancer (CRC) is the most common fatal malignancy in the non-smoking
population and Scotland is a high incidence country with an average number of 3445
annual registrations (1997-2001). Despite research and development in clinical practice,
the overall 5-year survival is only 51%. Curative surgical resection can increase survival
to 70%, but this is only applicable to patients with localised disease. One approach that
holds promise in reducing overall disease mortality involves primary prevention using
chemopreventive agents. Substantial evidence indicates that non-steroidal anti¬
inflammatory drugs (NSAIDs) protect against colorectal cancer, but the molecular basis is
not fully elucidated. The host laboratory has previously demonstrated that aspirin-induced
apoptosis in colorectal cancer cells is associated with modulation of the NFkB signalling
pathway. The transcription factor NFkB regulates expression of genes involved in
proliferation, apoptosis and carcinogenesis. Aspirin-induced apoptosis in colorectal
cancer cells was found to be dependent on aspirin-induced degradation of IkBoi, the
NFkB inhibitory protein, and NFkB nuclear translocation. Epidemiological data indicates
that the protective effect of NSAIDs is greater in colorectal cancer compared to other
cancer types, suggesting the possibility that aspirin might target distinct molecular
pathways in colonic epithelial cells.
The aims of this thesis were to investigate the specificity of this response for colorectal
cancer compared to other cancer cell types and to identify any potential molecular
markers for the response; to determine the influence ofmismatch repair (MMR) and p53
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status on the NFkB apoptotic response; to examine whether any detectable modulation of
NFkB signalling occurs within the constrained environment of clinical studies and finally
to analyse NFkB pathway genes Rel A and IkBa for mutations in colorectal cancer.
To investigate the question of specificity, the effects of aspirin on cell viability and NFkB
signalling were studied in a panel of colorectal cancer cell lines compared to cancer cell
lines of non-colonic origin. Aspirin induced a concentration-dependent decrease in viable
cell number, paralleled by proportionate increases in apoptosis in six colorectal cancer
cell lines. There was no consistent change in apoptosis in the five non-colorectal cancer
cell lines studied. In colorectal cancer cell lines, aspirin-mediated apoptosis was
associated with aspirin-induced IkBoi degradation and NFkB nuclear translocation. In
contrast, these changes in NFkB signalling were absent in non-colorectal cancer cell
lines, paralleling the lack of changes in cell viability and apoptosis observed. This work
establishes the degree of specificity of the aspirin-induced NFkB apoptotic response in
colorectal cancer. Further work to elucidate the molecular mechanism of this differential
sensitivity may lend insight into the mode of action of NSAIDs, and identify molecular
markers of response. Basal expression levels of COX-2 or of P-catenin did not relate to
susceptibility to NSAID-induced apoptosis. This suggests that COX-2 and P-catenin are
unlikely to play a predominant role in aspirin-mediated apoptosis via the NFkB pathway.
However, this work does emphasise the generality of the aspirin-induced NFkB apoptotic
response with respect to colorectal cancer genotype.
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The influence ofMMR and p53 status on the NFkB apoptotic response was determined,
as these pathways are deranged in colorectal cancer, and are implicated as NSAID targets.
Furthermore, this may potentially identify which subsets of colorectal cancer, with
respect to genotype, are susceptible to aspirin-mediated chemoprevention. This was
investigated by studying the effects of aspirin on HCT-116 (MMR deficient & wild-type
p53), HCT lib"""0113 (MMR proficient & wild-type p53) and HCT-116 p53_/" (p53 null)
colorectal cancer lines. Aspirin induced a dose-dependent decrease in viable cell number,
paralleled by proportionate increases in apoptosis in all three cell lines, which was
accompanied by IkBci degradation and NFkB nuclear translocation in each case. These
results show that the aspirin-induced NFkB apoptotic response occurs irrespective of
MMR and p53 status.
It is important to investigate the in vivo relevance of these molecular observations. Hence,
the effects of aspirin and the COX-2 selective inhibitor rofecoxib were studied in normal
mucosa and cancer of rectal cancer patients, and in normal mucosa of genetically
predisposed patients before and after ingestion for 7 days. The preliminary results show
that there was wide variability, in terms of ficBa expression, between patients and no
consistent change was demonstrated between baseline IkBcc protein expression and post-
treatment levels, in normal mucosa and rectal cancers of patients treated with NSAIDs.
The NFkB pathway plays a central role in death signalling and since altered regulation of
NFkB has been observed in colorectal cancers, it is possible that deranged NFkB
signalling in colorectal cancer may be due to mutations in the NFkB pathway genes, Rel
A and TkBa. Polymorphic DNA sequence variations, or mutations, in Rel A or IkBa genes
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could account for the variability in NFkB response observed in colorectal cancer patients
and also the cell-type specific nature of the NFkB apoptotic response. Flence, mutation
analysis of Rel A and IkBa genes was performed. This has identified a number of
interesting variants that merit further investigation.
The work in this thesis underscores the importance of NFkB as a key target for the anti-
tumour activity of NSAIDs in colorectal cancer. The results provide evidence of a
molecular rationale for the greater specificity of NSAID-mediated protection observed in
colorectal cancer compared to other cancers. Furthermore, the lack of association with
COX-2 and P-catenin expression and independence from MMR and p53 mutation status
emphasises the generality of the aspirin-induced NFkB apoptotic response in colorectal
cancer. This is clinically relevant when considering NSAIDs for chemoprevention in
genetically predisposed individuals and as adjuvant therapy for sporadic colorectal
cancers. The clinical studies demonstrate, for the first time, that changes in IkBcc protein
levels are detectable in normal mucosa and tumour biopsies from patients. However, the
intra- and inter-patient variability in IkBoc levels before and after NSAID treatment
precludes any conclusion pending further experimentation. The variability requires more
detailed controls than the pre- and post- sampling protocols shown here in pilot studies.
Overall, this thesis contributes to the understanding of NSAID-mediated apoptosis via
modulation of NFkB signalling in colorectal cancer, and may inform chemoprevention
trials and novel drug design targeting the signalling pathways involved.
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1.1.1 Incidence- demographic data, trends and survival
Colorectal cancer is the third most common cause of cancer with 1 million new cases
annually, comprising 9.4% of total cancer burden world wide (Parkin et al., 2005). The
disease is also ranked third as a cause of cancer mortality with 529 000 deaths per annum
worldwide. The gender distribution is similar for colon cancer (M: F, 1.1:1) but is slightly
greater in males for rectal cancer (M: F, 2:1). The rectal cancer risk is in fact 50% greater
in males, but there are fewer males alive in the peak age range. There is at least a 25-fold
variation in incidence between countries, which is high in North America, Western
Europe. Australia, and low in Africa and Asia (Parkin et al., 2005). The incidence has
been increasing in countries where the risk of colorectal cancer is low, such as parts of
Asia and Eastern Europe but has not changed in the high-risk countries (Parkin et al.,
2005). The rise in colorectal cancer incidence in low risk countries has been attributed to
progressive 'Westernisation' of lifestyle including diet. In contrast, the relative
stabilisation of incidence in high-risk countries may be due to improved health awareness
in younger generations. Scotland is a high incidence country, with an average number of
3445 annual registrations (1997-2001), and colorectal cancer is the second commonest
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cause of cancer death after lung cancer (Information and Statistics Division, 2005). The
lifetime risk of developing colorectal cancer for males is 6.1% and for females is 5% in
Scotland (1997-2001) (Information and Statistics Division, 2005). Extrapolation of
current trends in Scotland shows that the incidence of colorectal cancer is predicted to
increase in males, with a lesser increase in females, and mortality is predicted to decrease
over the next decade (Dunlop, 2001). Globally, incidence rates have been increasing in
countries where they were previously low and this has been attributed to changes in diet
and lifestyle.
1.1.2 Aetiology
Differences in incidence of colorectal cancer observed between developing nations and
developed or Western countries indicate a predominantly environmental aetiological
component. Data from studies of Japanese migrants to Hawaii show that the incidence of
colorectal cancer in first generation migrants rapidly reaches the high incidence rates
observed in the indigenous population (Kolonel et al., 2004). The high incidence rate in
first generation migrants indicates that risk factors could act relatively late in life,
suggesting that environmental causes play a significant role in the initiation of colorectal
cancer. In fact, as much as 70% of risk may be attributed to environmental factors and the
remaining aetiological contribution is due to genetic susceptibility.
1.1.2.1 Environmental factors
Environmental risk factors are defined as surroundings, conditions or influences that
affect tumour growth and these may be divided into dietary and lifestyle characteristics.
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The first observations of this nature were made by Burkitt, who suggested that low
colorectal cancer incidence in African countries was due to greater intake of fibre
compared to Western countries (Burkitt, 1971). Numerous observational studies have
indicated a protective effect attributed to fibre consumption, with 60% of studies showing
a relative risk of less than 0.8 with the highest fibre intake (Gatof and Ahnen, 2002). Two
recent observational studies have shown that dietary fibre intake is associated with
decreased risk of distal colon adenomas and colorectal carcinomas (Bingham et al.,
2003;Peters et al., 2003). Putative anti-tumour mechanisms include shortened stool transit
time and hence exposure to carcinogens. Fibre may also lower stool pH by binding bile
acids and thereby block conversion to harmful secondary bile acids. Butyrate is a short-
chain fatty acid produced by colonic bacterial-induced fermentation of fibre and has been
shown to protect against colorectal cancer depending on the concentration, duration of
exposure, and the type of fat in the diet (Lupton, 2004). Butyrate has also been shown to
be anti-neoplastic in colorectal cancer cell lines (Coxhead et al., 2005).
There is currently no evidence from randomised controlled trials to indicate that increased
dietary fibre intake will reduce the incidence or recurrence of adenomatous polyps within
a two to four year period (Fuchs et al., 1999; Schatzkin et al, 2000; Alberts et al., 2000;
Asano and McLeod, 2002). However, the time-period of these studies was only 3-4 years
and it is possible that longer intervention and follow-up may reveal a protective effect, or
indeed that the protection is imparted early in life. These studies highlight the drawback
of using adenomas as surrogate markers, as the majority of polyps do not progress to
cancer. However, it is concerning that there was a high rate of adenomas in both low and
high fibre groups in one study (Alberts et al., 2000), and in a phase III trial, fibre
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increased the risk for recurrent adenomas by 67% (Bonithon-Kopp et al., 2000). Indeed,
an increased risk of cancer by 35% was reported in one study (Fuchs et al., 1999).
Diets high in fat, especially animal fat, have been associated with an increased risk of
colorectal cancer and about 50% of studies show an increase in the relative risk (> 1.2)
with the highest dietary fat intake (Gatof and Ahnen, 2002). The mechanism of action
may be related to high fat diets inducing increased bile acid secretion, which can be
converted to carcinogens by colonic bacteria. Independent of fat, ingestion of red meat
has also been associated with an increased risk of colorectal cancer (Willett et al., 1990;
Giovannucci et al., 1994). The carcinogenic constituents are thought to be heterocyclic
amines formed during high temperature cooking of meat (Butler et al., 2003).
Heterocyclic amines require metabolic activation by Maccty1 transferase (NAT) prior to
binding DNA and NAT1 and NAT2 genes are responsible for activity (Lang et al., 1994).
Polymorphisms at the NAT1 or NAT2 locus resulting in rapid acetylation have been
shown to increase colorectal cancer risk, exemplifying gene-environment interactions
(Welfare et al., 1997; Le Marchand et al., 2001).
There is conflicting data on the role of fruit and vegetables and colorectal cancer risk,
with some evidence suggesting a lower risk of colorectal cancer (Track et al., 1990), but
other work indicating no protective effect (Michels et al., 2000). It is also unclear as to
which particular micronutrient may be responsible for any protection conferred. Folate is
one such micronutrient found in fruit and vegetables that may decrease colorectal cancer
risk (Giovannucci et al., 2003; Martinez et al., 2004). Folate is an important source of
methyl groups that are required for DNA synthesis, repair and methylation, and hence
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may influence mutation rate and gene expression (McKay et al., 2004). Polymorphisms in
a key enzyme involved in folate metabolism, methylenetetrahydrofolate reductase
(MTHFR), have been associated with decreased colorectal cancer risk (Le Marchand et
al., 2005b). However, the relationship between dietary intake, colorectal cancer risk and
polymorphic variants is complex (Sharp and Little, 2004). High alcohol consumption has
been shown to increase the risk of colorectal adenomas and cancer, in particular rectal
cancer, possibly by interfering with folate and methionine metabolism (Bagnardi et al.,
2001; Giovannucci et al., 1993). There is little doubt that diet plays a role in colorectal
cancer, but identification of the specific anti-carcinogenic dietary components and their
relative contribution to the any protective effect is difficult to unravel.
Lifestyle characteristics implicated as risk factors include a lack of physical activity and
obesity. Increased physical activity has been inversely associated with colorectal cancer
incidence with a magnitude of risk reduction as high as 40-50% (Gatof and Ahnen, 2002).
A recent study designed to examine for confounding variables in this association found
that it was an independent predictor (Slattery and Potter, 2002). Possible mechanisms
underlying anti-tumour activity related to physical activity are increased motility of
colonic contents, improved immune function and alterations in prostaglandins, insulin,
triglyceride and hormone levels.
High body mass index (BMI) is associated with an increased risk of colon cancer, and the
association appears to be stronger for men than for women. This difference could be due
to the protective effects of oestrogen on colorectal cancer risk in women, since oestrogen
levels increase with obesity in women. Substantial evidence indicates that women using
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hormone replacement therapy (HRT) have an approximately 30-40% decreased risk of
colorectal cancer and this may explain why the reduction in mortality over the last 20
years has been greater in women (Beral et al., 1999). Interestingly, central obesity
appears to increase colorectal cancer risk independently of BMI (Giovannucci et al.,
1995). Based on the observations that central obesity and physical inactivity are risk
factors for colorectal cancer, it has been suggested that associated insulin resistance and
consequent hyperinsulinemia may be the principal underlying risk factor (Giovannucci,
1995; Mathers, 2004; Slattery et al., 2005). Increasing studies report that polymorphisms
in components of the insulin-related pathway are associated with susceptibility to
colorectal cancer (Slattery et al., 2004a; Le Marchand et al., 2005a). The same group
suggest that NSAIDs may modulate colorectal cancer risk via an insulin-related pathway,
because of reported associations between polymorphisms in insulin receptor substrate 1
and vitamin D receptor genes, NSAID use and colorectal cancer risk (Slattery et al.,
2004b). Since inflammation is thought to lead to insulin resistance, NSAIDs may reduce
colorectal cancer by exerting anti-inflammatory effects and decreasing insulin resistance.
An early study suggested that approximately one third of the variation in cancer risk may
be due to smoking and dietary factors, and that the majority of cancers in those under the
age of 65 years may be potentially avoidable (Doll and Peto, 1981). A recent study
examined modifiable risk factors and estimated that 30-50% of colorectal cancer risk and
25-30% distal colonic adenoma risk might be preventable by moderate changes in diet
and lifestyle (Platz et al., 2000). Indeed, recent randomised controlled trials have shown
that daily ingestion of low doses of aspirin reduces the incidence of colorectal adenomas
(Baron et al., 2003; Sandler et al., 2003). Although environmental risk factors are
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acquired and hence theoretically preventable, experience in other diseases such as
ischaemic heart disease has shown that it is difficult to enforce dietary and lifestyle
modifications. In fact, the individual contribution of these risk factors to overall incidence
is small and lifestyle modification may only lead to a modest reduction in incidence
(Dunlop, 2001). Furthermore, it is increasingly apparent that it is the complex relationship
between diet and individual genotype that governs colorectal cancer risk (Mathers, 2004).
1.1.2.2 Genetic susceptibility
Genetic determinants increase susceptibility to environmental exposures, and conversely
the rate ofmutations can be affected by environmental factors. Environmental risk factors
may contribute to genetic defects in sporadic colorectal cancer by inducing DNA damage
in somatic cells and by formation of carcinogen-DNA adducts resulting in DNA
mutations (Gertig and Hunter, 1997). Furthermore, polymorphisms or mutations in
enzymes or other metabolic pathway machinery may influence susceptibility to
environmental risk factors.
The strongest evidence of a substantial genetic component comes from a study examining
44,788 pairs of twins which indicated that 35% of all colorectal cancer has a heritable
component, that is the proportion of susceptibility to cancer accounted for by genetic
factors (Lichtenstein et al., 2000). However, less than 5% of colorectal cancers are due to
dominant syndromes, such familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC), for which mutations in cancer susceptibility genes
have been identified (de la Chapelle, 2004). This indicates that there is a substantial
genetic contribution to colorectal cancer yet to be elucidated.
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Familial adenomatous polyposis is due to dominantly inherited mutations in the
adenomatous polyposis coli (APC) gene located on chromosome 5q 21. The APC gene is
a tumour suppressor gene involved in cell adhesion, cell signalling via the Wntl P catenin
pathway and cell proliferation. In addition to the inherited germline APC mutation, a
somatic mutation in the wild-type allele is required to initiate tumour development (Ichii
et al., 1992; Levy et al., 1994). Phenotypically, FAP is characterised by the development
of hundreds of colorectal adenomas during the second or third decade of life with 100%
risk of developing colorectal cancer if left untreated, as 1 or more adenomas may progress
to colorectal cancer (Debinski et al., 1996). FAP patients may also develop extra-colonic
manifestations such as retinal lesions, osteomas, desmoids and brain tumours. Disease
phenotype has been shown to correlate with the site of mutation within the APC gene
(Nugent et al., 1994). However, there is considerable phenotypic variation that is not
attributable to the site of APC mutation and this may be explained by modifier genes
(Crabtree et al., 2002). Patients with multiple or early-onset tumours, without mutations
in APC or MYH, do not appear to harbour mutations in other components of the Wnt
pathway such as p-catenin, APC2, axin, and glycogen synthase kinase-3p (Lipton et al.,
2003). In sporadic colorectal neoplasia, APC inactivation has also been demonstrated in
aberrant crypt foci, adenomas and in the majority of carcinomas (Powell et al., 1992; Jen
et al., 1994). The detection of APC mutations in the early stages of colorectal neoplasia
indicates the critical role ofAPC in colorectal cancer initiation (Fodde et al., 2001).
Hereditary non-polyposis colorectal cancer is a dominantly inherited syndrome
accounting for 1-5% of all colorectal cancer. HNPCC is due to mutations in the DNA
mismatch repair system, which serves to eliminate mismatch errors during DNA
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replication. In contrast to FAP, there are no clinical features that are pathognomonic of
HNPCC but it is characterised by early-onset cancer, fewer adenomas and extra-colonic
cancers such as endometrial, ovarian, stomach, small intestine and uroepithelial. Empiric
criteria for diagnosis of HNPCC are three or more relatives with histologically proven
colorectal cancer, one being a first-degree relative of the other two; two or more
generations affected; and at least one family member affected before age 50 years (Vasen
et al., 1991; Vasen et al., 1999). Nine MMR repair genes have been identified but 70-
85% of mutations affect hMLHl and hMSH2 and the remainder are in hPMS2 and
hMSH6 (Lynch and de la, 2003). DNA from HNPCC cancers displays a characteristic
instability, microsatellite instability (MSI), due to replication errors within
mononucleotide repeats. Hence, genes with repetitive DNA sequence such as BAX,
TGF/3RII and CTNNB1 may accumulate mutations as a result of replication errors.
Interestingly, about 13-15% of sporadic colorectal cancers exhibit MSI (Boland et al.,
1998; Brown et al., 1998). However, in sporadic cancers MSI is due to promoter
hypermethylation of hMLHl rather than somatic mutations found in HNPCC (Kuismanen
et al., 2000). Defects in the MMR system result in a mutation rate, which is 2-3 times
greater than normal cells culminating in accumulation of mutations and tumour
progression (Bhattacharyya et al., 1994).
Mutations in other genes have been described resulting in syndromes that predispose to
colorectal cancer, but these constitute a minority of the total disease burden. All such
syndromes are characterised by the presence of benign adenomas. Peutz-Jeghers is a
dominantly inherited syndrome characterised primarily by predisposition to benign
intestinal hamartomatous polyps and is due to inactivating mutations in the protein kinase
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gene LKB1 (STK11) (Hemminki et al., 1998). Juvenile polyposis is dominantly inherited
with mutations in SMAD4 and more recently BMPR1A genes, reflecting the genetic
heterogeneity of this syndrome (Lynch et al., 1997; Howe et al., 1998; Howe et al.,
2001a). Mutations in PTEN, a phosphatase that negatively regulates the phosphoinositol-
3-kinase (PI3K)/Akt pathway and mediates cell-cycle arrest and apoptosis, are
responsible for the dominantly-inherited Cowden's disease which is characterised by
colonic hamartomatous polyps (Liaw et al., 1997). However, the majority of genetically
determined colorectal cancers are not due to highly penetrant single gene mutations.
MYH-associated polyposis (MAP) is an autosomal recessive syndrome due to bi-allelic
mutations in the base excision repair gene MYH (Al Tassan et al., 2002). Phenotypically,
MYH-associated polyposis is similar to attenuated FAP. Germline MYHmutation carriers
have been shown to be associated with an increased risk of colorectal cancer (Halford et
al., 2003; Croitoru et al., 2004). The MYH gene has been localised to lp32-34 (Slupska et
al., 1996). Both pre-malignant lesions and colorectal cancers display loss of
heterozygosity (LOH) at lp, and tumours with lp LOH harbour monoallelic MYH
variants (Kambara et al., 2004). There is accumulating evidence supporting the presence
of low-penetrance variants as colorectal cancer susceptibility alleles, and such variants
may be responsible for the multifactorial inheritance of colorectal cancer (Kemp et al.,
2004).
In addition to recognised mutations that account for familial colorectal cancer syndromes,
the genetic basis for sporadic colorectal cancer is well established as a multi-step model
of carcinogenesis (Fearon and Vogelstein, 1990) (Figure 1.1). Colorectal cancer results
from the mutational activation of oncogenes and the inactivation of tumour suppressor
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genes resulting in an accumulation of genetic aberrations, each conferring a selective
growth advantage promoting clonal tumour development. There are at least seven
independent genetic events required for malignant transformation (Kinzler and
Vogelstein, 1996) and the cumulative effect of these somatic mutations results in
colorectal cancer. There are sequential changes that are required for colorectal cancer
development in four genes: APC, KRAS, SMAD4 and p53 (Fodde et al., 2001). The
sequential order of these genetic changes appears to be important in determining the
biological behaviour of tumours. APC mutations are evident in the earliest form of
neoplastic development such as aberrant crypt foci and are responsible for initiation of
tumorigenesis. Additional mutations such as in KRAS, which are present in 50% of
colorectal cancers, result in tumour progression. Subsequent mutations in SMAD4 and
p53 occur later in the tumorigenic sequence promoting further clonal expansion and
malignant transformation.
It has been suggested that research focus should be on molecular and signalling pathways
rather than individual genes, given that mutations in several different genes in the same
pathway can lead to cancer (Vogelstein, 2006). For example, mutations in APC and P-
catenin have been found in 85% and 8% of sporadic colorectal cancers respectively, but
there were no tumours with mutations in both APC and P-catenin. In fact, Vogelstein et al
have shown that all the gene pairs in Figure 1.1 are mutually exclusive in terms of
mutations, and suggest that approximately two-thirds of all sporadic colorectal cancers
have mutations in each of these pathways. In FAP, patients have numerous adenomas and
cancer develops as a result of one or more of these progressing as other mutations are
acquired, whereas in UNPCC the rate of accumulation of mutations is accelerated.
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Although the model explains the development of both familial and sporadic colorectal
cancers to some extent, there is a large hereditary component of colorectal cancer that is


















Figure 1.1 Genetic changes associated with the adenoma to carcinoma sequence in
colorectal cancer. Development of colorectal cancer is due to oncogene activation and
inactivation of tumour suppressor genes resulting in an accumulation of genetic
alterations. Genetic changes correlate with histological transformation from normal
mucosa to carcinoma. Gene pairs have been shown to be mutually exclusive in terms of
mutations. Adapted from Vogetstein 2006 (AACR Webcast)
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1.1.3 Treatment of Colorectal Cancer
Despite continuing research and development in both basic sciences and clinical practice,
the overall 5-year survival from colorectal cancer remains low at 51% (Information and
Statistics Division, 2005). Although mortality from colorectal cancer has decreased over
the last 40 years, this is primarily due to progress in surgical technique and peri-operative
care rather than any intervention that actually alters the natural history of the disease.
Surgery remains the mainstay of treatment for colorectal cancer, and offers the best
chance of a cure with 5-year survival following curative resection being 75% (Arbman et
al., 1995; Gordon et al., 1993; Kanemitsu et al., 2003; Frizelle et al., 2002). Although
curative surgery can increase survival, this is only appropriate in patients presenting with
localised disease. Advanced disease is present in approximately 20-24% of colorectal
cancers at presentation (Mella et al., 1997; Smith et al., 2003). Whether curative or
palliative, 90% of patients require surgery and there is considerable disease-related
morbidity and mortality.
Currently, the most accurate predictor of overall survival is stage of the cancer at
presentation. Colorectal cancer is staged by the TNM classification, which describes the
extent of the primary tumour (T), the involvement of regional lymph nodes (N), and the
absence or presence of distant metastasis (M). Colorectal cancer also continues to be
staged using the Dukes' classification (Dukes, 1951). Dukes' A tumours do not extend
beyond the muscuaris propria, Dukes' B tumours extend into the subserosa and serosa
and Dukes' C tumours represent lymph node metastasis. The 5-year survival for Dukes'
A, B and C is 71-85%, 57-64% and 36-38% respectively (Mulcahy and O'Donoghue,
1997). The overall 5-year survival for advanced colorectal cancer, which constitutes a
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significant proportion of the disease, remains poor at 3-10% (Mulcahy and O'Donoghue,
1997). The majority of colorectal cancer presents with later stage disease, and the
distribution by stage at presentation is 13% with Dukes A, 37% with Dukes B, 22% with
Dukes C and 24% with Dukes D (Smith et al., 2003). Clearly, both a curative outcome
and improved 5-year survival are more likely if colorectal cancer is detected at an earlier
stage. Colorectal cancer treatment is tailored for different stage disease, but surgical
resection remains the most effective. In addition to predicting survival, Dukes' staging is
also used to indicate those who require adjuvant therapy such as chemotherapy and
radiotherapy.
An absolute survival benefit of 4-13% with adjuvant chemotherapy has been
demonstrated in Dukes C colon cancers, with weaker evidence for Dukes C rectal cancers
(IMPACT, 1995; Dube et al., 1997). Hence, patients with Dukes C colorectal cancers
should be considered for adjuvant chemotherapy. The evidence is less convincing for
Dukes B tumours (IMPACT, 1995; Figueredo et al., 1997; Figueredo et al., 2004). The
QUASAR 1 trial randomised patients between adjuvant chemotherapy and observation
and demonstrated a small (1-5%) survival benefit in Dukes B patients (Gray et al., 2004).
Hence, given the potential toxicity routine use is not currently justified for patients with
Dukes B tumours. Such patients may be offered chemotherapy in the context of trials, or
if considered to have a 'high-risk' tumour exhibiting features such as lymphovascular
invasion and poor differentiation (IMPACT, 1995).
It is clear that adjuvant radiotherapy significantly decreases local recurrence following
curative resection of rectal cancer. The Dutch trial demonstrated a significant decrease in
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local recurrence from 8.2 to 2.4% with short-course preoperative radiotherapy, compared
to total mesorectal excision alone (Kapiteijn et al., 2001). However, no significant
survival benefit was demonstrated in a recent meta-analysis (Colorectal Cancer
Collaborative, 2001), which contradicted both the Swedish Rectal Cancer Trial (Swedish
Rectal, 1997) and a previous meta-analysis (Camma et al., 2000). Pre-operative
radiotherapy does lead to increased sexual dysfunction, slower recovery of bowel
function, and impaired daily activity post-operatively (Marijnen et al., 2005).
Nonetheless, a decrease has been demonstrated in local recurrence, which can be painful
and incapacitating. Hence, a selective approach is adopted by most, and pre-operative
radiotherapy is used for fixed or tethered T3/4 tumours and very low tumours in relation
to the anal sphincter. Post-operative radiotherapy is less beneficial, in terms of local
recurrence, than pre-operative radiotherapy and has no effect on survival, and thus is
reserved for those with positive resection margins. Pre-operative combined
chemoradiation may be used to downstage disease to allow sphincter preserving surgery
(Habr-Gama et al., 2004) and has been shown to confer a small survival benefit (Chau et
al., 2003; Gunderson et al., 2003). The survival benefit has to be balanced against
toxicity-related morbidity and impact on quality of remaining life.
Despite most patients undergoing potentially curative surgery and the availability of
adjuvant chemotherapy, about 50% of patients presenting with colorectal cancer die from
subsequent metastatic disease and 30-50% of patients treated with curative surgery will
develop advanced disease (Griffin et al., 1987; Abulafi and Williams, 1994; Young and
Rea, 2000). The annual expenditure on colorectal cancer is approximately £230 million in
the United Kingdom. This estimate may not include the cost of investigating symptomatic
patients to exclude the diagnosis of cancer, and so the true expenditure is probably far
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greater. There is no doubt as to the considerable advances in chemotherapy, and yet no
agent has been developed which imparts a significant survival benefit in colorectal
cancer. It is clear that survival may be improved by earlier detection or by strategies
aimed at prevention of the disease.
1.1.4 Screening and early detection
In view of the proportion of patients who present with advanced disease, there is
substantial rationale for colorectal cancer screening. Early detection of colorectal cancer
would lead to a shift in stage of presentation and thus impact upon survival. Colorectal
cancer biology is well characterised in terms of the adenoma-carcinoma sequence, and
hence lends itself to early detection. The incidence of adenomas from colonoscopy
studies in developed countries has shown rates ranging from 25 to 41% (Markowitz and
Winawer, 1997). However, given that the incidence of colorectal cancer is lower, only
10% of adenomas will progress and there are no means of predicting which adenomas
will develop into cancer. In addition, recent data from The National Polyp Study suggest
that adenoma prevalence results from a dynamic process of both formation as well as
regression of adenomas, which has implications for screening (Loeve et al., 2004).
Nonetheless, removal of adenomas by endoscopic polypectomy has been shown to
decrease the incidence of colorectal cancer (Citarda et al., 2001). The duration between
development from adenoma to carcinoma has been shown to be 5 to 10 years (Winawer et
al., 1997), which provides a 'latent period' for screening and subsequent intervention.
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Several potential modalities have been investigated for the purposes of screening
including barium enema, colonoscopy, flexible sigmoidoscopy and faecal occult blood
testing (FOBT). Barium enema is not as sensitive in detection of small adenomas since
the reported rate of detection of all adenomas was only 39% and only 48% of adenomas >
lcm were detected (Winawer et al., 2000). A 60-95% reduction in mortality from
colorectal cancer in the area examined was demonstrated with rigid sigmoidoscopy
(Newcomb et al., 1992; Selby et al., 1992). Flexible sigmoidoscopy is currently being
evaluated as a potential screening tool (Atkin et al., 1998). However, the obvious
disadvantage is the incidence of proximal colon cancers and adenomas in people with a
normal sigmoidoscopy (Rex et al., 1999; Imperiale et al., 2000). Colonoscopy has the
advantage of visualising the whole colon, and polypectomy results in a reduction in
colorectal cancer incidence (Citarda et al., 2001). However, there is a definite morbidity
and mortality risk associated with colonoscopy, which has to be balanced against
potential benefit. Hence, non-invasive screening modalities may be preferable. CT
colonography is emerging as a potential screening investigation but there are concerns
regarding the sensitivity of the test especially for small polyps and flat lesions (Mulhall et
al., 2005; Park et al., 2005). Colonoscopy still had the highest sensitivity for detecting
colonic polyps and cancers in a prospective comparison with barium enema and CT
colonography (Rockey et al., 2005).
Faecal occult blood testing is being evaluated as a population based screening tool. There
have been four randomised controlled trials evaluating FOBT in approximately 350,000
individuals (Kewenter et al., 1994; Hardcastle et al., 1996; Kronborg et al., 1996; Mandel
et al., 2000). These have shown that annual FOB testing reduced colorectal cancer
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incidence by 20% and colorectal cancer mortality by 16% (Towler et al., 1998).
However, sensitivity of the FOB test varied from 46% to 92% and remains an issue
especially concerning detection of adenomas that are not bleeding (Towler et al., 1998).
In fact, these studies showed a shift in the stage of distribution rather than an actual
reduction in colorectal cancer incidence within the study period. The number needed to
screen is 1400 to prevent one colorectal cancer death in 5 years (Rembold, 1998). Hence,
unnecessary investigation due to the low positive predictive value of FOB testing, with
the associated morbidity and mortality, is a key disadvantage. A new stool based test that
is currently being developed is the multi-targeted DNA-based assay panel (MTAP),
which detects 15 genetic alterations associated with colorectal cancer and has greater
sensitivity and specificity that FOBT (Ahlquist et al., 2000).
It is evident that no optimum screening modality has been identified for population-based
screening. However, surveillance is justified in high-risk groups such as patients with
HNPCC and FAP and in moderate risk patients with a significant family history, where
the risk benefit ratio is more favourable. In light of the high incidence of colorectal cancer
and the modest improvement in overall mortality, research efforts are being focused not
only towards earlier diagnosis and better treatment, but also prevention of the disease
using complementary strategies. Chemoprevention is the use of an agent that interrupts,
reverses or delays the development of invasive cancer by targeting key molecular
aberrations (Sporn, 1976). Amidst several potential agents currently being researched,
NSAIDs are conspicuous as the most convincing and consistent chemopreventive agents
that appear to be effective at all stages of colorectal cancer ranging from aberrant crypt
foci, to adenomas and carcinomas.
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1.2 NSAIDs and colorectal cancer prevention
There are several complimentary lines of evidence, from epidemiological and
observational studies; clinical trials, animal models and in vitro studies that suggest
NSAIDs possess anti-tumour activity against colorectal cancer.
1.2.1 Epidemiological evidence
1.2.1.1 Colorectal cancer
Substantial epidemiological evidence indicates that NSAIDs protect against development
of colorectal cancer. There is a 40-50% risk reduction in incidence of and mortality from
colorectal cancer in both cohort and case-control observational studies (Figure 1.2).
Taken together these 29 studies represent more than 18000 cases of colorectal cancer and
provide consistent evidence that aspirin and other NSAIDs reduce the overall risk by 40-
50%. The reliability of the anti-tumour effect is substantially strengthened by the fact that
the reduction in relative risk is consistent despite differing NSAID types and doses,
duration of ingestion, study groups and geographical location.
Only two studies have failed to demonstrate a protective effect from NSAID ingestion
(Paganini-Hill et al., 1989; Sturmer et al., 1998). The first study investigated the use of
NSAIDs in an elderly retirement community (Paganini-Hill et al., 1989). Since NSAID
use was determined at the beginning of the study, ingestion may have actually been
commenced or discontinued in the ensuing study period. Moreover, there are no data
available on the duration of NSAID use. This study also showed an increased risk of
ischaemic heart disease in aspirin users indicating the duration of aspirin use may have
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been short. The second study that did not demonstrate any reduction in colorectal cancer
incidence with NSAID use was the Physicians' Health Study (Gann et al., 1993). This
study was prematurely terminated because primary end-points were cardiovascular and
there was a significant reduction in myocardial infarction. Furthermore, moderate alcohol
intake appeared to be a predictor of aspirin use and this may have confounded the results.
The natural history of development from adenoma to carcinoma is ten to fifteen years and
it may be that a short duration intervention does not interrupt this sequence of events
(Winawer, 1999).
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Figure 1.2 Epidemiology studies of association between NSAIDs and colorectal
cancer. The relative risk estimates and confidence intervals refer to incidence and death
rate among regular NSAID users compared to non-users in cohort (blue) and case-
control (red) studies and in randomised controlled trials (green).
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1.2.1.2 Sporadic colorectal adenomas
Furthermore, numerous studies have shown NSAID users have a decreased risk of
developing colorectal adenomas, indicating that NSAIDs may affect early stages of
tumour development (Figure 1.3). These observational studies in isolation provide strong
evidence that NSAIDs retard the formation of adenomas. Since it is not feasible to
perform trials with colorectal cancer as the primary end-point, colorectal adenomas have
been used as biological surrogate markers. In three clinical trials examining the effect of
NSAIDs on sporadic adenomas (Hixson et al., 1993; Ladenheim et al., 1995; Matsuhashi
et al., 1997), sulindac treatment resulted in polyp regression in only one study
(Matsuhashi et al., 1997), but all of these trials examined small populations (Table 1.1).
Table 1.1 Epidemiology studies of association between NSAIDs and
sporadic adenomas
Study Date Patients Dosage Duration Design Results
no
„nn„ 5 sulindac 400mg „ clinical ? ..Hixson 1993 7 0 . on 6 months .. , reduction in2 piroxicam 20 mg trial .^ a polyp size
or number
44 patients no
i . . . 1QQ(- Sulindac 300 mg . ., R„ significantLandenheim 1995 . 4 months RCT reduction in
previous or placebo pQ|yp sjze
P°'yPs or number
Matsuhashi 1997 sulindac 300 mg 4 months c'|n'ca' 65/o polyps(20 polyps) a trial regressed
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Three recent randomised controlled trials have consistently demonstrated the
chemopreventive effect of aspirin against adenoma formation (Baron et al., 2003;
Benamouzig et al., 2003; Sandler et al., 2003). In fact one trial was terminated early
because of the significant protective effect of aspirin compared to placebo (Sandler et al.,
2003). All three trials showed a striking protective effect with low doses of aspirin
ranging from 81mg to 325mg, which are similar to those used in cardiovascular disease
prevention. Paradoxically, 81mg aspirin was found to be more protective than the 325mg
aspirin, and hence questions remain about the optimal dose.
It has been suggested that gastrointestinal bleeding secondary to NSAID ingestion leads
to earlier detection of tumours and is responsible for the apparent protective effect.
However, a case-control study compared the risk of developing colorectal cancer in
patients on aspirin compared to other anti-coagulants, and found the protective effect was
only present in the NSAID-treated group (Muller et al., 1994). Taken together these
randomised controlled trials strengthen the evidence that pharmacological doses of aspirin
reduce the incidence of colorectal adenomas in a moderate risk population defined as




















Figure 1.3 Studies of association between NSAIDs and sporadic colorectal
adenomas. The relative risk estimates and confidence intervals refer to incidence among
regular NSAID users compared to non-users in cohort (blue) and case-control (red)
studies and in randomised controlled trials (green).
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1.2.1.3 Familial adenoma syndromes
There is also ample evidence that, in addition to sporadic adenomas and colorectal
cancers, NSAIDs confer protection in familial syndromes associated with increased risk
of colorectal cancer. Indeed, the anti-tumour effect of NSAIDs was initially observed in
FAP patients with desmoid tumours, the first of whom was given indomethacin for
pericardial inflammation and regression of a mediastinal desmoid was noted (Waddell
and Gerner, 1980). Sulindac was then substituted for indomethacin and regression of
rectal adenomas was observed in three patients with FAP (Waddell and Loughry, 1983).
Several subsequent observational studies have also shown regression of polyps with
sulindac treatment (Table 1.2) (Waddell et al., 1989; Rigau et al., 1991; Winde et al.,
1993; Spagnesi etal., 1994).
This has been substantiated in three RCTs that demonstrated a reduced number and size
of polyps with sulindac (Labayle et al., 1991; Giardiello et al., 1993; Nugent et al., 1993).
The largest RCT examining the effect of celecoxib, a selective COX-2 inhibitor, in 77
FAP patients showed 28% fewer polyps and 31% reduction in the size of polyps
(Steinbach et al., 2000). Although one study did not show a protective effect with
nimesulide, another selective COX-2 inhibitor, on colonic polyps, there was a 15%
reduction in duodenal polyps (Dolara et al., 1999).
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p-value
Winde Labayle Nugent Giardello Dolara Steinbach
1993
15
1991colectomy&IRA 24duodenalpolyps 1993(14rectalpolyps) 22(18not 1993colectomised)








66.7%completeremission 33.3%partialremission 66.7%completere ission 33.3%partialremission duodenalpolyps<2mm regressed9/11noression polyps>3mm 56%reductionnumberpolyps 65%reductionpolypsize decreaseinumberandsizof polyps 78%completeregression 22%partialregression nochangei umberrsizf polyps 28%reductionnumberpolyps 30.7%reductionpolypsize





However, there have been concerns regarding the increased incidence of total and non-
gastrointestinal serious adverse events, with the COX-2 selective NSAIDs as compared
with non-selective NSAIDs, in the Celecoxib Long-term Arthritis Safety Study (CLASS)
and the Vioxx Gastrointestinal Outcomes Research (VIGOR) studies (Wright, 2002).
Recently, the significantly increased risk of cardiovascular events due to rofecoxib in a
polyp prevention trial (APPROVe) led to its withdrawal from the market (Bresalier et al.,
2005). The underlying mechanism of action is thought to be preferential COX-2
inhibition resulting in unopposed action of thromboxane leading to thrombotic events and
selective renal COX-2 inhibition resulting in salt and water retention, hypertension and
exacerbation of cardiac failure (Wright, 2002).
The CAPP-1 study randomised FAP carriers to a placebo or aspirin with or without
resistant starch (CAPP-1, 2003). There was no significant reduction due to either
intervention in polyp number after a year. However, secondary analysis of data from
patients enrolled for more than 1 year showed that both aspirin alone and the combined
aspirin/resistant starch treatment resulted in a significant reduction in polyp number. The
CAPP-2 study will determine whether aspirin and/or resistant starch reduce adenoma
initiation and progression in another genetically predisposed group, HNPCC carriers
(CAPP-2, 2005). However, a recent study investigated whether sulindac could prevent
adenomas in 41 phenotypically normal FAP patients, and found no difference between
the placebo and sulindac group, with respect to both the number and size of polyps
(Giardiello et al., 2002). The study period was 4 years and resistance to sulindac has been
described which may account for the results. It may also be that the mechanism of action
is related to the progression of, rather than the formation of, adenomas or that the doses
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used (75 and 150 mg sulindac) were inadequate for primary prevention. However, these
doses were sufficient to inhibit prostaglandins, as prostaglandin levels in colorectal
mucosa were lower in the sulindac group, which suggests prostaglandin-independent anti-
tumour mechanisms may predominate. It has been reported that polyps resume growth in
FAP patients once treatment has been stopped and that patients may develop some form
of resistance to NSAIDs (Giardiello et al., 1993). There have also been reports of patients
developing rectal cancer whilst on sulindac treatment (Niv and Fraser, 1994; Lynch et al.,
1995; Giardiello et al., 1996). Nonetheless, these studies provide valuable insights
because although FAP itself accounts for only 1-2% of all colorectal cancer, they provide
a model of APC inactivation which is present in 85% of all colorectal cancers (Thun et
al., 2002).
The observation that the protective effect of NSAIDs against both sporadic and familial
adenomas is evident with a similar magnitude of risk reduction to carcinomas, suggests
that the mechanism of action may be related to an early step in the adenoma-carcinoma
sequence. In keeping with this, patients on low doses of aspirin for at least a year showed
decreased overall density of aberrant crypt foci, the earliest precursor lesion identified in
colorectal cancer development (Shpitz et al., 2003).
In summary, there is overwhelming evidence that NSAIDs protect against development of
both colorectal adenomas and cancers in humans with a risk reduction in the order of 30-
50%. The striking feature of the epidemiological, observational and RCT evidence is the
consistency of the protective effect despite differences in study design, dosage, duration
and the type ofNSAID used, and the demographics and location of the study populations.
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However, there are associated side-effects such as gastrointestinal bleeding which
preclude current use of NSAIDs as chemopreventive agents. Hence, there is compelling
rationale to understand the molecular mechanism of action as this would not only inform
about colorectal cancer biology, but would also permit specific molecular targeting
resulting in development of novel chemopreventive agents with increased efficacy and
safety.
1.2.2 Animal models
Animal models of carcinogenesis using rodents have been useful for studying the effects
of NSAIDs in vivo. Colorectal cancers may be chemically-induced by azoxymethane or
dimethylhydrazine in rat models, and these also show a reduction in tumour burden in
response to treatment with NSAIDs: including sulindac (Piazza et al., 1997a),
indomethacin (Pollard and Luckert, 1981; Moorghen et al., 1988; Skinner et al., 1991)
nimesulide (Fukutake et al., 1998), pioxicam (Pereira et al., 1996; Piazza et al., 1997a)
and a selective COX-2 inhibitor SC58635 (Reddy et al., 1996). Furthermore, NSAIDs
decrease the development of pre-neoplastic aberrant crypt foci in azoxymethane rat
models (Yoshimi et al., 1997; Shpitz et al., 1998), indicating the mechanism of action
may be related to an early stage of tumorigenesis.
The animal model of FAP is the Min (multiple intestinal neoplasia) mouse, which has a
mutation in the Ape gene and develops small intestinal adenomas. A reduction in tumour
burden in Min mice has been demonstrated with several different NSAIDs. The
chemopreventive effects occur with both non- COX-2 selective NSAIDs such as sulindac
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(Beazer-Barclay et al., 1996; Chiu et al., 1997; Mahmoud et al., 1998a), aspirin (Boolbol
et al., 1996; Barnes and Lee, 1998; Mahmoud et al., 1998b), flurbiprofen (Wechter et al.,
1997), indomethacin (Chiu et al., 2000) and piroxicam (Jacoby et al., 1996), and also
with selective COX-2 inhibitors such as rofecoxib (Oshima et al., 2001).
There are limitations of animal models given that the correlation with human
carcinogenesis is imprecise, since Min models develop tumours of the small intestine
rather than colon. Nonetheless, animal models have been useful for affording several
insights regarding the effects of NSAIDs on specific molecular pathways. The
chemopreventive potential of NSAIDs has been shown in more than 90 of the >100
animal model studies published to date (Hawk ET et al., 2004). Overall, the data indicate
that non-selective NSAIDs suppress tumour growth to a greater extent and at lower doses
when treatment is begun before or concurrent with carcinogen exposure; that both non¬
selective and selective NSAIDs inhibit the early stages of carcinogenesis whereas
selective COX-2 inhibitors appear to be more effective in later stages and finally NSAIDs
must be given continuously to prevent tumour growth (Thun et al., 2002).
1.2.3 Mechanisms of Action
Substantial evidence from epidemiological, animal and in vitro work indicates that
NSAIDs protect against colorectal cancer, but the molecular basis is not completely
understood. Initially, studies have focused upon cyclooxygenase (COX) inhibition and the
resultant decrease in prostaglandin synthesis as the basis ofNSAID anti-tumour activity,
as this is the mechanism underlying their anti-inflammatory activity (Vane, 1971).
However, a growing body of evidence indicates that NSAIDs modulate COX-2
independent pathways, and that COX-2 inhibition may not be the predominant anti-
tumour mechanism of action in colorectal cancer (Tegeder et al., 2001). There are several
putative anti-tumour mechanisms of action which are COX-dependent and COX-
independent: inhibition of cell proliferation, inhibition of carcinogen activation,
augmentation of the immune response, inhibition of angiogenesis and the induction of
programmed cell death or apoptosis (Figure 1.4).
1.2.3.1 Cox-dependent mechanisms
1.2.3.1.1 Inhibition of carcinogen activation
The anti-tumour activity of NSAIDs may be, in part, due to their ability to inhibit
carcinogen activation. Colorectal cancers and adenomas express higher levels of COX-2
compared to normal mucosa (Eberhart et al., 1994). COX enzymes can metabolise pro-
carcinogens to carcinogens through their peroxidase activity (Levy, 1997). Examples
include the oxidisation of dihydrodiol of benzo[a]pyrene to its epoxide form which can
bind DNA and cause mutations, and COX-induced activation of aromatic amines to their
mutagenic forms. Prostaglandins can produce malondialdehyde, a mutagen and
carcinogen, and can result in the formation of peroxyl radicals, which can activate pro-
carcinogens (Shiff and Rigas, 1997). COXs can also indirectly produce free radicals,
which can activate transcription factors involved in cell proliferation. Hence, the ability of
NSAIDs to attenuate the carcinogen load may contribute to their protective effect in
colorectal cancer.
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1.2.3.1.2 Augmentation of immune response
It is well recognised that tumour cells escape immune-mediated surveillance and
subsequent immunologically induced destruction (Ahmad et al., 2004). Human leukocyte
antigen (HLA) classes I and II expression is decreased in colorectal cancers and
adenomas (McDougall et al., 1990; Tsioulias et al., 1993). Prostaglandins, especially
PGE2, are known to reduce expression of T-cell proliferation and cytotoxicity,
macrophage activation and lymphokine production thereby suppressing the immune
response (Husain et al., 2002). Therefore, NSAIDs may augment the immune response by
inhibiting production of prostaglandins with a resultant increase in expression of HLA
genes.
1.2.3.1.3 Inhibition of angiogenesis
Neovascularisation is important for tumour growth beyond 2-3mm in size and subsequent
metastasis. Prostaglandin production is increased in colorectal cancer and PGE2 has been
shown to stimulate angiogenesis (Hanahan et al., 1996). Furthermore, COX-1 has been
shown to regulate tube formation in endothelial cells (Tsujii et al., 1998), and COX-2
appears to regulate production of angiogenic factors such as vascular endothelial growth
factor (VEGF) by colorectal cancer cells (Williams et al., 2000). Indomethacin has been
shown to suppress growth of colorectal cancer cells via inhibition of angiogenesis by
decreasing VEGF production (Wang and Zhang, 2005). These data suggest that inhibition
of angiogenesis by NSAIDs may contribute to their anti-tumour activity.
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1.2.3.2 Cox-dependent and independent mechanisms
1.2.3.2.1 Inhibition of cell proliferation
Colorectal cancers have high levels of prostaglandins compared to normal mucosa (Rigas
et al., 1993). Since prostaglandins have been shown to stimulate cell proliferation (Qiao
et al., 1995), inhibition of prostaglandin production may decrease cell proliferation.
Indeed, several cell culture studies have demonstrated that NSAIDs consistently decrease
proliferation of colorectal cancer cell lines by inducing cell cycle arrest (Shiff et al., 1995;
Goldberg et al., 1996; Shiff et al., 1996; Qiao et al., 1998). Sulindac and rofecoxib, a
COX-2 selective NSAID, decrease DNA replication in polyps from Ape47/6 Min mice
indicating inhibition of cellular proliferation occurs in vivo (Oshima et al., 2001).
Furthermore, sulindac decreased proliferation indices in rectal mucosa of FAP patients
after 33 months of treatment (Winde et al., 1995). However, in another study of sulindac
in FAP patients there was no effect on proliferation, but an increase in apoptosis was
observed after 3 months (Pasricha et al., 1995). Nonetheless, sulindac has been shown to
decrease proliferation in colorectal cancer cells that do not produce prostaglandins
because of COX deficiency (Hanif et al., 1996), indicating that prostaglandin inhibition
may not be the critical mechanism of action. Furthermore, the concentration of NSAIDs
required for COX inhibition are lower than those needed for the anti-tumour effects in
cells and animal studies. Although evidence from cell culture, animal and patient studies
indicates that NSAIDs are growth inhibitory, it is unclear whether this effect is solely due
to decreased prostaglandin production, and hence COX-dependent.
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1.2.3.2.2 Induction of apoptosis
Programmed cell death or apoptosis is progressively inhibited during colorectal
carcinogenesis (Bedi et al., 1995). Numerous in vitro studies have shown that aspirin and
other NSAIDs induce apoptosis in colorectal cancer cells (Shiff et al., 1995; Hanif et al.,
1996; Shiff etal., 1996; Elder et al., 1997; Piazza et al., 1997b; Qiao et al., 1998; Castano
et al., 1999; Stark et al., 2001b). Several putative modes of action, both COX-dependent
and COX-independent, have been investigated (Figure 1.4). It has been shown that
NSAID-mediated apoptosis may be due to an increase in the prostaglandin precursor
arachidonic acid (Chan et al., 1998). The accumulation of arachidonic acid leads to the
conversion of sphingomyelin to ceramide, which can induce apoptosis (Jarvis et al.,
1996). Arachidonic acid can be metabolised by cyclooxygenases or lipoxygenase (LOX).
Inhibition of LOX has also been shown to induce apoptosis and both NS-398 (COX-2
selective) and sulindac lead to upregulation of 15- lipoxygenase-1 (15-LOX-l) which
induces apoptosis in colorectal cancer cells (Shureiqi et al., 2000). It has recently been
shown that induction of 15-LOX-l expression is involved in NSAID-mediated down-
regulation of PPAR5 and the resultant induction of apoptosis in colorectal cancer cells
(Shureiqi et al., 2003).
The PPAR family of intracellular nuclear hormone receptors have also been investigated
as potential NSAID targets. The PPARs function as ligand-dependant activators of
transcription (Lemberger et al., 1996). Sulindac has been shown to suppress PPARS
activity and induce apoptosis, suggesting a mechanism by which sulindac counters the
effects of APC inactivation that lead to increased PPARS activity (He et al., 1999).
However, a more recent study by the same group showed no difference in sensitivity to
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sulindac-induced apoptosis between PPARS+/+ and PPARS7" cell lines suggesting that
PPAR8 is not a major contributor to NSAID anti-tumour activity (Park et al., 2001).
NSAIDs have been shown to modulate expression of both pro- and anti-apoptotic genes.
NS-398, a selective COX-2 inhibitor, upregulated expression of the pro-apoptotic gene
Par-4 and induced apoptosis in colorectal cancer cells (Zhang and DuBois, 2000).
Sulindac has been shown to increase expression of the pro-apoptotic gene NAG-1
(NSAID-activated gene 1) in human colorectal cancer cells and in mouse colon (Kim et
al., 2002). Survivin is an anti-apoptotic protein that is over expressed in colorectal cancer
(Ambrosini et al., 1997). Sulindac decreases survivin expression in colorectal cancer cell
lines (Zhang et al., 2004). NSAIDs have been shown to inhibit the expression of the anti-
apoptotic protein Bc1-xl, resulting in an altered ratio of BAX to Bc1-xl and apoptosis in
colorectal cancer cells (Zhang et al., 2000). It has recently been shown that NSAIDs
induce cytoplasmic translocation of the second mitochondrial protein to be released
during apoptosis, SMAC/Diablo (Kohli et al., 2004). NSAID-induced apoptosis is
abrogated when SMAC/Diablo is disrupted by homologous recombination and RNA
interference in colorectal cancer cells, suggesting it plays an important role in NSAID-
mediated apoptosis. The p38/MAPK signalling pathway may be involved since sodium
salicylate induced-apoptosis in colorectal cancer cells was blocked by SB203580, a p38
MAPK inhibitor (Lee et al., 2003). Aspirin has also been shown to phosphorylate GSK-
3(3, a multifunctional serine/threonine kinase that negatively regulates RW(3-catenin
signalling, in colorectal cancer cell lines (Dihlmann et al., 2003). Additional potential
targets in NSAID-mediated apoptosis are (3-catenin and p53 signalling which shall be
discussed in greater detail in Chapter 5 and 6 respectively.
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It is clear that NSAIDs affect multiple signalling pathways and it is possible that their
potent anti-tumour activity results from multiple different effects on a variety of
signalling pathways and genes. It is therefore important to unravel the primary
chemopreventive effects from secondary phenomena.
1.2.3.3 Evidence supporting COX-independent anti-tumour
mechanisms
Colorectal cancer cell lines that do not express COX are as susceptible to the growth
inhibitory effects of NSAIDs as those which do have COX activity (Hanif et al., 1996;
Elder et al., 1997). Similarly, NSAIDs lacking COX-2 inhibitory activity are able to
inhibit colorectal cancer cell line growth (Piazza et al., 1995; Piazza et al., 1997b) . The
concentration required to inhibit growth is greater than that required to inhibit COX
activity (Hanif et al., 1996; Charalambous et al., 1998). Furthermore, formation of polyps
was not completely abrogated in the COX-2 null mice (Oshima et al., 1996), adding to
the accumulating evidence that COX-2 is not the only target ofNSAIDs.
There are conflicting reports regarding the cellular localisation of COX-2 in humans and
animal models. COX-2 has been shown to be expressed in malignant epithelial cells in
humans (Eberhart et al., 1994; Sano et al., 1995). A recent study showed that COX-2
localised to superficial interstitial macrophages in 75% of sporadic human adenomas and
was only located in the epithelium of 29% of adenomas (Chappie et al., 2000). In mice
adenomas COX-2 was expressed in epithelial cells (Williams et al., 1996) and also in the
stromal rather than in the neoplastic epithelial cells (Oshima et al., 1996; Shattuck-Brandt
et al., 2000). Non-neoplastic epithelium near the tumour also expresses COX-2 but that
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distant from it does not, suggesting a paracrine signalling effect between stromal and
epithelial cells (Hull et al., 1999; Chappie et al., 2000). The observation that, despite
differing localisation of COX-2 in mice and humans, NSAIDs are anti-neoplastic in both
species suggests that there may be alternative or additional mechanisms of action.
The transcription factor NFkB has been suggested as a target for the anti-inflammatory
effects of NSAIDs (Kopp and Ghosh, 1994). Constitutively high NFkB activity has been
observed in colorectal cancer suggesting that aberrant NFkB signalling may contribute to
colon carcinogenesis (Rayet and Gelinas, 1999). Furthermore, several growth regulatory
genes that are known to be deranged in colorectal cancer such as c-myc, p53, and COX-2,
are regulated by NFkB. Hence, the NFkB signalling pathway is a strong potential target
for the anti-tumour effects ofNSAIDs in the colon.
1.3 Transcription factor nuclear factor kB (NFkB)
The NFKB/Rel proteins are members of a family of ubiquitous transcription factors that
exist in all human cell types. NFkB was originally identified as a B-cell nuclear factor
which was able to bind to an intronic enhancer of the immunoglobulin K-light chain gene
and thus named accordingly (Sen and Baltimore, 1986). Group 1 proteins NFkBI
(p50/pl05) and NFkB2 (p52/pl00) are produced following proteolysis of precursor
proteins pi05 and pi00 respectively, and group 2 proteins include Rel A (synonomous
with p65), RelB and c-Rel which all have transactivating domains. All five proteins share
a common N-terminal 300 amino acid motif called the Rel homology domain (RHD)
which is responsible for nuclear localisation, DNA binding, dimerisation and interacting
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with IkB, the inhibitor ofNFkB (Siebenlist et al., 1994). The IkB family members (IkBcx,
IkBP, IkBS, IkBs, IxBy, Bc13) are characterised by the presence of ankyrin repeat
domains (ARDs) in their C-termini, which are responsible for NFkB-IkB inhibitory
interaction, of which IkBcc is most studied (Baeuerle and Baltimore, 1988; Baldwin, Jr.,
1996). The NFxB/Rel proteins can form various homodimers and heterodimers and the
complex composition and cell type result in transcriptional specificity of target gene
regulation. The most abundant form ofNFkB is a heterodimer composed of a p65 (Rel A)
and a p50 subunit (NFkBI) and further reference to NFkB will refer to this specific
heterodimer unless otherwise stated. A schematic diagram of the canonical NFkB
pathway is represented in Figure 1.5.
In resting cells, NFkB is sequestered pre-formed in the cytoplasm bound to its inhibitory
protein, IkBoc, and thus can be rapidly activated. IkBcc preferentially recognises theNFkB
(p50/p65) heterodimer and retains it in the cytoplasm, as a result of the direct interaction
between the nuclear localisation sequence and DNA binding region of NFkB with IkBoc
(Malek et al., 1998). In response to numerous different extracellular stimuli, a signal
cascade is initiated culminating in activation of an enzyme complex which phoshorylates
IkBcc at two critical N-terminal serine residues at position 32 and 36 (Traenckner et al.,
1995). This multi-subunit enzyme complex has been identified as the IkB kinase (IKK)
complex and is composed of two serine/threonine kinases, IKKa and IKKP and
additional proteins (Zandi et al., 1997). Once IkBa has been phosphorylated, it undergoes
polyubiquitination on lysines 21 and 22 by an E3 ubiquitin ligase, and is then targeted by
the ubiquitin-26S proteosome for degradation (Traenckner and Baeuerle, 1995; Baldi et
60
al., 1996). IkBcc degradation unmasks the nuclear localisation signal resulting in nuclear
translocation ofNFkB, where it binds to regulatory elements in promoters of target genes.
The NFkB transcription factor regulates several hundred target genes involved in cell
proliferation and death, inflammation and the immune response (Pahl, 1999). NFkB plays
a central role in regulating apoptotic pathways (Barkett and Gilmore, 1999) and
dysfunction ofNFkB signalling is implicated in the development of neoplasia (Elder and
Paraskeva, 1998; Hawkey, 1999; Rayet and Gelinas, 1999). Furthermore, several NFkB
driven genes are dysregulated in colorectal cancer supporting the notion that NFkB may
be a potential NSAID target.
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NFkB is bound to an inhibitor protein IkBcc in cytoplasm. Stimuli activate the IKK complex
leading to IkBoo phosphorylation at serines 32 and 36 and ubiquitination at lysines 21 and
22 by an E3 ubiquitin ligase, targeting kBa for degradation by the 26S proteosome. IkBcx
degradation unmasks the nuclear localising signal (NLS) on p65 permitting NFkB nuclear
translocation.
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1.4 Research aims and strategy of research
1.4.1 Hypothesis
Aspirin exerts a clinically relevant anti-tumour effect via modulation ofNFkB signalling.
1.4.2 Research questions
1. Is NFkB modulation responsible for aspirin-induced cell death in colorectal cancer?
2. Is the aspirin-induced NFkB molecular response specific to colorectal cancer?
3. Is there a role for COX-2 and P-catenin as potential molecular determinants of the
aspirin-induced NFkB response?
4. Does p53 mutation and DNA mismatch repair status influence sensitivity to aspirin?
5. Are the effects observed in vitro reproducible in normal colonic mucosa and
established tumours in patients?
6. Are there mutations present in the Rel A (p65) and IkBa genes in colorectal cancer?
1.4.3 Strategy of research
1.4.3.1 Cell culture studies
A panel of colorectal cancer cell lines will be treated with doses of aspirin relevant to
chemoprevention. Following aspirin treatment, IkBcc expression will be examined using
Western blotting. Immunofluorescence will be used to study NFkB activity following
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aspirin treatment. Apoptosis will be determined by immunocytochemistry and Annexin V
binding. IkBcc degradation and NFkB activation will be correlated with the level of
apoptosis. Cell lines from other tumours will also be treated with aspirin to determine the
specificity of the NFkB response for colorectal cancer. Basal levels of potential molecular
markers for response such as COX-2, (B-catenin, and p53 will be studied. To determine
whether mismatch repair status alters the aspirin response, the colorectal cancer cell lines
HCT-116 (mismatch repair deficient) and FICT-116+ch3 (mismatch repair proficient) will
be compared.
1.4.3.2 Clinical studies
It is essential to confirm that the mechanism involving the NFkB signalling pathway
observed in colorectal cancer cell lines represents the in vivo response to aspirin. The
effects of NSAIDs will be studied in rectal cancer and genetically predisposed patients
recruited to take a 7-day course of aspirin 300/600mg once daily (OD) or 600mg four
times daily (QDS). The higher (analgesic) dose is designed to maximise generation of a
biological effect, while the lower dose will allow determination of clinical relevance of
the effect for future chemoprevention. To investigate the role of COX-2, the effects of a
7-day course of 25mg rofecoxib (a selective COX-2 inhibitor) on NFkB signalling will be
studied in rectal cancer and genetically predisposed patients. All clinical studies have full
ethical approval.
After informed consent, biopsies will be taken from rectal tumour and normal mucosa
before and after treatment with the respective NSAID. Immunohistochemistry will be
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used to study apoptosis in the biopsies after NSAID treatment. Cytoplasmic and nuclear
protein extracts will be made using standard procedures. IkBoc and p65 proteins will be
examined in the cytoplasmic fraction using Western blotting. Electrophoretic mobility
shift assays (EMSAs) will be used to study NFkB nuclear translocation. IkBcx
degradation and NFkB activation will be correlated with the level of apoptosis.
1.4.3.3 Mutation screening
The NFkB pathway plays a pivotal role in death signalling, and altered regulation of
NFkB has been observed in colorectal cancers. It is hypothesised that deranged NFkB
signalling in colorectal cancer may be due to mutations in key components of the NFkB
pathway. Furthermore, mutations in the pathway may account for the variability in NFkB
response observed in colorectal cancers and any cell-type specificity of the NFkB
response. The principal objectives are to determine whether there are any mutations in Rel
A and IkBa genes in colorectal cancer. Mutation analysis of Rel A and IkBa genes will be
performed in 92 DNA samples. DNA will be extracted using standard protocols from
colorectal cancer cell lines, colorectal tumours, aspirin-treated colorectal cancer patients,
and genetically predisposed individuals with HNPCC and FAP. These biological






The colorectal cancer cell lines used were HRT-18, SW480, HT-29, DLD-1, LoVo and
HCT-116 and the sub-lines HCT-116+ch3 and HCT-116 p53"A. The HCT-116+ch3 sub-line
was a gift from Professor CR Boland, in which hMLHl expression has been restored by
chromosome 3 transfer, and these cells are DNA MMR proficient (Koi et al., 1994). The
HCT-116 p53 /" sub-line was created by targeted homologous recombination (Bunz et al.,
1999) and was a gift from Professor B Vogelstein. The breast cancer cell lines were
T47D, MCF-7, MDA-MB-231; ovarian cancer line was A2780 and endometrial cancer
line was HEC-l-A. The cell lines used are summarised in Table 2.1. All cell lines,
excluding the HCT-116 sub-lines, are available from the American and European Type
Culture Collections.
2.1.1.1 Generation of stable kBa S32/36 expressing cell lines
These cell lines were generated prior to my research period but are integral to establishing
the mechanism of action of NSAIDs, and therefore a brief description is included here.
The IkB s32/36 plasmid was a gift from Professor R Hay and contains IkBcc mutated at
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serines 32 and 36, which are critical for phosphorylation and ensuing degradation, cloned
into pcDNA3 with a C-terminal pk-tag (Roff et al., 1996). The HRT-18 cell line was
transfected with this plasmid and was grown under geneticin (Gibco BRL) selection.
Stable transfectants were screened by immunoblotting, using the anti-pk-tag antibody.
Expressing clones were grown in the absence of geneticin during aspirin treatment.
Table 2.1 Cell line characteristics
Cell line Cancer Type COX-2 APC p-catenin p53 MMR
HRT-18 colon unknown mutant wild-type mutant hMSH6
SW480 colon negative mutant wild-type mutant proficient
HT-29 colon positive mutant wild-type mutant proficient
DLD-1 colon negative mutant wild-type mutant hMSH6
LoVo colon positive mutant wild-type wild-type hMSH2
HCT-116 colon negative wild-type mutant wild-type hMLH1
HCT-116+ch3 colon negative wild-type mutant wild-type proficient
HCT-116p53"'~ colon negative wild-type mutant null hMLH1
MCF-7 breast negative wild-type wild-type wild-type proficient
MDA-MB231 breast positive wild-type wild-type wild-type unknown
T47D breast unknown wild-type wild-type wild-type proficient
A2780 ovarian unknown wild-type wild-type wild-type proficient




The technical staff in the animal facility were responsible establishing the xenografts and
for maintaining the animals. Xenografts were established by subcutaneous implantation
of a 0.1cm3 piece of third to sixth generation source HT-29 tumours in both flanks of
female Nu/Nu mice. The mice were euthanased 3-4 weeks later once the flank tumours
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were approximately 50-100cm3 in size and the tumours and other organs including small
and large intestine, lung, liver, breast, spleen and pancreas were harvested. The organs
were maintained ex vivo as short-term explants and treated with 10 mM aspirin. After
washing in PBS, the biopsy tissue was finely diced and incubated in DMEM medium
containing aspirin or carrier control for 5 hours. Following aspirin treatment, the biopsy
fragments were harvested, washed in PBS, and homogensied in lysis buffer to permit
cytoplasmic protein extraction as described in Section 2.6.2.1. Immunoblotting was as per
the cell line protocol for cytoplasmic IkBoi in Section 2.7. All animal experiments were
performed in accordance with UKCCCR guidelines (Workman P, 1998).
2.1.3 Patients
There were three patient study groups: patients with established rectal cancers and
patients who are genetically predisposed to developing colorectal cancer, such as those
with FAP and HNPCC (Table 2.2). The inclusion criteria for the rectal cancer group were
any patient over the age of 18 with a rectal cancer accessible using a rigid sigmoidoscope.
The inclusion criteria for the genetically predisposed group were any patients over the age
of 18 with known FAP or HNPCC. The exclusion criteria for all 3 study groups were
current/recent ingestion of NSAIDs or anti-coagulant medication, pregnancy, known
peptic ulcer disease or a tendency to indigestion / heartburn, allergy to NSAIDs, asthma,
bleeding diastheses, previous stroke and those with a history of significant rectal
bleeding. The treatment arms comprised either the COX-2 selective inhibitor rofecoxib or
aspirin (300-600mg OD or 600mg QDS). All studies had local ethical and management
approval (LREC numbers 99/5/8, 99/5/21, 99/5/50 and CTA Number 17844/0001/001).
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After informed consent, biopsies were taken from normal rectal mucosa and rectal
tumour, if present, before and after 7 days of respective NSAID treatment. Part of the
biopsy specimen was fixed in formalin for paraffin embedding and sectioning for H&E
staining, and part snap-frozen in liquid nitrogen for protein analysis. Cytoplasmic and
nuclear proteins were extracted as described in Section 2.6.2.
Table 2.2 Clinical studies
Study LREC no Cases NSAID type & dose
Patients
recruited












Aspirin 600 mg QDS
2 at 300 mg OD
4 at 600 mg OD
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600 mg OD 1
MMR Aspirin 600 mg QDS 6
FAP Aspirin 600 mg QDS 2









Rofecoxib 25mg OD 6




2.2 Cell line culture
Cells were grown as monolayers (37° C in 5% CO2) in RPMI (HRT-18, DLD-1 and
A2780), DMEM (HT-29, T47D, MCF-7, MDA-MB-231, HEC-l-A), L-15 (SW480) and
McCoy's 5A media (HCT-116, HCT-116+ch3, HCT-116 p53-/~) supplemented with 10%
foetal calf serum (FCS) and 1% penicillin/streptomycin (media from Gibco BRL, Paisley,
UK). The HCT-116 +ch3 cell line was grown under selection with 0.4mg/ml geneticin.
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2.3 Aspirin treatment
Cells were plated (1 x 106 cells /50ml flask) and grown until 60-70% confluent, prior to
treatment with aspirin or carrier control. Aspirin (Sigma, St Louis, USA) was prepared as
a 0.5 M stock solution in distilled water (final pH 7.0). Growth medium was replaced
with the respective low serum (0.5% FCS) medium, and cells were treated with aspirin at
1,3,5 and lOmM for 24 hours or with carrier as a control.
2.4 Cell viability assessment
Adherent cells were harvested and viable cell number determined by haemocytometric
counts with nigrosin exclusion. IC50 values for the colorectal cancer cell lines were
calculated using the XLfit 3™ software.
2.5 Apoptosis measurement
2.5.1 Annexin V
Cell surface phosphatidylserine is a marker for apoptosis and was detected via its
interaction with annexin V using the Annexin V-FITC apoptosis detection kit (Oncogene
Research Products, Cambridge, Mass., USA). Briefly, media from the flask of adherent
cells was transferred to a conical tube on ice to harvest any floating cells. Cells were then
washed with 2 mis of PBS, which was also added to the tube to collect any cells
dislodged during washing. Cells were incubated with 1ml of trypsin: versene (volume per
volume) just until the cells detached, and then resuspended in the conical tube containing
the media with the floating and washed cells. Cells were counted using a haemocytometer
and resuspended in cold IX binding buffer to approximately 1 x 106 cells /ml. Media
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binding reagent (1 Oju.1) was added to 0.5 ml of the cell suspension, which was incubated
with 1.25 p.1 of annexin V-FITC for 15 minutes at room temperature in the dark. Annexin
V was then removed by centrifugation at 1000 x g for 5 mins and cells were resuspended
in 0.5 ml of cold IX binding buffer and placed on ice. The counting was done using a
haemocytometer (two counting grids) in duplicate, and this was carried out immediately.
2.5.2 Acridine orange staining
Following treatment with aspirin, adherent cells were fixed with acetic acid: ethanol (9:1
volume/volume) and then stained with acridine orange stain at 0.5% final concentration
immediately prior to analysis by fluorescent microscopy by Dr L Stark.
2.5.3 Apoptotic counts
Dr Angus McGregor, Consultant Pathologist, kindly performed the apoptotic counts.
Apoptosis was quantified on haemotoxylin and eosin (Fl&E) stained sections using
morphological criteria and counting only epithelial cells showing unequivocal apoptotic
morphology (Howie et al., 1994; McGregor et al., 2003). Since apoptosis is infrequent in
tumour sections (< 1%), increasing the number of cells counted decreases the variation in
apoptotic counts. The "running mean" method may be used to determine the minimum
number of cells to be counted for the results to be reliable. In this method, the number of
apoptotic cells per 100 malignant cells is calculated for every 100 malignant cells, until
the difference between the successive means becomes negligibly small (< 1% of the
index). In this work on rectal cancer samples, an initial calculation of a running mean
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(cumulative mean of repeated counts, every 50 cells) was done with a cut-off at 0.5% (ie
>0.5% difference likely to be significant) counting 1100 cells.
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2.6.1.1 Cytoplasmic and nuclear extracts
Cells were washed with PBS, centrifuged (1200 rpm, 10 minutes) and cell pellets
resuspended in lysis buffer containing complete Protease Inhibitor Cocktail and 100 mM
Pefabloc (Roche Diagnostics, Manheim, Germany). The cell suspension was centrifuged
(6000 rpm, 15 minutes, 4° C) and the supernatant containing cytoplasmic proteins
aliquoted. Protein content was measured by the method of Bradford (BioRad, Hercules,
California, USA).
2.6.1.2 Whole cell extracts
Cells were washed with PBS, centrifuged (1200 rpm, 10 minutes) and cell pellets
resuspended in lysis buffer with 1:1000 DTT, 1:100 Pefabloc and 0.5% NP40 for 5
minutes and then centrifuged (3000 rpm, 10 mins). Supernatant was used as whole cell
extract and protein content was measured by the method of Bradford.
2.6.2 Human and mouse tissues
2.6.2.1 Cytoplasmic and nuclear extracts
The biopsies of normal mucosa, tumour or mouse organ were washed in PBS and then
diced into 0.5cm3 pieces, which were suspended in 3 volumes of lysis buffer. The tissue
and lysis buffer mixture then underwent three cycles of freeze (5 mins)- thawing and
homogenising with an eppedorf pestle. Debris was removed by centrifuging (13000rpm,
5min) and then cytoplasmic and nuclear fractions prepared from supernatant as described
above in the cell line protocol (Section 2.6.1.1).
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2.7 Western blotting
Cytoplasmic proteins (30 pg) were separated on a 10% SDS-PAGE gel, transferred to a
polyvinylidine difluoride membrane (BioRad) and blocked in 4% non-fat dry milk
solution with 0.3% Tween20 (Sigma). Membranes were probed with a sheep polyclonal
IkBcc antibody (a gift from Professor R Hay, University of St Andrews, UK), rabbit
polyclonal p65 antibody (Santa Cruz, California, USA), mouse monoclonal COX-2
antibody (Cayman Chemicals, Michigan, USA), mouse polyclonal (3-catenin antibody
(Chemicon, Hampshire, UK) and mouse monoclonal p53 antibody (AbCam, Cambridge,
UK). Monoclonal antibody to copper zinc SOD (The Binding Site, Birmingham, UK) was
used as a control for protein loading. Antigen-antibody complexes were visualised with
chemiluminescence (Amersham ECL Reagents, UK).
2.8 Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were carried out by incubating nuclear
extracts from untreated cells (6pg) with binding reaction mix (IX binding buffer [50mM
KC1, 20mM HEPES, 5% glycerol, ImM EDTA, ImM DTT], lpg BSA, lpg poly dl-dC,
25 frnol radioactively labeled oligo-DNA in a final volume of 20pl) for 30min prior to
analysis on a 4% native polyacrylamide gel. Double stranded oligonucleotides for NFkB
were obtained from Santa Cruz.
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2.9 Immunocytochemistry
Cells grown to 60-70% confluence on glass coverslips were treated with carrier or lOmM
aspirin for 24 hours (in respective 0.5% FCS medium). After treatment, cells were
washed with PBS, fixed with acetone: methanol (v/v) (-20° C, 10 minutes) and blocked
in 10% pre-immune donkey serum (Sigma) for 1 hour. Rabbit polyclonal antibody to
NFkB p65 (Santa Cruz) was applied for 1 hour followed by incubation with FITC-
conjugated donkey anti-rabbit IgG for 1 hour. The nuclei were stained with DAPI and the
coverslips mounted with Vectashield (Vector Laboratories, Burlingame, California,
USA).
2.10 Transfections and reporter assays
For transient transfection experiments, 50ml flasks of cells were grown to sub-confluency
(60-70%) and then transfected with 6pg of luciferase reporter plasmid and 3pg of P-
galactosidase control plasmid, using Lipofectamine as described by manufacturers
instructions (Gibco BRL). Following transfection, cells were grown in low serum (0.5%
FCS) medium then treated with aspirin (0-1 OmM) for 24hrs. Luciferase activity was
measured in cell extracts using a lucifcrase reporter assay kit (Promega) and read using a
luminometer. Transfection efficiency and cell viability were monitored by co-transfection
with a CMV-P-galactosidase reporter plasmid and P-galactosidase activity was quantified
with an assay kit (Promega), as per manufacturers' instructions. Relative luciferase
activity was calculated as unit of luciferase activity per unit of P-galactosidase activity.
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2.11 DNA extraction protocols
2.11.1 Cell lines
Isolation of genomic DNA from cell lines was carried out using a Nucleon II extraction
kit (Scotlab Bioscience, Strathclyde) according to manufacturer's instructions in a class 2
containment hood.
2.11.2 Paraffin-embedded sections
Tumour was micro-dissected from paraffin- embedded sections using a sterile scalpel and
DNA extracted using a QIAamp DNA minikit (QIAGEN Ltd, Crawley, UK) as per
manufacturer's instructions in a class 2 containment hood.
2.11.3 DNA concentration
DNA concentration was measured using a UV spectrophotometer (Pharmecia). Samples
were diluted and placed in quartz cuvettes and absorbancy was measured at 260nm and at
280nm. DNA concentration was calculated as follows:
DNA pg/ml= A260 x dilution factor x 50
260 280 * • •An A /A ratio of 1.8 was taken as optimum purity of DNA. Measurements were
done in duplicate and repeated if inconsistent. Stock DNA samples were then diluted to
100-200ng/pl
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2.11.4 DNA samples from patients
Colorectal tumour DNA samples were previously collected by Prof. M Dunlop and Dr S
Farrington (MRC Human Genetics Unit, Edinburgh). All samples have appropriate
ethical approvals. The DNA samples were diluted to approximately 1 OOng/pl for use.
2.12 Mutation analysis of Re! A and IkBa genes
2.12.1 PCR protocols and primers
Manipulation of oligonucleotides and all PCR techniques were performed in a biological
class 2 cabinet. Dedicated pipettes were used for PCR to minimise contamination of PCR
products. All primers were specifically designed using Primer3 software (Whitehead
Institute, Cambridge, MA http://www-gcnome.wi.mit.edu/cgi-bin/primer/primer3 www.cgi).
The primer sequences and cycling conditions are described in Table 2.3 for Rel A and
Table 2.4 for IkBa.
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Table 2.3 Re! A primers









TACTTCATAGCCCGCCTCCT 52, 59* and 62° C
p65 exon 4
AAGGTCTGGGCTCTGTGAGA
GTGAGGGAGATGCAGGAAAG 52, 59, 61 and 62° C
p65 exon 5
TGCCCCCACTGATAGTACCT
AACCCCCTTCCTCCTATTCA 55, 58,59, 61 and 62° C
p65 exon 6
CTCTCGTGGCTCAGGTCATC
CTTCTCAGCTTCACCCCTTG 55, 58,59, 61 and 62° C
p65 exon 7
GACCATCGGAGGGTTAGACA














55 and 62° C
*-bold indicates optimum temperature
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Table 2.4 IkBa primers
















58 and 62° C
IkBa exon 4
GGTGAAAGGAGTGAGGGTTG
TAAGCACGAGGAGCCTGACT 55,59, 60,61 & 62° C
IkBa exon 5
CAAATGCAGCCATAAGCATC
AAGGGAATGGCACCTCATTA 55,59, 60,61 & 62° C
IkBa exon 6
CTCCGGAAGCTTAACGTGTC
GGCAGTGTGCAGTGTGGATA 55,59, 60,61 & 62° C
PCR reactions were performed in a final volume of 50pl using AmpliTaq (Roche).
Reaction mix per sample:
PCR Buffer II lOx 5pl lx
MgCB 25 mM 5pi 2.5 mM
dNTP mix 2 mM 5pi 0.2 mM
AmpliTaq DNA polymerase 5U/pl 0.25pl 0.025 U
Forward primer 200ng/pl 0.5pl 100 ng
Reverse primer 200ng/pl 0.5pl 100 ng
DNA template 5pi
Sterile H20 (to 50pl) 28.75pl
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2.12.2 Agarose gel electrophoresis
Solutions
lOx Tris-Acetate EDTA (TAE) Loading buffer
2M Tris lOOmM Na2EDTA (pH 8.0)
5.7% w/v glacial acetic acid 0.25% w/v bromophenol blue
50mM Na2EDTA (pH 8.0) 30% w/v sucrose
Agarose gels were prepared using electrophoresis grade agarose (Flowgen) and lx TAE
electrophoresis buffer. Low percentage gels (ie 1.5%) and higher percentage gels (ie 3%)
were used to separate large and smaller DNA fragments respectively. 5-10 pi of PCR
products were loaded on gels with 2pi of loading buffer and a lkb size ladder (Gibco).
The DNA was separated at 45V until the dye front was about 1 cm from the end of the
gel. DNA was visualised by ethidium bromide (Biorad) staining followed by UV
illumination using a Herolab transilluminator (Herolab, Wiesloch). Gel images were
captured using a Herolab camera and Easywin 32 version 2 software.
2.12.3 PCR product purification
PCR products were cleaned for sequencing analysis using exonuclease 1 and shrimp
alkaline phosphatase (USB, Cleveland, USA).
Reaction mix per sample:




Samples were then transferred to an equilibrated thermal cycler (Hybaid) and run using
the following cycling conditions:




Sequencing of purified PCR products was performed in lOpl reactions using ABI PRISM
Ready Big Dye Terminator cycle sequencing kit (Perkin Elmer Applied Biosystems,
Cheshire, UK). Reaction mix per sample:
Purified DNA template 2pi
Forward primer 1 pi
Big dye 2pi
dH20 5pi
Samples were then transferred to a PCR system thermal cycler (Hybaid) and run using the





Sequencing reactions were performed in either individual Eppendorf tubes or in 96-well
plates and stored at 4°C prior to precipitation.
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2.12.5 DNA precipitation
Precipitation of sequenced DNA was performed by adding 55pl 95% ethanol and 2 p.1 3M
NaOAC (pH 4) to lOp.1 of the sequencing reaction and incubating at room temperature for
30 minutes. After incubation, the 96 well plates were spun in a Sorvall RT6000 centrifuge
at 2000 rpm for 30 minutes. The supernatant was removed by inverting the plate and then
pulse spinning inverted plates on tissue paper at 800 rpm. 150pl of 70% ethanol was
added to each sample and the plate inverted immediately. The pellets were further dried
by a pulse spin of inverted plates on tissue paper at 800 rpm and stored at -20°C.
2.12.6 Gel electrophoresis of sequenced DNA
Gel electrophoresis of sequenced DNA was carried out by the Technical Services
department at the MRC Human Genetics Unit, Edinburgh. The precipitated DNA pellets
were resuspended in 2-4pl of loading dye (PE Applied Biosystems) and heated at 90°C
for 2 minutes. The plates were incubated on ice until loading and were analysed on the
ABI 3700 DNA Analyzer as per manufacturer's instructions.
2.12.7 Analysis of sequence data
Sequence data was imported into the Sequencher program version 3.0.1 (Gene Codes
Corp., Michigan) to allow alignment of multiple sequences of the same fragment. The
relevant published sequence was compared to sequenced fragments. The Sequencher
program highlighted mismatches in individual base-pairs and the chromatograms for
these were then examined.
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2.13 Statistical methods
Statistical advice was provided by Dr Peter Teague (MRC, Human Genetics Unit,
Edinburgh) who confirmed that the statistical test being employed was the most
appropriate test to address any given null hypothesis. Wilcoxon signed rank test and
Student's paired t-test (Microsoft Excel and Graphpad Prism Software) were used to test
for differences between the distributions of two data sets. Rank and Pearson correlation
coefficients (Microsoft Excel and Graphpad Prism Software) were calculated to describe
the strength of an association between two variables.
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Chapter 3
Molecular effects of aspirin on NFkB
signalling in colorectal cancer
3.1 Introduction
Epidemiological data suggest that aspirin and other NSAIDs reduce the incidence and
mortality from colorectal cancer (Janne and Mayer, 2000). The molecular mechanism of
action responsible for the anti-tumour effects in colorectal cancer has not been fully
defined. There are several potential targets and mechanisms of anti-tumour activity as
discussed in Section 1.2.3. There is substantial rationale for the study of NFkB as an
important mechanism of aspirin-mediated apoptosis. Constitutive NFkB activity has been
observed in colorectal cancer, indicating that deranged NFkB signalling may promote
carcinogenesis (Rayet and Gelinas, 1999). NFkB regulates many genes involved in cell
proliferation and apoptosis, including genes known to be dysregulated in colorectal
cancer such as COX-2, c-myc and cyclin D-l. There is also evidence that NSAIDs
modulate the NFkB signalling pathway to exert their anti-inflammatory effects. Flence,
the NFkB signalling pathway is a strong potential target for the anti-tumour effects of
NSAIDs in the colon. In resting cells, NFkB is retained in an inactive cytoplasmic
complex by IkBcc, an inhibitory protein. The NFkB-IkBcc complex can shuttle between
the nucleus and cytoplasm but nuclear export is more efficient, and hence the complex is
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mainly cytoplasmic. Following stimulation, an enzyme cascade is triggered activating the
IKK enzyme complex, which phosphorylates IkBo. at serine residues 32 and 36. Once
phosphorylated, IkBcc is ubiquitinated at lysines 21 and 22, and this polyubiquitation
targets the protein for degradation by the 26S proteosome. Following hcBa degradation,
NFkB is free to translocate to the nucleus where it regulates target gene transcription.
Aspirin and its active metabolite sodium salicylate have been shown to inhibit the
activation of NFkB in T and pre-B lymphocytes, by inhibiting degradation of
lipopolysaccharide-induced IkB, and thereby preventing NFkB nuclear translocation
(Kopp and Ghosh, 1994). Glutamate-mediated induction ofNFkB is inhibited by aspirin
and sodium salicylate, and hence protects against glutamate-induced neurotoxicity in rat
neuronal cells (Grilli et al., 1996). It has also been reported that aspirin inhibits tumour
necrosis factor a (TNFa)-induced NFkB activity in human endothelial cells (Weber et
al., 1995). The common feature in these studies is that NSAIDs have been shown to
inhibit cytokine-induced NFkB activation. The mechanism of inhibition ofNFkB activity
has been attributed to competitive inhibition ofATP-binding to the IkB kinase (IKKB) by
aspirin and sodium salicylate in TNFa pre-treated COS and Jurkat cells (Yin et al., 1998).
However, high concentrations of NSAIDs have been shown to inhibit other cellular
kinases, and so the specificity of this effect for NFkB is unclear (Frantz and O'Neill,
1995). Subsequently, the NSAID sulindac was shown to reduce TNFa-mediated
increases in IKKp activity in HCT-15 and HT-29 colorectal cancer cells (Yamamoto et
al., 1999b). Hence, inhibition of IKKP and subsequent inhibition of NFkB signalling
have been reported as being responsible for the anti-tumour effects of NSAIDs in
colorectal cancer.
NFkB has been shown to act as an inducer or inhibitor of apoptosis, depending on cell-
type and the nature of stimulus (Fan et al., 2002). NFkB is constitutively active in
numerous cancer types and appears to confer a degree of resistance to apoptosis,
potentially by upregulating anti-apoptotic genes. Both constitutive NFkB activity and
NFkB activation in response to chemotherapy may be responsible for resistance to
chemotherapeutic agents (Wang et al., 1999a). Therefore, inhibition of NFkB activity
may increase susceptibility to apoptosis. Flowever, in the studies showing NSAID-
mediated inhibition of IKKP, cells were pre-treated with NSAIDs for a short period prior
to a burst of TNFa. Such experimental conditions are not representative of the in vivo
environment in which colonic epithelium is continuously exposed to NSAIDs. Therefore,
the relevance of these studies to the chemopreventive effects ofNSAIDs is unclear.
The aim of this work was to establish whether, in the absence of TNFa or other NFkB-
inducing agents, NSAIDs mediate an anti-tumour effect by targeting the NFkB pathway.
Therefore, these experiments were performed without the addition of cytokines, to
identify the underlying role of NFkB in NSAID-mediated apoptosis. This research was
being performed by Dr Stark in the host laboratory when I joined. My contribution to this
body of work was the studies at low aspirin concentrations (0, 0.5, 1, 2 mM), which
included assessment of cell viability and apoptosis, h<Ba degradation immunoblots and
NFkB nuclear translocation EMSAs following aspirin treatment. It was important to
investigate these effects at concentrations of aspirin relevant to those found in serum of
aspirin-treated patients. In addition, I harvested the normal and tumour tissue samples
from patients with colorectal cancer and performed the explant studies using aspirin.
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3.2 Overview of Methods
3.2.1 Cell line studies
SW480, HRT-18, and HCT-116 colorectal cancer cell lines were maintained and treated
with aspirin for 24 hours, as described in Section 2.2 and 2.3. Colorectal cancer cells
expressing IkBcc mutated at serines 32 and 36 were generated as stable and transient
transfectants as described Section 2.1.1.1. Following treatment with aspirin, cell viability
and apoptosis were assessed by haematocytometric counting and annexin V assaying
which are described in Sections 2.4 and 2.5.1 respectively. Morphological assessment of
apoptosis was analysed by acridine orange staining (Section 2.5.2). Western blotting was
used to determine the levels of cytoplasmic IkBcx (Section 2.7) and NFkB nuclear
translocation was studied using immunocytochemistry and EMSAs (Section 2.8 and 2.9).
3.2.2 Clinical studies
For the ex-vivo in-vitro studies, biopsies of normal mucosa and tumour were harvested
from patients undergoing resectional surgery for colorectal cancer. After washing in PBS,
the biopsy tissue was finely diced and incubated in RPMI medium containing aspirin or
carrier control for 5 hours. Following aspirin treatment, the biopsy fragments were
harvested, washed in PBS, and homogenised in lysis buffer to permit cytoplasmic protein
extraction as described in Section 2.6.2.1. Immunoblotting was as per the cell line
protocol for cytoplasmic IkBoc in Section 2.7.
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3.3 Results
3.3.1 Aspirin induces apoptosis in colorectal cancer
cells
The effects of aspirin on colorectal cancer cell viability were studied using the SW480
cell line. Cells were treated with 1-lOmM aspirin for 24 hours or 0.5-2mM aspirin for 48
hours. Following aspirin treatment, there was a concentration-dependent reduction in the
number of viable cells (Figure 3.1A&B). Apoptosis was studied to establish whether the
effects of aspirin were due to the induction of cell death, rather than a growth inhibitory
effect. Indeed there was a concentration-dependent increase in the proportion of cells
showing annexin V binding of phophatidylserine, a marker of apoptosis, following
treatment with aspirin (Figure 3.1A&B). Acridine orange staining of aspirin-treated cells
demonstrated morphological features of apoptosis including condensed cytoplasm,
granular chromatin and irregular condensed nuclei (Figure 3.1C). These results confirm
























































Figure 3.1 Aspirin induces apoptosis in colorectal cancer cells. SW480 cells
were treated with 1-1 OmM aspirin for 24 hours (A) or 0.5-2mM aspirin for 48 hours
(B). There was a concentration-dependent decrease in the viable cell count paralleled
by a concentration-dependent increase in the proportion of cells binding annexin V
(A&B). Aspirin-treated cells show morphological features of apoptosis after acridine
orange staining (C).
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3.3.2 Aspirin induces IkBoc degradation and NFkB
nuclear translocation in a concentration-dependent
manner in colorectal cancer cells
The effect of aspirin on the NFkB pathway was studied to determine whether aspirin-
induced apoptosis is associated with modulation of NFkB signalling. Since IkBcc
regulates NFkB by sequestering it in the cytoplasm, the effects of aspirin on IkBcc were
studied initially. Aspirin treatment for 24 or 48 hours induced degradation of cytoplasmic
IkBcc levels in a concentration-dependent manner in SW480 colorectal cancer cells
(Figure 3.2 A). Normally, upon stimulation IkBcc is phosphorylated at serines 32 and 36,
and then ubiquitinated, which targets the protein for degradation by the 26S proteosome.
Transfection experiments performed in SW480 cells using a dominant negative form of
IkBcc (lkbS32/36-tag), which is resistant to phosphorylation at the critical serine residues
and hence degradation, showed that aspirin treatment did not alter the levels of mutant
IkBcc protein (Figure 3.2B). This indicated that the phosphorylation sites are important
for the effect of aspirin on IkBcc. Furthermore, the aspirin-induced decrease in IkBcc
levels was abrogated by pre-incubation of SW480 cells with the MG132 proteosome
inhibitor (Figure 3.2C). Taken together, these results show that aspirin induces
phosphorylation and proteosome-mediated degradation of IkBcc.
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Figure 3.2 Aspirin induces kBa degradation and NFkB nuclear translocation in
colorectal cancer cells. Aspirin (24-48 hours) induced kBa degradation in SW480 cells
(A). Aspirin does not induce degradation of mutant kBa, resistant to phosphorylation(kB
as32/36 )(B). Aspirin-induced decrease in kBa is abrogated by pre-incubation with
MG132 proteosome inhibitor (C). Aspirin induces NFkB nuclear translocation (D).Super-
shift analysis shows the induced complex is p65 and p50 (E).
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Dissociation of IkBcc from NFkB normally permits translocation of NFkB from the
cytoplasm to the nucleus. EMSAs were used to examine whether nuclear translocation of
NFkB occurs following aspirin-induced IkBcc degradation. Indeed, aspirin-induced IkBoc
degradation was associated with nuclear translocation of NFkB in a concentration-
dependent manner (Figure 3.2D) and super-shift analysis revealed the induced complex to
be composed of p65 and p50 sub-units (Figure 3.2E). These results show that aspirin
induces ficBa degradation and nuclear translocation ofNFkB in colorectal cancer cells.
3.3.3 Kinetics of aspirin effects on NFkB signalling and
apoptosis
It is important to determine whether the observed effect of aspirin on IkBcc and NFkB
results in apoptosis, rather than being a consequence of it. The first piece of evidence
comes from time-course experiments in which aspirin treatment induced degradation of
IkBcc after 2-5 hours, which persisted beyond 24 hours (Figure 3.3A). Increased nuclear
NFkB DNA binding occurs 2 hours after treatment and persists for more than 16 hours
(Figure 3.3B). Hence, both IkBcc degradation and NFkB nuclear translocation occur prior
to apoptosis, which increases between 8 and 16 hours following aspirin treatment (Figure
3.3C) indicating a causal relationship between aspirin-induced effects ofNFkB signalling


































Figure 3.3 Kinetics of aspirin effects on NFkB signalling and apoptosis
Aspirin treatment induced kBa degradation after 2-5 hours (A) and there is increased
nuclear NFkB DNA binding at 2 hours which lasts for greater than 16 hours (B). Aspirin
induced apoptosis occurs between 8 and 16 hours following treatment (C).
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3.3.4 Aspirin-induced apoptotic response and NFkB
nuclear translocation is abrogated by mutant IkBgc
The next experiment was designed to establish whether there was a causal relationship
between NFkB nuclear translocation and aspirin-mediated apoptosis. The HRT-18
colorectal cancer cell line was stably transfected to constitutively express the IkBcx s32/3<' -
tag construct in which IkBo. is mutated at serines 32 and 36 with a C-terminal pk-tag. The
parental HRT-18 cell line showed substantial NFkB nuclear translocation following
aspirin treatment (Figure 3.4A). However, nuclear translocation ofNFkB was inhibited in
all clones expressing mutant IkBoc compared to parental cells (Figure 3.4A). Next, the
effects of aspirin on cell viability and apoptosis were examined. Interestingly, the HRT-
18 clones expressing IkBcc S32/3<> (hi, h28) grew in the presence of 1 mM aspirin
compared with a decrease in viable cell count in parental HRT-18 (Figure 3.4B).
Treatment with 5 mM aspirin also had significantly less effect (p<0.05, Student's t-test)
on the viability of mutant IkBcc expressing clones, compared to the parental colorectal
cancer cells (Figure 3.4B). These results show that abrogation of nuclear translocation of
NFkB protects colorectal cancer cells from aspirin-induced apoptosis. These data strongly
support the concept that aspirin-induced apoptosis of colorectal cancer cells depends on
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Figure 3.4 Aspirin-induced apoptosis and NFkB nuclear translocation is abrogated
by mutant IkBcx. HRT-18 cells stably transfected to constitutively express kBa S32/36 -
tag construct (mutated at serines 32 & 36). EMSA shows that NFkB translocates to
nucleus following aspirin treatment in parental HRT-18 cells but is inhibited in clones (hi
& h28) expressing mutant kBa (A). There is a decrease in viable cell count in parental
HRT-18 cells, but clones expressing kBa S32/36 grew in 1 mM aspirin, and 5 mM aspirin
had significantly less effect (p<0.05) on cell viability (B).
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3.3.5 Aspirin induces IkBoc degradation in colorectal
tumour samples treated with aspirin
Next, the potential clinical significance of the in vitro findings was investigated by
treating normal mucosa and rectal tumour biopsy samples from patients, undergoing
resection for rectal cancer, with aspirin. The biopsies were maintained ex vivo as short-
term explants and treated with 10 and 20 mM aspirin. There was IkBcc degradation in
tumour and to a lesser extent normal mucosa following 5 hours of treatment (Figure 3.5).
This experiment confirms that clinical tumour biopsy material shows the same IkBcc
response observed in cell line experiments, albeit in an artificial in vitro experimental













Figure 3.5 Aspirin induces IkBcx degradation in colorectal tumour biopsies.
Normal mucosa and rectal tumour biopsies were maintained ex vivo as short-term
explants and treated with 10 and 20 mM aspirin. Aspirin induces IkB« degradation in
tumour (B) and to a lesser extent normal mucosa (A) following 5 hours treatment. The
Western blots shown are representative of at least 3 independent experiments and
Cu/Zn SOD was used as a control for protein loading.
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3.4 Discussion
Despite substantial evidence that NSAIDs protect against colorectal cancer, the molecular
basis of this anti-tumour activity has not been fully elucidated. The work presented here
shows that aspirin has growth inhibitory effects in colorectal cancer cells due to the
induction of programmed cell death. Aspirin-induced apoptosis is paralleled by
degradation of IkBcx and by translocation of NFkB to the nucleus in a concentration-
dependent manner. Colorectal cancer cells expressing a super-repressor form of IkBcc
(lKBaS32/36) do not undergo aspirin-induced NFkB nuclear translocation resulting in
complete abrogation of apoptosis; confirming that IkBcc degradation and NFkB nuclear
translocation are required for aspirin-induced apoptosis. These data reveal a novel
mechanism of action for the anti-neoplastic effects ofNSAIDs against colorectal cancer.
Although the underlying mechanisms of anti-tumour activity are incompletely defined,
several studies show that NSAIDs inhibit growth of colorectal cancer cells (Shiff et al.,
1995; Elder et al., 1996; Ricchi et al., 1997; Castano et al., 1999). Potential mechanisms
responsible for NSAID-induced growth inhibition are cell cycle arrest, induction of
apoptosis and necrosis. The work presented in this chapter shows that aspirin induces
apoptosis observed by morphological changes such as nuclear chromatin condensation
and externalisation of phosphatidylserine. Nevertheless, the preceding molecular
interactions that culminate in NSAID-induced cell death are unclear and require further
investigation. The anti-inflammatory effects of NSAIDs are due to COX-inhibition and
decreased prostaglandin synthesis (Vane, 1971), and it was thought that this mechanism
may also underly the anti-tumour activity. However, mounting evidence from animal
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models and cell culture systems, described in Section 1.2.3.3, has shown that it is likely
that COX-2-independent mechanisms of action play an important role in NSAIDs anti-
tumour activity.
Aspirin-induced apoptosis in colorectal cancer cells subsequent to activation of NFkB
signalling, in terms of IkBoi degradation and NFkB nuclear translocation, contrasts
previous studies that show inhibition of NFkB following NSAIDs (Yin et al., 1998;
Yamamoto et al., 1999b). These studies showed NSAID-mediated inhibition of IKKP in
cells that were pre-treated with NSAIDs for a short period prior to a burst of TNFa to
activate NFkB signalling. However, given that colonic epithelium would be constantly
exposed to NSAIDs, these conditions are not considered to be representative of the in
vivo dynamics, and NSAIDs have been shown to inhibit colorectal cancer cell growth
without additional cytokine stimulation. Furthermore, a recent study reported that the
direct inhibitory effect of sodium salicylate upon IKKP activity in a cell-free model such
as kinase assays does not reflect the mechanism whereby sodium salicylate inhibits IKKP
activity in intact cells (Alpert and Vilcek, 2000). Therefore, although these previous
studies provide some mechanistic insights relevant to NFkB signalling, the importance of
these findings using TNFa stimulation to chemopreventive effects ofNSAIDs is unclear.
The experiments were performed in low-serum conditions since components of high
serum may activate the NFkB pathway. In addition, experiments examining the effects of
cytokines on NFkB have been traditionally incubated in low concentration serum prior to
treatment. However, serum withdrawal has been shown to promote apoptosis by NFkB
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nuclear translocation depending on the cell context (Campbell et al., 2004). Hence, it may
be possible that the NFkB and apoptotic responses to aspirin may be either due to or
being enhanced by the low serum conditions. Further work in the host laboratory has
shown that there is no difference in NFkB and apoptotic responses to aspirin which is
attributable to differing serum concentrations when colorectal cancer cells are treated in
0.5% and 10% FCS (Stark and Dunlop, 2005).
The higher concentrations of aspirin (5-10 mM) were used to maximise the likelihood of
generating a biological effect, while the lower concentrations (0.5-3 mM) determined the
clinical relevance. The lower aspirin concentrations used here are comparable to serum
levels achievable in patients taking aspirin for chronic inflammatory conditions (l-3mM)
(Pachman et al., 1979). Although the higher concentrations are greater than serum levels,
there is some evidence that local conditions may increase uptake and concentration of
salicylates (Alpert and Vilcek, 2000). Salicylates are organic acids and therefore
accumulate at mildly acidic environments such as sites of inflammation (Abramson and
Weissmann, 1989; Weissmann, 1991). This may be due to salicylates being uncharged at
low pH and hence readily crossing membranes, but then deprotonating and becoming
trapped as anions within the more neutral environment found within cells (Brooks and
Day, 1991). Hence, it is likely that the local concentration of salicylate at a site of
inflammation may reach levels greater than serum concentrations.
Since aspirin is largely hydrolysed to salicylate on first pass metabolism, it may be
debated that the effects of salicylate rather than aspirin should be investigated. Indeed,
data from the host laboratory show that sodium salicylate has the same effects on NFkB
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signalling as aspirin (Stark et al, 2001a). Nonetheless, the effects of aspirin on cell
viability, apoptosis and NFkB signalling are evident at the lowest concentration of aspirin
(1 mM), which is an achievable serum level in patients and hence relevant to long-term
chemopreventive use. Furthermore, the observation that the colorectal tumour tissue
explants respond in a similar manner to aspirin-treated colorectal cancer cells
demonstrates proof of principle, in terms of aspirin-mediated modulation of NFkB
signalling in vivo. Hence, it is important to perform the experiments with aspirin, as this is
the main agent that has been shown to be protective in the epidemiological studies, and
any clinical studies would use aspirin since patients cannot be given salicylate.
In summary, these results show that aspirin induces a concentration and time-dependent
reduction in cytoplasmic IkBcc in colorectal cancer cells that is due to phosphorylation-
dependent, proteosome-mediated degradation of the protein. The aspirin-induced IkBci
degradation is associated with nuclear translocation of NFkB, as determined by
electrophoretic mobility shift assays. Time-course and dose-response experiments aimed
at defining the kinetics of the aspirin effect indicate that IkBoc degradation and NFkB
nuclear translocation preceded cell death, suggesting a causal relationship. Furthermore,
inhibition of NFkB nuclear translocation in colorectal cancer cells generated to
constitutively express a super-repressor IkBcx (lKBaS32/36) completely abrogates aspirin-
induced apoptosis compared to their parental counterparts. These results identity a novel
mechanism of aspirin-mediated apoptosis involving the NFkB pathway.
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Chapter 4
Investigation of the cell specificity of the
NFkB response to aspirin
4.1 Introduction
Combined case-control data, including over 30,000 colorectal cancer cases, indicate a
45% reduction in risk of developing colorectal cancer in subjects taking NSAIDs.
Although there is evidence for a protective effect ofNSAIDs against non-gastrointestinal
cancers, the data are less convincing and the risk reduction much less. In breast cancer,
reports show conflicting results and a meta-analysis revealed a risk reduction of only 13%
in case-control studies (Khuder and Mutgi, 2001), considerably less than that in colorectal
cancer. Similarly, in endometrial and ovarian cancer the available evidence suggests that
NSAIDs confer little, if any, protection (Cramer et al., 1998; Rosenberg et al., 2000;
Fairfield et al., 2002; Meier et al., 2002). Collectively, published data suggests that there
is considerable heterogeneity of NSAID anti-tumour effects between cancer types. The
particular protective effect against colorectal cancer suggests the possibility that aspirin
might target distinct molecular pathways in colonic epithelial cells.
The previous work presented in Chapter 3 demonstrated that aspirin induces time- and
dose-dependent signal-specific degradation of IkBoc, nuclear translocation of NFkB and
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apoptosis in colorectal cancer cells. Time-course experiments indicated that IkBcc
degradation and NFkB nuclear translocation preceded cell death indicating a causal
relationship. This was confirmed in cells that were engineered to continuously express a
dominant negative mutant IkBcc (IkBccS32/36), which showed inhibition of both aspirin-
induced NFkB nuclear translocation and apoptosis compared to their parental
counterparts (Stark et al., 2001b). This work alluded to the notion of specificity since the
NFkB response was not observed in the control cell lines, which were non-colonic in
origin.
Here, the focus is on the important issue of the specificity of aspirin's protective effects,
as observed in epidemiological studies, and the aim was to investigate whether cell-type
specific effects on the NFkB signalling pathway reflect the differential protective effects
of aspirin in different cancer types. Firstly, the generality of the NFkB response to aspirin
in colorectal cancer was investigated by studying a panel of colorectal cancer cell lines
with different genetic defects common in bowel malignancy. The key aim was to
determine whether the lower protective effect observed for breast, ovarian and
endometrial cancer in epidemiological reports might be paralleled by differing effects of
aspirin on the NFkB signalling pathway. The specificity of the NFkB apoptotic response
was investigated by comparing the effects of NSAIDS in colorectal cancer cell lines to a
panel of cancer cell lines of non-colonic origin.
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4.2 Overview of Methods
4.2.1 Generality of NFkB response in colorectal cancer
The generality of the NFkB response in colorectal cancer was examined in panel of 6
colorectal cancer cell lines: HRT-18, SW480, HT-29, DLD-1, LoVo and HCT-116. These
cell lines have different genetic backgrounds with mutations in genes that are known to be
involved in colorectal cancer development (Table 2.1).
All cell lines were maintained as described in Section 2.2 and grown until 60-70%
confluent, prior to treatment with aspirin or carrier control at the same concentrations
(1,3,5 and lOmM) as the aspirin treatment (Section 2.3). Following aspirin treatment for
24 hours, adherent cells were harvested and the number of viable cells determined
(Section 2.4). Apoptosis was detected via the interaction of phosphotidylserine, which is
externalised during apoptosis, and annexin V (Section 2.5.1). Protein extracts were made
from cell lines after aspirin treatment as described in Section 2.6.1 and proteins
electrophoresed as described in Section 2.7. The Western blots were then probed with
antibody to IkBo. to detect changes in cytoplasmic levels. Copper zinc SOD antibody was
used as a loading control. Nuclear translocation of NFkB was detected by
immunofluorescence using antibody to p65, the transcriptionally active subunit of NFkB
as described in Section 2.9.
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4.2.2 Specificity of NFkB response to colorectal cancer
To determine whether the effects of aspirin on cell viability and NFkB signalling were
specific to colorectal cancer, the panel of colorectal cancer lines was compared to cancer
cell lines of non-colonic origin. The non-colorectal cancer cell lines were breast cancer
lines (T47D, MCF-7, MDA-MB-231); an ovarian cancer line (A2780) and an endometrial
cancer line (HEC-l-A). These non-colorectal cancer cell lines were exposed to aspirin in
an identical manner to the colorectal cancer panel and cell viability, apoptosis, IkBcc
degradation and NFkB nuclear translocation determined (as described above). Basal
levels of IkBcx and p65 proteins were examined in extracts from untreated cells from both
panels and quantified using densitometry to study whether differences in specificity may
be related to the constituents of the NFkB pathway. Copper zinc SOD antibody was used
as a loading control.
To further investigate the specificity of the aspirin-induced NFkB response, FIT-29
tumour xenografts and other organs including breast, lung, liver, pancreas, spleen, small
and large intestine were harvested from mice and maintained ex vivo as short term
explants. The explants were treated with aspirin or carrier control for 5 hours, following




4.3.1 Generality of NFkB response in colorectal cancer
4.3.1.1 Aspirin induces apoptosis in colorectal cancer cells
In triplicate dose-response experiments, cell lines were treated for 24 hours with aspirin at
concentrations of 1,3, 5 and 10 mM and viable cell number determined by
haemocytometric counts. There was a concentration-dependent decrease in viable cell
number in each of the six colorectal cancer cell lines studied (Figure 4.1A). The IC50
values were calculated from the growth curves of the aspirin-treated colorectal cancer cell
lines (Table 4.1). The mean IC50 value for the colorectal cancer cell lines was 2.38 mM
and the greatest incremental reduction in viability in these cells was observed between 0
and ImM concentrations, which is comparable to serum concentrations attainable in
humans (Pachman et al., 1979).
Table 4.1 IC50 values for colorectal cancer cell lines
Colorectal cancer cell line IC 50
HRT-18 3.1 +/- 0.69
SW480 1.5 +/- 0.12
HT29 1.9 +/- 0.68
DLD-1 2.9 +/- 0.58
LOVO 2.1 +/- 0.25
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Figure 4.1 Effect of aspirin on cell viability and apoptosis in colorectal cancer cell
lines. Aspirin treatment (0-1 OmM) for 24 hours induces a concentration-dependant
decrease in viable cell number in all colorectal cancer cell lines (A). All colorectal cancer
cell lines undergo apoptosis after aspirin treatment (0-5 mM) (B).
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Next, it was important to establish whether the reduction in viable cell number that was
observed in each of the colorectal cancer cell lines was due to induction of programmed
cell death. Annexin-V binding of phosphatidylserine residues externalised during
apoptosis was used to determine the proportion of cells undergoing programmed cell
death in response to increasing aspirin concentrations. Aspirin treatment induced a
concentration-dependent increase in apoptosis in all six of the colorectal cancer cell lines
studied, confirming that induction of apoptosis is responsible for the observed reduction
in cell viability (Figure 4.IB).
4.3.1.2 Aspirin induces kBa degradation and p65 nuclear
translocation in colorectal cancer cells
The previous work indicated that NFkB nuclear translocation is a key component of
aspirin-induced apoptosis in colorectal cancer cells (Stark et al., 2001b). The effect of
aspirin on cytoplasmic levels of IkBoc, was investigated using immunoblot analysis.
Aspirin treatment resulted in concentration-dependent degradation of IkBcx, as indicated
by a reduction in cytoplasmic protein levels (Figure 4.2A) in all colorectal cancer cell
lines. The IC50 values for the colorectal cancer cell lines range from 1,5 to 3.1mM aspirin,
demonstrating differential sensitivity to aspirin with respect to the concentration at which
50% of the cells are growth inhibited (Table 4.1). The SW480 and HT-29 cell lines have
IC50 values at the lower end of the range (1.5 and 1.9mM, respectively) and do undergo
IkBcc degradation at ImM, whereas the HRT-18 and DLD-1 cell lines have IC50 values of
3.1 and 2.9mM and also exhibit IkBoc degradation at 3mM. Hence, there is a close
relationship between IC50 values and IkBcc degradation for the individual colorectal
cancer cell lines.
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In order for the NFkB pathway to be activated, NFkB must translocate to the nucleus
following degradation of IkBcc. The effect of aspirin on NFkB was studied using
immunofluorescence analysis using an antibody to p65, which is the transcriptionally
active subunit ofNFkB. In untreated colorectal cancer cells, p65 was primarily located in
the cytoplasm as expected (Figure 4.2B, first panel). Following aspirin treatment there
was nuclear accumulation of p65 in the colorectal cancer cells (Figure 4.2B, second
panel). These results show that aspirin-induced apoptosis following IkBcc degradation and
NFkB nuclear translocation is a generic effect in colorectal cancer.
It is imperative to know whether aspirin as a chemopreventive would be effective in all
colorectal cancer given the genetic heterogeneity of the disease. Defects in genes
commonly mutated in colorectal cancer, and known to affect apoptotic pathways, might
influence the ability of aspirin to induce apoptosis. Hence, the colorectal cancer cell lines
were chosen as they harbour differing mutations in genes dysregulated in colorectal
cancer. However, mutation status for APC, P-catenin, p53 and DNA mismatch repair
genes (Table 2.1) does not appear to influence aspirin-induced apoptosis in colorectal
cancer lines, emphasising the relevance of the aspirin NFkB anti-tumour effect to
colorectal cancer in general. The effect of mutations in p53 and mismatch repair on the
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Figure 4.2 Aspirin-induces hcBa degradation and p65 nuclear translocation in
colorectal cancer cell lines. Aspirin (0-1 OmM) induces IkBcx degradation in a
concentration-dependent manner in the colorectal cancer cell lines (A). The Western
blots shown are representative of at least 3 independent experiments and copper zinc
SOD was used as a control for protein loading. Micrographs (63x) of
immunocytochemically stained cells show that aspirin treatment (10mM) induces
nuclear accumulation of p65 in the colorectal cancer cell lines (B).
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4.3.2 Specificity of the aspirin-induced NFkB apoptotic
response
4.3.2.1 Aspirin does not induce apoptosis in non-colorectal
cancer cells
The next aim was to determine whether the aspirin-induced NFkB apoptotic response was
a general anti-tumour effect that was occurring irrespective of cancer type. Hence, the
effect of aspirin on the growth of a panel of colorectal cancer cell lines was compared to
cell lines derived from other cancer types: breast (MCF-7, MDA-MB-231, T47D),
ovarian (A2780), and endometrial (HEC-l-A). The non-colorectal cancer cell lines were
chosen based on epidemiological data where there is some evidence to suggest a
protective effect in breast cancer and less so in ovarian and endometrial cancer.
The panel of non-colorectal cancer cell lines was treated for 24 hours with aspirin at
concentrations of 1, 3, 5 and 10 mM and viable cell number determined by
haemocytometric counts. In contrast to the colorectal cancer cell lines, there was no
demonstrable effect of aspirin on the viability of the non-colorectal cancer cell lines
MCF-7, MDA-MB-231, A2780 and HEC-l-A (Figure 4.3A). Furthermore, there was no
concentration-dependent increase in apoptosis in the non-colorectal cancer cell lines
following aspirin treatment, which was consistent with the lack of effect on cell viability
(Figure 4.3B). Interestingly, although the T47D breast cancer cells did exhibit a
concentration-dependent reduction in cell viability, this effect was not as pronounced as
that seen in colorectal cancer cells at low aspirin concentrations and furthermore, there
was no increase in apoptosis in this cell line. This suggests that T47D may be susceptible
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to aspirin in terms of cell viability but it is not due to the same mechanisms, including
apoptosis.
To confirm that the non-colorectal cancer cells were less sensitive to apoptosis, three non-
colorectal cancer cell lines (two breast and one ovarian) and one colorectal cancer cell
line (SW480) were treated with aspirin for a longer time period of 72 hours. Indeed, the
non-colorectal cancer cell lines were far less susceptible to apoptosis compared to the
colorectal cancer cell line despite treatment with aspirin for 72 h (Figure 4.3C). These
findings demonstrate that the anti-tumour activity of aspirin has a substantial degree of
specificity for colorectal cancer cells in vitro, reflecting the epidemiological evidence for
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Figure 4.3 Aspirin does not induce apoptosis in non-colorectal cancer cell lines.
Aspirin treatment (0-1 OmM) for 24 hours did not consistently affect viable cell number in
the non-colorectal cancer cell lines (A). There was no increase in apoptosis after
exposure for 24 hours (B) and 72 hours in the non-colorectal cancer cell lines (C).
113
4.3.2.2 Aspirin's lack of effects on apoptosis in non-colorectal
cancer cells are paralleled by failure to activate the NFkB
pathway
Variations in cell viability and apoptosis, observed between colorectal cancer and non-
colorectal cancer cell lines, may be attributable to differing responses of the NFkB
pathway to aspirin. Indeed, in contrast to the colorectal cancer lines, which all underwent
concentration-dependent IkBcc degradation, there was no change in IkBoc after aspirin in
any non-colorectal cancer cell line even at the highest dose of lOmM (Figure 4.4A).
Since these findings suggested a cell-type specific NFkB response to aspirin, it was
important to determine if the disparate IkBcc response was paralleled by a differential
effect on NFkB nuclear translocation in the non-colorectal cancer cell lines.
Immunofluorescence analysis showed that p65 was situated in the cytoplasm in untreated
cells; similar to untreated colorectal cancer cells (Figure 4.4B, first panel). However, in
keeping with the observation that there was no IkBcx degradation in the non-colorectal
cancer cells, aspirin treatment did not induce nuclear translocation of p65 in any of these
cell lines (Figure 4.4B, second panel). These data provide evidence of a link between the
NFkB response and apoptosis following aspirin exposure. The results establish that the
disparity in viability following exposure to aspirin in colorectal cancer cell lines
compared to lines derived from other cancer types is associated with markedly differing
responses of the NFkB pathway to aspirin. This work suggests that the effect of aspirin on


























Figure 4.4 Aspirin has no effect on NFkB signalling in non-colorectal cancer cell
lines. Aspirin (0-1 OmM) does not induce kBa degradation in the non-colorectal
cancer cell lines (A). The Western blots shown are representative of at least 3
independent experiments and copper zinc SOD was used as a control for protein
loading. Consistent with the lack of aspirin-induced kBa degradation , there is no
nuclear translocation of p65 upon aspirin treatment, as seen in micrographs (63 x) of
immunocytochemically stained non-colorectal cancer cells (B).
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4.3.2.3 Basal IkBcc and p65 protein levels and aspirin-induced
apoptosis in colorectal cancer cell lines
High basal NFkB activity and aberrant IkBoc expression have been observed in a number
of cancers including colorectal cancer (Rayet and Gelinas, 1999). In view of the findings
of a cell-type specific NFkB and death response to aspirin, the basal levels of IkBcc and
p65 were examined to investigate whether they might determine increased sensitivity to
apoptosis, and so could be potential molecular markers of response. Immunoblot analysis
of cytoplasmic extracts was used to examine basal levels of IkBo. and p65 in both the
colorectal cancer and non-colorectal cancer cell lines (Figure 4.5). There was no
detectable difference in expression of IkBcc or p65 or their relative levels (analysed by
densitometry) between colorectal and non- colorectal cancer cells that could account for
increased sensitivity to apoptosis. These results suggest that sensitivity to aspirin-induced
apoptosis is not related to the cytoplasmic pool of either protein available for stimulation.
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Figure 4.5 Basal levels of cytoplasmic IkBcx and p65 proteins in cancer cell lines.
Cytoplasmic extracts made from untreated cells & Western blots probed with kBa and
p65 antibody in colorectal cancer cell lines (A) and non-colorectal cancer cell lines (B).
The western blots shown are representative of at least 3 independent experiments and
copper zinc SOD was used as a control for protein loading.
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4.3.2.4 Aspirin induces kBa degradation in explants of HT-29
xenografts
To further investigate the specificity of the aspirin response, HT-29 tumour xenografts
and other organs including breast, lung, liver, pancreas, spleen, small and large intestine
were harvested from mice. The tumour xenograft and organs were maintained ex vivo as
short-term explants. The explants were washed in PBS, finely sliced, and incubated for 5
hours in DMEM medium containing carrier control or aspirin, at doses sufficient to
expose the bulk of the explant to therapeutic levels. Following 5 hours treatment with
aspirin, the tissue fragments were homogenized in lysis buffer, after which protein
extraction and Western blotting were performed. The Western blots show that aspirin
induces IkBoc degradation primarily in the HT-29 tumour xenograft and to a lesser extent
in normal colon and pancreas (Figure 4.6), supporting the notion that the effects of aspirin
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Figure 4.6 Aspirin induces IkBcx degradation in explants of HT-29 xenografts.
HT-29 xenografts and control organs (breast, lung, liver, pancreas, small and large
intestine, and spleen) were harvested from mice and incubated for 5 hours in DMEM
medium containing 10 mM aspirin or carrier control. Western blots of cytoplasmic protein
demonstrate kBa degradation following treatment in the HT-29 tumour xenograft and to
a lesser extent in normal colon and pancreas.
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4.4 Discussion
The work presented here confirms the importance of the NFkB pathway as a key target
for the anti-tumour activity of NSAIDs, and establishes that the effect is generic in
colorectal cancer. This is relevant to colorectal cancer chemoprevention aimed at the
population at large, which would encompass colorectal cancer of varying genetic
backgrounds. In addition, the data demonstrate a striking difference in the response to
aspirin, with respect to both cell viability and NFkB signalling, between colorectal cancer
cell lines and lines derived from other cancer types. These results show that aspirin-
induced apoptosis, associated with IkBci degradation and NFkB nuclear translocation,
was restricted to colorectal cancer cells. This relationship between aspirin-induced
apoptosis and the effect on NFkB signalling suggests a molecular rationale for the
particular sensitivity of colorectal cancer to NSAIDs compared to other cancers.
There is little data directly comparing the anti-tumour effects ofNSAIDs in vitro between
colorectal cancer cells and cancer cells of different tissue origin. A recent study has
demonstrated a tissue type-independent effect in prostate, lung, colon, tongue and
pancreatic cancer using nitric oxide-donating NSAIDs and although treatment with
conventional NSAIDs did have a growth inhibitory effect, it was observed at
concentrations in excess of the pharmacologically relevant range after 48 hours of
treatment (Kashfi et al., 2002). The data presented in this chapter establish that aspirin
has a considerable degree of specificity of apoptotic effect for colorectal cancer cells
compared to other cell lines studied, and this reflects the epidemiological observations in
the respective tumours. Aspirin induces apoptosis in a panel of colorectal cancer cell lines
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but has no effect on viability and apoptosis in cancer cell lines of non-colonic origin.
These results contrast with some previous reports of NSAID-induced growth inhibition
and apoptosis in breast and endometrial cancer cells (Noguchi et al., 1995; Planchon et
al., 1995; Han et al., 1998; Arango et al., 2001), but these differences are reconciled by
considering that the majority of these studies used NSAIDs other than aspirin (Noguchi et
al., 1995; Planchon et al., 1995; Han et al., 1998), whilst others only observed apoptosis
after long exposures (48-96 hours) to high concentrations of salicylate (Sotiriou et al.,
1999; Arango et al., 2001). The observation that aspirin decreased cell viability in one of
the three breast cancer lines (T47D) is consistent with epidemiological data that suggest a
lesser protective effect of NSAIDs against breast cancer. These results clearly indicate
important differences between colorectal cancer and other cancer types with respect to
aspirin effects on cell viability and apoptosis.
The work here shows that aspirin-induced apoptosis occurs following IkBcc degradation
and NFkB nuclear translocation, and that this effect is common to all colorectal cancer
cell lines studied. Notably, this effect on the NFkB pathway was consistent between
colorectal cancer cell lines despite heterogeneity of the lines, with respect to the profile of
mutations in APC, P-catenin, p53 and DNA mismatch repair genes (Table 2.1). In
contrast, aspirin treatment did not induce IkBcc degradation or NFkB nuclear
translocation in any cell lines derived from cancers of other tissue types, paralleling the
lack of consistent changes in cell viability and apoptosis in these lines. It was previously
established that the observed effect of aspirin on IkBoc and p65 is a cause of rather than a
consequence of apoptosis, based on the findings that the IkBcc degradation was signal-
specific and that nuclear translocation of NFkB and apoptosis were blocked by a
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dominant negative super-repressor IkBoc (Stark et al., 2001b). Hence, the weight of
evidence presented here correlating IkBcc degradation and p65 nuclear translocation with
apoptosis compared to the lack of response in non-colorectal cancer cell lines provides
considerable further support for a causal role of the NFkB response as an important
component of aspirin-induced apoptosis.
Having shown a striking difference between the colorectal cancer and non-colorectal
cancer cell lines, with respect to aspirin effects on NFkB signalling and apoptosis,
potential factors that might contribute to the ability of specific cell types to undergo
apoptosis were investigated. Increased NFkB activity has been observed in colorectal
cancer (Hardwick et al., 2001) and relative resistance to apoptosis has been attributed to
high constitutive NFkB activity in other cancers (Bours et al., 1994; Charalambous et al.,
2003; Lind et al., 2001). However, there was no evidence that the specificity of the
aspirin-NFKB response is related to differential expression of basal IkBoc or p65 proteins
or their relative expression. The SW480 and HT-29 colorectal cancer cell lines undergo
NFKB-mediated apoptosis, despite the considerable difference in basal NFkB activity
previously reported between these cell lines (Dejardin et al., 1999).
Aspirin concentrations used here are relevant to pharmacological levels in clinical
practice (l-3mM) (Insel P, 1996). Nonetheless, comparisons between cell culture
concentrations and serum levels are somewhat artificial because of the inability to
accurately mimic in vivo metabolism and tissue concentration of the agent in epithelial or
tumour cells. Decreased basal levels of apoptosis and hyperproliferative mucosa have
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been observed in patients with adenomas, suggesting the existence of a 'field defect' in
the colonic mucosa (Anti et al., 2001). Although proportionally less apoptosis was
observed at lower concentrations of aspirin, there is evidence that low levels of apoptosis
translate into significant tumour regression over time in cell kinetics studies (Pritchard
and Watson, 1996). It remains to be determined whether aspirin redresses the balance by
inducing apoptosis de novo in newly transformed colorectal epithelial cells destined to
become malignant clones. There is evidence of NFkB involvement in colonic crypt
differentiation and cell turnover in mouse colon, where NFkB activity is greater in
proliferating cells at the base of crypts compared to mature cells at the surface (Inan et al.,
2000). Thus, it is also possible that the drug corrects deranged mechanisms that permit
escape from normal cellular turnover and apoptosis.
In summary, the data presented here demonstrate that there are substantial differences in
the anti-tumour effects of aspirin and modulation of NFkB signalling between cancer
cells of different tissue origin. The molecular basis of NSAID anti-tumour activity is
complex, and these findings provide further evidence that the effects of aspirin on NFkB
signalling have particular relevance to colorectal cancer chemoprevention.
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Chapter 5
Investigation of molecular determinants of
NFkB response to aspirin
5.1 Introduction
Epidemiological data demonstrate a 40-50% reduction in relative risk of developing
colorectal cancer in NSAID users, indicating that there may be subsets of people who are
not protected by NSAID ingestion, and hence may not respond to chemopreventive
measures. Clearly, successful chemoprevention strategies would need to target those who
are most susceptible to the disease and those who would respond to such agents in order
to improve the risk benefit ratio. The work described in Chapter 4 establishes the relative
specificity for colorectal cancer of aspirin-induced apoptosis following IkBo, degradation
and nuclear translocation of NFkB. Elucidation of the molecular basis underlying the
specificity of aspirin-induced NFkB apoptotic response may shed further light on the
mechanism of action. Furthermore, it might be possible to identify potential molecular
markers that may predict both response to therapy and prognosis. Such molecular markers
may be related to heritable predisposition, environmental modifiers, defined somatic
genetic alterations or indeed to the mechanism of action of the agent. In this chapter,
cyclooxygenase-2 (COX-2) and (3-catenin proteins are investigated as potential markers
of specificity and response, as both are known to be dysregulated in colorectal cancer and
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to interact with the NFkB signalling pathway, and have been suggested as potential
molecular targets.
5.1.1 COX-2 and colorectal cancer
There has been considerable debate regarding the role of COX-2 and protection imparted
by NSAIDs in colorectal cancer. The analgesic, anti-pyretic, anti-inflammatory and anti¬
platelet effects of NSAIDs are attributable to inhibition of the cyclooxygenase enzymes
(Vane, 1971). The COX enzymes catalyse the rate-limiting step of prostaglandin
synthesis, involving conversion of arachidonic acid to the precursor prostaglandin H2,
which is then converted into other prostaglandins by prostaglandin synthases. There are
two isoforms of the COX enzymes and recently a third has been proposed, putatively
responsible for the anti-inflammatory effects of paracetamol (Willoughby et al., 2000;
Chandrasekharan et al., 2002). Cyclooxygenase-1 (COX-1) is constitutively expressed in
most cells under physiological conditions (Seibert et al., 1997) and regulates basal
turnover of prostaglandins involved in platelet aggregation, mucosal protection and renal
blood flow regulation.
COX-2 is the inducible form of the enzyme, which is not expressed under normal
conditions but is induced by a variety of stimuli, including growth factors, mitogens and
cytokines (Williams et al., 1999). COX-2 is not expressed by normal colonic mucosa and
is upregulated in colorectal adenomas and cancers (Eberhart et al., 1994; Chappie et al.,
2000). COX-2 is detectable in polyps as small as 2 mm (Oshima et al., 1996), indicating
that COX-2 expression occurs after other initiating events such as mutations in genes
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disrupted early in the adenoma-carcinoma sequence (Williams et al., 1997). The anti-
tumour function of COX-2 was further investigated when Min mice with Ape gene
mutations (Ape A716) were bred with COX-2 null mice (Oshima et al., 1996). COX-2 gene
disruption reduced the number and size of the intestinal polyps in the homozygous COX-
2 null offspring, indicating a role for COX-2 in colorectal cancer development. Several
mechanisms have been suggested by which increased COX-2 expression may initiate and
promote tumour growth including carcinogen activation, promotion of cellular
proliferation and angiogenesis (Williams et al., 1997), and these are discussed in more
detail in Section 1.2.3. COX-2 inhibition has been shown to play a role in aspirin-
mediated cell death and may be involved in the anti-tumour activity ofNSAIDs (Boolbol
et al., 1996). However, there is a growing body of evidence, which indicates that COX-2
is not the predominant target responsible for the anti-tumour activity of NSAIDs (as
discussed in Section 1.2.3.3).
5.1.2 Role of Wnt signalling in colorectal cancer
Inactivating mutation ofAPC (Nakamura et al., 1991) or AXIN2 (Liu et al., 2000), or by
activating mutation of P-catenin is almost universal in colorectal cancer (Sparks et al.,
1998), and results in increased nuclear P-catenin which drives Tcf/Lef-mediated
transcription promoting tumorigenesis (Korinek et al., 1997). P-catenin acts as a
transcriptional activator of growth promoting genes such as cyclin Dl, c-myc and PPAR8
(Mann et al., 1999) and survivin (Kim et al., 2003). Aspirin been shown to increase
apoptosis and decrease P-catenin in polyps in Min mice (Mahmoud et al., 1998b).
Sulindac sulfone has been shown to induce apoptosis and decrease P-catenin levels
(Thompson et al., 2000), and increase APC mRNA expression in rats with chemically-
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induced tumours (Kishimoto et al., 2000). Indomethacin has been shown to decrease
nuclear P-catenin in colorectal cancer cell lines (Smith et al., 2000). It has been reported
that NSAIDs might act by decreasing transcription of P-catenin/Tcf responsive genes
(Dihlmann et al., 2001). Furthermore, it is of interest to note that the P-catenin gene
(■CTNNB1) contains a potential binding site for NFkB and that IkBcc and P-catenin
undergo degradation by the same ubiquitin-mediated pathway (Winston et al., 1999).
Recently, P-catenin has been shown to form a complex with NFkB, resulting in a
reduction of NFkB DNA binding, transactivation activity, and target gene expression in
colon and breast tumour tissues (Deng et al., 2002). Thus, p-catenin may be involved in
transcriptional cross regulation ofNFkB.
The aim of this work was to determine any parallels in levels of expression of COX-2 or
P-catenin in colorectal cancer and aspirin-induced apoptosis mediated by modulation of
NFkB signalling, and hence might provide supporting evidence of the specificity of the
effect for colorectal cancer. Basal expression levels of COX-2 and P-catenin proteins
were compared between colorectal cancer cell lines that undergo aspirin-induced IkBcc
degradation, NFkB nuclear translocation and apoptosis and the non-colorectal cancer cell
lines that do not respond to aspirin (Chapter 4). Identification of molecular markers of
response would lend insight not only to the mechanism of action but towards targeted
therapy.
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5.2 Overview of methods
Protein extracts were made from the untreated colorectal cancer and non-colorectal cancer
cell lines studied in Chapter 4 as described in Section 2.6.1 and proteins electrophoresed
as described in Section 2.7. The COX-2 expression status of some of the cell lines has
been established previously and is shown in Table 5.1. The Western blots were then
probed with antibodies to COX-2 and [3-catenin to determine relative basal expression
levels. Copper zinc SOD antibody was used as a loading control. Protein levels were
quantified using densitometry and expressed as a ratio of either COX-2 or (3-catenin to
Cu/Zn SOD. The levels of protein expression were then correlated with IC50 values of
aspirin to investigate whether there was a relationship between the expression of these
proteins and susceptibility to aspirin-induced apoptosis via IkBcc degradation and NFkB
nuclear translocation.
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Table 5.2 APC and p-catenin mutation status of cell lines


























5.3.1 Basal COX-2 protein levels do not parallel the NFkB
response to aspirin
COX-2 expression might explain the heterogeneity of the aspirin response between the
colorectal cancer and non-colorectal cancer cell lines. Immunoblot analysis of
cytoplasmic proteins demonstrated considerable variation in basal levels of COX-2
between the colorectal cancer cell lines (Figure 5.1A). For example, SW480, FICT-116,
FIT-29 and LoVo cell lines differ considerably in COX-2 expression (Table 5.1) and yet
all underwent IkBcc degradation and apoptosis following aspirin treatment (Chapter 4).
Similarly there was variability of COX-2 levels between the colorectal cancer lines and
the non-colorectal cancer lines (Figure 5.IB). In addition, there was no demonstrable
association between level of COX-2 expression and IC50 values. Thus, there was no
relationship between basal levels of COX-2 expression and sensitivity to aspirin-induced
apoptosis. This provides further support for the notion that COX-independent
mechanisms play an important role in the anti-tumour effect ofNSAIDs.
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Figure 5.1 Basal COX-2 expression in cancer cell lines.
Cytoplasmic extracts made from untreated cells and Western blots probed with COX-2
antibody in colorectal cancer cell lines (A) and non-colorectal cancer cell lines (B). The
COX-2 standard supplied with the antibody indicates the appropriate band. The Western
blots shown are representative of at least 3 independent experiments and actin was
used as a control for protein loading.
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5.3.2 NFkB apoptotic response to aspirin is independent
of basal p-catenin expression
The APC and P-catenin mutation status of the colorectal and the non-colorectal cancer
cell lines studied in Chapter 4 is outlined in Table 5.2. The mutation status of the
colorectal cancer cell lines that respond and those that do not, non-colorectal cancer cell
lines, suggest that the anti-tumour effects of aspirin are independent of the type of
mutation responsible for increased expression of P-catenin. Next, the relationship
between P-catenin and response to aspirin was investigated by immunoblot analysis
(Figure 5.2). Within the cell line panels, three colorectal (DTD-1, LoVo, FICT-116) and
one non-colorectal (T47D) cancer cell lines expressed relatively higher levels of p-catenin
protein. The variable expression of basal P-catenin within both the colorectal and non-
colorectal cancer cell lines strongly suggests that P-catenin protein expression itself is not
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Figure 5.2 Basal (i-catenin expression in cancer cell lines.
Cytoplasmic extracts made from untreated cells & Western blots probed with (3-catenin
antibody in colorectal cancer cell lines (A) and non-colorectal cancer cell lines (B). The
Western blots shown are representative of at least 3 independent experiments and
copper zinc SOD was used as a control for protein loading.
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5.4 Discussion
Epidemiological data clearly indicate that the anti-tumour effect of aspirin appears to be
greater in colorectal cancer compared to cancers from other tissue types. There has been
little work thus far investigating the molecular nature of the specificity of this effect. The
work presented in Chapter 4 shows that aspirin-mediated apoptosis via IkBcc degradation
and nuclear translocation of NFkB occurs in colorectal cancer cell lines but not in cancer
cell lines of non-colonic origin (Din et al., 2004). The mechanism of action involving
apoptosis following modulation of NFkB signalling appears to be relatively specific for
colorectal cancer. However, the basal levels of p65 and IkBci proteins do not appear to be
conferring increased susceptibility to aspirin-mediated apoptosis (Chapter 4). It is
important to investigate the molecular basis of this relative specificity, as it would shed
further light on the mechanism of action and may lead to identification of biomarkers that
predict resistance to chemopreventive agents.
A recent study examined adenomas that develop in FAP patients whilst on treatment with
sulindac in order to identify molecular alterations that may be related to resistance to
sulindac (Keller et al., 2001). Immunohistochemical analysis revealed no differences in
p53, Bcl-2 and loss of heterozygosity at the APC locus between adenomas that were
responsive, and those that did not respond to sulindac. However, adenomas resistant to
sulindac displayed less loss of membranous P-catenin and less nuclear accumulation of p-
catenin. There was no change in stromal COX-2 expression but there was less epithelial
COX-2 expression compared to adenomas removed prior to sulindac treatment. The
authors concluded that their findings may be due to COX-2 and P-catenin being related to
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the underlying mechanism of NSAID action or may indicate the genotype of resistant
adenomas. However, since NSAIDs have been shown to decrease both COX-2 and |3-
catenin in vitro and in vivo, it is not possible to conclude that these differences are the
cause of sulindac resistance as they may be due to the treatment itself.
There is substantial rationale for investigating COX-2 as a potential molecular
determinant of response, in view of its role in colorectal cancer development and as a
pharmacological target for NSAIDs. Additionally, the promoter region of the human
COX-2 gene has NFkB consensus sites (Appleby et al., 1994), and NFkB has been shown
to regulate COX-2 gene transcription (Schmedtje, Jr. et al., 1997). Recent evidence
indicates that COX-2 activity and resultant production of prostaglandins can function both
as positive as well as negative regulators of NFkB (Poligone and Baldwin, 2001)
suggesting a degree of cross-regulation between COX-2 and NFkB.
With respect to specificity, COX-2 expression is more common in 69% of endometrial
cancers and 89% of ovarian serous cystadenocarcinomas compared with normal tissue
(Landen, Jr. et al., 2003). Additionally, it has been reported that the inconclusive nature
of an NSAID effect in epidemiological data in breast cancer might be related to the
observation that only a subset of breast cancers express COX-2 (Howe et al., 2001b). In
the work presented here, there was no relationship between COX-2 protein levels and
apoptotic response to aspirin in any cell type. Furthermore, there was considerable
variation in COX-2 expression within the colorectal cancer cell lines, which were all
susceptible to aspirin-induced apoptosis. Expression of COX-2 is regulated at several
levels including transcriptional and post-transcriptional regulation via stabilisation of
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COX-2 mRNA and COX-2 degradation (Shao et al., 2000b). Both the SW480 and HT-29
colorectal cancer cell lines undergo NFKB-mediated apoptosis, despite striking
differences COX-2 mRNA and protein expression between these cell lines (Table 5.1).
The magnitude of the apoptotic response in the colorectal cancer cell lines did not
correlate with the levels of COX-2 expression. This work contributes to the mounting
persuasive evidence that COX-2-independent as well as COX-2-dependent mechanisms
play a role in the anti-tumour effects ofNSAIDs (Rigas and Shiff, 2000).
In view of the well-characterised dysregulation of Writ signalling in colorectal cancer
compared to other cancers, P-catenin was investigated as a potential molecular
determinant of response to aspirin. The colorectal cancer cell lines studied here have
known APC or P-catenin mutations (Table 5.2) and it can be observed that aspirin-
mediated apoptosis occurs irrespective of the type of mutation responsible for the
upregulation of P-catenin. The differing expression of basal P-catenin within both the
colorectal and non-colorectal cancer cell lines indicates that P-catenin protein expression
itself does not govern sensitivity to aspirin-induced apoptosis via NFkB nuclear
translocation. These results indicate that aspirin-induced apoptosis secondary to IkBoc
degradation and NFkB nuclear translocation occur irrespective of early mutational events
in colorectal cancer.
Although investigation of COX-2 and P-catenin, in the context of the cell lines studied,
has not identified either as potential molecular determinant of the NFkB apoptotic
response to aspirin; these results are nonetheless relevant to NSAID-mediated
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chemoprevention. Chemoprevention is highly relevant those with a hereditary
predisposition to colorectal cancer where the risk benefit ratio of any chemopreventive
agent would be reduced. Patients with FAP have mutations of the tumour suppressor gene
APC increasing their risk of colorectal cancer and such mutations also occur in 85% of
patients with sporadic colorectal cancers (Powell et al., 1992). Mutations in APC result in
increased levels of nuclear (3 catenin, which drives transcription of growth promoting
genes. NSAIDs have been shown to induce apoptosis both in murine models of FAP
(Boolbol et al., 1996; Mahmoud et al., 1998b) and in patients with FAP (Pasricha et al.,
1995; Keller et al., 1999;Stoner et al., 1999).
In addition to investigation of candidate molecular markers of response to aspirin,
strategies aimed at systematic identification of putative molecular markers should be
undertaken. In this respect, a bioinformatics-based approach to identify differential
expression of genes in colorectal cancer compared to other cancers, especially where
there is little evidence of a chemopreventive effect of NSAIDs, may be useful. These
candidate molecular markers may then be investigated further with respect to interactions
with the NFkB signalling pathway to provide mechanistic insight.
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Chapter 6
Influence of mismatch repair and p53
signalling on NFkB response to aspirin
6.1 Introduction
Research efforts are focussed at both the clinical level to determine dose and duration of
usage and also the molecular level, to fully delineate the mechanisms involved in NSAID
anti-tumour activity and to inform novel drug design. It is also important to determine
whether there are subsets of colorectal cancers that are more or less susceptible to
NSAID-mediated chemoprevention, as this will add insight at a mechanistic level and for
rational development of clinical trials.
The work in Chapter 3 showed that NFkB plays a pivotal role in aspirin-mediated
apoptosis in colorectal cancer cells (Stark et al., 2001b). NFkB has been shown to have
both pro- and anti-apoptotic effects (Barkett and Gilmore, 1999). Such disparate effects
are due to differences in stimuli, NFkB composition, cell-type and distinct kB binding
specificities of individual complexes resulting in diverse target gene specificity (Epinat
and Gilmore, 1999). The relative specificity of this NFkB-dependent effect for colorectal
cancer compared to other cancer cell types was described in Chapter 4 (Din et al., 2004).
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However, it is also important to determine whether there is heterogeneity within
colorectal cancer with respect to the NFicB-dependent apoptotic response.
It is well established that genomic instability, by increasing mutational load, promotes
neoplastic progression in colorectal cancer. The p53 tumour suppressor gene is involved
in cell cycle control, apoptosis and maintenance of genomic stability and is frequently
somatically mutated in colorectal tumours, heralding malignant transformation (Baker et
al., 1989; Baker et al., 1990; Honma et al., 2000). Another important contributor to
genomic instability is defective DNA MMR resulting in microsatellite instability (MSI)
(Veigl et al., 1998). MSI is the hallmark of tumours arising in HNPCC and is also found
in 15% of sporadic colorectal cancers (Boland et al., 1998; Brown et al., 1998). The
majority of MSI tumours are due to germline mutations in hMLHl, hMLH2 and I1MSH6
genes in familial cases, and due to hMLHl promoter hypermethylation in sporadic
cancers (Kuismanen et al., 2000). The result of such defects is rapid accumulation of
mutations in growth-regulatory genes such as BAX, TCF4, and TGF/3RII contributing to
accelerated tumorigenesis (Peltomaki, 2001). Although an increased rate of p53 mutations
would be expected, there is in fact an inverse relationship between p53 mutations and
severity ofmicrosatellite instability (Cottu et al., 1996; Samowitz et al., 2001).
There is considerable rationale for studying the effect of p53 and MMR on the aspirin
NFkB response. Firstly, it is important to define the generality of the response with
respect to p53 and to elucidate its effectiveness in terms of late mutational events in
colorectal cancer. Secondly, the influence of MMR on the NFkB response should be
investigated given that clinical trials of polyp prevention using aspirin in HNPCC carriers
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are already underway (CAPP-2, 2005). There is evidence that p53 signalling and DNA
MMR are molecular targets for NSAIDs (Ruschoff et al., 1998; Shao et al., 2000a; Goel
et al., 2003), suggesting that the anti-tumour effect may, in part, involve countering the
effects of genetic instability in colorectal cancer. In addition, there is evidence of
interaction between p53 and NFkB (Wu and Lozano, 1994) through regulatory
interdependence involving competition for common co-activators (Webster and Perkins,
1999). Genetic aberrations in tumours have also been shown to be involved in
determining response to chemotherapeutic agents (O'Connor et al., 1997; Weller, 1998;
Ribic et al., 2003).
In light of the importance of p53 and MMR in colorectal cancer and given that genomic
instability can influence response to chemotherapeutics, it is highly relevant to determine
the p53 and hMLHl dependency of the effects of aspirin on NFkB signalling.
140
6.2 Overview of methods
An HCT-116 colorectal cancer cell line model was used to definitively address the role of
p53 and MMR status in the NFicB-dependent apoptotic response to aspirin (Table 6.1).
Table 6.1 HCT-116 cell line characteristics
Colorectal cancer cell line MMR mutation status p53 function
HCT-116 hMLH1 deficient wild-type
HCT-116+ch3 hMLH1 proficient wild-type
HCT-116p53_/" hMLH1 deficient p53 null
The HCT-116 cell line has a homozygous mutation in hMLHl resulting in a truncated,
non-functional protein (Boyer et al., 1995). The HCT-116 sub-line where hMLHl
expression is restored by chromosome 3 transfer (HCT-116+ch3) is competent in DNA
MMR (Koi et al., 1994). The p53 null HCT-116 sub-line (HCT-116 p53"A) was created by
targeted homologous recombination (Bunz et al., 1999). All three cell lines were
maintained and treated with aspirin (1,3,5 and lOmM) or carrier control (at same
concentrations as aspirin) as described in Sections 2.2 and 2.3. After aspirin treatment,
cell viability and apoptosis were assessed by haematocytometric counting and annexin V
assays described in Sections 2.4 and 2.5. Cytoplasmic protein extracts were made
(Section 2.6.1.1) and Western blotting was used to determine cytoplasmic IkBoi (Section
2.7). NFkB nuclear translocation was studied using immunocytochemistry (Section 2.9).
For transfection experiments, cell lines were transiently transfected with the 3enhancer-
ConA NFicB-dependent luciferase reporter construct in which transcription of the firefly




6.3.1 p53 and hMLH1 expression and basal expression
of IkBgc and p65 proteins in colorectal cancer cell lines
The best model to specifically address whether p53 and hMLHl influence the aspirin-
induced NFkB apoptotic response is by using HCT-116 colorectal cancer cell lines that
differ with respect to the specific genetic change under investigation. The protein levels
of p53 and hMLHl were determined in each cell line. This confirmed that hMLHl was
not expressed in the parental HCT-116 cell line but was expressed in the HCT-116 +ch3
cell line (Figure 6.1A). As expected there was no p53 protein detected in the HCT-116
p53_/" cell line, but p53 was expressed in the parental HCT-116 cell line which has wild-
type p53 (Figure 6.1 A). It was first important to consider whether p53 and hMLHl
mutation status might affect basal levels of IkBcx and p65 proteins. Immunoblot analysis
of untreated cytoplasmic extracts demonstrated that basal expression of IkBoc and p65
was similar in each HCT-116 cell line genotype (Figure 6.IB). These results indicate that
changes in MMR mutation status and p53 expression do not affect the cytoplasmic pool
of IkBcc or p65 proteins. Basal levels ofNFkB DNA binding were examined to determine
whether constitutive NFkB DNA binding is affected by changes in p53 or MMR status.
EMSAs performed on nuclear extracts of untreated cells showed basal NFkB DNA
binding in the three colorectal cancer cell lines (Figure 6.1 C). The differences in basal
NFkB DNA complexes in the HCT-116 +ch3 and HCT-116 p53~''~ cell lines compared to the











































Figure 6.1 Basal expression of p53, hMLH1, IxBa & p65 in untreated HCT-116 cell
lines. Cytoplasmic extracts made from untreated cells & Western blots probed with p53 &
hMLH1 antibodies to confirm expression profile (A). Cytoplasmic extracts were probed
with IkBcx & p65 antibodies to examine basal expression (B). The Western blots shown
are representative of at least 3 independent experiments and copper zinc SOD was used
as a loading control. EMSA using NFkB consensus oligonucleotide demonstrated basal
NFkB DNA binding in nuclear extracts(C).
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6.3.2 Aspirin induces apoptosis in colorectal cancer cell
lines independent of p53 and MMR status
To determine the p53 and MMR dependence of the effects of aspirin on cell viability, the
HCT-116 +ch3 (wild-type p53 and hMLHl proficient) and HCT-116 p53~'~ (p53 null and
hMLHl deficient) cell lines were compared to the parental HCT-116 (wild-type p53 and
hMLHl deficient) colorectal cancer cell line. In triplicate dose-response experiments, all
colorectal cancer cell lines were treated for 16 hours with aspirin (1, 3, 5 and 10 mM) and
viable cell number determined by haemocytometric counts. Aspirin treatment resulted in
a concentration-dependent decrease in the number of viable cells in all three colorectal
cancer cell lines (Figure 6.2A). Furthermore, the cell lines showed proportionate
decreases in cell viability at each concentration increment, indicating a similar pattern of
response to aspirin, irrespective of p53 or MMR status (Figure 6.2B). The IC50 values
were calculated from the growth curves of the aspirin-treated colorectal cancer cell lines
(Table 6.2), and there were no significant differences in levels of cell death between cell
line genotypes (Student's t-test).
Table 6.2 IC50 values for colorectal cancer cell lines
Fold increase apoptosis
CRC cell line IC50
3mM aspirin 5 mM aspirin
HCT-116 2.8 +/-0.26 2.3 3.1
HCT-116+ch3 3.1 +/- 1.6 2.4 2.6
HCT-116p53"'" 4.3+/-0.82 1.5 1.8
144
It was next confirmed that the reduction in viable cell number in each of the cell lines was
indeed due to apoptosis for all three genotypes, and not simply a growth inhibitory effect.
Following aspirin treatment, cells were stained with Annexin V, which binds
phosphatidylserine residues that are externalised during apoptosis and thus serves as a
marker for programmed cell death. Consistent with the reduction in cell viability, aspirin
induced a concentration-dependent increase in the proportion of apoptotic cells in all
three colorectal cancer cell lines (Figure 6.2C). There was no significant difference in
apoptotic response between any of the HCT-116, HCT-116 TCh3 and HCT-116 p53"/" cell
lines. These data suggest that aspirin induces apoptosis in colorectal cancer cells and that
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HCT-116 HCT-116+ch3 HCT-116 p53"7"
Figure 6.2 Effect of aspirin on cell viability and apoptosis in HCT-116 cell lines.
Aspirin treatment (0-1 OmM) induces a concentration-dependant decrease in viable cell
number in all cell lines (A). The decrease in cell viability is proportionate at each
concentration increment indicating a similar pattern of response in each cell line (B).
Annexin V assay used to determine that all cell lines undergo apoptosis after aspirin
treatment (0-5 mM) (C).
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6.3.3 Aspirin induces hcBa degradation and NFkB
nuclear translocation in colorectal cancer irrespective of
MMR and p53 status
Having shown that all three colorectal cancer cell lines undergo aspirin-induced apoptosis
irrespective ofMMR and p53 status, the effect of aspirin on NFkB signalling was studied
in each cell line. The previous work (Chapter 3 & 4) showed that aspirin induces IkBoc
degradation, permitting NFkB to migrate to the nucleus and that the NFkB nuclear
translocation was essential for aspirin-induced apoptosis. Aspirin treatment induced
equivalent degradation of IkBcc in a concentration-dependent manner in HCT-116, HCT-
116 +ch3 and HCT-116 p53_/" lines (Figure 6.3). Next, it was determined whether aspirin-
induced IkBcc degradation was accompanied by NFkB nuclear translocation in the
colorectal cancer cell lines. Immunofluorescence analysis showed that p65, the
transcriptionally active subunit of NFkB, was predominantly located in the cytoplasm in
all untreated cells (Figure 6.4A). After treatment with aspirin for 16 hours, there was
nuclear accumulation of p65 in all three colorectal cancer cell lines irrespective of p53
and MMR status (Figure 6.4B). These findings show that aspirin-induced apoptosis due to
modulation of the NFkB pathway occurs irrespective of derangements in p53 signalling
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Figure 6.3 Aspirin induces licBa degradation in HCT-116 cell lines. Following aspirin
treatment, cytoplasmic extracts were probed with IkBcx antibody. Western blot analysis
shows that aspirin treatment (0-1 OmM) for 16 hours induces ItcBa degradation in a
concentration-dependent manner in the HCT-116 (A), HCT116+ch3 (B) and HCT-116 p53"/_
(C) colorectal cancer cell lines.
148












Figure 6.4 Aspirin induces nuclear translocation of p65 HCT-116 cell lines.
Micrographs (63 x) of immunocytochemically stained cells show p65 is mainly located
in the cytoplasm in untreated cells (A). Aspirin treatment (10mM) for 16 hours induces
nuclear accumulation of p65 in the HCT-116, HCT116+ch3 and HCT-116 p53 / CRC cell
lines. DAPI staining indicates the position of the nucleus.
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6.3.4 Aspirin-mediated repression of NFkB driven
reporter activity is unrelated to MMR and p53 status
Paradoxical to the understanding of the classical NFkB pathway, aspirin-induced nuclear
translocation of NFkB has been shown to repress NFkB transcriptional activity in
colorectal cancer cell lines (Stark et al., 2000). This work showed that aspirin-induced
NFkB nuclear translocation and repression of NFKB-driven transcription, and that this
was not a generic inhibitory effect on signalling pathways or transcriptional machinery
itself. Studies of the kinetics of the response demonstrated that IkBcc degradation and
NFkB nuclear translocation precede repression of NFKB-driven transcription, indicating a
causal relationship. Furthermore, inhibition of NFkB nuclear translocation by super-
repressor IkBcc inhibited aspirin-mediated repression of NFkB transcriptional activity.
This observation is further supported by the finding that NFkB induced by some
cytotoxic stimuli acts as an active repressor of anti-apoptotic genes (Campbell et al.,
2004).
Hence, the effect of aspirin on NFKB-driven transcription was investigated to determine
whether p53 or MMR mutation status affect the ability of aspirin to induce NFkB
transcriptional repression in colorectal cancer cells. The cell lines were transiently
transfected with the 3enhancer-ConA NFKB-dependent luciferase reporter construct in
which transcription of the firefly luciferase gene is driven by 3 kB binding sites (Roff et
al., 1996). A reporter plasmid with deleted kB sites served as control. Following
transfection, cells were exposed to aspirin for 16hrs. There was substantial repression of
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the basal levels ofNFicB-driven reporter activity following aspirin exposure. There was a
concentration-dependent decrease in NFicB-driven reporter activity in each cell line
genotype, irrespective of p53 or MMR status (Figure 6.5). These findings show that p53
and MMR status do not influence aspirin-induced repression of NFkB transcriptional
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HCT-116 HCT 116 +ch3 HCT 116 P53-'-
Figure 6.5 Aspirin induces repression of NFicB-driven transcription in HCT-116 cell
lines. Cells transfected with ConA NFicB-dependent luciferase reporter, containing 3 kB
binding sites (A), or equivalent plasmid with kB consensus sites deleted ConA AkB (B).
All cells co-transfected with control CMV-p-galactosidase plasmid. After 16hrs treatment
aspirin (0-10 mM), luciferase and p-galactosidase assays were performed on cell lysates
and relative luciferase activity calculated.
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6.4 Discussion
This work shows that aspirin causes apoptosis and modulates NFkB signalling in a p53
and MMR independent fashion. Furthermore, these results show that aspirin induces
nuclear translocation of p65 that is associated with repression of kappa-B driven
transcription, again independent of p53 and MMR status. This considerably extends
previous observations that aspirin's effects on NFkB signalling are central to aspirin-
mediated apoptosis in colorectal cancer cells (Stark et al., 2001a; Din et al., 2004).
It is well established that aspirin has a chemopreventive effect in colorectal cancer but the
mechanism of action has not been fully characterised. p53 function and DNA mismatch
repair have been proposed as potential targets responsible for the anti-tumorigenic
properties ofNSAIDs (Ruschoff et al., 1998; Shao et al., 2000a).
The p53 signalling pathway is central to regulating cell growth and death, and
stabilisation of p53 by mutation is a key event occurring late in colorectal tumorigenesis
(Baker et al., 1990). Several studies have shown an association between p53 mutation
status and sensitivity to chemotherapeutic dmgs in colorectal and other cancers
(O'Connor et al., 1997; Weller, 1998). The p53 pathway has been postulated as a potential
target since NSAIDs have been shown to alter levels of p53 (Goldberg et al., 1996; Kralj
et al., 2001). Furthermore, cross-talk has been reported between p53 and NFkB through
competition for common co-activators (Webster and Perkins, 1999). Indeed, wild-type
p53 has been shown to suppress constitutive NFkB activity and lead to apoptosis (Shao et
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al., 2000a), suggesting that tumours expressing wild-type p53 may be more susceptible to
aspirin-induced apoptosis.
Previous data indicated that colorectal cancer cell lines expressing wild-type p53 were not
more sensitive to aspirin-induced apoptosis mediated by NFkB signalling, but there were
differences other than p53 status between the cell lines studied (Din et al., 2004). In this
work, the effects of p53 on the NFicB-induced apoptotic response were specifically
investigated by using HCT-116 cells in which the p53 gene has been homozygously
disrupted by targeted homologous recombination (Bunz et al., 1999). Using this
approach, these findings indicate conclusively that aspirin-induced apoptosis is
independent of p53. Furthermore, p53 does not appear to play a role in aspirin-induced
effects on NFkB signalling or on the repression of NFkB transcriptional activity. These
findings are important in terms of chemoprevention since colorectal cancers with mutant
p53 have been shown to differ in behaviour from those expressing wild-type p53, with
respect to response to chemotherapeutic agents and prognosis (Weller et al., 1998; Bunz
et al., 1999).
Defective DNA mismatch repair is charactersitic of HNPCC and around 15% of all
colorectal cancers also show genetic instability, mainly due to epigenetic silencing of
hMLHl but also due to somatic MMR gene defects (Herman et al., 1998). The DNA
MMR system has been implicated as a potential pathway for modulation that may
contribute to NSAID anti-tumour activity (Ruschoff et al., 1998; Goel et al., 2003). The
results in Chapter 4 suggested that MMR-proficient cells may be more sensitive to
aspirin-induced apoptosis since the MMR-deficient cell lines had greater IC50 values than
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MMR-proficient cell lines. Hence, this work specifically examined whether MMR status
influenced IkBcc degradation-dependent aspirin-induced apoptosis, by comparing the
MMR-deficient HCT-116 cell line to its proficient counterpart HCT-116+ch3. There was a
dose-dependent increase in apoptosis after 16 hours treatment with aspirin that paralleled
IkBci degradation, NFkB nuclear translocation and repression of NFicB-driven
transcription. Indeed the HCT-116 cells have a marginally lower IC50 value and show a
greater fold increase in apoptosis when compared to the MMR-proficient cell line but this
was not significant (Table 6.2). Although there were no significant differences detected in
the aspirin-NFKB apoptotic response attributable to MMR status, long-term in vitro
aspirin exposure has been shown to select for microsatellite stability in colorectal and
gastric cancer cell lines (Ruschoff et al, 1998; Yamamoto et al., 1999a). It has also been
shown that aspirin treatment increased MMR protein expression and apoptosis in
colorectal cancer cell lines (Goel et al., 2003). Despite substantial rationale for study of
the influence of MMR on the aspirin-induced NFkB apoptotic response, there was no
evidence for MMR dependency of these effects, suggesting that the MMR system is not
the predominant pathway responsible for NSAID-mediated anti-tumour activity.
This work consolidates previous findings that aspirin-induced apoptosis occurs after IkBcc
degradation, NFkB nuclear translocation and repression of NFkB driven transcription.
The results presented here shed further light on the complex mechanisms by which
NSAIDs induce cell death in colorectal cancer. Elucidation of the mechanism lies in
defining the relative contribution of putative targets to aspirin's anti-tumour activity.
There was no evidence to suggest the involvement of p53 or DNA mismatch repair on
inducing the NFkB pathway, nor on the ensuing apoptotic response following aspirin.
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Genomic instability due to p53 or MMR dysfunction has been to shown to be associated
with resistance to chemotherapeutic agents. Hence, these findings have relevance to
rational design of novel therapeutics. In addition, since the effects of aspirin on NFkB and
apoptosis occur in cancers arising from different genetic backgrounds, these findings have
clinical relevance when considering design of chemoprevention trials not only in
genetically predisposed individuals with defective MMR, but also in the general
population and also since p53 mutational events are important during development and
progression of colorectal neoplasia.
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Chapter 7
Clinical studies of the effects of NSAIDs on
NFkB signalling
7.1 Introduction
The majority of patients with colorectal cancer present with late stage disease and 50%
will die from metastatic disease. Novel approaches aimed at early detection, prevention
and treatment of colorectal cancer are being pursued to reduce the considerable associated
morbidity and mortality, and prolong survival. Although patients with more advanced
disease may be offered chemotherapy, it is not possible to predict who will benefit from
the survival advantage, and this has to be offset against potential treatment-related
toxicity. Identification of molecular and genetic events responsible for colorectal
carcinogenesis has advanced rapidly over the last three decades. Conventional
chemotherapy works on the basis that malignant cells divide more rapidly than normal
cells. Novel therapies are being sought that target specific molecular pathways that may
underlie the development of colorectal cancer. Despite extensive molecular and genetic
characterisation of the disease, not all findings have translated into clinical benefit for
colorectal cancer patients. Translational studies form the first step towards bridging the
gap between the molecular advances and progress in terms of colorectal cancer survival.
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NSAIDs have shown much promise as potential chemopreventive agents based on
epidemiological studies. Numerous mechanisms of action have been investigated in vitro
using cell culture and animal models, which then need to be confirmed in a clinical
setting. In the previous work, aspirin has been shown to induce apoptosis in colorectal
cancer cells through modulation of the NFkB pathway. Aspirin induces degradation of
the inhibitory protein IkBcc and allows NFkB to translocate to the nucleus where it can
regulate target gene transcription. Aspirin also induced IkBcc degradation in short-term
explants from HT-29 tumour xenografts and colorectal cancer patients (Stark et al.,
2001b; Din et al., 2004). Although, the ex-vivo explant experiments suggested that aspirin
is able to modulate the NFkB pathway in tissue specimens, the aspirin concentrations
were used to generate a biological effect and therefore the clinical relevance is unclear.
Having demonstrated this mechanism of aspirin's action in vitro, it was next important to
establish the relevance of these findings to the clinical scenario in patients with colorectal
cancer. Hence, the next step was to conduct a clinical study in patients to establish
whether the molecular observations of aspirin's effects on NFkB occur in vivo, at
pharmacologically attainable concentrations of aspirin.
The aim of this work was to establish whether the modulatory effect ofNSAIDs on NFkB
signalling could be detected in pilot clinical study protocols in vivo, to demonstrate the
translational potential of this mechanism of action in colorectal cancer patients. Hence,
the work presented in this chapter was aimed specifically at assessing whether reduction
in iKBa and induction of apoptosis, observed in vitro, could be demonstrated in pilot
studies in patients.
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Patients with rectal cancer recruited to the study were treated with aspirin or the COX-2
selective inhibitor rofecoxib for 1 week. The goal of any potential chemopreventive agent
is to achieve a low risk to benefit ratio and those at greatest risk, such as patients with
HNPCC or FAP, may be the group who would benefit most from chemoprevention. In
addition, it is important to establish whether any effects of aspirin occur at earlier stages
in development of colorectal cancer. Therefore, patients with HNPCC or FAP were
recruited to the study. Biopsies were taken from normal rectal mucosa, rectal tumour and
polyps (if present) before and after treatment and examined for evidence of NFkB
modulation and apoptosis. This is the first study to examine the in vivo effects ofNSAIDs
on NFkB signalling in patients. There are clearly limitations of clinical studies employing
molecular endpoints, as well as practical difficulties in execution of such research to
minimise the effect of biological variability and sampling artefacts. Nonetheless, the
clinical research presented here shows that studies involving repeated sigmoidoscopy and
biopsy are feasible and acceptable. Furthermore, there is reason to be optimistic since the
pilot data show tentative evidence that future studies of aspirin can detect real differences
once the level of variability has been defined.
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7.2 Overview of Methods
Three study groups were assembled: patients with established rectal cancer and
genetically predisposed patients with HNPCC or FAP. The inclusion criteria were
patients over the age of 18. The exclusion criteria were patients already taking NSAIDs or
anti-coagulants, allergy, asthma, pregnancy, peptic ulcer disease, bleeding disorder and
previous stroke.
The dosing regimens were selected on pragmatic grounds and comprised COX-2 selective
inhibitor rofecoxib 25mg OD or aspirin 300-600mg OD or 600mg QDS. The higher
(analgesic) dose of aspirin is designed to maximise any biological effect, while the lower
dose will allow determination of the clinical relevance for future chemoprevention, when
the lower dose would be more practical.
All studies had local ethical, management and MHRA approval (LREC numbers
99/5/8,99/5/21,99/5/50 and CTA Number 17844/0001/001), which were written and
applied for by myself. Molecular endpoints are changes in the level of apoptosis, IkBoc
degradation, NFkB nuclear translocation and expression of downstream NFkB driven
genes. This work is in progress and the results presented here are on IkBcc degradation
and apoptosis. Given the short duration of treatment there was no expectation of a
clinically detectable effect.
Briefly, after informed consent biopsies were taken from normal rectal mucosa and rectal
tumour (if present) before and after 7 days ofNSAID treatment. Immediately, part of the
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biopsy specimen was fixed in formalin for paraffin embedding and sectioning for H&E
staining. Another part of the biopsy was snap-frozen in liquid nitrogen for protein
analysis. Cytoplasmic and nuclear proteins were extracted as described in Section 2.6.2.
Western blots of cytoplasmic proteins were used to assess the levels of IkBcx. Apoptotic
counts in H&E stained sections were performed by Dr Angus McGregor as described in
Section 2.5.3.
The Quantity One (BioRad) imaging densitometer software was used to quantity the
protein levels of IkBcx. Repeat biopsies were not taken from patients, nor were patients
entered into the study more than once. To assess one aspect of intra-experimental
variation, Western blots of the same protein extracts from individual patients were
repeated and quantified as a measure of reproducibility. Wilcoxon signed rank test was
used to establish whether there were significant differences between pre- and post-
treatment IkBo. protein levels. Dr Peter Teague, MRC Human Genetics Unit statistician,
verified the statistical methods employed. This work presented here is pilot data and the
clinical studies are ongoing.
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7.3 Results
7.3.1 hcBa expression in vivo after NSAIDs
7.3.1.1 Rectal cancer patient study
IkBcc levels were determined in biopsies of normal mucosa and rectal tumour before and
after aspirin or rofecoxib administration in 16 patients with rectal neoplasia (14
adenocarcinoma, 2 large adenomas). Cytoplasmic protein, extracted from biopsies of
normal rectal mucosa and tumour before and after treatment, was analysed by Western
blotting for IkBoc levels. IkBcc band intensity was quantified by densitometry in triplicate
and corrected for control protein loading.
Basal IkBcx levels in protein extracts from normal mucosa and rectal tumours before
treatment with NSAIDs are shown in Figure 7.1. Inter-sample variability was noted in
pre-treatment levels of IkBci in extracts from untreated normal mucosa and from rectal
tumours. Since upregulation of NFkB signalling has been observed in colorectal cancer
(Rayet and Gelinas, 1999), IkBo, levels in normal mucosa (n=16) were compared to IxBa
in matched rectal tumours (n=16). There were no significant differences in basal IkBcc
expression prior to NSAID treatment in normal rectal mucosa compared to rectal tumour
from the same patient (p=0.27, Wilcoxon signed rank test).
Next, IkBcc levels were determined in normal mucosa and rectal tumours before and after
treatment with NSAIDs. IkBcc protein levels were quantified by densitometry, corrected
for control protein loading, and the actual optical density values are shown in Table 7.1.
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JP 0.91 1.17 - 28.1 1.24 0.94 24.1 -
ES 1.04 1.01 2.6 - 0.99 0.95 4.3 -




















GW 1.21 1.17 2.8 - 1.18 1.18 no change
*- Units are optical density (OD) and number given is the average of repeat density
measurements on different gels for each patient
The number of patients that have lower cytoplasmic IkBcc band intensity in samples taken
after NSAID treatment was 9 (56.25%) in normal mucosa and 11 (68.75%) in rectal
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tumours. Representative Western blots from the patients demonstrating lower levels of
cytoplasmic IkBci expression after NSAID treatment are shown in Figure 7.2. However,
there were 6 patients (37.5%) in whom normal mucosa showed a greater IkBoc band
intensity, and 4 patients (25%) in whom rectal tumour also showed greater IkBcc band
intensity in the post-treatment biopsies. One patient had samples that showed no
difference in IkBcc protein levels in rectal tumour in post- compared to pre-treatment
biopsies (Table 7.1). The IkBcc levels for patients treated with the higher dose of aspirin
(600mg QDS) are shown in Figure 7.3C. There may be a difference in IkBcc after
treatment in this group but this was not significant when considering multiple testing.
Hence, no conclusion can be drawn.
The results show variability in IkBoc expression both before and after treatment with
NSAIDs. If a pragmatic cut-off of a difference of >5% change in IkBoc densitometry
levels before and after treatment is used, then there are lower IkBcc levels in normal
mucosa in 6 patients (37.5%) and in rectal tumour in 8 patients (50%). However, there
were also greater IkBcc levels in normal mucosa and rectal tumours in 6 (37.5%) and 3
(18.75%) patients respectively. These results suggest that there is considerable variability
in IkBcc protein expression and since there is no placebo group it is not possible to
attribute any change in IkBcc levels to treatment with NSAIDs. Hence, these pilot studies
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patient ID
Figure 7.1 Basal IkBgc expression in untreated normal mucosa and matched rectal
tumours. The Y-axis shows the mean optical density of IkB« in untreated normal
mucosa and matched rectal tumours in the 16 rectal cancer study patients (Subjects 1-
16). SD=standard deviation
normal tumour normal tumour normal tumour
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Figure 7.2 licBa expression in rectal cancer patients after NSAIDs
Cytoplasmic protein was extracted from normal rectal mucosa and matched rectal
cancer from patients treated with either aspirin or rofecoxib (RCX) for 7 days.
Representative Western blots demonstrate differences in kBa expression both in
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aspirin 600mg QDS n=6 rofecoxib 25mg OD n=5
Figure 7.3 kBa expression in normal mucosa & rectal tumours after NSAIDs
These graphs show the mean IkBoc levels in the whole treatment group (A), the low dose
aspirin group (B), the 600mg aspirin QDS group (C) and the rofecoxib group (D).
SD=standard deviation,* Wiicoxon signed rank test
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7.3.1.2 Studies in genetically predisposed individuals
7.3.1.2.1 HNPCC patients
Biopsies of normal rectal mucosa were taken from 9 patients with HNPCC before and
after treatment with aspirin or rofecoxib for 1 week. Cytoplasmic IkBoc protein levels
were quantified by densitometry in triplicate and corrected for control protein loading and
the basal IkBoc levels in normal mucosa before treatment with NSAIDs are shown in
Figure 7.4. Next, IicBa levels were assessed in normal mucosa before and after treatment
with NSAIDs. The actual optical density values, corrected for control protein loading are
shown in Table 7.2.
Table 7.2 kBq protein expression following NSAIDs in HNPCC patients




kBa-pre kBa-post % lower % higher
AM
MF







MB 0.89 0.96 - 7.9
RGL 1.23 1.08 12.2 -
MGL
600 mg aspirin QDS
0.93 1.19 - 28.0
BM 1.11 1.11 no change
JSN 0.82 0.61 25.6 -
JW 1.12 0.81 27.7 -
JME 25 mg rofecoxib OD 1.09 1.01 7.3 -
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The number of patients that have lower cytoplasmic IkBcc expression in normal mucosa
was 5 out of 9 (55.56%) and representative Western blots are shown in Figure 7.5.
However, there is greater IkBoc expression in normal mucosa in 3 out of 9 (33.3%)
patients and no change in IkBci levels in normal in 1 patient. If a meaningful difference in
IkBcc expression is arbitrarily taken as >5% change in IkBcc band intensity, then there is a
decrease in IkBoc in normal mucosa in 5 patients and an increase in 3 patients
highlighting the variability in IkBcc levels. The data presented by NSAID dose are shown
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Figure 7.4 Basal licBa expression in untreated normal mucosa HNPCC patients
The Y-axis shows the mean optical density of kBa in untreated normal mucosa in the 9
HNPCC study patients (Subjects 17-25). SD=standard deviation
normal normal normal
kBa "*** ~ » Ml 4ft
CuZnSOD mm • ■ i 4^^
aspirin 300mg 600mg 600mg
OD QDS QDS
Figure 7.5 kBa expression in HNPCC patients after NSAIDs
Cytoplasmic protein was extracted from normal rectal mucosa of HNPCC carriers
treated with NSAIDs for 7 days. Representative Western blots demonstrate differences





















































aspirin 600mg QDS n=6 rofecoxib 25mg OD n=1
Figure 7.6 kBa expression in normal mucosa from HNPCC patients after NSAIDs.
These graphs show the mean kBa levels in the whole treatment group (A), the low dose




Eight patients with FAP were treated with aspirin or rofecoxib, and biopsies taken from
normal rectal mucosa and rectal polyps (present in 3 patients) before and after treatment.
IkBcc protein levels were quantified by densitometry in triplicate and corrected for control
protein loading. The basal IkBoc levels in normal mucosa and rectal polyps before
treatment with NSAIDs are shown in Figure 7.7. IkBoc levels were studied in FAP normal
mucosa and rectal polyps before and after treatment with NSAIDs. The actual optical
density values, corrected for control protein loading are shown in Table 7.3.




















1.20 1.13 5.8 - 1.04 1.04 no change
BT 600 mg 1.47 1.31 10.9
- - - - -
KW
aspirin
QDS 1.18 1.14 3.4 - 1.26 1.44 - 20.3
AC 1.11 1.35 - 21.6 - - - -











GS 0.97 1.01 - 4.1 - - -
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The number of patients demonstrating lower cytoplasmic IkBcc expression was 4 out of 8
(50%) in normal mucosa and 2 out of 3 (66.67%) in rectal polyps, and representative
Western blots are shown in Figure 7.8. There is higher IkBcc expression in 4 (50%)
normal mucosa specimens and in 1 (12.5%) rectal polyp sample. IkBcc expression in the
different NSAID treatment groups is shown in Figure 7.9. If a 5% change in IkBcc
expression is taken as a significant change, then there is lower IkBcc in normal mucosa in
3 patients (37.5%), but also higher IkBcc band intensity in 3 patients (37.5%). In the FAP
polyp group, there is a decrease in IkBoc levels in 1 patient and an increase in 1 patient.
Hence, it is clear that the extent of IkBcc variability needs to be elucidated further.
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Figure 7.7 Basal licBa expression in untreated normal mucosa and matched rectal
polyps from FAP patients The Y-axis shows the mean optical density of kBa in
untreated normal mucosa of 8 FAP patients and matched rectal polyps in 3 patients














Figure 7.8 licBa expression in FAP patients after NSAIDs
Representative Western blots show that kBa expression in normal mucosa and polyp
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Figure 7.9 IkBcx expression in normal mucosa & rectal polyp in FAP after NSAIDs.
These graphs show the mean kBa levels in the whole treatment group (A), the low dose
aspirin group (B), the 600mg aspirin QDS group (C) and the rofecoxib group (D).
SD=standard deviation
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7.3.2 Apoptosis in rectal cancer after NSAIDs
Apoptosis was assessed by counting apoptotic bodies in H&E stained sections of biopsies
from rectal cancer patients before and after treatment with NSAIDs. The apoptotic counts
were calculated using a running mean method (described in Section 2.5.3) and are shown
in Table 7.4.






















0 0 no change 0.20 0.40 higher
SF 0 0 no change 1.77 0.63 lower
HG 0.07 0 lower 0.20 0.27 higher
JS 600 mgaspirin OD 0 0 no change 0.03 0.83 higher
MC 0 0 no change 3.00 1.13 lower
DB 0.50 2.50 higher 1.90 1.95 higher




- - - 0.73 0.60 lower
JL 0 0.50 higher 0.60 1.00 higher
JP 0 0 no change 0.50 0.95 higher
ES 0 0 no change 0 0.60 higher





0 0 no change 0 0.25 higher
DW 0 0.33 higher 0.50 0.60 higher
AW 0 0 no change 0 1.70 higher
GW 0 0 no change 3.37 4.03 higher
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It was essential to have a validated measure of apoptosis performed by a pathologist
experienced in the technique, and hence the apoptotic counts were kindly done by Dr
Angus McGregor who was blinded to the treatment regimens.
There is variability in the basal levels of apoptosis in both normal mucosa and rectal
cancers, but the basal level of apoptosis of rectal cancers as a group was greater than
normal mucosa as a group (p= 0.007, Wilcoxon signed rank test) (Figure 7.1 OA). In terms
of overall response, there were greater apoptotic counts in rectal tumour biopsies of 13
patients (81.3%) and in normal mucosa of 3 patients (18.7%) (Figure 7.10B). The
apoptotic response was marginally greater in rectal tumours compared to normal rectal
mucosa when examining the whole group of NSAIDs (Figure 7.11A). There is tentative
evidence for a dose-dependent effect since there was no increase in apoptotic counts
compared to pre-treatment levels in either normal rectal mucosa or in rectal tumours
following treatment with low-dose aspirin, 300 or 600 mg once daily (Figure 7.1 IB).
However, the apoptotic counts were greater following treatment with the 2.4g aspirin
dose and with rofecoxib in both normal mucosa and rectal tumours (Figure 7.11 C&D).
These results suggest that both COX-2 selective and non-specific NSAIDs may induce
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Figure 7.10 Apoptosis in rectal cancer patients after NSAIDs
Basal pre-treatment apoptotic counts in normal mucosa and matched rectal cancers (A).
There was increased apoptosis in tumour biopsies of 13 patients and in normal mucosa
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Figure 7.11 Apoptosis in normal mucosa and rectal tumours after NSAIDs
These graphs show the mean apoptotic counts (+/- SE) in the whole rectal cancer study
group (A), the low dose aspirin group (B), the 600mg aspirin QDS group (C) and the
rofecoxib group (D). SE=standard error ,* Wilcoxon signed rank test
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7.3.3 Serum salicylate
Epidemiological studies have focussed on populations using NSAIDs for their analgesic
effects and there are no definitive data on the dose required for a chemopreventive effect.
It is also important to investigate the relevance of the aspirin concentrations to those used
in the in vitro experiments described in earlier chapters. Hence, venous blood was drawn
from subjects who were administered aspirin 300mg aspirin OD (n=2), 600mg aspirin OD
(n=4) and 600mg aspirin QDS (n=8) for 7 days. Serum salicylate levels were measured
by a standard colorimetric assay of Trinder by the Department of Clinical Biochemistry
(Western General Hospital, Edinburgh). Measurements of serum salicylate levels in 14
study subjects ranged from 0.05 to 1.13 mM (mean 0.37 mM, SE +/- 0.13 mM) and Figure
7.12 shows that the dose of aspirin ingested correlates, to some extent, with the serum
salicylate levels (r=0.69, correlation coefficient).
7.3.4 Potential side-effects of study
There were 2 patients with rectal cancers who felt that there was an increase in bleeding
per rectum after the second set of biopsies, following NSAID ingestion, and were
admitted for overnight observation. It is difficult to know whether this was due to aspirin
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Figure 7.12 Serum salicylate levels in patients after aspirin
The Y-axis shows the mean (+/- SE) serum salicylate levels in mmol/L. The X-axis
shows the doses of aspirin (mg/day) in patients ingesting 300mg aspirin once daily (n=2),




Despite epidemiological evidence showing that NSAIDs protect against colorectal cancer
with a 40-50% reduction in relative risk (Thun et al., 1993), it would be unwise at present
to recommend their widespread use for chemoprevention purposes. NSAIDs are
associated with adverse gastrointestinal effects including bleeding and perforated peptic
ulcers (Bidaut-Russell and Gabriel, 2001). The lifetime risk of colorectal cancer is 1 in 20
and the risk of a fatal complication has been estimated at 1 in every 2000 NSAID
prescription over 2 months duration (Tramer et al., 2000). Selective COX-2 inhibitors
have been designed to reduce gastrointestinal morbidity and although associated with
fewer ulcers, it is unclear whether such small endoscopically-defined ulcers predict
complications (Wright, 2002). Interestingly, focus on COX-2 related drug development
has revealed that COX-2 is integral to gastrointestinal mucosal defence (Wallace and
Devchand, 2005). In addition, since development of COX-2 inhibitors, there is a risk that
more people in general are commenced NSAIDs thereby increasing the overall associated
risks (Girvin et al., 2004). The COX-2 selective inhibitor rofecoxib was withdrawn due to
increased risk of sudden cardiac events and deaths that were observed in a polyp
prevention trial (Bresalier et al., 2005). Indeed, a recent study showed that COX-2
inhibitors were not any safer than conventional NSAIDs (Hippisley-Cox et al., 2005).
Hence, it is evident that the COX-2 selective NSAIDs will not be ideal chemopreventive
agents. Given the considerable protective effect of NSAIDs in clinical studies, there is
compelling rationale to identify the molecular mechanism of action in order to inform
new and safer drug design.
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The work outlined in the previous chapters has identified that the NFkB signalling
pathway is central to aspirin-induced apoptosis in colorectal cancer cells. However, the
dynamics of this pathway and the contribution that specific NFkB complexes make to a
physiological response are relatively ill defined in vivo (Barkett and Gilmore, 1999). The
aim of this work was to investigate whether the in vitro findings translate into modulation
of the NFkB signalling pathway by NSAIDs in patients, and to determine whether
pharmacologically relevant doses could induce a detectable effect in pilot clinical studies
using pre-treatment biopsies within patients as controls. It is well known that NFkB plays
a role in regulation of cell proliferation and death in several cell types including epithelial
cells in the colon (Inan et al., 2000). In mouse colon, expression of the p65 NFkB subunit
is greater in proliferating cells at the crypt base compared to mature cells at the crypt
surface (Inan et al., 2000). The decreased NFkB activity observed at the crypt surface is
consistent with the observation that the inhibitor IkBP is highly expressed in mature
surface colonic epithelial cells (Wu et al., 1999). Decreased NFkB activity at the crypt
surface may contribute to dampened NFkB responses developed by intestinal epithelial
cells to preserve homeostasis in an otherwise hostile colonic environment (Jobin and
Sartor, 2000). The dynamic nature of NFkB pathway constituent expression, during
epithelial cell maturation and progression up the colonic crypt, indicates that NFkB may
participate in regulating epithelial cell turnover (Inan et al., 2000). Increased constitutive
activity of NFkB has been reported in colorectal cancer especially poorly differentiated
and mucinous tumours (Lind et al., 2001; Evertsson and Sun, 2002). Increased NFkB
expression may also contribute to colorectal cancer angiogenesis through increased
VEGF expression (Yu et al., 2004). Taken together these data suggest that NFkB may
play an important role in the pathogenesis of colorectal carcinoma.
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These pilot clinical studies are the first to examine aspirin effects in vivo and in particular
focussing on NFkB. However, this analysis cannot assess the dynamic state of IkBcc, as it
is based on static measurement of IkBcc protein levels by Western blotting. The results
show that IkBcc protein expression can be detected in normal mucosa and rectal cancer
biopsies, but that there was considerable variability both in basal and post-treatment IkBcc
levels. There are several potential sources of variability that may be related to biopsy
sampling, such as the time of day when biopsied or the effect of the sigmoidoscopy and
biopsy itself, or may be related to the dose of NSAID. Indeed, the changes in IkBoc
expression may be due to inherent variability of the protein and unrelated to treatment
with NSAIDs. Therefore, it will be important to further define intra-patient variability in
terms of IkBcc expression. Hence, IkBoc expression will be determined in separate
biopsies of untreated normal mucosa and rectal cancers taken at the same time-point from
the same patient. Basal IkBcc expression will also be studied in untreated normal mucosa
and rectal tumours taken at the different study time-points (0 and 7days). Although the in
vitro experiments (Chapter 3) showed that NSAIDs degrade IkBcc, any decrease in IkBcc
protein expression may be due to degradation of the protein or decreased protein
transcription, or may be due to variability in experimental detection. Subsequent work has
suggested that IkBcc is being degraded, since there is an increase in IkBoc phosphorylation
in vivo after NSAIDs and phosphorylation is known to precede IkBcx degradation (Din et
al., 2005).
There were no significant differences between basal expression of IkBcc protein in
matched normal and tumour specimens that would indicate altered basal levels of IkBcx in
tumours. However, due to small numbers, subtle differences cannot be excluded. The
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differences in IkBcx, levels following NSAID treatment may be real but given the degree
of variability this cannot be confirmed within the experimental conditions used here.
While the IkBcc expression changes induced by NSAIDs could only be small, there is
evidence in Drosophila that small differences in nuclear concentrations of NFkB
complexes can result in profound physiological differences (Govind, 1999).
NFkB signalling can result in regulation of pro or anti-apoptotic genes depending on the
stimulus, cell type and the composition of the activated complex (Barkett and Gilmore,
1999). Apoptosis not only regulates cell number and type, but also eliminates damaged
cells and those with DNA aberrations, thereby preventing proliferation of malignant
clones (Pritchard and Watson, 1996). Interestingly, there is a lower incidence of
spontaneous apoptosis in the colon compared with the small intestine, which may account
for higher incidence of colon cancers as a result of cells harbouring mutations not being
eliminated (Potten, 1992). Indeed progressive inhibition of apoptosis has been observed
in the transition from normal colonic epithelium to adenomas and carcinomas (Bedi et al.,
1995). In these studies, apoptosis has only been studied in the rectal cancer group thus far.
Clearly the data generated by the apoptotic counts is subject to the same issues related to
variability. The data show greater apoptotic counts in tumour biopsies of 13 patients
(81.3%) and in normal mucosa of 3 patients (18.7%) after NSAIDs. In normal colonic
epithelium, spontaneous apoptosis is not as common as in the small intestine and
apoptotic counts tend to be less than 1.0. Counting of apoptotic bodies is the best-
validated method for quantification, but the half-life of these fragments varies according
to the apoptosis-inducing agent and determines the number of fragments seen at a single
time point (Pritchard and Watson, 1996). Apoptosis is rapid and often completed within
184
4-9 hours (Pritchard and Watson, 1996). The post-treatment biopsies were all taken
within 16 hours of the final NSAID dose. It may be that NSAIDs induce an initial burst in
apoptosis, followed by a persistent but lower level increase in apoptotic turnover. The
timing of aspirin-induced apoptosis in colorectal epithelium is being explored in new
clinical studies in the host laboratory. There is evidence that low levels of apoptosis
translate into significant tumour regression over time in cell kinetics studies (Pritchard
and Watson, 1996). These results are consistent with other in vivo work showing
increased apoptosis in colonic epithelium from patients with NSAID-induced colitis (Lee,
1993) and in adenomas of sulindac treated FAP patients (Keller et al., 1999).
It is also important to note that the biopsies of both normal mucosa and rectal tumour,
although predominately epithelial, would also include stromal cell populations. Hence,
any effect ofNSAIDs on NFkB signalling may be even more pronounced if examining an
isolated epithelial colonic cell population. Alternatively, aspirin may affect numerous
populations including stromal, epithelial, and colonic crypt stem cells. Investigation of the
effects of aspirin on these individual cell types using microdissection may shed further
light as to the relative contribution of both direct epithelial and indirect paracrine-type
effects on NFkB signalling.
This in vivo research has provided some interesting insights into study of the effects of
aspirin on NFkB signalling. It has highlighted the difficulties of translating laboratory
research to 'proof of principle' pilot clinical studies and the importance of clinical trial
design when investigating molecular end-points. The results show that IkBcc protein
expression can be detected in both normal mucosa and rectal tumours of rectal cancer and
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genetically-predisposed patients but that there is considerable degree of variability, which
requires further investigation. The variability may be due to confounding physiological
factors, sampling and experimental variation or indeed may be real. Studies investigating
the variability in IkBcc in normal mucosa and rectal cancers of untreated patients are
underway following ethical approval. This work has also informed new clinical studies
which include shorter time-points to further delineate the kinetics of mechanism of action
in vivo and recruitment has commenced following ethical approval. It is also necessary to
investigate the effects of aspirin on NFkB activity and effects on relevant downstream
genes. This work is also ongoing. It will be also be important to determine whether NFkB
modulation can be used as a surrogate endpoint in clinical chemoprevention trials.
Chemoprevention trials are problematic due to the duration, the numbers of patients
required to show clinical benefit and the cost involved. Hence, identification of a
molecular surrogate marker of response would be a major advance.
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Chapter 8
Mutation analysis of Rel A and IkBa genes in
colorectal cancer tissue
8.1 Introduction
The functions of the NFkB signalling pathway are intimately involved in carcinogenesis,
and altered regulation of NFkB has been reported in colorectal cancer. The hypothesis
explored in this chapter is that aberrant NFkB signalling in colorectal cancer may be due
to mutations in genes encoding key components of the pathway. To date there have been
no studies examining the mutation status of genes encoding proteins involved in NFkB
signalling in colorectal cancer. In this chapter, Rel A (synonymous with p65) and IkBa
were investigated as strong candidates due to the central role played by the respective
proteins, p65 and IkBoc, in aspirin-induced effects on NFkB signalling. Mutations in
either gene may be responsible for the variability in NFkB response observed in rectal
cancer patients (Chapter 7) and the cell-type specificity of the response, and providing
rationale for investigation of genetic aberrations of Rel A and IkBa.
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8.1.1 Rel A genomic structure and function
The human Rel A gene comprises 10 exons spanning about 8.1 kb (Deloukas and van
Loon, 1993). Rel A is located on chromosome 11ql2-ql3 (Deloukas et al., 1994). The
structure and important functional domains and amino acids are represented schematically
in Figure 8.1. Exon 1 contains the 5' untranslated region ofmRNA and codes the first 12
amino acids of p65. Exons 2-7, approximately 300 amino acids, make up the Rel
homology domain (RHD) of which the first 200 amino acids are involved in specific
DNA binding and last 100 amino acids in dimerisation. The nuclear localisation signal
(NLS) consisting of amino acids 301-304 (KRKR) is located in exon 8. The Rel A gene
encodes the p65 subunit of NFkB which is responsible for transcriptional activity. There
are two transactivation (TA) domains that are present in exon 10, TA1 comprises the last
30 amino acids and TA2 is made up of the 90 amino acids immediately adjacent to TA1.
There is also a putative nuclear export sequence, LSEALLQLQF, in the second
transactivation domain of exon 10 (Harhaj and Sun, 1999).
The crystal structure of the NFkB-IkBcc complex has been determined (Huxford et al.,
1998; Jacobs and Harrison, 1998). There are several regions of contact between p65 and
IkBoi; ankyrin repeats 1 and 2 of IkBcc contact the c-terminal extension of p65 including
the NLS, and repeats 5 and 6 contact the dimerisation domain of p65 (Jacobs and
Harrison, 1998). The nuclear localisation sequence of p65 is sequestered by the first two
ankyrin repeats of IkBoc. This is the mechanism for cytoplasmic retention of p65 by
IkBcl Indeed, mutations involving the NLS of p65 may interfere with the ability of IkBcc
to mask the NLS, rendering NFkB continuously activated.
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Although, the classical pathway for NFkB activation is one where IkBcc undergoes
degradation permitting NFkB nuclear translocation, there are other mechanisms that
contribute to NFkB activation. Increasingly, post-translational modifications have been
shown to play an important role in activation of p65 (Campbell and Perkins, 2004). A
number of stimuli are known to phosphorylate p65 at different serine residues, such as
Pin-1 at T254 (Ryo et al., 2003), PKA at S276 (Zhong et al., 1997), PKCz at S311
(Duran et al., 2003), casein kinase II at S529 (Wang et al., 2000) and NIK/IKK at S536
(Jiang et al., 2003). Phosphorylation at these sites increases p65 transcriptional activity, in
contrast to phosphorylation at T435 by protein phosphatase 4 and at T505 by ARF which
results in inhibition (Rocha et al., 2003; Yeh et al., 2004). More recently, acetylation sites
have been identified at lysine residues. Acetylation by p300 and PCAF at K122 and K123
reduces p65 binding to DNA (Kiernan et al., 2003), whereas acetylation by p300 and
CBP acetyltransferases at K218, K221 and K310 increase p65 transcriptional activation
(Chen et al., 2002). Hence, a polymorphism or mutation at any one of these sites may
affect target gene transcriptional specificity ofNFkB, which is clearly regulated at several
levels.
8.1.2 IkBa genomic structure and function
The IkBa gene maps to chromosome 14q and consists of 6 exons spanning approximately
3.5kb, which are schematically represented in Figure 8.2. Exon 1 encodes the signal
receiving domain (SRD) which does not physically participate in NFkB-IkBcc complex
formation (Hatada et al., 1992; Jaffray et al., 1995; Sun et al., 1996). However, exon 1
contains key serine residues, S32 and S36, which are important phosphorylation sites and
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lysine residues upstream, K21 and K22, which undergo ubiquitination that targets the
protein for degradation by the 26S proteosome. Approximately the last 10 amino acids of
exon 1 and exons 2-5 comprise the ankyrin repeat domain (ARD). There are 6 ankyrin
repeats, about 33 amino acids each, which form 5 finger-like projections that interact with
the dimerisation domain of p65 (Huxford et al., 1998). The NTS of p65 is sequestered by
the first 2 ankyrin repeats and repeats 4-6 contact the RHD of p65 (Jacobs and Harrison,
1998). Hence, mutations in IkBa may affect both its degradation by effects on
phosphorylation and ubiquitination sites, and its ability to bind to p65, by direct effects on
the p65 interacting domain or by indirectly affecting protein structure and NFKB-lKBa
complex formation, which may disrupt NFkB regulation.
There are chromosomal regions and genetic loci that undergo loss of heterozygosity in
colorectal cancer including APC at 5q, p53 at 17p and DCC at 18q. Interestingly, LOH
has been reported both at chromosome 11 q and chromosome 14q in colorectal cancer
(Tomlinson and Bodmer, 1996; Weber et al., 1999; Lee et al., 2000; Thorstensen et al.,
2001). Moreover, chromosome 14 monosomy has been reported in both primary and
metastatic colorectal cancer (Thorstensen et al., 2001). Indeed, loss of the entire
chromosome or a large part may confer a selective growth advantage due to loss of
several tumour suppressor genes simultaneously. More recently, genome-wide linkage
analysis of colorectal cancer families in Sweden identified regions of interest in
chromosomes 11 and 14, suggesting these may harbour novel predisposition genes
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8.1.3 NFkB signalling and carcinogenesis
NFkB regulates numerous pathways involved in oncogenesis including the cell cycle, cell
differentiation, cell migration and control of apoptotic signalling. NFkB may promote
carcinogenesis through its modulation of genes governing the balance between cell
proliferation and cell death. The proto-oncogene c-myc and cell cycle protein cyclin D1
are targets of the APC pathway (He et al., 1998; Shtutman et al., 1999). Mutations in Writ
signalling are common in colorectal cancer resulting in increased Lef-l/Tcf-driven
expression of both c-myc and cyclin Dl. The c-myc promoter contains an NFkB binding
site and gene expression is stimulated by NFkB, leading to aberrant cell proliferation
(Pahl, 1999). c-myc has also been shown to induce a truncated form of Rel A with which
it forms a complex (Chapman et al., 2002). NFkB also induces expression of cyclin Dl,
through promoter NFkB binding sites and so indirectly regulates G1 to S phase cell cycle
progression (Guttridge et al., 1999). Interactions between NFkB and other cell cycle
regulators, including Rb, p53 and p21 genes, may also influence cell proliferation and
survival (Hinata et al., 2003).
In addition, NFkB regulates genes encoding growth factors including bone
morphogenetic protein-2 (Feng et al., 2003) and platelet derived growth factor
(Khachigian et al., 1995). These genes are involved in clonal expansion and perhaps
tumour initiation. Several cytokines are regulated by NFkB including interleukins,
RANTES (Moriuchi et al., 1997) and TNFa (Collart et al., 1990). These act as tumour
cell growth factors, and may result in continual autocrine or paracrine stimulation of cells
that are already 'primed' through mutation and clonal selection. In addition to regulating
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genes involved in cell proliferation, NFkB signalling may also contribute to growth of
new blood vessels due to regulation of genes involved in angiogenesis such as VEGF
(Chilov et al., 1997), and to this end increased NFkB expression has been shown to
correlate with increased VEGF expression (Yu et al., 2004).
The ability of a tumour to spread is a fundamental property defining the malignant
phenotype. NFkB regulates several genes associated with cellular invasion and
metastasis, such as cell surface protease matrix metalloproteinases (MMP-9) (Bond et al.,
1998), urinary plasminogen activator (Novak et al., 1991), and cell adhesion molecules
including ELAM-1, ICAM-land VCAM-1 (Whelan et al., 1991; Iademarco et al., 1992;
van de Stolpe et al., 1994). Furthermore, it has been shown that inhibition of high
constitutive NFkB activity using mutant IkBcc decreased the frequency of metastases
(Huang et al., 2000; Fujioka et al., 2003), indicating a potential role for aberrant NFkB
signalling in tumour dissemination.
The role of NFkB in mediating programmed cell death is complex and may be pro- or
anti-apoptotic depending on the environment and stimulus (Barkett and Gilmore, 1999).
NFkB may contribute to growth of abnormal cells via up-regulation of anti-apoptotic
genes such as cellular inhibitors of apoptosis (cIAPs) (You et al., 1997; Stehlik et al.,
1998), members of Bcl2 family such as BcI-xl (Chen et al., 2000) and down-regulation of
pro-apoptotic genes including Fas, caspase 11 and TRAIL. It is uncertain what determines
whether NFkB activation is pro- or anti-apoptotic and it is the balance of signals, under a
number of cellular and molecular scenarios, which determines the fate of any given cell.
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It is clear that aberrations in NFkB signalling may confer a survival advantage on newly
transformed cells destined to become malignant clones. However, there are conflicting
data which indicate NFkB may also inhibit growth of squamous cell carcinoma in skin
and that NFkB blockade triggers invasive human epidermal neoplasia (Shishodia and
Aggarwal, 2004). A model reconciling these dichotomous NFkB roles in tumour
promotion and suppression has been suggested. NFkB may act as a tumour suppressor in
the early stages of tumorigenesis. Thereafter, accumulation ofmutations in NFkB, NFkB-
interacting genes or genes with kB promoter sequences, normally the target of NFkB
regulation, results in loss of its tumour suppressor activity and the cancer promoting
effects predominate (Perkins, 2004).
8.1.4 Evidence that aberrations of NFkB are involved in
cancer
Evidence indicating oncogenic potential of NFkB originated from work on the avian
retroviral protein v-Rel, a viral homolgue of c-Rel, which causes tumours in animal
models (Gilmore, 1999), and c-Rel itself consistently transforms cells in culture (Gilmore
et al., 2004). Moreover, NFkB activation has been shown to result in cellular
transformation and several oncogenes, such as ras and c-myc, mediate their effects
through activation of NFkB (Aggarwal, 2004). Constitutive activation of NFkB in both
haematological and solid malignancies may be promoting growth, since suppression of
NFkB activity has been shown to inhibit cell proliferation, induce cell cycle arrest and
apoptosis in tumours (Bharti and Aggarwal, 2002).
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Rel A and IkBa genes are strong candidates since mutational activation or amplification of
Rel A or upstream signals, or mutational inactivation of IkBa due to mutations in
localisation or degradation sites may lead to aberrant NFkB signalling.
Possible explanations for high constitutive NFkB activity in tumours are firstly that IkBoo
is mutated and unable to mask the nuclear translocation signal in p65; secondly mutations
in Rel A prevent IkBcc binding or that the p65 upstream signal-transduction cascades are
constitutively activated (Wang et al., 1999b). Furthermore, functionally relevant
mutations have been identified in constituents of the NFkB signalling pathway. c-Rel,
nfkbl, nfkb2 and bcl-3 have been implicated in both haematological and solid tumour
development through gene amplification and chromosomal rearrangement leading to
overexpression (Rayet and Gelinas, 1999). Chromosomal rearrangements and
amplifications of Rel A are less common in haematological malignancies (Trecca et al.,
1997). Rel A gene amplification has been observed in squamous head and neck, stomach
and breast carcinoma and over-expression in thyroid cancer cell lines, but the role of Rel
A in solid tumours is not fully defined (Rayet and Gelinas, 1999). The constitutive
activation of NFkB in Hodgkin's lymphoma has been attributed to somatic mutations
identified in the IkBa gene in Hodgkin's disease cell lines and patients (Wood et al.,
1998; Cabannes et al., 1999; Krappmann et al., 1999). Hence, there is substantial
justification to study genetic alterations in Rel A and IkBa in colorectal cancer, given the
key role of NFkB in aspirin-mediated anti-tumour effects presented in the preceding
chapters.
196
8.1.5 Evidence for deranged NFkB signalling in
colorectal cancer
Several lines of evidence indicate that NFkB signalling is abnormal in colorectal cancer.
Altered regulation and increased expression ofNFkB has been observed in the colorectal
cancer cell line HT-29 and its metastatic counterpart F1TM-29, specifically over-
expressing p52 in the metastatic cells (Bours et al., 1994). NFkB binding has been shown
to be increased in colorectal cancers, compared with adjacent normal mucosa, and high
constitutive NFkB activity has been observed in poorly differentiated and mucinous
tumours (Lind et al., 2001; Evertsson and Sun, 2002). Increased IKKa protein levels
were observed, in association with increased NFkB expression, in tumour samples
compared to matched normal colonic epithelium (Charalambous et al., 2003). There is
evidence that deranged NFkB signalling occurs early and is present in pre-malignant
lesions, since increased NFkB expression has been observed in the stromal component of
colorectal adenomas (Flardwick et al., 2001). Furthermore, expression of p65
significantly increased in the transition from normal mucosa to adenoma and to
adenocarcinoma (Charalambous et al., 2003; Yu et al., 2003). One of these studies also
provides circumstantial evidence to suggest that increased expression of p65 is associated
with a significant decrease in the apoptotic index (Yu et al., 2003). Taken together, these
studies strengthen the notion that increased NFkB expression and activity promotes
tumourigenic behaviour in colorectal cancer.
NFkB may also determine the cellular response to chemotherapeutic agents (Ravi and
Bedi, 2004). There was variability between rectal cancer patients in the magnitude of the
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NFkB response to aspirin described in Chapter 7. This may be due to the baseline status
of components of the NFkB pathway, which appear to be aberrantly active/expressed in
some tumours and colorectal cancer cell lines. Interestingly, the patients with higher basal
levels of IkB proteins were more responsive to NSAIDs in terms of IkB degradation and
apoptosis.
Despite the substantial evidence discussed above suggesting that NFkB signalling is
deranged in cancer, no mutations have been reported in key components of the pathway
in colorectal cancer. The aim of this work was to determine Rel A and IkBa gene mutation
prevalence in colorectal cancer using a panel of human colorectal cancers. Mutations in
Rel A and IkBa in colorectal cancer are a plausible explanation for the variation in
response to NSAIDs.
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8.2 Overview of Methods
A 96-well plate was set up comprising DNA from patients with FAP, HNPCC, and
sporadic colorectal cancers, including those from NSAID-treated patients in Chapter 7
and patient characteristics are described in Table 8.1. DNA from 5 of the colorectal
cancer cell lines used in this study (SW480, HRT-18, HT-29, HCT-116 and LoVo), one
positive control and 4 negative controls was also included using the methods described in
Section 2.11 and 2.12.
Table 8.1 Patient characteristics of DNA for mutation analysis
Age MSI-stable MSI-low MSI-high FAP NSAID group
10-20 3 - 1 - -
20-30 4 2 4 1 -
30-40 4 4 4 1 -
40-50 4 - 4 - 3
50-60 5 2 3 - 2
60-70 4 - 4 - 6
70-80 5 2 3 - 4
>80 4 1 - - 2
Total (n=86) 33 11 23 2 17
Mutation analysis comprised PCR for 10 exons in Rel A and 6 exons in IkBa, followed by
automated sequencing on an ABI3700 as described in 2.12. Sequencher 3.0 software was
used to analyse the chromatograms and sequence was compared to the published genomic
sequence. Primers for both Rel A and IkBa genes were designed to include the intronic
splice acceptor and splice donor sites to investigate any variants that may be modifying
splicing. Hence, all variants were analysed using the following programs to check for
generation of potential alternative splicing sites: ESE finder
http://rulai.cshl.edu/tools/ESE/. BDGP Splice Site Prediction by Neural Network-




This work is currently ongoing and therefore the results are the most up to date at the time
of writing this thesis. Nonetheless, the results presented here represent a sufficiently
complete body ofwork to draw scientific conclusions. The conditions for the primers that
were not working have been optimised and analysis of the remaining exons is underway.
8.3.1 Analysis of Rel A gene
Analysis of exons 3-7 and 10 of Rel A is shown in Table 8.2.
Table 8.2 Summary sequence analysis of Rel A gene
Rel A PCR product size (bp) Number sequenced % Yield
Exon 1 231 -- --
Exon 2 343 34 37
Exon 3 254 36 39.1
Exon 4 218 80 87
Exon 5 259 81 88
Exon 6 203 82 89.1
Exon 7 330 86 93.5
Exon 8&9 330 -- --
Exon 10A 334 -- -
Exon 10B 291 63 68.5
Exon 10C 362 51 55.4
The variants identified to date in the Rel A gene are summarised below in Table 8.3.
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Table 8.3 Variants identified in Re! A gene
Number Number Predicted





















The intronic C to T change at position IVS4 +27 was observed in 6 samples
(7.5%)(Figure 8.3A). Analysis of matched normal DNA did not reveal the same change
identified in tumour samples. This indicates the variant is a somatically acquired mutation
with clonal amplification, suggesting it is functionally important. In exon 10, there was
also a single nucleotide change (G—>C, nucleotide 1436) at codon 432, which results in a
change from a neutral non-polar to a basic polar amino acid (glycine to arginine) (Figure
8.3B). This may be important as it is within the second transactivation domain, which
starts at codon 430. It is also near the phosphorylation site at T435 and close to the
putative nuclear export sequence, which commences at codon 436 (Harhaj and Sun,
1999). A potential deletion/insertion was identified in exon 7 suggested by a double
sequence extending 3' with normal sequence commencing at codon 259 (Figure 8.3C). At
the time ofwriting, the potential deletion/insertion has yet to be identified and is currently
undergoing further sequencing using forward and reverse primers to ensure the variant is
not an artefact of sequencing compression. The wild-type and variant sequences were
compared using the programs in section 8.2 to check if any of the variants create
alternative splicing sites. There were no significant differences found suggesting that
these changes do not disrupt splicing events.
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Figure 8.3 A & B Rel A variants
Intronic change (C to T) observed in 6 samples at IVS4+27(A).
Single nucleotide change (G-»C) in exon 10B codon 432 (B).
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MJfWJfOtCA®AGAffiffiCAGAGNCTCAT& TCT CaWCATOfnGTCNTATACT9NAACTCT TNt(htCN T GAhNN G GNCNC A GGG AGG ttGN h i G\CAGACCCCAGCCTGCAGGCTCCTTGCGTGTCTCCATGCAGCT CGGC GCCTT CAGAGCCCA GGAATTCCAGTA CT C GATACAGG ACACAGCi
50160789212345 codon259 GACCCCAGCCTGCAGGCTCCTGTGCGTGTCTCCATGCAGCTGCGGCGGCCTTCCGACCGGGAGCTCAGTGAGCCCATGGAATTCCAGTACCTGCCAGATACAG Figure8.3CRelAvariantexo7 Possibledeletion/insertionge e atings condaryequ cea dther uminnorm lsfrc do259.
8.3.2 Analysis of IkBa gene
Sequence analysis of exons 3-6 of the IkBa gene is summarised in Table 8.4 below.
Table 8.4 Summary of sequence analysis of IkBa gene
IkBa PCR product size (bp) Number sequenced % Yield
Promoter - -- --
Exon 1A 346 -- -
Exon 1B 383 -- --
Exon 2 289 -- --
Exon 3 351 -- --
Exon 4 195 55 59.8
Exon 5 362 61 66.3
Exon 6 212 69 75
Two variants have been identified and are listed in Table 8.4.
Table 8.5 Variants identified in IkBa gene
IkBa Number with variant
Number
analysed Change Nucleotide position
Intron 4 36 55 C—»T IVS4 +17
3' UTR 46 69 T-»C 3" UTR +2
There was a single nucleotide transition (C—>T) at 17 nucleotides into intron 4 of IkBa
observed in the 36 of 55 samples (65% frequency) (Figure 8.4A). This variant has been
previously identified as a polymorphism in lymphoma patients (Jungnickel et al., 2000),
multiple myeloma patients (45% frequency) and in healthy individuals (46% frequency)
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(Parker et al., 2002; Rieder et al., 2003). This appears to be a common single nucleotide
polymorphism with heterozygous and homozygous genotypes identified (Figure8.4A).
There was also a nucleotide change (T to C) 2 nucleotides downstream from the stop
codon in 46 samples (66% frequency)(Figure 8.4B). This variant has also been previously
reported as a polymorphism since it was found not only in patients with lymphomas and
multiple myelomas (frequency 83%) and but also in healthy individuals (frequency 33%)
(Parker et al., 2002; Rieder et al., 2003).
It is recognised that alternative splicing of IkBP may provide a means to selectively
control the amount of IkBP, bound to NFkB, to be released under NFKB-activating
conditions (Hirano et al., 1998). Hence, wild-type and variant IkBa sequences were
compared using the programs in section 8.2 to determine whether any variants might
influence splicing. No significant effects were predicted, suggesting that these changes do

















B TQfC GTTAT GAGC GCAAAGGGGC
wild type TGACGTTATGAGTGCAAAGGGGC
variant TGACGTTATGAGCGCAAAGGGGC
Figure 8. 4 IkBa variants
Single nucleotide transition (C to T) at IVS4+17 with heterozygous and homozygous
genotypes (A). Single nucleotide change (T to C) at 3'UTR + 2 in 46 samples (B)
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8.3.3 Polymorphisms and NSAID study patients
Polymorphisms are known to determine susceptibility to disease, but increasing evidence
suggests that polymorphisms may determine response to prevention or intervention
agents. There was no association between the Rel A and IkBa variants identified and
response to NSAIDs, in terms of IkBcc degradation (Table 8.6). However, the number of
patients is not adequate to detect such any subtle effects of the variants.
Table 8.6 Variants and NSAID study patients












WT WT VAR Yes
SF WT WT VAR No
HG WT WT VAR Yes
JS 600 mg aspirin OD WT WT VAR No
MC WT WT WT Yes
DB WT WT WT Yes
JM WT WT WT Yes
JC 600 mg aspirin QDS WT VAR WT Yes
JL WT WT VAR No
ES WT VAR - Yes
DW WT VAR - Yes
AW rofecoxib 25 mg OD WT WT VAR No
GW WT VAR VAR No





The work presented in this chapter aimed to determine whether there are any DNA
sequence variants of likely functional consequences in Rel A and IkBa genes in colorectal
cancer. Increased expression and altered regulation of NFkB has been reported in
colorectal cancer cell lines, adenomas and carcinomas (Bours et al., 1994; Hardwick et
al., 2001; Lind et al., 2001). High constitutive activity and aberrant NFkB signalling
observed in colorectal cancer may be due to the presence of mutations in p65 and IkBoc.
The Rel A gene codes for p65 which is the transcriptionally active subunit ofNFkB, and
hence central for downstream regulation of NFKB-driven genes. Since mutations have
been identified in IkBoc, which through its inhibitory function plays a key role in
regulating NFkB, it is essential to examine the IkBa gene for mutations.
8.4.1 Rel A and significance of variants
There is very little published data on mutation prevalence of Rel A. No mutations were
found in Rel A both in HeLa cells and in HTM-29 cells, a metastatic cell line derived
from colorectal cancer (Legrand-Poels et al., 2000). Indeed, structural alterations of Rel A
appear to be rare events in lymphoid neoplasia. In one case ofmultiple myeloma, a point
mutation was identified resulting in an amino acid substitution at codon 494 (Glu to Asp)
in the transactivation domain, which reduced its transactivation potential (Trecca et al.,
1997). Disruption of Rel A in mice results in massive liver cell apoptosis and embryonic
lethality at 15 days of gestation (Beg et al., 1995b). This suggests that defects in Rel A
that disrupt growth and survival may be irreconcilable with cellular transformation, and
hence constitutive activation ofNFkB may select for tumour growth and survival (Rayet
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and Gelinas, 1999). Indeed, this would support the notion that aspirin-mediated
chemoprevention corrects disturbed mechanisms that permit escape from normal cellular
turnover and apoptosis.
A number of variants of p65 that result in alternative splicing have been previously
identified (Deloukas and van Loon, 1993). The first variant reported, p65A, is generated
through an alternative splice acceptor sequence 30 nucleotides downstream of the native
p65 splice acceptor site (Ruben et al., 1992). The p65A protein lacks amino acids 222-
231, necessary for p65/p50 interaction and for DNA binding. There is also a potential
alternative acceptor splice site within intron 5, which may generate a longer variant of
p65 due to the insertion of 19 amino acids between amino acids 187 and 188 (Deloukas
and van Loon, 1993). Further p65 variants created by alternative splicing, p65A2 and
p65A3 lack codons for amino acids 13-25 and 187- 293 respectively (Lyle et al., 1994;
Maxwell and Mukhopadhyay, 1995). Recognition of the alternative acceptor splice sites
may be a regulated event and such splice variants of p65 may be responsible for selective
transcriptional activity (Narayanan et al., 1992).
The analysis of Rel A revealed a single nucleotide change (C to T) in 6 samples at 27
nucleotides into the fourth intron. This variant has previously been identified as having an
allele frequency of 0.05 and an expected heterozygosity of 0.1 (Rieder et al., 2003).
Bioinformatics did not predict generation of alternative splicing sites due to this Rel A
variant. It would have been useful to investigate transcripts of this variant from the
respective tumours, but these were not available for analysis. However, this variant was
only identified in 6 tumour samples and was not present in matched normal tissue, and
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hence it is likely to be an acquired mutation with a prevalence of 7.5%. Further
investigation of this variant is planned with fresh tumour samples, which would permit
both RNA and protein extraction, to examine RNA transcripts and protein expression in
order to determine functional significance.
Two exonic variants were identified in Rel A. There was a potential deletion/insertion in
exon 7 which appeared to generate a secondary sequence and then resume normal
sequence from codon 259 onwards. This variant may be important functionally due to its
close proximity to the phosphorylation site at T254, which results in increased nuclear
accumulation and stability of p65, and enhanced NFkB activity. The second variant
identified was a single nucleotide change (G—>C, nucleotide 1436) in exon 10 and results
in a change from the amino acid glycine to arginine (codon 432). This variant is within
the second transactivation domain of p65, which starts at codon 430. The variant may also
affect phosphorylation at T435 by protein phosphatase 4 which results in inhibition of
p65 activity (Yeh et al., 2004). Lastly, the putative nuclear export sequence of p65
commences at codon 436 (Harhaj and Sun, 1999), and hence this change may affect p65
export resulting in increased nuclear accumulation and constitutive activation. Hence, the
potential consequence of this variant may be increased NFkB transcriptional activity,
either due to disruption of an inhibitory phosphorylation site or due to defective nuclear
export.
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8.4.2 IkBa and significance of variants
The role of IkBcc in cellular transformation is not as well defined as that for NFkB. Anti-
sense expression of IkBa transcripts have been shown to transform NIH3T3 cells
suggesting that inactivation of IkB proteins promotes tumour development (Beauparlant
et al., 1994). Inactivation of the IkBa gene in mice results in neonatal fatality and hence
precludes study of tumour development (Beg et al., 1995a). Somatic mutations have been
identified in IkBa in Hodgkin's disease, some of which result in loss of NFkB regulatory
feedback, suggesting a tumour suppressor role (Krappmann et al., 1999; Cabannes et al.,
1999; Jungnickel et al., 2000). There is also some evidence that germline polymorphisms
may be associated with a predisposition to multiple myeloma (Parker et al., 2002).
In this chapter, IkBa mutation analysis has identified a number of variants in intron 4 and
in the 3' untranslated region. A single nucleotide transition (C to T) was identified at 17
nucleotides into intron 4, and this has been previously identified as a polymorphism
(Jungnickel et al., 2000). The estimated heterozygosity of this polymorphism is 0.21
(Rieder et al., 2003). There was also a nucleotide change (T to C) present at 2 nucleotides
after the stop codon in IkBa. This change has also been previously reported as a
polymorphism and found in lymphomas, multiple myelomas and healthy controls
(Jungnickel et al., 2000; Parker et al., 2002). The expected heterozygosity for this variant
is 0.5 (Rieder et al., 2003). This polymorphism is just beyond the stop codon and thus
may be important for transcriptional regulation of IkBa. There is evidence that the 3TJTR
ofmRNA may modulate gene expression and disease susceptibility (Conne et al., 2000).
The size and prevalence of introns in human gene sequence (up to 99%), suggests introns
could be important functional elements. For example, deletion of an intron in hMLHI
211
results in increased susceptibility to colorectal cancer (Farrington et al., 1998). Hence,
changes in both the intronic and untranslated regions of genes may have functional
significance.
It is well established that polymorphisms may account for variation between individuals
with respect to vulnerability to disease. An association between COX-1 and COX-2
polymorphisms and adenoma risk has been reported (Ulrich et al., 2004; Ali et al., 2005).
The expanding field of pharmacogenomics is focussed on correlating therapeutic response
to individual genetic profile. A study examining polymorphisms in cytokines and
colorectal cancer risk in a Scottish population, found that carriers of the variant IL-10-592
(A) allele ingesting regular aspirin had a 50% reduced risk of colorectal cancer, compared
to carriers of the A allele who did not use aspirin, or carriers with the CC genotype
ingesting aspirin (Macarthur et al., 2005). Polymorphisms in enzymes involved in aspirin
metabolism, UGT1A6 and CYP2C9, have been shown to modify the effect of aspirin on
colorectal adenoma development (Bigler et al., 2001; Chan et al., 2005). Although there
was no apparent association between the ReIA and IkBa polymorphisms and response in
the NSAID study, the numbers required to detect variations would be substantial. It is
likely that subsets of the population defined by genotype have a differential response to
chemopreventive agents.
Mutation analysis has identified a number of potential functionally important variants.
The variant in Rel A at codon 432 may be functionally relevant as it is in the
transactivation domain of the protein. The Rel A intronic variant was only identified in
tumour tissue suggesting it is an acquired mutation. The polymorphisms in IkBa have
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been previously identified but may play a role in determining disease susceptibility and
response to agents. Immunohistochemistry will be carried out to investigate whether
protein expression is altered. In addition, RT-PCR analysis would be performed to
determine the effects of variants on RNA transcripts. This work will continue with
sequence analysis of the remainder of the Rel A and IkBa genes. This research will inform





Worldwide, there are 500,000 new cases of colorectal cancer per annum. There has been
some recent improvement in mortality but overall 5-year survival is 51%. Research
endeavour has begun to focus on early detection and prevention using drugs that
intervene in tumour development. The ideal chemopreventive agent should inhibit
carcinogenesis and influence tumour biology, have an acceptable toxicity profile, and
should possess differential activity between normal and abnormal epithelium (Thiery-
Vuillemin et al., 2005). With respect to these criteria, NSAIDs fulfil the requirement as
potential chemopreventive agents in colorectal cancer. Despite the 40-50% risk reduction
in colorectal cancer, the safety profile of NSAIDs is a relative barrier to widespread use
as primary chemopreventive agents. Hence, there is compelling rationale to define the
molecular basis of the protective effect ofNSAIDs in colorectal cancer, in order to target
the mechanism of action precisely. The work presented in this thesis contributes to the
understanding of the mechanism of NSAID-mediated anti-tumour activity via modulation
ofNFkB signalling in colorectal cancer.
The NFkB signalling pathway is critical in several cellular processes such as
proliferation, invasion and death, which may influence tumour development and
progression. Genes regulated by NFkB, including COX-2 and p53, and NFkB signalling
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itself are deregulated in colorectal cancer. Indeed there appears to be progressively
aberrant expression ofNFkB from adenomas to carcinomas, indicating that NFkB plays a
key role in colorectal carcinogenesis (Yu et al., 2003). The initial findings of Stark and
Dunlop in the host laboratory identified a novel mechanism of action underlying aspirin-
induced apoptosis in colorectal cancer cells (Chapter 3). This work showed that aspirin
induces apoptosis in colorectal cancer cells that is paralleled by IicBa degradation and
NFkB nuclear translocation in a dose-dependent manner. The effects of aspirin on NFkB
and apoptosis were totally abrogated in colorectal cancer cells engineered to express
mutant IkBoc that is resistant to degradation. Previous work had indicated that aspirin
inhibited NFkB by decreasing IKK(3 activity, following TNFa stimulation of the NFkB
signalling pathway (Yin et al., 1998; Yamamoto et al., 1999b). Chapter 3 describes the
effects of aspirin on NFkB signalling and apoptosis in the absence of stimulating agents
such as TNFa, which more accurately reproduces colorectal epithelial exposure to
NSAIDs. The effects on NFkB are evident at low doses of aspirin that are realistic in
humans, and hence relevant to chemoprevention.
The importance of NFkB as a central target for aspirin-mediated apoptosis, relevant
particularly to colorectal cancer, is further highlighted by the work presented in Chapter
4. This demonstrated a striking difference in the response to aspirin between colorectal
cancer cell lines and lines derived from breast, ovarian and endometrial cancers, with
respect to both cell viability and NFkB signalling. Aspirin-induced apoptosis, associated
with ficBa degradation and NFkB nuclear translocation, was restricted to colorectal
cancer cell lines. The relationship between aspirin-induced apoptosis and the effects on
NFkB signalling, suggests a molecular rationale for the greater sensitivity of colorectal
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cancer to NSAIDs compared to other cancers. These results provide mechanistic support
for the epidemiological observations that NSAIDs provide greater protection from
colorectal cancer compared to other cancers.
In addition to demonstrating that the effect of aspirin on NFkB signalling and apoptosis is
relatively specific for colorectal cancer, the data in Chapter 4 show that this effect occurs
in a wide range of colorectal cancer cell lines. These colorectal cancer cell lines have
varying genetic backgrounds emphasising the generality of the aspirin-induced NFkB
apoptotic response in colorectal cancer. The data strongly suggest that the aspirin-induced
NFkB apoptotic effect is likely to confer broad preventive activity against colorectal
cancer. Nonetheless, it would be important to identify whether there are subsets of
colorectal cancers that are more or less susceptible to NSAID-mediated chemoprevention.
Indeed, identification of molecular markers that predict response with respect to NSAID-
mediated chemoprevention and adjuvant therapy would be informative.
In the literature, the COX-2 enzyme has been implicated as both a molecular target of
NSAIDs and a potential marker of response. However, the results presented in Chapter 5
demonstrate that COX-2 expression levels are unrelated to susceptibility to aspirin-
induced apoptosis via NFkB modulation. This is consistent with substantial evidence
suggesting that COX-2 is not the predominant mechanism for the anti-tumour effects of
NSAIDs. By using colorectal cancer cell lines that are similar other than a specific
genetic change under investigation, the results presented in Chapter 6 show that colorectal
cancer cells undergo apoptosis, following IkBcc degradation and NFkB nuclear
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translocation, in a manner that is independent of p53 and MMR mutation status. The
results from Chapters 4 and 5 show colorectal cancer cells are sensitive to aspirin-
mediated apoptosis independent ofAPC mutation status and P-catenin expression. This is
particularly relevant since aberrant Wnt signalling is the earliest molecular derangement
in colorectal tumorigenesis. Hence, it is evident that the aspirin-induced NFkB apoptotic
response occurs irrespective of early (APC, P-catenin, COX-2), intermediate (MMR) and
late (p53) mutational events in colorectal cancer development. These results emphasise
that aspirin has potential to prevent all subtypes examined irrespective of such molecular
events, and imply that aspirin could target all colorectal neoplastic cells as they arise. This
is important when considering translating these findings to clinical studies aimed at
defining the NFkB response to aspirin in human colonic epithelium and tumours.
It was essential to ensure that the aspirin-induced NFkB apoptotic response predicts that
identifiable groups at high risk of colorectal cancer, with currently definable genetic
defects, could potentially benefit from chemoprevention. Indeed, the risks associated with
chemoprevention would be balanced against the higher risk of developing colorectal
cancer in genetically predisposed groups such as HNPCC and FAP. The results from
Chapter 4 and 6 show that colorectal cancer cell lines with mutations in DNA MMR
genes are all susceptible to aspirin-induced apoptosis. This data is relevant not only to
prevention but also to potential therapeutic use since MMR status has been shown to
confer resistance to certain chemotherapy. The finding that the aspirin-induced NFkB
response is not influenced by APC mutation status and aberrant p-catenin expression is
relevant to patients with FAP. Furthermore, the clinical studies presented in Chapter 7
suggest that there may be evidence of modulation of NFkB in both HNPCC and FAP
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patients. From a prevention standpoint in genetically predisposed groups, the studies of
HNPCC and FAP could be instructive as to whether modulation of NFkB signalling in
normal mucosa of such patients can be demonstrated. However, it is unclear whether any
patients responded to NSAIDs, manifest as changes in IkBcx levels, because of the
variability in IkBcc levels. Possible explanations include variations in therapeutic levels,
pharmacokinetic, and pharmacodynamic differences and also the possibility that specific
somatic genetic events other than the causative mutation may impact on NSAID response.
This must remain speculative as elucidating the underlying reason for differential
response in high-risk groups and in average risk groups lies outwith the remit of this
thesis.
Having identified a novel molecular mechanism of action in vitro, it was key to
investigate whether this translated into an effect in patients at moderate risk of colorectal
cancer. The fraction of basic scientific research making a successful transition to clinical
use or benefit is limited. For example, the impact of the EGFR inhibitor gefitinib on
overall lung cancer survival in clinical trials was disappointing compared to that predicted
from the encouraging molecular work (Comis, 2005). The research presented in Chapter 7
is the first to examine the effects of NSAIDs on NFkB signalling and apoptosis in
patients with established rectal cancer. The results show that changes in IkBcx expression
and apoptosis are detectable rectal cancer patients but there is high level of variability and
further experiments are required to define the intra-patient variability of the protein and
the effects in untreated patients. Subsequent experiments, in addition to the work that
constitutes this thesis, have shown that aspirin does indeed induce p65 nuclear
translocation in these rectal cancer patients (Din et al., 2005). The effect of NSAIDs on
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NFkB signalling in vivo is supported by research in two mouse models which shows that
aspirin induces cytoplasmic IkBo. degradation, p65 nuclear translocation and cleavage of
caspase-3 in xenografted HT-29 tumours and in adenomas from ApcMm+'~ mice (Stark et
al., 2006).
Activation of the NFkB pathway normally results in increased NFkB transcriptional
activity. However, aspirin-induced nuclear translocation of NFkB has been shown to
repress NFkB transcriptional activity in colorectal cancer cell lines (Stark et al., 2000).
This work showed that aspirin induces NFkB nuclear translocation and repression of
NFKB-driven transcription, which is not a general inhibitory effect on signalling
pathways or transcriptional machinery. Studies into the kinetics of this response
demonstrated that IkBcc degradation and NFkB nuclear translocation precede repression
of NFKB-driven transcription, commensurate with a causal relationship. Furthermore,
inhibition of NFkB nuclear translocation by super-repressor IkBcc inhibited aspirin-
mediated repression ofNFkB transcriptional activity. The data from Chapter 6 show that
p53 and MMR mutation status do not affect the property of aspirin to induce NFkB
transcriptional repression in colorectal cancer cells. Indeed, it has been shown that NFkB
induced by some cytotoxic stimuli acts as a repressor of anti-apoptotic gene expression
(Campbell et al., 2004). There is increasing evidence that NFkB can act as an activator or
repressor of transcription, dependent on the nature of stimulus and cell environment.
Recently, the host laboratory further elucidated the mechanism underlying repression
occurring as a consequence of p65 nuclear translocation by demonstrating that aspirin
induces nucleolar sequestration of p65, the transcriptionally active subunit of NFkB
(Stark and Dunlop, 2005). Furthermore, identification of a nucleolar localisation signal
219
(NoLS) at the N-terminus of p65 and use of a dominant negative mutant of p65 shows
that aspirin-induced nucleolar sequestration of p65 is responsible for decreased basal
NFkB transcriptional activity and apoptosis. This suggests that aspirin might cause
repression of NFKB-driven anti-apoptotic genes and such studies are currently underway.
It is vital to investigate the effects of aspirin on NFkB activity and effects on relevant
downstream genes. In this group of rectal cancer patients, aspirin has been shown to
decrease expression of the NFKB-driven anti-apoptotic gene BCL-xl and increase
expression of the pro-apoptotic BAX gene in rectal tumours (Macdonald ADH et al.,
2004; Macdonald ADH et al., 2005b). Furthermore, in these aspirin treated rectal cancer
patients, there is decreased expression of the cell adhesion molecule ICAM-1, which is
known to be deranged in colorectal cancer and be involved in metastasis (Macdonald
ADH et al., 2005a). These results suggest that NSAIDs are affecting expression ofNFKB-
driven genes in vivo. The next phase will involve determining which downstream genes
are relevant to the apoptotic response, and defining the balance between pro- and anti-
apoptotic genes.
Constitutive NFkB activation is known to permit escape from apoptosis and to be
associated with resistance to chemotherapeutics. Such activation may be due to alterations
in the NFkB pathway genes, uncontrolled IKK stimulation or constitutive activation of
other upstream kinases. Mutations and deletions in IkBa have previously been observed in
lymphomas, which also show constitutive activation of NFkB. The work presented in
Chapter 8 screened a panel of colorectal cancers for mutations and polymorphic variants
220
in Rel A and IkBa genes. This analysis has identified somatic mutations and other variants
that merit further study. Regions of both the Rel A and IkBa genes, highly relevant to
function of the respective proteins, have not been fully sequenced yet but completion of
analysis of both genes is ongoing. The variant in Rel A at codon 432 is in the
transactivation domain and may be functionally relevant. The Rel A intronic variant is
highly likely to be important, as it is an acquired mutation only identified in tumour
tissue. It will also be important to determine whether the IkBa polymorphisms play a
functional role in determining susceptibility to colorectal cancer or response to NSAIDs.
This work will inform whether there is a genetic component contributing to deregulated
NFkB signalling in colorectal cancer.
There are other potential NFkB pathway candidate genes such as upstream kinases that
may be responsible for continual activation of the NFkB pathway. A recent analysis of
human colorectal cancers for genetic mutations in 340 serine/threonine kinases revealed
mutations in eight genes, including three constituents of the phosphatidylinositol-3-OH
kinase (PI3K) pathway (Parsons et al., 2005). Overall 40% of colorectal cancers had a
mutation in at least one or more of the eight PI3K genes. The PI3K pathway is involved
in cell survival and is negatively regulated by the tumour suppressor gene PTEN
(phosphatase and tensin homologue) (Di Cristofano and Pandolfi, 2000). This may be
important since NFkB has been shown to downregulate expression of PTEN and prevent
apoptosis (Vasudevan et al., 2004). It has been reported that NSAIDs activate PTEN in
colorectal cancer cell lines (Chu et al., 2004). Hence, it is plausible that NSAID-mediated
repression ofNFkB results in increased expression of PTEN and apoptosis.
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Research in prevention and treatment of cancer is advancing and molecular targeted
therapies are rapidly evolving into clinical practice, including Her-2 in breast cancer,
BCR-ABL in chronic myeloid leukaemia, C-KIT in gastrointestinal stromal tumours, and
EGFR in lung cancer (Thiery-Vuillemin et al., 2005). Such molecular targeted treatment
confers a greater degree of specificity than standard empirical therapy. NSAIDs are
emerging as important chemopreventive agents and also possibly as therapeutic agents
against colorectal cancer. It is clear that NSAIDs have a number of different cell and
molecular effects, and the observed relative cell-type specificity suggests that distinct
pathways might be targeted by aspirin in colorectal cancer cells. The research in this
thesis demonstrates that aspirin induces apoptosis following modulation of the NFkB
pathway, providing evidence of a molecular rationale for the greater specificity of
NSAID-mediated protection observed in colorectal cancer compared to other cancers.
The lack of dependency on COX-2 and P-catenin expression, and independence from
MMR and p53 mutation status emphasises the generality of the aspirin-induced NFkB
apoptotic response in colorectal cancer. Establishing the molecular basis of patient
variability in response to aspirin would be a major advance, since currently available
agents could be targeted to people who are at risk of colorectal neoplasia but also based
on whose response could be predicted from molecular markers. Indeed, the validity of
investigating chemopreventive mechanisms of action in cancer tissue may be called into
question. However, it is not feasible to study molecular mechanisms of prevention in
normal colonic tissue given the time-frame involved in development to cancer. The
advantage of studying cancer cells is that it informs which molecular pathways NSAIDs
may be affecting. This permits study of individual deranged pathways in colorectal cancer
including early aberrations in Writ signalling and late events such as p53. Indeed, it is the
investigation of NSAIDs as chemopreventive agents in cancer cells that has brought to
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light their therapeutic potential. With respect to prevention, the host laboratory has shown
that aspirin suppress tumorigenesis in Ape""11"' and AppAm!+, Msh.2'1' mice (Sansom et al.,
2001). Indeed, the effect was only seen when animals were exposed to aspirin in utero,
suggesting aspirin affects neoplastic transformation at the very earliest stages of
development. Unfortunately, p65 null animals are non-viable, but it would be interesting
to investigate the specific role of nucleolar targeting ofNFkB using in vivo models. Thus,
the effects of aspirin on xenografted tumour cells stably expressing p65 lacking the NoLS
(Stark and Dunlop, 2005) could be compared to cells expressing wild-type p65. Another
approach would be to generate a genetically modified animal in which wild-type p65 has
been replaced by an exogenous p65 that lacks the NoLS, through germline targeting. The
phenotype of animals expressing the p65-NoLS"'" would be of considerable interest, and
in particular when crossed with ApcMm animals and treated with aspirin. This might
require generating a conditional knockout using cre-recombinase technology given the
embryonic lethality of p65 null animals.
The central role of NFkB signalling as a key target in NSAID-mediated apoptosis is
supported and substantially strengthened by the cell line data presented in this thesis. The
concept of chemoprevention is based upon intervening in the tumourigenesis process by
which a normal cell acquires defects, which permit clonal expansion of abnormal cell
populations. Hence, it may be that NSAIDs prevent tumour cell expansion by shifting the
balance towards apoptosis via NFkB modulation of apoptosis-related genes. It may also
be that other NFkB related effects such as inhibition of angiogenesis contribute to the
anti-tumour activity. The NFkB pathway is complex and modulation of signalling
activates numerous pathways that positively and negatively regulate survival. The
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challenge lies in identifying which specific components may be targeted to shift the
balance towards eliminating tumour cells. The research presented in this thesis
contributes to understanding the molecular mechanism underlying NSAID-mediated anti-





Colorectal Adenoma Prevention Programme 2 (CAPP2). http://www.capp2.com . 2005.
Abramson, S. B. and Weissmann, G. (1989) The mechanisms of action of nonsteroidal
antiinflammatory drugs. Arthritis Rheum 32: 1-9.
Abulafi, A. M. and Williams, N. S. (1994) Local recurrence of colorectal cancer: the
problem, mechanisms, management and adjuvant therapy. Br J Surg 81: 7-19.
Aggarwal, Bharat B. (2004) Nuclear factor-KB: The enemy within. Cancer Cell 6: 203-
208.
Ahlquist, D. A., Skoletsky, J. E., Boynton, K. A., Harrington, J. J., Mahoney, D. W.,
Pierceall, W. E., Thibodeau, S. N., and Shuber, A. P. (2000) Colorectal cancer screening
by detection of altered human DNA in stool: feasibility of a multitarget assay panel.
Gastroenterology 119: 1219-1227.
Ahmad, M., Rees, R. C., and Ali, S. A. (2004) Escape from immunotherapy: possible
mechanisms that influence tumor regression/progression. Cancer Immunol Immunother
53: 844-854.
A1 Tassan, N., Chmiel, N. H., Maynard, J., Fleming, N., Livingston, A. L., Williams, G.
T., Hodges, A. K., Davies, D. R., David, S. S., Sampson, J. R., and Cheadle, J. P. (2002)
Inherited variants of MYH associated with somatic G:C—>T:A mutations in colorectal
tumors. Nat Genet 30: 227-232.
Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., Marshall, J. R., van
Leeuwen, J. B., Reid, M. E., Ritenbaugh, C., Vargas, P. A., Bhattacharyya, A. B.,
Earnest, D. L., and Sampliner, R. E. (2000) Lack of effect of a high-fiber cereal
supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention
Physicians' Network. NEngl JMed 342: 1156-1162.
225
Ali, I. U., Luke, B. T., Dean, M., and Greenwald, P. (2005) Allellic variants in regulatory
regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer
93: 953-959.
Alpert, D. and Vilcek, J. (2000) Inhibition of IkappaB kinase activity by sodium
salicylate in vitro does not reflect its inhibitory mechanism in intact cells. J Biol Chem
275: 10925-10929.
Ambrosini, G., Adida, C., and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin,
expressed in cancer and lymphoma. Nat Med 3: 917-921.
Anti, M., Armuzzi, A., Morini, S., Iascone, E., Pignataro, G., Coco, C., Lorenzetti, R.,
Paolucci, M., Covino, M., Gasbarrini, A., Vecchio, F., and Gasbarrini, G. (2001) Severe
imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract
in subjects with a history of large adenomas. Gut 48: 238-246.
Appleby, S. B., Ristimaki, A., Neilson, K., Narko, K., and Hla, T. (1994) Structure of the
human cyclo-oxygenase-2 gene. Biochem J302: 723-727.
Arango, H. A., Icely, S., Roberts, W. S., Cavanagh, D., and Becker, J. L. (2001) Aspirin
effects on endometrial cancer cell growth. Obstet Gynecol 97: 423-427.
Arbman, G., Nilsson, E., Storgren-Fordell, V., and Sjodahl, R. (1995) Outcome of
surgery for colorectal cancer in a defined population in Sweden from 1984 to 1986. Dis
Colon Rectum 38: 645-650.
Asano, T. and McLeod, R. S. (2002) Dietary fibre for the prevention of colorectal
adenomas and carcinomas. Cochrane Database Syst Rev CD003430.
Atkin, W. S., Hart, A., Edwards, R., Mclntyre, P., Aubrey, R., Wardle, J., Sutton, S.,
Cuzick, J., and Northover, J. M. A. (1998) Uptake, yield of neoplasia, and adverse effects
of flexible sigmoidoscopy screening. Gut 42: 560-565.
Baeuerle, P. A. and Baltimore, D. (1988) I kappa B: a specific inhibitor of the NF-kappa
B transcription factor. Science 242: 540-546.
Bagnardi, V., Blangiardo, M., La Vecchia, C., and Corrao, G. (2001) A meta-analysis of
alcohol drinking and cancer risk. Br J Cancer 85: 1700-1705.
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M.,
vanTuinen, P., Ledbetter, D. H., Barker, D. F., and Nakamura, Y. (1989) Chromosome 17
deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221.
226
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K.,
Hamilton, S., and Vogelstein, B. (1990) p53 gene mutations occur in combination with
17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-
7722.
Baldi, L., Brown, K., Franzoso, G., and Siebenlist, U. (1996) Critical Role for Lysines 21
and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkappaB-alpha. J Biol Chem
271: 376-379.
Baldwin, A. S., Jr. (1996) The NF-kappa B and I kappa B proteins: new discoveries and
insights. Annu Rev Immunol 14: 649-683.
Barkett, M. and Gilmore, T. D. (1999) Control of apoptosis by Rel/NF-kappaB
transcription factors. Oncogene 18: 6910-6924.
Barnes, C. J. and Lee, M. (1998) Chemoprevention of spontaneous intestinal adenomas in
the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114:
873-877.
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R.,
McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., Snover, D. C.,
Church, T. R., Allen, J. I., Beach, M., Beck, G. J., Bond, J. H., Byers, T., Greenberg, E.
R., Mandel, J. S., Marcon, N., Mott, L. A., Pearson, L., Saibil, F., and van Stolk, R. U.
(2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl JMed 348:
891-899.
Beauparlant, P., Kwan, I., Bitar, R., Chou, P., Koromilas, A. E., Sonenberg, N., and
Hiscott, J. (1994) Disruption of I kappa B alpha regulation by antisense RNA expression
leads to malignant transformation. Oncogene 9: 3189-3197.
Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., Vogelstein,
B., and Kinzler, K. W. (1996) Sulindac suppresses tumorigenesis in the Min mouse.
Carcinogenesis 17: 1757-1760.
Bedi, A., Pasricha, P. J., Akhtar, A. J., Barber, J. P., Bedi, G. C., Giardiello, F. M.,
Zehnbauer, B. A., Hamilton, S. R., and Jones, R. J. (1995) Inhibition of apoptosis during
development of colorectal cancer. Cancer Res 55: 1811-1816.
Beg, A. A., Sha, W. C., Bronson, R. T., and Baltimore, D. (1995a) Constitutive NF-kappa
B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient
mice. Genes Dev 9: 2736-2746.
227
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995b) Embryonic
lethality and liver degeneration in mice lacking the RelA component of NF-kappa B.
Nature 376: 167-170.
Benamouzig, R., Deyra, J., Martin, A., Girard, B., Jullian, E., Piednoir, B., Couturier, D.,
Coste, T., Little, J., and Chaussade, S. (2003) Daily soluble aspirin and prevention of
colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology
125: 328-336.
Beral, V., Hermon, C., Kay, C., Hannaford, P., Darby, S., and Reeves, G. (1999)
Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000
women from Royal College of General Practitioners' oral contraception study. BMJ 318:
96-100.
Bharti, A. C. and Aggarwal, B. B. (2002) Nuclear factor-kappa B and cancer: its role in
prevention and therapy. Biochemical Pharmacology 64: 883-888.
Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J., and Meuth, M. (1994)
Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA
91: 6319-6323.
Bidaut-Russell, M. and Gabriel, S. E. (2001) Adverse gastrointestinal effects of NSAIDs:
consequences and costs. Best Practice & Research Clinical Gastroenterology 15: 739-
753.
Bigler, J., Whitton, J., Lampe, J. W., Fosdick, L., Bostick, R. M., and Potter, J. D. (2001)
CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon
adenoma risk. Cancer Res 61: 3566-3569.
Bingham, S. A., Day, N. E., Luben, R., Ferrari, P., Slimani, N., Norat, T., Clavel-
Chapelon, F., Kesse, E., Nieters, A., Boeing, H., Tjonneland, A., Overvad, K., Martinez,
C., Dorronsoro, M., Gonzalez, C. A., Key, T. J., Trichopoulou, A., Naska, A., Vineis, P.,
Tumino, R., Krogh, V., Bueno-de-Mesquita, H. B., Peeters, P. H., Berglund, G.,
Hallmans, G., Lund, E., Skeie, G., Kaaks, R., and Riboli, E. (2003) Dietary fibre in food
and protection against colorectal cancer in the European Prospective Investigation into
Cancer and Nutrition (EPIC): an observational study. Lancet 361: 1496-1501.
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R.
W., Meltzer, S. J., Rodriguez-Bigas, M. A., Fodde, R., Ranzani, G. N., and Srivastava, S.
(1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer
detection and familial predisposition: development of international criteria for the
determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-
5257.
228
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R.,
Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J., and The
VIGOR Study Group (2000) Comparison of Upper Gastrointestinal Toxicity of
Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. NEngl JMed 343: 1520-
1528.
Bond, M., Fabunmi, R. P., Baker, A. H., and Newby, A.C. (1998) Synergistic
upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an
absolute requirement for transcription factor NF-kB. FEBS Letters 435: 29-34.
Bonithon-Kopp, C., Kronborg, O., Giacosa, A., Rath, U., and Faivre, J. (2000) Calcium
and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised
intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:
1300-1306.
Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J.
T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M.
M. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by
sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-
2560.
Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M. P., and Castronovo, V. (1994)
The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I
kappa B-related proteins in tumor cell lines. Biochem Pharmacol 47: 145-149.
Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barrett, J. C.,
Kolodner, R. D., and Kunkel, T. A. (1995) Microsatellite instability, mismatch repair
deficiency, and genetic defects in human cancer cell lines. Cancer Res 55: 6063-6070.
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K.,
Tines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., and Baron, J. A. (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. NEngl JMed 352: 1092-1102.
Brooks, P. M. and Day, R. O. (1991) Nonsteroidal antiinflammatory drugs—differences
and similarities. NEngl JMed 324: 1716-1725.
Brown, S. R., Finan, P. J., and Bishop, D. T. (1998) Are relatives of patients with
multiple HNPCC spectrum tumours at increased risk of cancer? [see comments]. Gut 43:
664-668.
229
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams,
J., Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1999) Disruption of p53 in human
cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
Burkitt, D. P. (1971) Epidemiology of cancer of the colon and rectum. Cancer 28: 3-13.
Butler, L. M., Sinha, R., Millikan, R. C., Martin, C. F., Newman, B., Gammon, M. D.,
Ammerman, A. S., and Sandler, R. S. (2003) Heterocyclic amines, meat intake, and
association with colon cancer in a population-based study. Am JEpidemiol 157: 434-445.
Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F., and Hay, R. T. (1999) Mutations in the
IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.
Oncogene 18: 3063-3070.
Camma, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., and Cottone, M. (2000)
Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 284: 1008-
1015.
Campbell, K. J. and Perkins, N. D. (2004) Post-translational modification of RelA (p65)
NF-kappaB. Biochem Soc Trans 32: 1087-1089.
Campbell, K. J., Rocha, S., and Perkins, N. D. (26-3-2004) Active repression of
antiapoptotic gene expression by RelA (p65) NF-kappa B. Mol Cell 13: 853-865.
CAPP-1 (2003) Abstracts presented at the Spring Conference 2003 of the Cancer
Genetics Group, 12-13 May 2003, Southampton, UK. Familial Cancer 2: 135-149.
Castano, E., Dalmau, M., Barragan, M., Pueyo, G., Bartrons, R., and Gil, J. (1999)
Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in
HT-29 human colon adenocarcinoma cells [In Process Citation]. Br J Cancer 81: 294-
299.
Chan, A. T., Tranah, G. J., Giovannucci, E. L., Hunter, D. J., and Fuchs, C. S. (2005)
Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
JNatl Cancer Inst 97: 457-460.
Chan, T. A., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Mechanisms
underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U
S A 95: 681-686.
Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S.,
and Simmons, D. L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by
230
acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.
Proc Natl Acad Sci USA 99: 13926-13931.
Chapman, N. R., Webster, G. A., Gillespie, P. J., Wilson, B. J., Crouch, D. H., and
Perkins, N. D. (2002) A novel form of the RelA nuclear factor kappaB subunit is induced
by and forms a complex with the proto-oncogene c-Myc. Biochem J 366: 459-469.
Chappie, K. S., Cartwright, E. J., Hawcroft, G., Tisbury, A., Bonifer, C., Scott, N.,
Windsor, A. C., Guillou, P. J., Markham, A. F., Coletta, P. L., and Hull, M. A. (2000)
Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol
156: 545-553.
Charalambous, D., Skinner, S. A., and O'Brien, P. E. (1998) Sulindac inhibits colorectal
tumour growth, but not prostaglandin synthesis in the rat. J Gastroenterol Hepatol 13:
1195-1200.
Charalambous, M. P., Maihofner, C., Bhambra, U., Lightfoot, T., and Gooderham, N. J.
(2003) Upregulation of cyclooxygenase-2 is accompanied by increased expression of
nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial
cells. Br J Cancer 88: 1598-1604.
Chau, I., Chan, S., and Cunningham, D. (2003) Overview of preoperative and
postoperative therapy for colorectal cancer: the European and United States perspectives.
Clin Colorectal Cancer 3: 19-33.
Chen, C., Edelstein, L. C., and Gelinas, C. (2000) The Rel/NF-kappa B Family Directly
Activates Expression of the Apoptosis Inhibitor Bcl-xL. Mol Cell Biol 20: 2687-2695.
Chen, L. F., Mu, Y., and Greene, W. C. (2002) Acetylation of RelA at discrete sites
regulates distinct nuclear functions ofNF-kappaB. EMBO J 21: 6539-6548.
Chilov, D., Kukk, E., Taira, S., Jeltsch, M., Kaukonen, J., Palotie, A., Joukov, V., and
Alitalo, K. (1997) Genomic Organization of Human and Mouse Genes for Vascular
Endothelial Growth Factor C. JBiol Chem 272: 25176-25183.
Chiu, C. H., McEntee, M. F., and Whelan, J. (1997) Sulindac causes rapid regression of
preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res
57:4267-4273.
Chiu, C. H., McEntee, M. F., and Whelan, J. (2000) Discordant effect of aspirin and
indomethacin on intestinal tumor burden in 4/?c(Min/+)mice. Prostaglandins Leukot
Essent Fatty Acids 62: 269-275.
231
Chu, E. C., Chai, J., and Tarnawski, A. S. (2004) NSAIDs activate PTEN and other
phosphatases in human colon cancer cells: novel mechanism for chemopreventive action
of NSAIDs. Biochemical and Biophysical Research Communications 320: 875-879.
Citarda, F., Tomaselli, G., Capocaccia, R., Barcherini, S., Crespi, M., and Group, The
Italian Multicentre Study (2001) Efficacy in standard clinical practice of colonoscopic
polypectomy in reducing colorectal cancer incidence. Gut 48: 812-815.
Collart, M. A., Baeuerle, P., and Vassalli, P. (1990) Regulation of tumor necrosis factor
alpha transcription in macrophages: involvement of four kappa B-like motifs and of
constitutive and inducible forms ofNF-kappa B. Mol Cell Biol 10: 1498-1506.
Colorectal Cancer Collaborative, Group (2001) Adjuvant radiotherapy for rectal cancer: a
systematic overview of 8507 patients from 22 randomised trials. The Lancet 358: 1291-
1304.
Comis, R.L. (2005) The Current Situation: Erlotinib (Tarceva(R)) and Gefitinib
(Iressa(R)) in Non-Small Cell Lung Cancer. Oncologist 10: 467-470.
Conne, B., Stutz, A., and Vassalli, J. D. (2000) The 3' untranslated region of messenger
RNA: A molecular 'hotspot' for pathology? Nat Med 6: 637-641.
Cottu, P. H., Muzeau, F., Estreicher, A., Flejou, J. F., Iggo, R., Thomas, G., and Hamelin,
R. (1996) Inverse correlation between RER+ status and p53 mutation in colorectal cancer
cell lines. Oncogene 13: 2727-2730.
Coxhead, J. M., Williams, E. A., and Mathers, J. C. (2005) DNA mismatch repair status
may influence anti-neoplastic effects of butyrate. Biochem Soc Trans 33: 728-729.
Crabtree, M. D., Tomlinson, I. P. M., Hodgson, S. V., Neale, K. , Phillips, R. K. S., and
Houlston, R. S. (2002) Explaining variation in familial adenomatous polyposis:
relationship between genotype and phenotype and evidence for modifier genes. Gut 51:
420-423.
Cramer, D. W., Harlow, B. L., Titus-Ernstoff, L., Bohlke, K., Welch, W. R., and
Greenberg, E. R. (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet
351: 104-107.
Croitoru, M. E., Cleary, S. P., Di Nicola, N., Manno, M., Selander, T., Aronson, M.,
Redston, M., Cotterchio, M., Knight, J., Gryfe, R., and Gallinger, S. (2004) Association
Between Biallelic and Monoallelic Germline MYH Gene Mutations and Colorectal
Cancer Risk. JNatl Cancer Inst 96: 1631-1634.
232
de la Chapelle, A. (2004) Genetic Predisposition to Colorectal Cancer. Nat Rev Cancer 4:
769-780.
Debinski, H. S., Love, S., Spigelman, A. D., and Phillips, R. K. (1996) Colorectal polyp
counts and cancer risk in familial adenomatous polyposis. Gastroenterology 110: 1028-
1030.
Dejardin, E., Deregowski, V., Chapelier, M., Jacobs, N., Gielen, J., Merville, M. P., and
Bours, V. (1999) Regulation of NF-kappaB activity by I kappaB-related proteins in
adenocarcinoma cells. Oncogene 18: 2567-2577.
Deloukas, P., Dauwerse, J. G., van Ommen, G. J., and van Loon, A. P. (1994) The human
NFKB3 gene encoding the p65 subunit of transcription factor NF-kappa B is located on
chromosome 11 q 12. Genomics 19: 592-594.
Deloukas, P. and van Loon, A. P. (1993) Genomic organization of the gene encoding the
p65 subunit of NF-kappa B: multiple variants of the p65 protein may be generated by
alternative splicing. Hum Mol Genet 2: 1895-1900.
Deng, J., Miller, S. A., Wang, H. Y., Xia, W„ Wen, Y„ Zhou, B. P., Li, Y„ Lin, S. Y„
and Hung, M. C. (2002) (3-catenin interacts with and inhibits NF-kB in human colon and
breast cancer. Cancer Cell 2: 323-334.
Di Cristofano, A. and Pandolfi, P. P. (2000) The multiple roles of PTEN in tumor
suppression. Cell 100: 387-390.
Dihlmann, S., Siermann, A., and von Knebel, Doeberitz (2001) The nonsteroidal anti¬
inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling.
Oncogene 20: 645-653.
Dihlmann, S., Klein, S., and Doeberitz, M. (2003) Reduction of (3-Catenin/T-Cell
Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased
Stabilization of Phosphorylated {beta}-Catenin. Mol Cancer Ther 2: 509-516.
Din, F. V., Dunlop, M. G., and Stark, L. A. (2004) Evidence for colorectal cancer cell
specificity of aspirin effects on NFkappaB signalling and apoptosis. Br J Cancer 91: 381-
388.
Din, F. V. N., Stark, L. A., and Dunlop, M. G. (2005) NSAIDs induce apoptosis via
NFkB modulation in colorectal cancer patients. Colorectal Disease 7 [SI], 5. Ref Type:
Abstract
233
Djureinovic, T., Skoglund, J., Vandrovcova, J., Zhou, X., Kalushkova, A., Iselius, L., and
Lindblom, A. (2005) A genome-wide linkage analysis in Swedish families with
hereditary non-FAP/non-HNPCC colorectal cancer. Gut. RefType: Electronic Citation
Dolara, P., Caderni, G., and Tonelli, F. (1999) Nimesulide, a selective anti-inflammatory
cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in
familial adenomatous polyposis. Scand J Gastroenterol 34: 1168.
Doll, R. and Peto, R. (1981) The causes of cancer: quantitative estimates of avoidable
risks of cancer in the United States today. JNatl Cancer Inst 66: 1191-1308.
Dube, S., Heyen, F., and Jenicek, M. (1997) Adjuvant chemotherapy in colorectal
carcinoma: results of a meta-analysis. Dis Colon Rectum 40: 35-41.
Dukes, C. E (1951) The surgical pathology of tumours of the colon. Med Press 226: 512-
515.
Dunlop, M. G. (2001) Colorectal Cancers. Scottish Executive Health Department.
Edinburgh, The Scottish Executive. Cancer Scenarios: An aid to planning cancer services
in Scotland in the next decade. 48-62 RefType: Report
Duran, A., Diaz-Meco, M. T., and Moscat, J. (1-8-2003) Essential role of RelA Ser311
phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 22: 3910-
3918.
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois,
R. N. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal
adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
Elder, D. J., Hague, A., Hicks, D. J., and Paraskeva, C. (1996) Differential growth
inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines:
enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma
relative to adenoma cell lines. Cancer Res 56: 2273-2276.
Elder, D. J., Halton, D. E., Hague, A., and Paraskeva, C. (1997) Induction of apoptotic
cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-
selective nonsteroidal anti- inflammatory drug: independence from COX-2 protein
expression. Clin Cancer Res 3: 1679-1683.
Elder, D. J. and Paraskeva, C. (1998) COX-2 inhibitors for colorectal cancer [news]. Nat
Med 4: 392-393.
234
Epinat, J. C. and Gilmore, T. D. (1999) Diverse agents act at multiple levels to inhibit the
Rel/NF-kappaB signal transduction pathway. Oncogene 18: 6896-6909.
Evertsson, S. and Sun, X. F. (2002) Protein expression ofNF-kappaB in human colorectal
adenocarcinoma. Int JMol Med 10: 547-550.
Fairfield, K. M., Hunter, D. J., Fuchs, C. S., Colditz, G. A., and Hankinson, S. E. (2002)
Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control
13: 535-542.
Fan, C., Yang, J., and Engelhardt, J. F. (2002) Temporal pattern ofNFkappaB activation
influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci 115: 4843-4853.
Farrington, S. M., Lin-Goerke, J., Ling, J., Wang, Y., Burczak, J. D., Robbins, D. J., and
Dunlop, M. G. (1998) Systematic analysis of hMSH2 and hMLHl in young colon cancer
patients and controls. Am JHum Genet 63: 749-759.
Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis.
Cell 61:759-767.
Feng, J. Q., Xing, L., Zhang, J. H., Zhao, M., Horn, D., Chan, J., Boyce, B. F., Harris, S.
E., Mundy, G. R., and Chen, D. (2003) NF-kB Specifically Activates BMP-2 Gene
Expression in Growth Plate Chondrocytes in Vivo and in a Chondrocyte Cell Line in
Vitro. JBiol Chem 278: 29130-29135.
Figueredo, A., Germond, C., Maroun, J., Browman, G., Walker-Dilks, C., and Wong, S.
(1997) Adjuvant therapy for stage II colon cancer after complete resection. Provincial
Gastrointestinal Disease Site Group. Cancer Prev Control 1: 379-392.
Figueredo, A., Charette, M. L., Maroun, J., Brouwers, M. C., and Zuraw, L. (2004)
Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer
Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site
Group. J Clin Oncol 22: 3395-3407.
Fodde, R., Smits, R., and Clevers, H. (2001) APC, signal transduction and genetic
instability in colorectal cancer. Nat Rev Cancer 1: 55-67.
Frantz, B. and O'Neill, E. A. (1995) The effect of sodium salicylate and aspirin on NF-
kappa B. Science 270: 2017-2019.
235
Frizelle, F. A., Emanuel, J. C., Keating, J. P., and Dobbs, B. R. (2002) A multicentre
retrospective audit of outcome of patients undergoing curative resection for rectal cancer.
NZMedJ 115: 284-286.
Fuchs, C. S., Giovannucci, E. L., Colditz, G. A., Hunter, D. J., Stampfer, M. J., Rosner,
B., Speizer, F. E., and Willett, W. C. (1999) Dietary fiber and the risk of colorectal cancer
and adenoma in women. NEngl JMed 340: 169-176.
Fujioka, S., Sclabas, G. M., Schmidt, C., Frederick, W. A., Dong, Q. G., Abbruzzese, J.
L., Evans, D. B., Baker, C., and Chiao, P. J. (2003) Function of Nuclear Factor kB in
Pancreatic Cancer Metastasis. Clin Cancer Res 9: 346-354.
Fukutake, M., Nakatsugi, S., Isoi, T., Takahashi, M., Ohta, T., Mamiya, S., Taniguchi, Y.,
Sato, H., Fukuda, K., Sugimura, T., and Wakabayashi, K. (1998) Suppressive effects of
nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon
carcinogenesis in mice. Carcinogenesis 19: 1939-1942.
Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., and Hennekens, C. H. (1993) Low-
dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst
85: 1220-1224.
Gatof, D. and Ahnen, D. (2002) Primary prevention of colorectal cancer: diet and drugs.
Gastroenterol Clin North Am 31: 587-623, xi.
Gertig, Dorota M. and Hunter, David J. (1997) Genes and environment in the etiology of
colorectal cancer. Seminars in Cancer Biology 8: 285-298.
Giardiello, F. M., Hamilton, S. R. , Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P.,
Booker, S. V., Robinson, C. R., and Offerhaus, G. J. (1993) Treatment of colonic and
rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:
1313-1316.
Giardiello, F. M., Offerhaus, J. A., Tersmette, A. C., Hylind, L. M., Krush, A. J.,
Brensinger, J. D., Booker, S. V., and Hamilton, S. R. (1996) Sulindac induced regression
of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive
factors. Gut 38: 578-581.
Giardiello, F. M., Yang, V. W., Hylind, L. M., Krush, A. J., Petersen, G. M., Trimbath, J.
D., Piantadosi, S., Garrett, E., Geiman, D. E., Hubbard, W., Offerhaus, G. J., and
Hamilton, S. R. (2002) Primary chemoprevention of familial adenomatous polyposis with
sulindac. NEngl JMed 346: 1054-1059.
236
Gilmore, T. D. (1999) Multiple mutations contribute to the oncogenicity of the retroviral
oncoprotein v-Rel. Oncogene 18: 6925-6937.
Gilmore, T. D., Kalaitzidis, D., Liang, M. C., and Starczynowski, D. T. (2004) The c-Rel
transcription factor and B-cell proliferation: a deal with the devil. Oncogene 23: 2275-
2286.
Giovannucci, E. (1995) Insulin and colon cancer. Cancer Causes Control 6: 164-179.
Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., and Willett,
W. C. (1994) Intake of fat, meat, and fiber in relation to risk of colon cancer in men.
Cancer Res 54: 2390-2397.
Giovannucci, E., Stampfer, M. J., Colditz, G. A., Rimm, E. B., Trichopoulos, D., Rosner,
B. A., Speizer, F. E., and Willett, W. C. (1993) Folate, methionine, and alcohol intake and
risk of colorectal adenoma. JNatl Cancer Inst 85: 875-884.
Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J., and Willett,
W. C. (1995) Physical Activity, Obesity, and Risk for Colon Cancer and Adenoma in
Men|. Ann Intern Med 122: 327-334.
Giovannucci, E., Chen, J., Smith-Warner, S. A., Rimm, E. B., Fuchs, C. S., Palomeque,
C., Willett, W. C., and Hunter, D. J. (2003) Methylenetetrahydrofolate Reductase,
Alcohol Dehydrogenase, Diet, and Risk of Colorectal Adenomas. Cancer Epidemiol
Biomarkers Prev 12: 970-979.
Girvin, B., Rafferty, T., Stevenson, M. R., and Johnston, G. D. (2004) Uptake of COX-2
selective inhibitors and influence on NSAID prescribing in Northern Ireland.
Pharmacoepidemiol Drug Saf 13: 153-157.
Goel, A., Chang, D. K., Ricciardiello, L., Gasche, C., and Boland, C. R. (2003) A Novel
Mechanism for Aspirin-mediated Growth Inhibition of Human Colon Cancer Cells. Clin
Cancer Res 9: 383-390.
Goldberg, Y., Nassif, I. I., Pittas, A., Tsai, L. L., Dynlacht, B. D., Rigas, B., and Shiff, S.
J. (1996) The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon
cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene
12:893-901.
Gordon, N. L., Dawson, A. A., Bennett, B., Innes, G., Eremin, O., and Jones, P. F. (1993)
Outcome in colorectal adenocarcinoma: two seven-year studies of a population. BMJ 307:
707-710.
237
Govind, S. (1999) Control of development and immunity by rel transcription factors in
Drosophila. Oncogene 18: 6875-6887.
Gray, R. G., Barnwell, J., Hills, R., McConkey, C., Williams, N., and Kerr, D. (2004)
QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including
3238 colorectal cancer patients. J Clin Oncol (Meeting Abstracts) 22: 3501.
Griffin, M. R., Bergstralh, E. J., Coffey, R. J., Beart, R. W., Jr., and Melton, L. J., Ill
(1987) Predictors of survival after curative resection of carcinoma of the colon and
rectum. Cancer 60: 2318-2324.
Grilli, M., Pizzi, M., Memo, M., and Spano, P. (1996) Neuroprotection by Aspirin and
Sodium Salicylate Through Blockade of NF-kappa B Activation. Science 274: 1383-
1385.
Gunderson, L. L., Haddock, M. G., and Schild, S. E. (2003) Rectal cancer: Preoperative
versus postoperative irradiation as a component of adjuvant treatment. Semin Radiat
Oncol 13: 419-432.
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., and Baldwin, A. S. (1999)
NF-kappa B Controls Cell Growth and Differentiation through Transcriptional Regulation
ofCyclin Dl. Mol Cell Biol 19: 5785-5799.
Habr-Gama, A., Perez, R. O., Kiss, D. R., Rawet, V., Scanavini, A., Santinho, P. M., and
Nadalin, W. (2004) Preoperative chemoradiation therapy for low rectal cancer. Impact on
downstaging and sphincter-saving operations. Hepatogastroenterology 51: 1703-1707.
Halford, S. E. R., Rowan, A. J., Lipton, L., Sieber, O. M., Pack, K., Thomas, H. J. W.,
Hodgson, S. V., Bodmer, W. F., and Tomlinson, Ian P. M. (2003) Germline Mutations
but Not Somatic Changes at the MYH Locus Contribute to the Pathogenesis of
Unselected Colorectal Cancers. Am JPathol 162: 1545-1548.
Han, E. K., Arber, N., Yamamoto, H., Lim, J. T., Delohery, T., Pamukcu, R., Piazza, G.
A., Xing, W. Q., and Weinstein, I. B. (1998) Effects of sulindac and its metabolites on
growth and apoptosis in human mammary epithelial and breast carcinoma cell lines.
Breast Cancer Res Treat 48: 195-203.
Hanahan, D., Christofori, G., Naik, P., and Arbeit, J. (1996) Transgenic mouse models of
tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for
preclinical therapeutic models. Eur J Cancer 32A: 2386-2393.
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and
Rigas, B. (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on
238
induction of apoptosis in colon cancer cells by a prostaglandin- independent pathway.
Biochem Pharmacol 52: 237-245.
Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S.,
Balfour, T. W., James, P. D., and Mangham, C. M. (1996) Randomised controlled trial of
faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477.
Hardwick, J. C., van den Brink, G. R., Offerhaus, G. J., van Deventer, S. J., and
Peppelenbosch, M. P. (2001) NF-kappaB, p38 MAPK and JNK are highly expressed and
active in the stroma of human colonic adenomatous polyps. Oncogene 20: 819-827.
Harhaj, E. W. and Sun, S. C. (1999) Regulation of RelA Subcellular Localization by a
Putative Nuclear Export Signal and p50. Mol Cell Biol 19: 7088-7095.
Hatada, E. N., Nieters, A., Wulczyn, F. G., Naumann, M., Meyer, R., Nucifora, G.,
McKeithan, T. W., and Scheidereit, C. (1992) The Ankyrin Repeat Domains of the NF-
{kappajB Precursor pl05 and the Protooncogene bcl-3 Act as Specific Inhibitors of NF-
{kappajB DNA Binding. PNAS 89: 2489-2493.
Hawk ET, Umar, A., and Viner, J. L. (2004) Colorectal cancer chemoprevention—an
overview of the science. Gastroenterology 126(5): 1423-1447.
Hawkey, C. J. (1999) COX-2 inhibitors [see comments]. Lancet 353: 307-314.
He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. (1999) PPARdelta is an APC-
regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P.
J., Vogelstein, B., and Kinzler, K. W. (1998) Identification of c-MYC as a Target of the
APC Pathway. Science 281: 1509-1512.
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell,
G., Warren, W., Aminoff, M., Hoglund, P., Jarvinen, H., Kristo, P., Pelin, K., Ridanpaa,
M., Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., Olsen, A. S., Stratton, M. R., de
la, Chapelle A., and Aaltonen, L. A. (1998) A serine/threonine kinase gene defective in
Peutz-Jeghers syndrome. Nature 391: 184-187.
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J. P., Markowitz, S.,
Willson, J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein,
B., Kunkel, T. A., and Baylin, S. B. (1998) Incidence and functional consequences of
hMLHl promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA
95: 6870-6875.
239
Hinata, K., Gervin, A. M., Jennifer, Zhang Y., and Khavari, P. A. (2003) Divergent gene
regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of
human skin. Oncogene 22: 1955-1964.
Hippisley-Cox, J., Coupland, C., and Logan, R. (2005) Risk of adverse gastrointestinal
outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal
anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-
1316.
Hirano, F., Chung, M., Tanaka, H., Maruyama, N., Makino, I., Moore, D. D., and
Scheidereit, C. (1998) Alternative Splicing Variants of Ikappa Bbeta Establish
Differential NF-kappa B Signal Responsiveness in Human Cells. Mol Cell Biol 18: 2596-
2607.
Hixson, L. J., Earnest, D. L., Fennerty, M. B., and Sampliner, R. E. (1993) NSAID effect
on sporadic colon polyps. Am J Gastroenterol 88: 1652-1656.
Honma, M., Momose, M., Tanabe, H., Sakamoto, H., Yu, Y., Little, J. B., Sofuni, T., and
Hayashi, M. (2000) Requirement of wild-type p53 protein for maintenance of
chromosomal integrity. Mol Carcinog 28: 203-214.
Howe, J. R., Bair, J. L., Sayed, M. G., Anderson, M. E., Mitros, F. A., Petersen, G. M.,
Velculescu, V. E., Traverso, G., and Vogelstein, B. (2001a) Germline mutations of the
gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet
28: 184-187.
Howe, J. R., Roth, S., Ringold, J. C., Summers, R. W., Jarvinen, H. J., Sistonen, P.,
Tomlinson, I. P., Houlston, R. S., Bevan, S., Mitros, F. A., Stone, E. M., and Aaltonen, L.
A. (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086-
1088.
Howe, L. R., Subbaramaiah, K., Brown, A. M., and Dannenberg, A. J. (2001b)
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr
Relat Cancer 8: 97-114.
Howie, S. E., Sommerfield, A. J., Gray, E., and Harrison, D. J. (1994) Peripheral T
lymphocyte depletion by apoptosis after CD4 ligation in vivo: selective loss of CD44-
and 'activating' memory T cells. Clin Exp Immunol 95: 195-200.
Huang, S., DeGuzman, A., Bucana, C. D., and Fidler, I. J. (2000) Nuclear Factor-KB
Activity Correlates with Growth, Angiogenesis, and Metastasis of Human Melanoma
Cells in Nude Mice. Clin Cancer Res 6: 2573-2581.
240
Hubbard, W. C., Alley, M. C., McLemore, T. L., and Boyd, M. R. (1988) Profiles of
prostaglandin biosynthesis in sixteen established cell lines derived from human lung,
colon, prostate, and ovarian tumors. Cancer Res 48: 4770-4775.
Hull, M. A., Booth, J. K., Tisbury, A., Scott, N., Bonifer, C., Markham, A. F., and
Coletta, P. L. (1999) Cyclooxygenase 2 is up-regulated and localized to macrophages in
the intestine ofMin mice. Br J Cancer 79: 1399-1405.
Husain, S. S., Szabo, I. L., and Tamawski, A. S. (2002) NSAID inhibition of GI cancer
growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol
97: 542-553.
Huxford, T., Huang, D. B., Malek, S., and Ghosh, G. (1998) The crystal structure of the
IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation [see
comments]. Cell 95: 759-770.
Iademarco, M. F., McQuillan, J. J., Rosen, G. D., and Dean, D. C. (1992)
Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). JBiol
Chem 267: 16323-16329.
Ichii, S., Horii, A., Nakatsuru, S., Furuyama, J., Utsunomiya, J., and Nakamura, Y. (1992)
Inactivation of both APC alleles in an early stage of colon adenomas in a patient with
familial adenomatous polyposis (FAP). Hum Mol Genet 1: 387-390.
IMPACT (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT)
investigators. Lancet 345: 939-944.
Imperiale, T. F., Wagner, D. R., Lin, C. Y., Larkin, G. N., Rogge, J. D., and Ransohoff,
D. F. (2000) Risk of advanced proximal neoplasms in asymptomatic adults according to
the distal colorectal findings. NEngl JMed 343: 169-174.
Inan, M. S., Tolmacheva, V., Wang, Q. S., Rosenberg, D. W., and Giardina, C. (2000)
Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the
colon. Am JPhysiol Gastrointest Liver Physiol 279: G1282-G1291.
Information and Statistics Division, Scotland. Colorectal Cancer. Information and
Statistics Division, Scotland website. 2005. Ref Type: Electronic Citation
Insel P (1996) Analgesic-antipyretic and antiinflammatory agents and drugs employed in
the treatment of gout. In The Pharmacological Basis of Therapeutics. Hardman, J.G.,
Limberd, L.E., Molinoff, P.B., Rudden, R.W., and Gilman, A.G. (eds.) New York:
McGraw-Hill, pp. 617-659.
241
Jacobs, M. D. and Harrison, S. C. (1998) Structure of an IkappaBalpha/NF-kappaB
complex [see comments]. Cell 95: 749-758.
Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K., Cole, C. E.,
Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. (1996)
Chemoprevention of spontaneous intestinal adenomas in the Ape Min mouse model by
the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56: 710-714.
Jaffray, E., Wood, K. M., and Hay, R. T. (1995) Domain organization of I kappa B alpha
and sites of interaction with NF- kappa B p65. Mol Cell Biol 15: 2166-2172.
Janne, P. A. and Mayer, R. J. (2000) Chemoprevention of colorectal cancer. N Engl J
Med 342: 1960-1968.
Jarvis, W. D., Grant, S., and Kolesnick, R. N. (1996) Ceramide and the induction of
apoptosis. Clin Cancer Res 2: 1-6.
Jen, J., Kim, H., Piantadosi, S., Liu, Z. F., Levitt, R. C., Sistonen, P., Kinzler, K. W.,
Vogelstein, B., and Hamilton, S. R. (1994) Allelic loss of chromosome 18q and prognosis
in colorectal cancer. NEngl JMed 331: 213-221.
Jiang, X., Takahashi, N., Matsui, N., Tetsuka, T., and Okamoto, T. (2003) The NF-kappa
B Activation in Lymphotoxin beta Receptor Signaling Depends on the Phosphorylation of
p65 at Serine 536. JBiol Chem 278: 919-926.
Jobin, C. and Sartor, R. B (2000) The Ikappa B/NF-kappa B system: a key determinant of
mucosal inflammation and protection. Am J Physiol Cell Physiol 278: C451-C462.
Jungnickel, B., Staratschek-Jox, A., Brauninger, A., Spieker, T., Wolf, Jurgen, D.,
Volker, H., Martin L., Rajewsky, K., and Kuppers, R. (2000) Clonal Deleterious
Mutations in the IxBa Gene in the Malignant Cells in Hodgkin's Lymphoma. J Exp Med
191: 395-402.
Kambara, T., Whitehall, V. L., Spring, K. J., Barker, M. A., Arnold, S., Wynter, C. V.,
Matsubara, N., Tanaka, N., Young, J. P., Leggett, B. A., and Jass, J. R. (2004) Role of
inherited defects of MYH in the development of sporadic colorectal cancer. Genes
Chromosomes Cancer 40: 1-9.
Kanemitsu, Y., Kato, T., Hirai, T., Yasui, K., Morimoto, T., Shimizu, Y., Kodera, Y., and
Yamamura, Y. (2003) Survival after curative resection for mucinous adenocarcinoma of
the colorectum. Dis Colon Rectum 46: 160-167.
242
Kapiteijn, E., Marijnen, C. A., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T.,
Rutten, H. J., Pahlman, L., Glimelius, B., van Krieken, J. H., Leer, J. W., and van de
Velde, C. J. (2001) Preoperative radiotherapy combined with total mesorectal excision for
resectable rectal cancer. N Engl JMed 345: 638-646.
Kashfi, K., Ryann, Y., Qiao, L. L., Williams, J. L., Chen, J., Del Soldato, P., Traganos,
F., and Rigas, B. (2002) Nitric oxide-donating nonsteroidal anti-inflammatory drugs
inhibit the growth of various cultured human cancer cells: evidence of a tissue type-
independent effect. JPharmacol Exp Ther 303: 1273-1282.
Keller, J. J., Offerhaus, G. J., Drillenburg, P., Caspers, E., Musler, A., Ristimaki, A., and
Giardiello, F. M. (2001) Molecular analysis of sulindac-resistant adenomas in familial
adenomatous polyposis. Clin Cancer Res 7: 4000-4007.
Keller, J. J., Offerhaus, G. J., Polak, M., Goodman, S. N., Zahurak, M. L., Hylind, L. M.,
Hamilton, S. R., and Giardiello, F. M. (1999) Rectal epithelial apoptosis in familial
adenomatous polyposis patients treated with sulindac. Gut 45: 822-828.
Kemp, Z., Thirlwell, C., Sieber, O., Silver, A., and Tomlinson, I. (2004) An update on the
genetics of colorectal cancer. Hum Mol Genet 13: R177-R185.
Kewenter, J., Brevinge, H., Engaras, B., Haglind, E., and Ahren, C. (1994) Results of
screening, rescreening, and follow-up in a prospective randomized study for detection of
colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J
Gastroenterol 29: 468-473.
Khachigian, L. M., Resnick, N., Gimbrone, M. A., Jr., and Collins, T. (1995) Nuclear
factor-kappa B interacts functionally with the platelet-derived growth factor B-chain
shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J
Clin Invest 96: 1169-1175.
Khuder, S. A. and Mutgi, A. B. (2001) Breast cancer and NSAID use: a meta-analysis. Br
J Cancer 84: 1188-1192.
Kiernan, R., Bres, V., Ng, R. W. M., Coudart, M. P., El Messaoudi, S., Sardet, C., Jin, D.
Y., Emiliani, S., and Benkirane, M. (2003) Post-activation Turn-off of NF-kappa B-
dependent Transcription Is Regulated by Acetylation of p65. J Biol Chem 278: 2758-
2766.
Kim, K. S., Baek, S. J., Flake, G. P., Loftin, C. D., Calvo, B. F., and Eling, T. E. (2002)
Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-
1) in human and mouse tissue. Gastroenterology 122: 1388-1398.
243
Kim, Paul J., Plescia, Janet, Clevers, Hans, Fearon, Eric R., and Altieri, Dario C. (2003)
Survivin and molecular pathogenesis of colorectal cancer. The Lancet 362: 205-209.
Kinzler, K. W. and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell
87: 159-170.
Kishimoto, Y., Takata, N., Jinnai, T., Morisawa, T., Shiota, G., Kawasaki, H., and
Hasegawa, J. (2000) Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC
mRNA in the colon of rats treated with azoxymethane. Gut 47: 812-819.
Kohli, M., Yu, J., Seaman, C., Bardelli, A., Kinzler, K. W., Vogelstein, B., Lengauer, C.,
and Zhang, L. (2004) SMAC/Diablo-dependent apoptosis induced by nonsteroidal
antiinflammatory drugs (NSAIDs) in colon cancer cells. PNAS 101: 16897-16902.
Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and
Boland, C. R. (1994) Human chromosome 3 corrects mismatch repair deficiency and
microsatellite instability and reduces N-methyl-N'-nitro-N- nitrosoguanidine tolerance in
colon tumor cells with homozygous hMLHl mutation. Cancer Res 54: 4308-4312.
Kolonel, Laurence N., Altshuler, David, and Henderson, Brian E. (2004) The Multiethnic
Cohort Study: Exploring Genes, Lifestyle And Cancer Risk. Nat Rev Cancer 4: 519-527.
Kopp, E. and Ghosh, S. (1994) Inhibition ofNF-kappa B by sodium salicylate and aspirin
[see comments]. Science 265: 956-959.
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W.,
Vogelstein, B., and Clevers, H. (1997) Constitutive transcriptional activation by a beta-
catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
Kralj, M., Kapitanovic, S., Kovacevic, D., Lukac, J., Spaventi, S., and Pavelic, K. (2001)
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and
apoptosis of colon carcinoma cells. J Cancer Res Clin Oncol 127: 173-179.
Krappmann, D., Emmerich, F., Kordes, U., Scharschmidt, E., Dorken, B., and
Scheidereit, C. (1999) Molecular mechanisms of constitutive NF-kappaB/Rel activation
in Hodgkin/Reed-Sternberg cells. Oncogene 18: 943-953.
Kronborg, O., Fenger, C., Olsen, J., Jorgensen, O. D., and Sondergaard, O. (1996)
Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet
348: 1467-1471.
244
Kuismanen, S. A., Holmberg, M. T., Salovaara, R., de la, Chapelle A., and Peltomaki, P.
(2000) Genetic and epigenetic modification of MLH1 accounts for a major share of
microsatellite-unstable colorectal cancers. Am JPathol 156: 1773-1779.
Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., Mclntyre, T. M., Zimmerman, G.
A., White, R. L., and Prescott, S. M. (1996) Prostaglandin H synthase 2 is expressed
abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad
SciUSA 93: 4816-4820.
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O.,
Trousset, M., and Attali, P. (1991) Sulindac causes regression of rectal polyps in familial
adenomatous polyposis. Gastroenterology 101: 635-639.
Ladenheim, J., Garcia, G., Titzer, D., Herzenberg, H., Lavori, P., Edson, R., and Omary,
M. B. (1995) Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083-
1087.
Landen, C. N., Jr., Mathur, S. P., Richardson, M. S., and Creasman, W. T. (2003)
Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J
Obstet Gynecol 188: 1174-1176.
Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer-Jensen, M.,
and Kadlubar, F. F. (1994) Rapid metabolic phenotypes for acetyltransferase and
cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase
the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3: 675-682.
Le Marchand, L., Kolonel, L. N., Henderson, B. E., and Wilkens, L. R. (2005a)
Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3
levels and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol
Biomarkers Prev 14: 1319-1321.
Le Marchand, L., Hankin, J. H., Wilkens, L. R., Pierce, L. M., Franke, A., Kolonel, L. N.,
Seifried, A., Custer, L. J., Chang, W., Lum-Jones, A., and Donlon, T. (2001) Combined
Effects ofWell-done Red Meat, Smoking, and Rapid N-Acetyltransferase 2 and CYP1A2
Phenotypes in Increasing Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev 10:
1259-1266.
Le Marchand, L., Wilkens, L. R., Kolonel, L. N., and Henderson, B. E. (2005b) The
MTHFR C677T Polymorphism and Colorectal Cancer: The Multiethnic Cohort Study.
Cancer Epidemiol Biomarkers Prev 14: 1198-1203.
245
Lee, A. S., Seo, Y. C., Chang, A., Tohari, S., Eu, K. W., Seow-Choen, F., and McGee, J.
O. (2000) Detailed deletion mapping at chromosome 1 lq23 in colorectal carcinoma. Br J
Cancer 83: 750-755.
Lee, E. J., Park, H. G., and Kang, H. S. (2003) Sodium salicylate induces apoptosis in
HCT116 colorectal cancer cells through activation of p38MAPK. Int J Oncol 23: SOS-
SOS.
Lee, F. D. (1993) Importance of apoptosis in the histopathology of drug related lesions in
the large intestine. J Clin Pathol 46: 118-122.
Legrand-Poels, S., Schoonbroodt, S., and Piette, J. (2000) Regulation of interleukin-6
gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J
349: 765-773.
Lemberger, T., Desvergne, B., and Wahli, W. (1996) Peroxisome proliferator-activated
receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev
Biol 12: 335-363.
Levy, D. B., Smith, K. J., Beazer-Barclay, Y., Flamilton, S. R., Vogelstein, B., and
Kinzler, K. W. (1994) Inactivation of both APC alleles in human and mouse tumors.
Cancer Res 54: 5953-5958.
Levy, G. N. (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and
colon cancer. FASEB J11: 234-247.
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M.,
Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R. (1997) Germline mutations of the
PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat
Genet 16: 64-67.
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M.,
Pukkala, E., Skytthe, A., and Hemminki, K. (2000) Environmental and heritable factors in
the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and
Finland. NEngl JMed 343: 78-85.
Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L.
L., Copeland, E. M., Ill, and Mackay, S. (2001) Nuclear factor-kappa B is upregulated in
colorectal cancer. Surgery 130: 363-369.
246
Lipton, L., Sieber, O. M., Thomas, H. J. W., Hodgson, S. V., Tomlinson, I. P. M., and
Woodford-Richens, K. (2003) Germline mutations in the TGF-P and Wnt signalling
pathways are a rare cause of the "multiple" adenoma phenotype. JMed Genet 40: 35e.
Liu, W., Dong, X., Mai, M., Seelan, R. S., Taniguchi, K., Krishnadath, K. K., Hailing, K.
C., Cunningham, J. M., Qian, C., Christensen, E., Roche, P. C., Smith, D. I., and
Thibodeau, S. N. (2000) Mutations in AXIN2 cause colorectal cancer with defective
mismatch repair by activating beta-catenin/TCF signalling [In Process Citation], Nat
Genet 26: 146-147.
Liu, X. H. and Rose, D. P. (1996) Differential expression and regulation of
cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125-
5127.
Loeve, F., Boer, R., Zauber, A. G., Van Ballegooijen, M., Van Oortmarssen, G. J.,
Winawer, S. J., and Habbema, J. D. (2004) National Polyp Study data: evidence for
regression of adenomas. Int J Cancer 111: 633-639.
Lupton, Joanne R. (2004) Microbial Degradation Products Influence Colon Cancer Risk:
the Butyrate Controversy. JNutr 134: 479-482.
Lyle, R., Valleley, E. M., Sharpe, P. T., and Hewitt, J. E. (1994) An alternatively spliced
transcript, p65 delta 2, of the gene encoding the p65 subunit of the transcription factor
NF-kappa B. Gene 138: 265-266.
Lynch, E. D., Ostermeyer, E. A., Lee, M. K., Arena, J. F., Ji, H., Dann, J., Swisshelm, K.,
Suchard, D., MacLeod, P. M., Kvinnsland, S., Gjertsen, B. T., Heimdal, K., Lubs, H.,
Moller, P., and King, M. C. (1997) Inherited mutations in PTEN that are associated with
breast cancer, cowden disease, and juvenile polyposis. Am JHum Genet 61: 1254-1260.
Lynch, H. T. and de la, Chapelle A. (2003) Hereditary colorectal cancer. N Engl J Med
348: 919-932.
Lynch, H. T., Thorson, A. G., and Smyrk, T. (1995) Rectal cancer after prolonged
sulindac chemoprevention. A case report. Cancer 75: 936-938.
Macarthur, M., Sharp, L., Hold, G. L., Little, J., and El Omar, E. M. (2005) The role of
cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in
the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14: 1613-1618.
247
Macdonald ADH, Din, F. V. N., Stark, L. A., and Dunlop, M. G. (2004) Aspirin-Induced
Apoptosis And Effects on NFkB Responsive Genes, Bax & Bc1-xl. SARS Yearbook, 44.
Ref Type: Abstract
Macdonald ADH, Din, F. V. N., Stark, L. A., and Dunlop, M. G. (2005a) Aspirin
represses NFkB driven transcription of ICAM-1 gene in colorectal cancer. Colorectal
Disease 7 [Supp 1], 57. Ref Type: Abstract
Macdonald ADH, Din, F. V. N., Stark, L. A., and Dunlop, M. G. (2005b) Aspirin
represses NFkB driven transcription of the Bel- xl gene in colorectal cancer. Journal of
the Royal Colleges of Surgeons of Edinburgh and Ireland 3[3], S19. Ref Type: Abstract
Mahmoud, N. N., Boolbol, S. K., Dannenberg, A. J., Mestre, J. R., Bilinski, R. T.,
Martucci, C., Newmark, H. L., Chadburn, A., and Bertagnolli, M. M. (1998a) The sulfide
metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine
model of familial adenomatous polyposis. Carcinogenesis 19: 87-91.
Mahmoud, N. N., Dannenberg, A. J., Mestre, J., Bilinski, R. T., Churchill, M. R.,
Martucci, C., Newmark, H., and Bertagnolli, M. M. (1998b) Aspirin prevents tumors in a
murine model of familial adenomatous polyposis. Surgery 124: 225-231.
Malek, S., Huxford, T., and Ghosh, G. (1998) Ikappa Balpha functions through direct
contacts with the nuclear localization signals and the DNA binding sequences of NF-
kappaB. JBiol Chem 273: 25427-25435.
Mandel, J. S., Church, T. R., Bond, J. H., Ederer, F., Geisser, M. S., Mongin, S. J.,
Snover, D. C., and Schuman, L. M. (2000) The effect of fecal occult-blood screening on
the incidence of colorectal cancer. NEngl JMed 343: 1603-1607.
Mann, B., Gelos, M., Siedow, A., Hanski, M. L., Gratchev, A., Ilyas, M., Bodrner, W. F.,
Moyer, M. P., Riecken, E. O., Buhr, H. J., and Hanski, C. (1999) Target genes of beta-
catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.
Proc Natl Acad Sci USA 96: 1603-1608.
Marijnen, C. A. M., van de Velde, C. J. H., Putter, H., van den Brink, M., Maas, C.P.,
Martijn, H., Rutten, H. J., Wiggers, T., Kranenbarg, E. K., Leer, J.W., and Stiggelbout, A.
M. (2005) Impact of Short-Term Preoperative Radiotherapy on Health-Related Quality of
Life and Sexual Functioning in Primary Rectal Cancer: Report of a Multicenter
Randomized Trial. J Clin Oncol 23: 1847-1858.
Markowitz, A. J. and Winawer, S. J. (1997) Management of colorectal polyps. CA Cancer
J Clin 47: 93-112.
248
Martinez, M. E., Henning, S. M., and Alberts, D.S. (2004) Folate and colorectal
neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence.
Am J Clin Nutr 79: 691-697.
Mathers, J. C. (2004) The biological revolution - towards a mechanistic understanding of
the impact of diet on cancer risk. Mutation Research/Fundamental and Molecular
Mechanisms ofMutagenesis 551: 43-49.
Matsuhashi, N., Nakajima, A., Fukushima, Y., Yazaki, Y., and Oka, T. (1997) Effects of
sulindac on sporadic colorectal adenomatous polyps. Gut 40: 344-349.
Maxwell, S. A. and Mukhopadhyay, T (1995) A novel NF-kB p65 spliced transcript
lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene 166: 339-340.
McDougall, C. J., Ngoi, S. S., Goldman, I. S., Godwin, T., Felix, J., DeCosse, J. J., and
Rigas, B. (1990) Reduced expression of HFA class I and II antigens in colon cancer.
Cancer Res 50: 8023-8027.
McGregor, A. H., More, F. J., Simpson, K. J., and Harrison, D. J. (2003) Fiver death and
regeneration in paracetamol toxicity. Hum Exp Toxicol 22: 221-227.
McKay, J. A., Williams, E. A., and Mathers, J. C. (2004) Folate and DNA methylation
during in utero development and aging. Biochem Soc Trans 32: 1006-1007.
Meier, C. R., Schmitz, S., and Jick, H. (2002) Association between acetaminophen or
nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon
cancer. Pharmacotherapy 22: 303-309.
Mella, J., Biffin, A., Radcliffe, A. G., Stamatakis, J. D., and Steele, R. J. (1997)
Population-based audit of colorectal cancer management in two UK health regions.
Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical
Epidemiology and Audit Unit. Br J Surg 84: 1731-1736.
Michels, K. B., Giovannucci, E., Joshipura, K. J., Rosner, B. A., Stampfer, M. J., Fuchs,
C. S., Colditz, G. A., Speizer, F. E., and Willett, W. C. (2000) Prospective Study of Fruit
and Vegetable Consumption and Incidence of Colon and Rectal Cancers. J Natl Cancer
Inst 92: 1740-1752.
Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P., Appleton, D. R., and Watson, A. J.
(1988) A protective effect of sulindac against chemically-induced primary colonic
tumours in mice. J Pathol 156: 341-347.
249
Moriuchi, H., Moriuchi, M., and Fauci, A. S. (1997) Nuclear factor-kappa B potently up-
regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J
Immunol 158: 3483-3491.
Mulcahy, H. E. and O'Donoghue, D. P. (1997) Duration of colorectal cancer symptoms
and survival: the effect of confounding clinical and pathological variables. European
Journal ofCancer 33: 1461-1467.
Mulhall, B. P., Veerappan, G. R., and Jackson, J. L. (2005) Meta-analysis: computed
tomographic colonography. Ann Intern Med 142: 635-650.
Muller, A. D., Sonnenberg, A., and Wasserman, I. H. (1994) Diseases preceding colon
cancer. A case-control study among veterans. Dig Dis Sci 39: 2480-2484.
Nakamura, Y., Nishisho, I., Kinzler, K. W., Vogelstein, B., Miyoshi, Y., Miki, Y., Ando,
H., Horii, A., and Nagase, H. (1991) Mutations of the adenomatous polyposis coli gene in
familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symp
22: 285-292.
Narayanan, R., Klement, J. F., Ruben, S. M., Higgins, K. A., and Rosen, C. A. (1992)
Identification of a naturally occurring transforming variant of the p65 subunit of NF-
kappa B. Science 256: 367-370.
Newcomb, P. A., Norfleet, R. G., Storer, B. E., Surawicz, T. S., and Marcus, P. M. (1992)
Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84: 1572-
1575.
Niv, Y. and Fraser, G. M. (1994) Adenocarcinoma in the rectal segment in familial
polyposis coli is not prevented by sulindac therapy. Gastroenterology 107: 854-857.
Noguchi, M., Earashi, M., Minami, M., Miyazaki, I., Tanaka, M., and Sasaki, T. (1995)
Effects of piroxicam and esculetin on the MDA-MB-231 human breast cancer cell line.
Prostaglandins Leukot Essent Fatty Acids 53: 325-329.
Novak, U., Cocks, B. G., and Hamilton, J. A. (1991) A labile repressor acts through the
NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 19: 3389-3393.
Nugent, K. P., Farmer, K. C., Spigelman, A. D., Williams, C. B., and Phillips, R. K.
(1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal
polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J
Surg 80: 1618-1619.
250
Nugent, K. P., Phillips, R. K., Hodgson, S. V., Cottrell, S., Smith-Ravin, J., Pack, K., and
Bodmer, W. F. (1994) Phenotypic expression in familial adenomatous polyposis: partial
prediction by mutation analysis. Gut 35: 1622-1623.
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A.,
Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K.
W. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the
National Cancer Institute anticancer drug screen and correlations with the growth-
inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300.
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E.,
Trzaskos, J. M., Evans, J. F., and Taketo, M. M. (1996) Suppression of intestinal
polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Cell 87: 803-809.
Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, M. M.,
and Evans, J. F. (2001) Chemoprevention of intestinal polyposis in the Apcdelta716
mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733-1740.
Pachman, L. M., Olufs, R., Procknal, J. A., and Levy, G. (1979) Pharmacokinetic
monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. Arthritis
Rheum 22: 826-831.
Paganini-Hill, A., Chao, A., Ross, R. K., and Henderson, B. E. (1989) Aspirin use and
chronic diseases: a cohort study of the elderly. BMJ 299: 1247-1250.
Pahl, H. L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors.
Oncogene 18: 6853-6866.
Park, B. H., Vogelstein, B., and Kinzler, K. W. (2001) Genetic disruption of PPARdelta
decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98:
2598-2603.
Park, S. H„ Ha, H. K„ Kim, M. J., Kim, K. W„ Kim, A. Y„ Yang, D. H., Lee, M. G„
Kim, P. N., Shin, Y. M., Yang, S. K., Myung, S. J., and Min, Y. I. (2005) False-negative
results at multi-detector row CT colonography: multivariate analysis of causes for missed
lesions. Radiology 235: 495-502.
Parker, Judy, Kaplon, Mike K., Alvarez, Consuelo J., and Krishnaswamy, Guha (10-10-
1997) Prostaglandin H Synthase Expression Is Variable in Human Colorectal
Adenocarcinoma Cell Lines. Experimental Cell Research 236: 321-329.
251
Parker, K. M., Ma, M. H., Manyak, S., Altamirano, C. V., Tang, Y. M., Frantzen, M.,
Mikail, A., Roussos, E., Sjak-Shie, N., Vescio, R. A., and Berenson, J. R. (2002)
Identification of polymorphisms of the IkBcc gene associated with an increased risk of
multiple myeloma. Cancer Genetics and Cytogenetics 137: 43-48.
Parkin, D. Max, Bray, Freddie, Ferlay, J., and Pisani, Paola (2005) Global Cancer
Statistics, 2002. CA Cancer J Clin 55: 74-108.
Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L.,
Silliman, N., Ptak, J., Szabo, S., Willson, J. K., Markowitz, S., Kinzler, K. W.,
Vogelstein, B., Lengauer, C., and Velculescu, V. E. (2005) Colorectal cancer: mutations
in a signalling pathway. Nature 436: 792.
Pasricha, P. J., Bedi, A., O'Connor, K., Rashid, A., Akhtar, A. J., Zahurak, M. L.,
Piantadosi, S., Hamilton, S. R., and Giardiello, F. M. (1995) The effects of sulindac on
colorectal proliferation and apoptosis in familial adenomatous polyposis.
Gastroenterology 109: 994-998.
Peltomaki, P. (2001) Deficient DNA mismatch repair: a common etiologic factor for
colon cancer. Hum Mol Genet 10: 735-740.
Pereira, M. A., Barnes, L. H., Steele, V. E., Kelloff, G. V., and Lubet, R. A. (1996)
Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and
prevention of colon cancer in rats. Carcinogenesis 17: 373-376.
Perkins, Neil D. (2004) NF-[kappa]B: tumor promoter or suppressor? Trends in Cell
Biology 14: 64-69.
Peters, U., Sinha, R., Chatterjee, N., Subar, A. F., Ziegler, R. G., Kulldorff, M., Bresalier,
R., Weissfeld, J. L., Flood, A., Schatzkin, A., and Hayes, R. B. (2003) Dietary fibre and
colorectal adenoma in a colorectal cancer early detection programme. Lancet 361: 1491-
1495.
Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C.,
Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L.,
Ahnen, D. J., and Pamukcu, R. (1997a) Sulindac sulfone inhibits azoxymethane-induced
colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-
2915.
Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu,
R., and Ahnen, D. J. (1997b) Apoptosis primarily accounts for the growth-inhibitory
properties of sulindac metabolites and involves a mechanism that is independent of
252
cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57: 2452-
2459.
Piazza, G. A., Rahm, A. L., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H.,
Brendel, K., Burt, R. W., Alberts, D. S., and Pamukcu, R. (1995) Antineoplastic drugs
sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55:
3110-3116.
Planchon, P., Veber, N., Magnien, V., Prevost, G., Starzec, A. B., and Israel, L. (1995)
Evidence for separate mechanisms of antiproliferative action of indomethacin and
prostaglandin on MCF-7 breast cancer cells. Life Sci 57: 1233-1240.
Platz, E. A., Willett, W. C., Colditz, G. A., Rimm, E. B., Spiegelman, D., and
Giovannucci, E. (2000) Proportion of colon cancer risk that might be preventable in a
cohort ofmiddle-aged US men. Cancer Causes Control 11: 579-588.
Poligone, B. and Baldwin, A. S. (2001) Positive and negative regulation ofNF-kappaB by
COX-2: roles of different prostaglandins. J Biol Chem 276: 38658-38664.
Pollard, M. and Luckert, P. H. (1981) Effect of indomethacin on intestinal tumors induced
in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558-559.
Potten, C. S. (1992) The significance of spontaneous and induced apoptosis in the
gastrointestinal tract ofmice. Cancer Metastasis Rev 11:179-195.
Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S.
N., Vogelstein, B., and Kinzler, K. W. (1992) APC mutations occur early during
colorectal tumorigenesis. Nature 359: 235-237.
Pritchard, D. M. and Watson, A. J. (1996) Apoptosis and gastrointestinal pharmacology.
Pharmacol Ther 72: 149-169.
Qiao, L., Hanif, R., Sphicas, E., Shiff, S. J., and Rigas, B. (1998) Effect of aspirin on
induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol
55: 53-64.
Qiao, L., Kozoni, V., Tsioulias, G. J., Koutsos, M. I., Hanif, R., Shiff, S. J., and Rigas, B.
(1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell
lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258: 215-223.
Ravi, Rajani and Bedi, Atul (2004) NF-[kappa]B in cancer—a friend turned foe. Drug
Resistance Updates 7: 53-67.
253
Rayet, B. and Gelinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer.
Oncogene 18: 6938-6947.
Reddy, B. S., Rao, C. V., and Seibert, K. (1996) Evaluation of cyclooxygenase-2 inhibitor
for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56: 4566-
4569.
Rembold, Christopher M. (1998) Number needed to screen: development of a statistic for
disease screening. BMJ311: 307-312.
Rex, D. K., Chak, A., Vasudeva, R., Gross, T., Lieberman, D., Bhattacharya, I., Sack, E.,
Wiersema, M., Farraye, F., Wallace, M., Barrido, D., Cravens, E., Zeabart, L., Bjorkman,
D., Lemmel, T., and Buckley, S. (1999) Prospective determination of distal colon
findings in average-risk patients with proximal colon cancer. Gastrointest Endosc 49:
727-730.
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R.
M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M.,
and Gallinger, S. (2003) Tumor microsatellite-instability status as a predictor of benefit
from fluorouracil-based adjuvant chemotherapy for colon cancer. NEngl JMed 349: 247-
257.
Ricchi, P., Pignata, S., Di, Popolo A., Memoli, A., Apicella, A., Zarrilli, R., and
Acquaviva, A. M. (1997) Effect of aspirin on cell proliferation and differentiation of
colon adenocarcinoma Caco-2 cells. Int J Cancer 73: 880-884.
Rieder, M. J, Daniels, R. L., da Ponte, S. H., astings, N. C., Ahearn, M. O., Rajkumar, N.,
Yi, Q., and Nickerson, D. A. SeattleSNPs.NHLBI HL66682 Program for Genomic
Applications, UW-FHCRC, Seattle, WA. 2003. Ref Type: Electronic Citation
Rigas, B., Goldman, I. S., and Levine, L. (1993) Altered eicosanoid levels in human
colon cancer. JLab Clin Med 122: 518-523.
Rigas, B. and Shiff, S. J. (2000) Is inhibition of cyclooxygenase required for the
chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current
contradiction. Med Hypotheses 54: 210-215.
Rigau, J., Pique, J. M., Rubio, E., Planas, R., Tarrech, J. M., and Bordas, J. M. (1991)
Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115: 952-
954.
254
Rocha, S., Campbell, K. J., and Perkins, N.D. (2003) p53- and Mdm2-Independent
Repression ofNF-kB Transactivation by the ARF Tumor Suppressor. Molecular Cell 12:
15-25.
Rockey, D. C., Paulson, E., Niedzwiecki, D., Davis, W., Bosworth, H. B., Sanders, L.,
Yee, J., Henderson, J., Hatten, P., Burdick, S., Sanyal, A., Rubin, D. T., Sterling, M.,
Akerkar, G., Bhutani, M. S., Binmoeller, K., Garvie, J., Bini, E. J., McQuaid, K., Foster,
W. L., Thompson, W. M., Dachman, A., and Halvorsen, R. (2005) Analysis of air
contrast barium enema, computed tomographic colonography, and colonoscopy:
prospective comparison. Lancet 365: 305-311.
Roff, M., Thompson, J., Rodriguez, M. S., Jacque, J. M., Baleux, F., Arenzana-Seisdedos,
F., and Hay, R. T. (1996) Role of IkappaBalpha ubiquitination in signal-induced
activation ofNFkappaB in vivo. JBiol Chem 271: 7844-7850.
Rosenberg, L., Palmer, J. R., Rao, R. S., Coogan, P. F., Strom, B. L., Zauber, A. G.,
Stolley, P. D., and Shapiro, S. (2000) A case-control study of analgesic use and ovarian
cancer. Cancer Epidemiol Biomarkers Prev 9: 933-937.
Ruben, S. M., Narayanan, R., Klement, J. F., Chen, C. H., and Rosen, C. A. (1992)
Functional characterization of the NF-kappa B p65 transcriptional activator and an
alternatively spliced derivative. Mol Cell Biol 12: 444-454.
Ruschoff, J., Wallinger, S., Dietmaier, W., Bocker, T., Brockhoff, G., Hofstadter, F., and
Fishel, R. (1998) Aspirin suppresses the mutator phenotype associated with hereditary
nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A 95: 11301-
11306.
Ryo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y. C., Wulf, G., Rottapel, R.,
Yamaoka, S., and Lu, K. P. (2003) Regulation of NF-kB Signaling by Pinl -Dependent
Prolyl Isomerization and Ubiquitin-Mediated Proteolysis of p65/'RelA. Molecular Cell
12: 1413-1426.
Samowitz, W. S., Holden, J. A., Curtin, K., Edwards, S. L., Walker, A. R., Lin, H. A.,
Robertson, M. A., Nichols, M. F., Gruenthal, K. M., Lynch, B. J., Leppert, M. F., and
Slattery, M. L. (2001) Inverse relationship between microsatellite instability and K-ras
and p53 gene alterations in colon cancer. Aiyi J Pathol 158: 1517-1524.
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli,
N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., Steinbach, G., and Schilsky, R. (2003) A
randomized trial of aspirin to prevent colorectal adenomas in patients with previous
colorectal cancer. NEngl JMed 348: 883-890.
255
Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S.,
Kato, H., Kondo, M., and Hla, T. (1995) Expression of cyclooxygenase-1 and -2 in
human colorectal cancer. Cancer Res 55: 3785-3789.
Sansom, O. J., Stark, L. A., Dunlop, M. G., and Clarke, A. R. (2001) Suppression of
Intestinal and Mammary Neoplasia by Lifetime Administration of Aspirin in ApcMin/+
and ApcMin/+, Msh2-/- Mice . Cancer Res 61: 7060-7064.
Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., Shike, M., Weissfeld, J.,
Burt, R., Cooper, M. R., Kikendall, J. W., and Cahill, J. (2000) Lack of effect of a low-
fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial
Study Group. NEngl JMed 342: 1149-1155.
Schmedtje, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N., and Runge, M. S. (1997)
Hypoxia induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human
vascular endothelial cells. JBiol Chem 272: 601-608.
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., and Isakson, P. (1997)
Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol
400A: 167-170.
Selby, J. V., Friedman, G. D., Quesenberry, C. P., Jr., and Weiss, N. S. (1992) A case-
control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J
Med 326: 653-657.
Sen, R. and Baltimore, D. (1986) Inducibility of kappa immunoglobulin enhancer-binding
protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928.
Shao, J., Fujiwara, T., Kadowaki, Y., Fukazawa, T., Waku, T., Itoshima, T., Yamatsuji,
T., Nishizaki, M., Roth, J. A., and Tanaka, N. (2000a) Overexpression of the wild-type
p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in
human colon cancer cells. Oncogene 19: 726-736.
Shao, J., Sheng, H., Inoue, H., Morrow, J. D., and DuBois, R. N. (2000b) Regulation of
constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275:
33951-33956.
Sharp, L. and Little, J. (2004) Polymorphisms in Genes Involved in Folate Metabolism
and Colorectal Neoplasia: A HuGE Review. Am JEpidemiol 159: 423-443.
256
Shattuck-Brandt, R. L., Varilek, G. W., Radhika, A., Yang, F., Washington, M. K., and
DuBois, R. N. (2000) Cyclooxygenase 2 expression is increased in the stroma of colon
carcinomas from IL-10(-/-) mice. Gastroenterology 118: 337-345.
Shiff, S. J., Koutsos, M. I., Qiao, L., and Rigas, B. (1996) Nonsteroidal antiinflammatory
drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and
apoptosis. Exp Cell Res 222: 179-188.
Shiff, S. J., Qiao, L., Tsai, L. L., and Rigas, B. (1995) Sulindac sulfide, an aspirin-like
compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in
FTT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503.
Shiff, S. J. and Rigas, B. (1997) Nonsteroidal anti-inflammatory drugs and colorectal
cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992-
1998.
Shishodia, Shishir and Aggarwal, Bharat B. (2004) Nuclear factor-KB: a friend or a foe in
cancer? Biochemical Pharmacology 68: 1071-1080.
Shpitz, B., Bomstein, Y., Mekori, Y., Cohen, R., Kaufman, Z., Neufeld, D., Galkin, M.,
and Bernheim, J. (1998) Aberrant crypt foci in human colons: distribution and
histomorphologic characteristics. Hum Pathol 29: 469-475.
Shpitz, B., Klein, E., Buklan, G., Neufeld, D., Nissan, A., Freund, H. R., Grankin, M.,
and Bernheim, J. (2003) Suppressive effect of aspirin on aberrant crypt foci in patients
with colorectal cancer. Gut 52: 1598-1601.
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R., and Ben
Ze'ev, A. (1999) The cyclin D1 gene is a target of the beta -catenin/LEF-1 pathway.
PNAS 96: 5522-5527.
Shureiqi, L, Chen, D., Lee, J. J., Yang, P., Newman, R. A., Brenner, D.E., Lotan, R.,
Fischer, S. M., and Lippman, S. M. (2000) 15-LOX-l: a Novel Molecular Target of
Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells. J
Natl Cancer Inst 92: 1136-1142.
Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J. B., Leesnitzer, L. M., Morris, J. S.,
Fan, H. Z., Fischer, S. M., and Lippman, S. M. (2003) The 15-lipoxygenase-l product 13-
S-hydroxyoctadecadienoic acid down-regulates PPAR-S to induce apoptosis in colorectal
cancer cells. PNAS 100: 9968-9973.
257
Siebenlist, U., Franzoso, G., and Brown, K. (1994) Structure, regulation and function of
NF-kappa B. Annu Rev Cell Biol 10: 405-455.
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A.,
Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent,
J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S. (2000) Gastrointestinal toxicity
with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid
arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis
Safety Study. JAMA 284: 1247-1255.
Skinner, S. A., Penney, A. G., and O'Brien, P. E. (1991) Sulindac inhibits the rate of
growth and appearance of colon tumors in the rat. Arch Surg 126: 1094-1096.
Slattery, M. L., Murtaugh, M., Caan, B., Ma, K. N., Neuhausen, S., and Samowitz, W.
(2005) Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J
Cancer 115: 148-154.
Slattery, M. L. and Potter, J. D. (2002) Physical activity and colon cancer: confounding or
interaction? Med Sci Sports Exerc 34: 913-919.
Slattery, M. L., Samowitz, W., Curtin, K., Ma, K. N., Hoffman, M., Caan, B., and
Neuhausen, S. (2004a) Associations among 1RS1, IRS2, IGF1, and IGFBP3 genetic
polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 13: 1206-
1214.
Slattery, M. L., Samowitz, W., Hoffman, M., Ma, K. N., Levin, T. R., and Neuhausen, S.
(2004b) Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-
related pathway. Cancer Epidemiol Biomarkers Prev 13: 538-545.
Slupska, M. M., Baikalov, C., Luther, W. M., Chiang, J. H., Wei, Y. F., and Miller, J. H,
(1996) Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY
gene whose function is required for the repair of oxidative DNA damage. JBacteriol 178:
3885-3892.
Smith, J. A., King, P. M., Lane, R. H., and Thompson, M. R. (2003) Evidence of the
effect of 'specialization' on the management, surgical outcome and survival from
colorectal cancer in Wessex. Br J Surg 90: 583-592.
Smith, M. L., Hawcroft, G., and Hull, M. A. (2000) The effect of non-steroidal anti¬
inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms
of action. Eur J Cancer 36: 664-674.
258
Sotiriou, C., Lacroix, M., Lagneaux, L., Berchem, G., and Body, J. J. (1999) The aspirin
metabolite salicylate inhibits breast cancer cells growth and their synthesis of the
osteolytic cytokines interleukins-6 and -11. Anticancer Res 19: 2997-3006.
Spagnesi, M. T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A., and
Bianchini, F. (1994) Rectal proliferation and polyp occurrence in patients with familial
adenomatous polyposis after sulindac treatment. Gastroenterology 106: 362-366.
Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Mutational analysis
of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58: 1130-1134.
Sporn, M. B. (1976) Approaches to prevention of epithelial cancer during the
preneoplastic period. Cancer Res 36: 2699-2702.
Stark, L., Din, F. V. N., and Dunlop, M. G. Aspirin-induced Apoptosis of Colorectal
Cancer Cells is caused by Nuclear Translocation of Repressive NFkB Complexes.
Proceedings of the American Association of Cancer Research 41, 495. 2000.
Ref Type: Abstract
Stark, L. A., Din, F. V. N., Zwacka, R. M., and Dunlop, M. G. (2001a) Aspirin-induced
activation of the NF-kB signaling pathway: a novel mechanism for aspirin-mediated
apoptosis in colon cancer cells. FASEB J15: 1273-1275.
Stark, L. A., Din, F. V. N., Zwacka, R. M., and Dunlop, M. G. (2001b) Aspirin-induced
activation of the NF-kB signaling pathway: a novel mechanism for aspirin-mediated
apoptosis in colon cancer cells. FASEB J 00-0529fje.
Stark, L. A. and Dunlop, M. G. (2005) Nucleolar Sequestration of RelA (p65) Regulates
NF-KB-Driven Transcription and Apoptosis. Mol Cell Biol 25: 5985-6004.
Stark, T. A., Reid K, Sansom O, Din, F. V. N., Guichard S, Jodrell DI, Clarke A, and
Dunlop, M. G. Aspirin activates the NFkB signalling pathway and induces apoptosis in
vivo, in two animal models of colorectal cancer. 2005. Ref Type: Unpublished Work
Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B.R., and Lipp, J.
(1998) Nuclear Factor (NF)-KB-regulated X-chromosome-linked iap Gene Expression
Protects Endothelial Cells from Tumor Necrosis Factor a -induced Apoptosis. JExp Med
188:211-216.
Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B.,
Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. (2000)
259
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
N Engl JMed 342: 1946-1952.
Stoner, G. D., Budd, G. T., Ganapathi, R., DeYoung, B., Kresty, L. A., Nitert, M., Fryer,
B., Church, J. M., Provencher, K., Pamukcu, R., Piazza, G., Hawk, E., Kelloff, G., Elson,
P., and van Stolk, R. U. (1999) Sulindac sulfone induced regression of rectal polyps in
patients with familial adenomatous polyposis. Adv Exp Med Biol 470: 45-53.
Sturmer, T., Glynn, R. J., Lee, I. M., Manson, J. E., Buring, J. E., and Hennekens, C. H.
(1998) Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the
Physicians' Health Study. Ann Intern Med 128: 713-720.
Sun, S., Elwood, J., and Greene, W. C. (1996) Both amino- and carboxyl-terminal
sequences within I kappa B alpha regulate its inducible degradation. Mol Cell Biol 16:
1058-1065.
Swedish Rectal, Cancer Trial (1997) Improved Survival with Preoperative Radiotherapy
in Resectable Rectal Cancer. NEngl JMed 336: 980-987.
Tamura, M., Sebastian, S., Yang, S., Gurates, B., Ferrer, K., Sasano, H., Okamura, K.,
and Bulun, S. E. (2002) Up-regulation of Cyclooxygenase-2 Expression and
Prostaglandin Synthesis in Endometrial Stromal Cells by Malignant Endometrial
Epithelial Cells. A PARACRINE EFFECT MEDIATED BY PROSTAGLANDIN E2
AND NUCLEAR FACTOR-kappa B. JBiol Client 277: 26208-26216.
Tegeder, I., Pfeilschifter, J., and Geisslinger, G. (2001) Cyclooxygenase-independent
actions of cyclooxygenase inhibitors. FASEB J15: 2057-2072.
Thiery-Vuillemin, A., Nguyen, T., Pivot, X., Spano, J. P., Dufresnne, A., and Soria, J. C.
(2005) Molecularly targeted agents: Their promise as cancer chemopreventive
interventions. European Journal ofCancer 41: 2003-2015.
Thompson, W. J., Piazza, G. A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D.,
and Pamukcu, R. (2000) Exisulind induction of apoptosis involves guanosine 3',5'-cyclic
monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated
beta-catenin. Cancer Res 60: 3338-3342.
Thorstensen, L., Qvist, H., Nesland, J. M., Giercksky, K. E., and Lothe, R. A. (2001)
Identification of two potential suppressor gene regions on chromosome arm 14q that are
commonly lost in advanced colorectal carcinomas. Scand J Gastroenterol 36: 1327-1331.
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., and Heath, C. W. Jr
(1993) Aspirin use and risk of fatal cancer [see comments]. Cancer Res 53: 1322-1327.
260
Thun, M. J., Henley, S. J., and Patrono, C. (2002) Nonsteroidal Anti-inflammatory Drugs
as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. J Natl Cancer
Inst 94: 252-266.
Tomlinson, I. P. and Bodmer, W. F. (1996) Chromosome 11 q in sporadic colorectal
carcinoma: patterns of allele loss and their significance for tumorigenesis. J Clin Pathol
49: 386-390.
Towler, B., Irwig, L., Glasziou, P., Kewenter, J., Weller, D., and Silagy, C. (1998) A
systematic review of the effects of screening for colorectal cancer using the faecal occult
blood test, hemoccult. BMJ311: 559-565.
Traenckner, E. B. and Baeuerle, P. A. (1995) Appearance of apparently ubiquitin-
conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact
cells. J Cell Sci Suppl 19: 79-84.
Traenckner, E. B., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., and Baeuerle, P. A.
(1995) Phosphorylation of human IkB-cc on serines 32 and 36 controls IkB-cx proteolysis
and NF-kB activation in response to diverse stimuli. EMBO J14: 2876-2883.
Tramer, M. R., Moore, R. A., Reynolds, D. J., and McQuay, H. J. (2000) Quantitative
estimation of rare adverse events which follow a biological progression: a new model
applied to chronic NSAID use. Pain 85: 169-182.
Trecca, D., Guerrini, L., Fracchiolla, N. S., Pomati, M., Baldini, L., Maiolo, A. T., and
Neri, A. (1997) Identification of a tumor-associated mutant form of the NF-kappaB RelA
gene with reduced DNA-binding and transactivating activities. Oncogene 14: 791-799.
Trock, B., Lanza, E., and Greenwald, P. (1990) Dietary fiber, vegetables, and colon
cancer: critical review and meta-analyses of the epidemiologic evidence. J Natl Cancer
Inst 82: 650-661.
Tsioulias, G. J., Triadafilopoulos, G., Goldin, E., Papavassiliou, E. D., Rizos, S.,
Bassioukas, P., and Rigas, B. (1993) Expression of HLA class I antigens in sporadic
adenomas and histologically normal mucosa of the colon. Cancer Res 53: 2374-2378.
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. (1998)
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
Ulrich, C. M., Bigler, J., Sparks, R., Whitton, J., Sibert, J. G., Goode, E. L., Yasui, Y.,
and Potter, J. D. (2004) Polymorphisms in PTGS1 (=COX-l) and risk of colorectal
polyps. Cancer Epidemiol Biomarkers Prev 13: 889-893.
261
van de Stolpe, A., Caldenhoven, E. , Stade, B. G., Koenderman, L., Raaijmakers, J. A.,
Johnson, J. P., and van der Saag, P. T. (1994) 12-0-tetradecanoylphorbol-13-acetate- and
tumor necrosis factor alpha- mediated induction of intercellular adhesion molecule-1 is
inhibited by dexamethasone. Functional analysis of the human intercellular adhesion
molecular-1 promoter. JBiol Chem 269: 6185-6192.
Vane, J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for
aspirin-like drugs. Nat New Biol 231: 232-235.
Vasen, H. F., Mecklin, J. P., Khan, P. M., and Lynch, H. T. (1991) The International
Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis
Colon Rectum 34: 424-425.
Vasen, H. F., Watson, P., Mecklin, J. P., and Lynch, H. T. (1999) New clinical criteria for
hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the
International Collaborative group on HNPCC. Gastroenterology 116: 1453-1456.
Vasudevan, Krishna Murthi, Gurumurthy, Sushma, and Rangnekar, Vivek M. (2004)
Suppression of PTEN Expression by NF-{kappa}B Prevents Apoptosis. Mol Cell Biol 24:
1007-1021.
Veigl, M. L., Kasturi, L., Olechnowicz, J., Ma, A. H., Lutterbaugh, J. D., Periyasamy, S.,
Li, G. M., Drummond, J., Modrich, P. L., Sedwick, W. D., and Markowitz, S. D. (1998)
Biallelic inactivation of hMLHl by epigenetic gene silencing, a novel mechanism causing
human MSI cancers. Proc Natl Acad Sci USA 95: 8698-8702.
Vogelstein, B. Using Cancer Genetics to Minimize Morbidity and Mortality from Cancer.
(2006).http://www.aacr.org/home/scientists/meetings—workshops/previous-annual-
meetings/2006-aacr-annual-meeting/webcast-sessions.aspx# Ref Type: Audiovisual
Waddell, W. R., Ganser, G. P\, Cerise, E. J., and Loughry, R. W. (1989) Sulindac for
polyposis of the colon. Am J Surg 157: 175-179.
Waddell, W. R. and Gerner, R. E. (1980) Indomethacin and ascorbate inhibit desmoid
tumors. J Surg Oncol 15: 85-90.
Waddell, W. R. and Loughry, R. W. (1983) Sulindac for polyposis of the colon. J Surg
Oncol 24: 83-87.
Wallace, J. L. and Devchand, P. R. (2005) Emerging roles for cyclooxygenase-2 in
gastrointestinal mucosal defense. British J ofPharmocology 145: 275-282.
262
Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. (1999a) Control of
inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by
inhibition ofNF-kappaB. NatMed 5: 412-417.
Wang, D., Westerheide, S. D., Hanson, J. L., and Baldwin, A.S., (2000) Tumor Necrosis
Factor alpha -induced Phosphorylation of RelA/p65 on Ser529 Is Controlled by Casein
Kinase II. JBiol Chem 275: 32592-32597.
Wang, H. M. and Zhang, G. Y. (2005) Indomethacin suppresses growth of colon cancer
via inhibition of angiogenesis in vivo. WorldJ Gastroenterol 11: 340-343.
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., and Chiao, P. J.
(1999b) The nuclear factor-kappa B RelA transcription factor is constitutively activated
in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127.
Weber, C., Erl, Wolfgang, P.A., and Weber, P. C. (1995) Aspirin Inhibits Nuclear Factor-
kB Mobilization and Monocyte Adhesion in Stimulated Human Endothelial Cells.
Circulation 91: 1914-1917.
Weber, T. K., Conroy, J., Keitz, B., Rodriguez-Bigas, M., Petrelli, N. J., Stoler, D. L.,
Anderson, G. R., Shows, T. B., and Nowak, N. J. (1999) Genome-wide allelotyping
indicates increased loss of heterozygosity on 9p and 14q in early age of onset colorectal
cancer. Cytogenet Cell Genet 86: 142-147.
Webster, G. A. and Perkins, N. D. (1999) Transcriptional cross talk between NF-kappaB
and p53. Mol Cell Biol 19: 3485-3495.
Wechter, W. J., Kantoci, D., Murray, E. D., Jr., Quiggle, D. D., Leipold, D. D., Gibson,
K. M., and McCracken, J. D. (1997) R-flurbiprofen chemoprevention and treatment of
intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and
treatment of colon cancer. Cancer Res 57: 4316-4324.
Weissmann, G. (1991) Aspirin. Sci Am 264: 84-90.
Welfare, M. R., Cooper, J., Bassendine, M. F., and Daly, A. K. (1997) Relationship
between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of
England. Carcinogenesis 18: 1351-1354.
Weller, M. (1998) Predicting response to cancer chemotherapy: the role of p53. Cell
Tissue Res 292: 435-445.
263
Whelan, J., Ghersa, P., Hooft, van Huijsduijnen, Gray, J., Chandra, G., Talabot, F., and
DeLamarter, J. F. (1991) An NF kappa B-like factor is essential but not sufficient for
cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene
transcription. Nucleic Acids Res 19: 2645-2653.
Willett, W. C., Stampfer, M. J., Colditz, G. A., Rosner, B. A., and Speizer, F. E. (1990)
Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study
among women. NEngl JMed 323: 1664-1672.
Williams, C., Luongo, C., Radhika, A., Zhang, T., Lamps, L., Nanney, L., Beauchamp,
R., and DuBois, R. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas.
Gastroenterology 111: 1134-1140.
Williams, C. S., Mann, M., and DuBois, R. N. (1999) The role of cyclooxygenases in
inflammation, cancer, and development. Oncogene 18: 7908-7916.
Williams, C. S., Smalley, W., and DuBois, R. N. (1997) Aspirin use and potential
mechanisms for colorectal cancer prevention. J Clin Invest 100: 1325-1329.
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. (2000) Host
cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594.
Willoughby, D. A., Moore, A. R„ and Colville-Nash, P. R. (2000) COX-1, COX-2, and
COX-3 and the future treatment of chronic inflammatory disease [In Process Citation],
Lancet 355: 646-648.
Winawer, S. J. (1999) Natural history of colorectal cancer. Am JMed 106: 3S-6S.
Winawer, S. J., Fletcher, R. H., Miller, L., Godlee, F., Stolar, M. H., Mulrow, C. D.,
Woolf, S. H., Glick, S. N., Ganiats, T. G., Bond, J. H., Rosen, L., Zapka, J. G., Olsen, S.
J., Giardiello, F. M., Sisk, J. E., Van Antwerp, R., Brown-Davis, C., Marciniak, D. A.,
and Mayer, R. J. (1997) Colorectal cancer screening: clinical guidelines and rationale.
Gastroenterology 112: 594-642.
Winawer, S. J., Stewart, E. T., Zauber, A. G., Bond, J. H., Ansel, H., Waye, J., Hall, D.,
Hamlin, J., Schapiro, M., O'Brien, M. J., Sternberg, S., Gottlieb, L. S., and The National
Polyp Study Work Group (2000) A Comparison of Colonoscopy and Double-Contrast
Barium Enema for Surveillance after Polypectomy. NEngl JMed 342: 1766-1772.
Winde, G., Gumbinger, H. G., Osswald, H., Kemper, F., and Bunte, H. (1993) The
NSAID sulindac reverses rectal adenomas in colectomized patients with familial
adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac
administration. Int J Colorectal Dis 8: 13-17.
264
Winde, G., Schmid, K. W., Schlegel, W., Fischer, R., Osswald, H., and Bunte, H. (1995)
Complete reversion and prevention of rectal adenomas in colectomized patients with
familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment.
Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing
adenomas exceeding 33 months. Dis Colon Rectum 38: 813-830.
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., and Harper, J. W.
(1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with
phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates
IkappaBalpha ubiquitination in vitro. Genes Dev 13: 270-283.
Wood, K. M., Roff, M., and Hay, R. T. (1998) Defective IkappaBalpha in Hodgkin cell
lines with constitutively active NF-kappaB. Oncogene 16: 2131-2139.
Workman P (1998) United Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second
Edition). Br J Cancer 77: 1-10.
Wright, J. M. (2002) The double-edged sword of COX-2 selective NSAIDs. CMAJ 167:
1131-1137.
Wu, G. D., Huang, N., Wen, X., Keilbaugh, S. A., and Yang, H. (1999) High-level
expression of I kappa B-beta in the surface epithelium of the colon: in vitro evidence for
an immunomodulatory role. JLeukoc Biol 66: 1049-1056.
Wu, H. and Lozano, G. (1994) NF-kappa B activation of p53. A potential mechanism for
suppressing cell growth in response to stress. JBiol Chem 269: 20067-20074.
Yamamoto, H., Itoh, F., Fukushima, H., Hinoda, Y., and Imai, K. (1999a) Overexpression
of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite
instability [In Process Citation]. Int J Cancer 84: 400-403.
Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. (1999b) Sulindac Inhibits
Activation of the NF-kappaB Pathway. JBiol Chem 274: 27307-27314.
Yeh, Pei Yen, Yeh, Kun Huei, Chuang, Shuang En, Song, Ying Chyi, and Cheng, Ann Lii
(2004) Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-kB
Activation by Protein Phosphatase 4-mediated NF-kB p65 Thr Dephosphorylation. JBiol
Chem 279: 26143-26148.
265
Yin, M. J., Yamamoto, Y., and Gaynor, R. B. (1998) The anti-inflammatory agents
aspirin and salicylate inhibit the activity of IkB kinase-beta [see comments]. Nature 396:
77-80.
Yoshimi, N., Kawabata, K., Hara, A., Matsunaga, K., Yamada, Y., and Mori, H. (1997)
Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-
induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 88:
1044-1051.
You, M., Ku, P. T., Hrdlickova, R., and Bose, H. R., Jr. (1997) ch-IAPl, a member of the
inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-
Rel oncoprotein. Mol Cell Biol 17: 7328-7341.
Young, Annie and Rea, Daniel (2000) ABC of colorectal cancer: Treatment of advanced
disease. BMJ 321: 1278-1281.
Yu, H. G., Yu, L. L., Yang, Y., Luo, H. S., Yu, J. P., Meier, J. J., Schrader, H., Bastian,
A., Schmidt, W. E., and Schmitz, F. (2003) Increased expression of RelA/nuclear factor-
kappa B protein correlates with colorectal tumorigenesis. Oncology 65: 37-45.
Yu, H. G., Zhong, X., Yang, Y. N., Luo, H. S., Yu, J. P., Meier, J. J., Schrader, H.,
Bastian, A., Schmidt, W. E., and Schmitz, F. (2004) Increased expression of nuclear
factor-kappaB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int
J Colorectal Dis 19: 18-22.
Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) The
IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta,
necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91: 243-252.
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. (2000) Role ofBAX in
the apoptotic response to anticancer agents. Science 290: 989-992.
Zhang, T., Fields, J. Z., Ehrlich, S. M., and Boman, B. M. (2004) The Chemopreventive
Agent Sulindac Attenuates Expression of the Antiapoptotic Protein Survivin in Colorectal
Carcinoma Cells. JPharmacol Exp Ther 308: 434-437.
Zhang, Z. and DuBois, R. N. (2000) Par-4, a proapoptotic gene, is regulated by NSAIDs
in human colon carcinoma cells. Gastroenterology 118: 1012-1017.
Zhong, H., SuYang, H., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1997) The
transcriptional activity of NF-kappaB is regulated by the IkappaB- associated PKAc
subunit through a cyclic AMP-independent mechanism. Cell 89: 413-424.
266
Appendix I: Presentations
1. University ofEdinburgh School of Surgery Day, November 1999, Edinburgh
Molecular Basis of the Antineoplastic Activity ofAspirin in Colorectal Cancer
FVN Din, LA Stark and MG Dunlop
2. Genes and Cancer Meeting, December 1999, Warwick
Aspirin-mediated IkB Degradation and Apoptosis in Colorectal Cancer (poster)
FVN Din, LA Stark and MG Dunlop
3. Association of Coloproctology: Scottish Chapter Meeting, March 2000, Stirling
Molecular Basis of the Anti-tumour Activity ofAspirin in Colorectal Cancer
FVN Din, LA Stark and MG Dunlop
4. American Association of Cancer Research, April 2000, San Francisco
Aspirin-induced IkBcc degradation & apoptosis in colorectal cancer cell lines (poster)
FVN Din, MG Dunlop and LA Stark
5. Surgical Research Society, October 2000, Cork
Molecular Basis of Aspirin-induced Apoptosis in Colorectal Cancer
FVN Din, LA Stark and MG Dunlop
6. Scottish Society for Experimental Medicine, October 2000, Edinburgh
Aspirin and Colorectal Cancer Chemoprevention
FVN Din. LA Stark and MG Dunlop
267
7. 4th Nottingham International Colorectal Cancer Symposium, October 2001
Aspirin Effects on NFkB & Apoptosis: Evidence for Colorectal Cancer Specificity
FVN Din, LA Stark and MG Dunlop
8. Association of Coloproctology, Manchester, July 2002
Aspirin Effects on NFkB & Apoptosis: Independence from MMR & p53 Status
FVN Din, LA Stark and MG Dunlop
9. Association of Coloproctology, Edinburgh, July 2003
Aspirin Effects on NFkB & Apoptosis:Evidence for Colorectal Cancer Cell Specificity
FVN Din. LA Stark and MG Dunlop
10. Clinical & Scientific Meeting Royal College of Surgeons Nov 2003 Edinburgh
Surgeon-in-Training Medal Session: Aspirin-Induced Apoptosis Following NFkB
Nuclear Translocation is not influenced by Mismatch Repair and p53 Status
FVN Dm, LA Stark and MG Dunlop
11. Society of Academic and Research Surgery, Belfast, January 2004
Aspirin Induced Apoptosis And Effects On NFkB Responsive Genes, Bax and BcI-Xl
A Macdonald, F Din, L Stark and M Dunlop
12. Keystone Symposia: NFkB, Utah, January 2004
Aspirin Induced Apoptosis & Effects On NFkB Responsive Genes, Bax and BcI-Xl
A Macdonald, F Din, L Stark and M Dunlop (poster)
13. Cancer Research Centre Symposium, Edinburgh, February 2004
Aspirin Effects on NFkB & Apoptosis: Independence from DNA MMR & p53 Status
FVN Din, LA Stark and MG Dunlop
268
14. Int. Society for Hereditary Gastrointestinal Tumours, Newcastle June 2005
Aspirin-induced nuclear translocation ofNFkB & apoptosis in colon cancer is
independent of p53 mutation status & MMR proficiency
FVN Din. LA Stark & MG Dunlop
15. Royal College of Surgeons' Quincentenary Meeting Edinburgh, July 2005
NSAIDs Induce Activation ofNFkB & Apoptosis in Rectal Cancer Patients
FVN Dm, LA Stark AND MG Dunlop
16. Royal College of Surgeons' Quincentenary Meeting, Edinburgh, July 2005
Aspirin Represses NFicB-driven Transcription ofBcl-XL Gene in Colorectal Cancer
A Macdonald, F Din. L Stark and M Dunlop
17. Association of Coloproctology Tripartite Meeting Dublin, July 2005
Aspirin Represses NFicB-driven Transcription of ICAM-1 Gene in Colorectal Cancer
A Macdonald, F Din. L Stark and M Dunlop (poster)
18. Association of Coloproctology Tripartite Meeting Dublin, July 2005
NSAIDs Induce Apoptosis via NFkB Modulation in Colorectal Cancer Patients
FVN Din, LA Stark AND MG Dunlop
19.Wilfrid Card Lecture, Edinburgh, November 2005





1. Aspirin-induced activation of the NF-kB signalling pathway: a novel mechanism
for aspirin-mediated apoptosis in colon cancer cells.
FASEB J. 2001; 15(7): 1273-5.
LA Stark, FVN Din, RM Zwacka and MG Dunlop
2. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B
signalling and apoptosis
British Journal of Cancer. 2004 Jul 19; 91(2): 381-8
FVN Din, MG Dunlop and LA Stark
3. Aspirin-induced apoptosis following NFkB nuclear translocation is not influenced
by mismatch repair and p53 Status.
British Journal of Cancer 2005 92:1137-43
FVN Din, MG Dunlop & LA Stark.
4. Aspirin activates the NFkB signalling pathway and induces apoptosis in vivo, in
two animal models of colorectal cancer
Accepted Carcinogenesis
LA Stark, K Reid, O Sansom, FV Din, S Guichard, DI Jodrell, A Clarke & MG Dunlop
Published Peer Reviewed Abstracts
1. Aspirin-induced IkBcx degradation and apoptosis in colorectal cancer cell lines.
Proceedings of the American Association ofCancer Research 2000 Volume 41,495
FVN Din, MG Dunlop and LA Stark
270
2. Aspirin induced apoptosis of colorectal cancer cells is caused by nuclear
translocation of repressive NFkB complexes
Proceedings of the American Association ofCancer Research 2000 Volume 41, 495
LA Stark, FVN Din and MG Dunlop
3. Molecular basis of aspirin-induced apoptosis in colorectal cancer.
British Journal of Surgery 2001, Volume 88, (5): 755-756
FVN Din, LA Stark and MG Dunlop
4. Aspirin-Induced Apoptosis Following NFkB Nuclear Translocation Is Not
Influenced by Mismatch Repair and p53 Status
Colorectal Disease Supp. 2002 4 1:11
FVN Din, MG Dunlop & LA Stark
5. Aspirin Effects on NFkB Signalling & Apoptosis: Evidence for Colorectal Cancer
Cell Specificity
Colorectal Disease Supp. 2003 5 1:22-23
FVN Din, LA Stark and MG Dunlop
6. Aspirin Induced Apoptosis And Effects on NFkB Responsive Genes, Bax & BcI-xl
SARS Yearbook 2004 (http://www.surgicalresearch.org.uk/pdf%27s/FINALSARS.pdfAbstraCt 19, pg 44,
A Macdonald, F Din, L Stark and M Dunlop
7. Aspirin-Induced Nuclear Translocation of NFkB and Apoptosis in Colorectal
Cancer is Independent of p53 Status and Mismatch Repair Proficiency
Familial Cancer Supp 2005 4 (Supp 1): 57
FVN Din, LA Stark and MG Dunlop
271
8. Aspirin Represses NFkB driven Transcription of Bc1-xl gene in colorectal cancer
Journal of the Royal Colleges of Surgeons Supp 2005 3 3:S19
A Macdonald, F Din, L Stark and MG Dunlop.
9. NSAIDs Induce Activation ofNFkB & apoptosis in Rectal Cancer Patients
Journal of the Royal Colleges of Surgeons Supp 2005 3 3:S6
FVN Din, LA Stark and MG Dunlop
10. Aspirin represses NFkB driven transcription of ICAM-1 in colorectal cancer
Colorectal Disease Supp. 2005 7 1:57
A Macdonald, F Din, L Stark and MG Dunlop.
11. NSAIDs Induce Apoptosis via NFkB Modulation in Colorectal Cancer Patients
Colorectal Disease Supp. 2005 7 1:5
FVN Din, LA Stark and MG Dunlop
272
Appendix III: Prizes
Chiene Medal in Surgery
School of Surgery Day
Molecular basis ofthe antineoplastic activity ofaspirin in colorectal cancer
November 1999
Sir James Black Prize -1st prize
Scottish Society for Experimental Medicine
Aspirin and colorectal cancer chemoprevention
October 2000
Colon and Rectal Disease Research Foundation Prize
Association ofColoproctology ofGreat Britain and Ireland









The FASEB Journal express article 10.1096/fj.00-0529fje. Published online March 20, 2001.
Aspirin-induced activation of the NF-kB signaling pathway:
a novel mechanism for aspirin-mediated apoptosis in colon
cancer cells
L.A. Stark, F.V.N. Din, R.M. Zwacka, and M.G. Dunlop
Colon Cancer Genetics Group, University of Edinburgh Dept. of Oncology, Division of Clinical
and Molecular Medicine and MRC Human Genetics Unit, Western General Hospital, Crewe Rd.,
Edinburgh, Scotland
Corresponding author: Lesley Stark, Colon Cancer Genetics Group, MRC Human Genetics Unit,
Western General Hospital, Edinburgh EH4 2XU, United Kingdom. E-mail:
Lesley.Stark@hgu.mrc.ac
ABSTRACT
The use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a
lower risk of colorectal cancer. However, the underlying mechanism is complex and remains to
be fully elucidated. NSAIDs have modulated NF-kB in response to stimulating cytokines, but the
link between NF-kB and aspirin-induced growth inhibition of colorectal cancer cells has yet to
be thoroughly investigated. In the present study, we examined the effects of aspirin on the NF-
kB pathway and the association between these effects and apoptotic tumor cell death. We found
that aspirin induced a concentration and timedependent reduction in cytoplasmic IkBcx in
colorectal cancer cells that was due to phosphorylation-dependent, proteosome-mediated
degradation of the protein. With aspirin-induced IkBcx degradation, we observed nuclear
translocation of NF-kB, as determined by immunocytochemistry and electrophoretic mobility
shift assays (EMSAs). The NF-kB response to aspirin preceded cell death and was, therefore,
more likely to be a cause than a consequence. To further investigate this relationship, we
generated HRT18 and CT26 colon cancer cells that constitutively expressed a super-repressor
IkBoi. We found that inhibition of NF-kB nuclear translocation in these cells abrogated aspirin-
induced apoptosis. When we investigated the cell specificity of the aspirin-induced response, we
observed both iKBa degradation and growth inhibition in a panel of colorectal cancer cells, but
there was no effect in cells of noncolonic origin. Thus we conclude that aspirin induces
activation of NF-kB, which is required for its anti-tumor activity and may contribute to the
protective effect of aspirin that has been observed in clinical trials.
Key words: NF-kappaB • colorectal cancer • NSAIDs • IkBcx • chemoprevention
An estimated 250,000 people are diagnosed with colorectal cancer annually in the UnitedStates and Europe (http://www.aacr.org/), and 500,000 people are diagnosed worldwide.Half of these patients have metastatic disease at initial presentation, and current
conventional chemotherapies impart only marginal survival benefit (1). Hence, much effort is
focused on developing strategies for early detection and prevention. One class of compounds that
have shown promise in the prevention of colon cancer are aspirin and related nonsteroidal anti¬
inflammatory drugs (NSAIDs) (2-6). . NSAIDs have inhibited the growth of colorectal cancer
cells in vitro (7-11) , inhibited tumor formation in the colons of carcinogen treated rodents (12-
14), and reduced adenoma counts in humans with familial adenomatous polyposis (15-18). The
most compelling evidence that NSAIDs prevent colon cancer comes from epidemiological data
indicating that people who regularly take NSAIDs have a 40-50% reduced risk of dying from
this disease compared with matched controls (2, 17, 19). However, the detrimental side effects of
NSAIDs limit their potential as chemopreventative agents (20). Therefore, to allow development
of safer alternatives, we need to understand the mechanisms by which NSAIDs exert their
chemopreventative effects. These mechanisms appear to be complex and have yet to be fully
elucidated.
There is a body of literature that suggests that the antineoplastic activity of NSAIDs is
predominantly mediated by inhibition of the cyclooxygenase (COX) enzymes (4, 5, 21).
Consistent with this, overexpression of COX-2 is associated with the progression of colon
cancer. However, NSAIDs have been effective against colon cancer cell lines that do not express
COX-1 or COX-2 enzymes (8, 22) and also against mouse embryo fibroblasts that are null for
both COX-1 and COX-2 genes (23). Furthermore, NSAID metabolites that do not appreciably
affect the catalytic activity of COXs retain their anti-tumor properties in tissue culture (24-26)
and animal experiments (13, 14). These data provide powerful evidence that COX is not the only
target for NSAIDs in the colon. Other pharmacological targets for NSAIDs have been identified.
Recently, He et al . (27) demonstrated that sulindac inhibits DNA binding of the PPAR5 nuclear
receptor, reversing the effects of adenomatous polyposis coli (APC) mutations in colorectal
cancer cells. However, again this mechanism did not fully account for NSAID-induced growth
inhibition of the cells studied, which indicates that other mechanisms may also be involved.The
NF-kB signaling pathway was previously identified as a target for the anti-inflammatory effects
of aspirin and related NSAIDs (28, 29). NF-kB generally exists as a heterodimer of the p50 and
p65 polypeptides, bound in the cytoplasm by the inhibitor protein IkB (30, 31). Following
cellular stimulation by a number of cytokines or pathogens, IkB is phosphorylated by the IkB
kinase (IKK) complex at serines 32 and 36, then degraded by the 26S proteosome (30-33).
Subsequently, NF-kB translocates to the nucleus, where it binds to regulatory elements within
the promoter region of target genes.
In addition to regulating cellular responses to cytokines and pathogens, the NF-kB pathway plays
an essential role in controlling cellular growth properties and apoptotic cell death (32, 33).
Consistent with this, inappropriate signaling of NF-kB has been involved in tumor formation in
lymphomas, breast, skin, and bladder cancers (34-37). Dejardin et al. (38) and others recently
reported that colon cancer cell lines also show abnormally high NF-kB activity and low IkB
levels (39, 40), which indicates that dysregulation of NF-kB may also contribute to colon
carcinogenesis. In support of this notion, several growth regulatory genes that are known to be
involved in colon cancer, including c-myc, p53, and COX-2, are regulated by NF-kB (34). Thus,
the NF-kB signaling pathway is a strong potential target for the anti-tumor effects of NSAIDs in
the colon.
Yamamoto et al. (41) previously demonstrated that NSAIDs inhibit cytokine-mediated IkB
kinase (IKK) activation, and consequently NF-kB activation, in colorectal cancer cells and
suggested that this specific interference is responsible for the antineoplastic activity of these
agents. However, in this and other studies showing NSAID-mediated inhibition of IKK, cells
were pretreated with NSAIDs for a short period prior to a burst of tumor necrosis factor (TNF).
Such experimental conditions are not representative of the in vivo situation in which colonic
epithelium are continuously exposed to NSAIDs. Furthermore, in tissue culture experiments,
NSAIDs inhibit the growth of colorectal cancer cells without additional cytokine stimulation (8-
11). Therefore, the relevance of these studies to the chemopreventative effects of NSAIDs is
unclear.
Our goal was to determine whether, in the absence of TNF or other stimulating agents, NSAIDs
mediate an anti-tumor effect by targeting the NF-kB pathway. By performing these experiments
without the addition of cytokines, we aimed to identify the underlying role of NF-kB in NSAID-
mediated apoptosis. We demonstrate that, contrary to short-term treatment with aspirin plus
cytokine, prolonged treatment with aspirin alone induces degradation of IkBcc and nuclear
translocation of NF-kB in colorectal cancer cells. Furthermore, NF-kB nuclear translocation is
required for aspirin-induced apoptosis. These studies identify an intrinsic activity of aspirin that
is highly relevant to colon cancer chemoprevention.
METHODS
Reagents
Aspirin and sodium salicylate (NaSal) were supplied by Sigma (St. Louis, Mo.) and solubilized
in water using 10 N NaOH, and the pH was adjusted to 7.0. All other chemicals and reagents
were from standard commercial sources and of the highest quality.
Plasma salicylate
We investigated the relevance of the aspirin concentrations used in in vitro experiments. Patients
were given 600 mg 4 times daily for 7 days. Blood was drawn at the end of this period, and
plasma salicylate levels were measured by a standard colorimetric assay (Trinder method).
Epidemiological studies have focused on populations that take NSAIDs for their analgesic
effects, although there are no definitive data on the dose required for a chemopreventative effect.
Hence, we studied subjects given a short course of analgesic doses of aspirin, because this seems
to best reflect the use in the published cohort and case-control studies. Measurements of plasma
salicylate levels in 10 study subjects ranged from 0.05 to 1.13 mM (mean 0.5 mM, se +/- 0.14
mM), which is within the ranges used in the in vitro experiments.
Cell culture
SW480, HRT18 (genetically identical to DLD-1 and HCT-8/15) (42), HCT116, and CT26 colon
cancer cell lines and the lung adenocarcinoma cell line, A549, are all available from the
American/European Type Culture Collections (ATCC/ ECACC). SW480 cells were maintained
in L-15 medium, HRT18 in RPMI 1640, HCT116 in McCoy's 5A medium, and CT26, A549,
and 293 cells in DMEM. All media were supplied by Gibco BRL (Paisley, U.K.) and
supplemented with penicillin (100 IU/ml), streptomycin (100 ug/ml), and 10% fetal calf serum
(FCS).
Viability and apoptosis assays
Cells were plated at a density of 1 x 105 per 50-ml flask, grown until 60-80% confluent
(generally 24-48 h), andthen treated continuously with 1-20 mM aspirin or sodium salicylate, in
low-serum (0.5% FCS) medium, for a further 24 h, or as specified in text. Adherent cells were
washed in PBS, harvested using a cell scraper, pipetted vigorously, and then counted on a
hemocytometer. Nigrosin dye was added before counting to identify necrotic cells. Staining for
cell surface phosphatidyleserine was used as a marker for apoptosis and was carried out using an
Annexin V-FITC apoptosis detection kit (Oncogene Research Products, Cambridge, Mass.) as
per the manufacturer's instructions. Apoptotic cells were counted using fluorescent microscopy.
For morphological analysis of apoptosis, adherent cells were fixed by acetic acid:ethanol (9:1
v/v) and mixed with acridine orange stain (0.5% final concentration) directly prior to analysis by
fluorescent microscopy.
Immunoblot analysis and electrophoretic mobility shift assays
Cytoplasmic and nuclear extracts were made as previously described (43). Briefly, adherent cells
were lysed for 5 min in lysis buffer (50 mM NaCl, 10 mM HEPES, 500 mM sucrose, 1 mM
EDTA, 0.5 mM spermidine, 0.15 mM spermine, 0.2% Triton X-100, Complete protease inhibitor
cocktail [Roche Diagnostics, Mannheim, Germany], 100 mM Pefabloc (Roche Diagnostics]),
and then nuclei were pelleted by centrifugation at 6000 rpm for 15 min. Nuclei were lysed in
hypotonic buffer (350 mM NaCl, 10 mM HEPES, 25% glycerol, 0.1 mM EDTA, 0.5 mM
spermidine, 0.15 mM spermine, protease inhibitors, and Pefabloc as above) for 30 min, and
debris was cleared by centrifugation at 13,000 rpm for 5 min. Bradford assays (BioRad,
Hercules, Calif.) were used to measure protein content. Cytoplasmic extracts (30 jag) were
resolved on 10% SDS polyacrylamide gels, and immunoblots were performed by standard
procedures. The mouse monoclonal antibody to IkBcx was a gift from Prof. R. Hay (St.
Andrews). Membranes were probed with horseradish peroxidase-conjugated monoclonal
antibody to Cu/Zn SOD (The Binding Site, Birmingham, U.K.) as a control for protein loading.
The anti-pk-tag antibody was a gift from Dr. R. Randall (St. Andrews) and has been described
(44). Antibody conjugates were detected using Amersham (Little Chalfont, U.K.) ECL protocol.
Electrophoretic mobility shift assays (EMSAs) were carried out by incubating nuclear extracts (6
jag) with binding reaction mix (IX binding buffer [50 mM KC1, 20 mM HEPES, 5% glycerol, 1
mM EDTA, 1 mM DTT], 1 jag BSA, 1 jag poly dl-dC, 25 fmol radioactively labeled oligo-DNA
in a final volume of 20 jal) for 30 min prior to analyses on a 4% native polyacrylamide gel. For
supershift assays, nuclear extracts were preincubated with 1 ul of anti-p50 or p65 antibodies (1
jag/jal) (Santa Cruz, Santa Cruz, Calif.) for 1 h on icebefore other assay reagents were added.
Double-stranded oligonucleotides for wild-type and mutant NF-kB were obtained from Santa
Cruz.
Immunocytochemical staining
SW480 cells were grown on sterilized coverslips until 60-80% confluent and then treated with
aspirin in low-serum (0.5% FCS) medium for 24 h. Cells were washed twice in cold PBS for 10
min each and then fixed in 1:1 methanol:acetone at -20°C for 20 min before being blocked in
10% nonimmune donkey serum (Sigma) for a further 30 min. Negative control coverslips were
kept in 1.5% donkey serum without exposure to either of the primary antibodies, rabbit
polyclonal to p65 or goat polyclonal to p50 (Santa Cruz) whereas the remaining coverslips were
incubated for 1 h with the primary antibody at a 1:100 dilution in 1.5% donkey serum. After
extensive washing in PBS, all coverslips were incubated with either FITC-conjugated antirabbit
(for p65) or antigoat (for p50) (Jackson ImmunoResearch, West Grove, Penn.) for 30 min and
then washed again in PBS. Coverslips were mounted in Vectastain (Vector Laboratories,
Burlingame, Calif.) containing 1:25 xmg/ml DAPI, and cells were analyzed using fluorescent
microscopy.
Transfections and generation ofstable IkBs32/36 expressing cell lines
The IkB!,32/36 plasmid was a gift from R. Hay and contains IkBcx mutated at serines 32 and 36,
cloned into pcDNA3 with a C-terminal pk-tag (43). For transient transfection experiments, cells
were transfected using Lipofectamine (as described by the manufacturer, Gibco BRL), grown for
24 h in low-serum (0.5% FCS) medium, and then treated continuously with aspirin (0-10 mM)
for another 24 h. Immunoblots were performed on cytoplasmic extracts using anti-pk tag
antibody as described above. Transfected CT26 and HRT18 cells were grown under Geneticin
(Gibco BRL) selection, and stable transfectants were screened by immunoblotting, using the
anti-pk-tag antibody. Expressing clones were grown in the absence of Geneticin during aspirin
treatment.
Aspirin treatment ofclinical samples
Normal mucosa and tumor biopsies were collected from patients undergoing resection for
colorectal cancer. Biopsies were washed in PBS, finely sliced, and incubated for 5 h in RPMI
medium containing aspirin or carrier control. Tissue fragments were homogenized in lysis buffer,
after which protein extraction and immunoblotting were performed, as described above.
RESULTS
Aspirin induces apoptosis in colorectal cancer cells
To establish that pharmacologically relevant doses of aspirin induce the death of colorectal
cancer cells, we incubated SW480 cells with 1-10 mM aspirin for 24 h, or 0.5-2 mM aspirin for
48 h. These concentrations are comparable to salicylate levels that we measured in plasma (0.05-
1.13 mM, mean 0.5 mM, SE +/- 0.14 mM, 77=10) from patients given a short course of analgesic
doses of aspirin (600 mg 4 times daily), which we considered to reasonably represent the use in
published cohort and case-control studies of chemoprevention. We found that aspirin induced a
dose-dependent reduction in the number of viable colorectal cancer cells (SW480) (Fig. 1A, B).
This was accompanied by an increase in the percentage of cells showing externalization of
phosphatidylserine (PS), a marker for apoptosis detected by FITC-annexinV binding (Fig. 1A,
B). Treated cells also showed morphological features of apoptosis, including condensed
cytoplasm, granular chromatin, and irregular condensed nuclei (Fig. 1C). However, nuclear
fragmentation and classical apoptotic bodies were rarely seen.
We wished to definitively establish that aspirin-treated cells, which appeared to be apoptotic,
were dying by an active process rather than simply by toxic necrosis. Hence, we examined the
requirement for de novo protein synthesis, one of the original criteria used for identifying
apoptosis (45). Inhibition of protein synthesis by cyclohexamide (10 pM) abrogated the aspirin-
induced (10 mM) growth inhibition (Fig. ID), thereby confirming that aspirin-treated cells do
indeed die by apoptosis.
Aspirin induces apoptosis in association with degradation of IkBo and nuclear
translocation of NF-kB
To determine whether the apoptotic response we observed in SW480 cells was attributable to
modulation of the NF-kB signaling pathway, we investigated the effects of aspirin on the NF-kB
inhibitor protein, ItcBc^using Western blot analysis. Prolonged (24M-8 h) treatment with aspirin
induced a dose-dependent reduction in cytoplasmic IkBoc levels (Fig. 2A, B) that correlated
directly with a reduction in the number of viable cells (Fig. 2C). Levels of control protein
(Cu/ZnSOD) were unaffected by aspirin (data not shown). In the classical pathway of NF-kB
activation, IkBoc is phosphorylated at serines 32 and 36 before degradation by the 26S
proteosome. To determine whether the aspirin-induced reduction in cytoplasmic IkBcx was
caused by phosphorylation and degradation of the protein, we first transfected SW480 cells with
a dominant negative form of iKBa (lKBS32/36-tag), which was resistant to phosphorylation at the
critical S32/36 residues and hence resistant to signal-mediated degradation. The IKBa expression
construct contained a C-terminal pk tag to allow discrimination between endogenous and
recombinant protein (43). We found that aspirin (1-10 mM) had no effect on levels of the mutant
protein (Fig. 3A), which indicates that these phosphorylation sites are important for the aspirin
effect on IkBcc To examine the role of the proteosome in this effect, we preincubated SW480
cells with the MG132 proteosome inhibitor prior to treatment. This also blocked aspirin-induced
reduction in IkBcc levels (Fig. 3B). These results clearly indicate that prolonged treatment with
aspirin mediates phosphorylation and proteosome-mediated degradation of IkBou Furthermore,
they also raise the possibility that IkBo degradation is associated with cell death.
IkBcc degradation results in nuclear translocation of NF-kB complexes. To determine whether
this also occurs after aspirin treatment, we used EMSAs to investigate nuclear levels of activated
NF-kB. We found that aspirin-induced IkBcc degradation was indeed accompanied by a dose-
dependent increase in nuclear NF-kB DNA binding complexes (Fig. 4A, B). Binding of the
induced NF-kB complex to the labeled probe was inhibited by competition with an excess of
unlabeled wild-type, but not mutant, kB oligonucleotide (Fig. 4C). Supershift analysis with
specific antibodies revealed the presence of p65 and, to a lesser extent p50, subunits of NF-kB in
the induced complex (Fig. 4C). The findings from EMSAs were further corroborated by
immunocytochemistry performed on aspirin-treated cells. Before aspirin treatment, p65 was
mainly localized in the cytoplasm, but following 24 h of treatment with 10 mM aspirin there was
a dramatic change, with extensive nuclear staining for this protein (Fig. 4D). Nuclear staining for
p50 also increased following aspirin (10 mM) treatment, although this was less dramatic because
of higher constitutive levels of nuclear p50 (data not shown). In contrast, there was no change in
cellular localization of the control (Cu/ZnSOD) protein (data not shown). These results confirm
that exposure of colorectal cancer cells to 24 h of aspirin activates the NF-kB pathway.
Kinetics of aspirin-induced IkBo degradation, NF-kB nuclear translocation, and cell death
in colorectal cancer cells
To eliminate the possibility that NF-kB nuclear translocation was a consequence of cell death,
we studied the kinetics of the aspirin effects on NF-kB signaling and cell viability. In contrast to
the early transient iKBaa degradation observed following TNF-aa treatment, aspirin (10 mM)
treatment induced complete degradation of iKBa after 2-5 h, and the protein remained absent for
more than 24 h (Fig. 5A, 2A). Similarly, an increase in nuclear NF-kB DNA binding was
observed 2 h after treatment and persisted for more than 16 h (Fig, 5B). In comparison, aspirin-
induced apoptosis, determined by externalization of phosphatidylserine, was not detected until
16 h after treatment. These results show that apoptosis occurred after NF-kB nuclear
translocation, and they raise the intriguing possibility that there is a causal relationship between
aspirin-induced NF-kB activation and subsequent cell death.
Inhibition of NF-kB nuclear translocation inhibits aspirin-induced apoptosis
To definitively prove the relationship between NF-kB nuclear translocation and aspirin-mediated
growth inhibition, we generated stable transfectants of HRT18 and CT26 colon cancer cells,
which constitutively express the lKBS32/36-tag construct. Although we were able to study transient
SW480 IkBS32/36 transfectants, numerous attempts at establishing stable IkBs32/i6 transfectants of
SW480 cells were unsuccessful. Clones expressing the transgene were identified by Western blot
analysis using the anti-pk tag antibody. Two HRT18 (lKBS32/36hl, h28) and two CT26
(lKBs32/36ct3, ct4) clones were chosen, as these expressed particularly high levels of mutant
protein (data not shown). As expected from our studies of transient transfected cells, in which we
showed that lKBaS32/36 is resistant to aspirin-induced degradation (Fig. 3A), nuclear translocation
of NF-kB was inhibited in all independent clones expressing mutant IkBcc when compared with
respective parental cells. Parental lines showed substantial NF-kB nuclear translocation
following aspirin treatment (1-5 mM) (Fig. 6A). If nuclear translocation of NF-kB were
contributing to apoptosis, then inhibition should protect against aspirin-induced cell death.
Indeed, the IkBS32/36 expressing clones grew in the presence of 1 mM aspirin compared with a
32.4% and 55.8% reduction in viable cell counts in parental HRT18 and CT26 cells, respectively
(Fig 6B). Treatment with 5 mM aspirin also had significantly less effect (P<0.05) on the viability
of mutant IKBa expressing clones than on the viability of parental lines (Fig. 6B). The decrease
in viable cell number observed in parental cells was attributable to apoptosis, as shown by
annexin V staining (data not shown). These data support the notion that aspirin-induced
apoptosis of colorectal cancer cells depends on nuclear translocation of NF-kB, which is a
consequence of phosphorylation and degradation of IkBcx.
Cell specificity of aspirin-induced IKBa degradation and apoptosis
Epidemiological studies indicate that NSAID-mediated protection is relatively specific to
colorectal tumors (46). Therefore, we wanted to determine whether cells not derived from
colorectal tumors also responded to aspirin with similar effects on the NF-kB pathway and cell
viability. In all 4 colorectal cancer cell lines tested (3 human and 1 mouse [CT26]), 5 mM aspirin
induced substantial IkBo. degradation and 10 mM aspirin induced almost complete degradation
(Fig. 7A). In contrast, 10 mM aspirin had no effect on IKBa in embryonic kidney (293) or in lung
adenocarcinoma (A549) cells (Fig. 7A). Substantial growth inhibitory effects were also observed
in all colorectal cancer cell lines treated with 5 or 10 mM aspirin. Numbers of viable SW480,
HRT18, CT26, and HCT116 cells decreased by 6.7-, 2.2-, 4.4-, and 2-fold, respectively,
following treatment with 5 mM aspirin (Fig. 7B). On the contrary, numbers of viable 293 cells
increased in the presence of 5 mM aspirin, whereas A549 cells only showed a 1.2-fold decrease
in viability following treatment (Fig. 7B). These results suggest that aspirin-mediated IkBcx
degradation and apoptosis may be cell-type-specific.
Aspirin induces IkB<x degradation in normal colonic mucosa and tumors from rectal cancer
patients
To investigate the potential clinical significance of our results, we treated biopsy samples of
normal mucosa and tumor material from patients undergoing marginal resection for rectal
cancer. The biopsies were maintained ex vivo as short-term explants and treated with 10 and 20
mM aspirin. IkBo degradation was observed in both the tumor and, to a lesser extent, in normal
mucosa following 5 h treatment, whereas there was no effect on levels of the control
(Cu/ZnSOD) protein (Fig. 8). These data confirm that clinical tumor biopsy material shows the
same iKBa response observed in cell line experiments.
DISCUSSION
Our findings shed further light on the complex mode of action of NSAIDs. We show that, in the
absence of additional NF-kB activating agents, aspirin induces IkBcx degradation and nuclear
translocation of NF-kB complexes in colorectal cancer cells. Furthermore, we provide
compelling evidence that NF-kB nuclear translocation is predominantly responsible for aspirin-
induced cell death. Taken together, our findings describe a novel mechanism of action for aspirin
and have implications for the development of novel chemopreventative agents.
NSAIDs are known to reduce the growth of colorectal cancer cells both in vitro and in vivo, but
the underlying cellular mechanism involved is still unclear. Some studies suggest NSAID-
induced growth inhibition is due to cell cycle arrest (9, 11, 47), whereas others have reported
induction of apoptosis and necrosis (7, 8, 11, 25, 48). . Here we demonstrate that aspirin induces
two hallmarks of apoptosis in colorectal cancer cells: externalization of phosphatidylserine (Fig.
FA) and nuclear chromatin condensation (Fig. IB). However, no nuclear fragmentation was
evident by morphological analysis. This is consistent with data from Qiao et al. (10, 48), who
also demonstrated that aspirin induces an "atypical" form of apoptosis that docs not involve
oligonucleosomal or nuclear fragmentation. De novo protein synthesis is required for apoptosis
but not for passive necrosis (45). Our data showing that cyclohexamide inhibits aspirin-induced
cell death confirms that this is an active process and indicates that the drug has specific
antineoplastic activity that involves apoptosis.
Several pharmacological targets for NSAIDs have previously been identified, some of which are
associated with an ability to inhibit the growth of colon cancer cells (28, 29, 49-52). For
example, specific inhibition of COX-2 reduces adenocarcinoma formation in APC mutant mice
(12, 53), and sulindac inhibits the DNA binding potential of PPAR8,thus inducing apoptosis of
colon cancer cells (27). However, modulation of these targets does not fully account for the anti¬
tumor effects of these agents. The NF-kB transcription factor plays an important role in cell
growth and death (9, 54), so we considered that this signaling pathway might be a candidate
target for NSAIDs. We show that aspirin mediates a reduction in cytoplasmic hcBa levels in
colorectal cancer cells that is time- and concentration-dependent (Figs. 2 and 5). This reduction
is blocked by pretreatment of cells with the MG132 proteosome inhibitor and by mutation of
IkBcx at the critical S32/36 phosphoacceptor sites (Fig. 3), which indictates that it is due to
phosphorylation and proteosome-mediated degradation of the protein. Using EMSAs and
immunocytochemistry, we demonstrate that IkBcx degradation results in nuclear translocation of
p50/p65 NF-kB complexes (Fig. 4). confirming aspirin stimulates the NF-kB pathway. A direct
link between aspirin-induced stimulation of the NF-kB pathway and apoptosis was implied by
the correlation between IkBcc degradation and reduced cell viability (Figs. 2C and 7). Time
course experiments indicated that the NF-kB response to aspirin occurred before detectable cell
death (Fig. 4). suggesting a causal relationship. This was confirmed in cells that we engineered to
continuously express a dominant negative mutant IkBoi (IkBoi S32/36). These cells showed
inhibition of both aspirin-induced NF-kB nuclear translocation and apoptosis, compared with
their parental counterparts (Fig. 6). We considered that the lack of apoptotic response to aspirin
in the mutant IkBcx expressing clones was due to their slower rate of growth, compared with
parental cells. However, this is unlikely because they grew at a similar rate to other colorectal
cancer cell lines (SW480) in which aspirin induced substantial apoptosis. Thus, from these
experiments we conclude that aspirin-induced apoptosis is due, at least in part, to nuclear
translocation of NF-kB complexes.
This study is the first to show stimulation of the NF-kB pathway by aspirin. Our data appear to
contradict previous in vitro studies indicating that aspirin and its metabolite, sodium salicylate,
bind to and directly inhibit IKK|3, the kinase responsible for phosphorylating bcBa (29, 41).
However, in these studies, direct inhibition of IKKP by aspirin required IKK to be pre-activated
by TNF or a similar stimulating agent. Furthermore, recent studies performed on intact cells
suggest that direct inhibition of IKK activity by sodium salicylate does not occur in an in vivo
setting (55). Therefore, the discrepancy between our findings, using intact cells treated only with
aspirin, and these other studies is most likely explained by differences in the experimental
systems used. It is now of considerable interest to identify the upstream targets of aspirin
responsible for stimulation of the NF-kB pathway. One potential candidate is the p38 MAP
kinase, which is activated by sodium salicylate to induce apoptosis (56-58) and can activate the
NF-kB pathway upstream of IkB phosphorylation (59). Alternatively, aspirin may indirectly
activate NF-kB by inducing the secretion of soluble factors. Indeed, this might explain the
delayed time course of aspirin-induced IxBa degradation we observe (Fig. 5). Identification of
the upstream pathways leading to NF-kB activation would allow the development of agents
designed specifically to target the proteins involved. Such agents would have potential as more
potent and specific chemopreventative drugs.
Our finding that NF-kB nuclear translocation induces apoptosis in colorectal cancer cells is
intriguing given that we (60) and others (40, 61, 62) have demonstrated that TNF-induced NF-
KBis anti-apoptotic in colorectal cancer cells. The DNA binding specificity and selective
transcriptional activation of downstream NF-kB target genes is determined by the dimeric
composition of the NF-kB complex and by the transcriptional co-factors recruited to the complex
(63). It seems likely that these are dependent on the kinetics of induction. We observed
fundamental differences in the kinetics of IkBoc degradation induced by aspirin compared with
TNF (Fig. 5A). IkBcx degradation was evident 2-5 h following aspirin treatment versus 30 min
following TNF treatment, and aspirin-induced IkBo degradation persisted for more than 24 h,
whereas TNF-induced degradation was transient. Therefore, the disparate cellular consequences
of NF-kB activation induced by TNF and by aspirin may be accounted for by the differences in
kinetics of activation resulting in different NF-kB DNA binding complexes. Consistent with this
hypothesis, we found predominantly p50 and p65 proteins in aspirin-induced NF-kB complexes
(Fig. 4C) whereas a previous study from this laboratory reported predominantly c-rel/p65
complexes after TNF treatment in the same cell type (12). It was previously reported that NF-kB
can be both pro- and anti- apoptotic in the same cell type, depending on the inducer, which
provides additional support for this notion (33). Further work is under way in our laboratory to
determine the composition of the aspirin-induced NF-kB DNA binding complexes and the
downstream genes activated by these complexes. Using EMSAs and immunocytochemistry, we
did not observe the high constitutive levels of nuclear p50/p65 NF-kB complexes that have been
reported in other studies (38). However, we have some evidence that there may be subtle
differences in levels of IkBcx in patient colonic tumor material, compared with normal mucosa,
which is now the subject of further detailed study.
Our finding that aspirin-induced IkBcx degradation and apoptosis are more apparent in cells of
colonic origin is in keeping with epidemiological studies indicating that NSAIDs impart
relatively selective protection against colorectal cancer in humans. It seems unlikely that cellular
specificity is related to overexpression of COX-2, because we observed aspirin-induced IkBo
degradation in a cell line that does not express COX-2 (HCT-116) (52). Furthermore, salicylate,
which is a very poor inhibitor of COX-2 (46), induced the same effect on colon cancer cells that
we observed for aspirin (data not shown). That we detected some IkBo degradation in normal
colonic mucosa, but substantially more in colonic tumor tissue, would suggest that this
specificity is related to a tissue-specific protein that is dysregulated during carcinogenesis.
Identification of molecular mechanisms underlying this specificity could provide surrogate
markers that might indicate a likely NSAID response and so might inform clinical trials.
We observed activation of the NF-kB pathway and cell death at doses as low as 0.5 mM aspirin.
This is comparable to the salicylate levels we measured in the plasma of human subjects (0.5
mM) and also those used in the treatment of arthritic disease (1-3 mM) (64). The doses of aspirin
required for chemoprevention have not yet been fully established. Although some
epidemiological data indicate that aspirin is chemopreventative when taken at low dose, it has
been demonstrated that aspirin has unusual accumulation characteristics, in that serum levels
increase disproportionately with dose following repetitive administration (65). Therefore, the
lower doses used in this study may be comparable to levels achievable in a chemopreventative
setting. Even at the highest doses studied, we show aspirin-induced cell death is an active
process (Fig. 1C), indicating the mechanisms identified using these doses are significant to the
antineoplastic activity of this agent.
In summary, the experimental data presented here show that aspirin induces degradation of IkBcx
and consequently, nuclear translocation of p50/p65 NF-KBcomplexes in colon cancer cells. This
nuclear translocation is predominantly responsible for the ability of aspirin to induce apoptosis.
The NF-kB and death response to aspirin appear relatively cell-specific since they were evident
in numerous colon cancer cell lines but not in cell lines of noncolonic origin. Finally, aspirin
induced stimulation of the NF-kB pathway in explants of normal and tumor tissue from colon
cancer patients, a result that underscores the relevance of these molecular findings to clinical
material. Defining the key elements of the anti-tumor effect described here will undoubtedly help
inform the development of novel chemopreventative agents.
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figure 1. Aspirin induces apoptosis in colorectal cancer cells. (A, B) SW480 cells were treated with (A) 0—10 mM
spirin for 24 h or (B) 0—2 mM aspirin for 48 h in low-serum medium. The number of viable cells (■) was determined by
emocytometric counts. The -percentage of apoptotic cells (A) was determined by phosphatidylserine exposure, measured |
i a minimum of 200 cells using FITC-annexinV binding. The data presented represent the means of at least three
tdependent experiments (+/- SE). A substantial proportion of aspirin-treated cells showed phosphatidylserine exposure,
v'hieh is indicative of membrane unpacking and apoptosis. (C) Fluorescent microscope images (x 40) of acridine orange-
tained SW480 cells, treated for 24 h with buffer (i) or 5 mM aspirin (ii and iii). Aspirin-treated cells have morphological
eatures of apoptosis. (D) Cyclohexamide (10 pM) (CHX) blocks aspirin-induced growth inhibition of SW480 cells,
lemocytometric counts of viable SW480 cells following 24 h of treatment with 10 mM aspirin in the presence or absence
if CHX.
:ig. 2
A Aspirin dose (mM)
0 3 5 10 20
— IkBQ
B o 0.5 1 2
kBa


















< igure 2. Aspirinmediates a reduction in cytoplasmic IkBoc levels in colorectal cancer cells. (A, B) Anti-lKBa
Vestern blots of cytoplasmic extracts from SW480 cells treated with (A) 0—20 mM aspirin for 24 h or (B) 0-2 mM
spirin for 48 h. (C) Reduction in IicBa levels is concomitant with aspirin-induced apoptosis. IicBa protein levels (A)
vere quantified from Western blots using standard software (given as light units,LU) and correlated with viable cell
lumber (■). IicBa levels are corrected for differences in protein loading between tracks using Cu/ZnSOD levels. One
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' igure 3. Aspirin induces phosphorylation and proteosome-mediated degradation of IkBcc. (A) IkBoc mutated at
te ser-32 and ser-36 phosphorylation sites is unaffected by aspirin. Anti-pk tag Western blot of cytoplasmic extracts from
W480 cells transfected with an lKBs,l2/36-pk lag expression vector, prior to 24 h of treatment with 0-10 mM aspirin.
B) Proteosome inhibition blocks aspirin-mediated reduction in cytoplasmic IkBoc. Anti-lKBa Western blot of
ytoplasmic extracts from cells incubated with the MG132 proteosome inhibitor (50 pM) for 5 h, prior to aspirin (10 mM)
■eatment for 24 h.
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igure 4. Aspirin induces nuclear translocation of NF-kB. (A, B) Electrophoretic mobility shift assays using NF-kB
onsensus oligonucleotide, performed on nuclear extracts from SW480 cells treated with (A) 0-20 mM aspirin for 24 h or
B) 0-1 mM aspirin for 48 h. (C) Competition electrophoretic mobility shift assays indicated the identity and specificity
f NF-KB-induced complexes. The band induced by 10 mM aspirin was supershifted (indicated by arrows) when
ntibodies to ap50 and ap65 were included in the assay. Excess (100-fold) unlabeled wild-type (wt) NF-kB
oligonucleotide competed with the binding of p50/p65 heterodimers to the labeled probe but not excess (100-fold)
nutated (mt) NF-kB sequences. Supershift and competition assays indicate the lower band is a combination of
onspecific (NS) binding and p50 homodimers. (D) Micrographs (63 x) showing immunofluorescent analysis of SW480
ells either untreated (I) or treated with 10 mM aspirin for 24 h (II), then immunocytochemically stained with p65
ntibodies. The signal was detected using FITC-conjugated secondary antibody.
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figure 5. Kinetics of aspirin-induced NF-kB activation and cell death. (A) Western blot of cytoplasmic extracts from
IW480 cells treated with 10 mM aspirin (upper panel) or 100 ng/ml TNFa (lower panel) for 0—5 h. Anti-lKBa antibody
vas used. (B) Electrophoretic mobility shift assays using NF-kB consensus oligonucleotide, performed on nuclear
sxtracts from SW480 cells treated with 10 mM aspirin for 0—16 h. Induction of NF-kB is apparent after 2 h. (C) SW480
xlls were treated with 10 mM aspirin for 0-16 h; then the percentage of apoptotic cells was determined in a minimum of
ZOO cells by annexinV-FITC binding to externalized phosphatidylserine. The data shownn represent the means of at least
hree independent experiments (+/- se).
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figure 6. IkBs32/36 inhibits aspirin-mediated nuclear translocation of NF-kB and apoptosis. HRT18 (h) and CT26
ct) colorectal cancer cells were transfected with the lKBs32/36-tag plasmid, and stable clones were generated. Antitag
mmunoblots identified 2 clones from each parental cell line that showed high levels of expression of the mutant protein
IkBs32/36 hi, h28, ct3, and ct4) (not shown). (A) EMSAs, performed on nuclear extracts from HRT18 and CT26 parental
ells, and MBs32/36hl, h28, ct3, and ct4 clones, treated with aspirin for 24 h. Aspirin-induced p50/p65 complexes are not
•resent in mutant IkBoc expressing cells. (B) Hemocytometric counts of viable HRT18 (•) and CT26 (O) parental cells
nd lKBs32/36hl (■), h28 (A), ct3 (□), and ct4 (A) clones following 24 h of aspirin treatment. Data presented represent
4ie mean of 4 independent experiments (+/- SE). At 1 and 5 mM aspirin, the difference between the number of viable
reated and nontreated cells was significantly less in the clones expressing the mutant protein (E<0.05) compared with the
tarental cells.
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figure 7. Cell specificity of aspirin-mediated IicBa degradation and growth inhibition. SW480, HRT18, HCT116,
nd CT26 (mouse) colon cancer cells and 293 (embryonic kidney) and A549 (lung adenocarcinoma) control cells were
reated with aspirin (0—10 mM) for 24 h. (A) Anti-lKBa immunoblot of cytoplasmic extracts. (B) Hemocytometric
ounts of viable cells (mean of four experiments, +/- SE).
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figure 8. Aspirin induces IkBoc degradation ex vivo. Anti-lKBoc and Cu/ZnSOD (control) immunoblots of
cytoplasmic extracts from clinical biopsy material from rectal tumors and normal colonic mucosa, treated in tissue culture
or 5 h with 0-20 mM aspirin.
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Evidence for colorectal cancer cell specificity of aspirin effects on
NFtcB signalling and apoptosis
FVN Din1, MG Dunlop*1' and LA Stark1
' Colon Cancer Genetics Group, University ofEdinburgh Department ofOncology and MRC Human Genetics Unit Western General Hospital, Crewe Rd,
Edinburgh EH4 2XU, Scotland
Epidemiological evidence indicates that non-steroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) to a
greater degree than other non-gastrointestinal cancers, but the molecular basis for this difference is unknown. We previously reported
that aspirin induces signal-specific IkBci degradation followed by NFkB nuclear translocation in CRC cells, and that this mechanism
contributes substantially to aspirin-induced apoptosis. Here, we explored the hypothesis that cell-type specific effects on NFkB
signalling are responsible for the observed differences in protection by aspirin against CRC compared to breast and gynaecological
cancers. We also assessed whether COX-2 expression, mutation status of adenomatous polyposis coli (APC), /?-catenin, p53, or DNA
mismatch repair (MMR) genes in CRC lines influenced aspirin-induced effects. We found that aspirin induced concentration-dependent
IxBa degradation, NFkB nuclear translocation and apoptosis in all CRC lines studied. However, there was no such effect on the other
cancer cell types, indicating a considerable degree of cell-type specificity. The lack of effect on NFkB signalling, paralleled by absence of
an apoptotic response to aspirin in non-CRC lines, strongly suggests a molecular rationale for the particular protective effect of NSAIDs
against CRC. Effects on NFkB and apoptosis were observed irrespective of COX-2 expression, or mutation status in APC, /J-catenin,
p53 and DNA MMR genes, underscoring the generality of the aspirin effect on NFkB in CRC cells. These findings raise the possibility of
cell-type specific targets for the development of novel chemopreventative agents.
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Colorectal cancer (CRC) is common in developed countries
(Parkin et al, 1999) and is a major contributor to cancer-related
morbidity and mortality. Chemoprevention is an inherently
appealing approach to combat the disease, and non-steroidal
anti-inflammatory drugs (NSAIDs) have been associated with a
substantial reduction in CRC incidence and mortality (Thun et al,
1993; Collet et al, 1999; Langman et al, 2000). Combined case-
control data, including over 30 000 CRC cases, indicate a 45%
reduction in the risk of developing CRC in subjects taking NSAIDs.
Although there is evidence for a protective effect of NSAIDs
against non-gastrointestinal cancers, the data are less convincing
and the risk reduction much less. In breast cancer, reports show
conflicting results and a recent meta-analysis revealed a risk
reduction of only 13% in case-control studies (Khuder and Mutgi,
2001), considerably lesser than that in CRC. Similarly, in
endometrial and ovarian cancer, the available evidence suggests
that NSAIDs confer little, if any, protection (Cramer et al, 1998;
Rosenberg et al, 2000; Fairfield et al, 2002; Meier et al, 2002).
Collectively, published data suggest that there is considerable
heterogeneity of NSAID anti-tumour effect between cancer types.
The particular protective effect against CRC suggests the
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possibility that aspirin might target distinct molecular pathways
in colonic epithelial cells. Elucidation of the molecular mechanism
of this apparent differential sensitivity would lend further insight
into both the mode of action of NSAIDs as well as identification of
molecular markers of response.
The anti-tumour activity of NSAIDs has primarily been
attributed to inhibition of the cyclooxygenase-2 enzyme (COX-2)
and the resultant decrease in production of prostaglandins, as this
remains the best-characterised effect (Vane, 1971). However,
accumulating evidence from animal and cell culture experiments
has shown that COX-2 inhibition is not the sole basis of NSAID
anti-tumour activity (Alberts et al, 1995; Hanif et al, 1996; Elder
et al, 1997; Piazza et al, 1997), suggesting that other targets are also
involved. We previously reported that aspirin activates the NFkB
signalling pathway and that this mechanism is of central
importance to aspirin-mediated apoptosis in CRC cells (Stark
et al, 2001). The NFkB transcription factor is normally sequestered
in the cytoplasm by an inhibitor protein, IkB«. Following
stimulation of the NFkB pathway, KBa is phosphorylated,
ubiquitinated and targeted for proteosomal degradation. Dissocia¬
tion from IkBk results in translocation of NFkB to the nucleus,
where it contributes to the co-ordinated transcription of genes
involved in inflammation, cell proliferation and apoptosis (Pahl,
1999). Our previous work demonstrated that aspirin induces time-
and dose-dependent signal-specific degradation of IkBs, nuclear
translocation of NFkB and apoptosis in CRC cells. Time-course
experiments indicated that IkBs degradation and NFkB nuclear
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translocation preceded cell death, suggesting a causal relationship.
This was confirmed in cells we engineered to continuously express
a dominant-negative mutant ItcBa (I;cBaS32/36), which showed
inhibition of both aspirin-induced NFkB nuclear translocation and
apoptosis compared to their parental counterparts (Stark et al,
2001). This work alluded to the notion of specificity since the
NFkB response was not observed in the control cell lines 293 HEK
and A549, which were non-colorectal in origin.
Here, we focus on the important issue of the specificity of
aspirin's protective effects, as observed in epidemiological studies,
and we set out to determine whether cell-type specific effects on
the NFkB signalling pathway reflect the differential protective
effects of aspirin in different cancer types. In particular, we wished
to determine whether the lower protective effect observed for
breast, ovarian and endometrial cancer can be explained by
differing effects on the NFkB signalling pathway. We also
investigated the generality of the NFkB response to aspirin in
CRC by studying a panel of CRC cell lines with different genetic
defects common in bowel malignancy. Here, we present evidence
showing clear differences in NFkB response that parallel the
epidemiological data, supporting the notion that the ability of
aspirin to modulate the NFkB signalling pathway is a key
determinant of the anti-tumour effect and that this is cell-type
specific. Our findings provide further insight into the complex
mechanisms by which NSAIDs exert an anti-tumour effect in CRC
cells, and raise the possibility of cell-type specific molecular targets
in CRC.
MATERIALS AND METHODS
Cell line culture and treatment
The CRC cell lines used were HRT-18, SW480, HT-29, DLD-1,
LoVo and HCT116; breast cancer lines were T47-D, MCF-7 and
MDA-MB-231; ovarian cancer line was A2780 and endometrial
cancer line was HEC-l-A. All cancer cell lines are available from
the American Type Culture Collection. The mutation status for the
adenomatous polyposis coli (APC), p53, /J-catenin and DNA
mismatch repair (MMR) genes of the cell lines studied is shown in
Table 1. Cell lines were grown as monolayers (37°C in 5% C02) in
RPMI (HRT-18, DLD-1 and A2780), DMEM (HT-29, T47-D, MCF-
7, MDA-MB-231, HEC-l-A), L-15 (SW480) and McCoy's 5A media
(HCT116) supplemented with 10% foetal calf serum (FCS) and 1%
penicillin/streptomycin (media supplied by Gibco BRL, Paisley,
UK). Cells were plated (1 x 106 cells/50 ml flask) and grown until
60-70% confluent, prior to treatment with aspirin or carrier
control at the same concentrations as the aspirin treatment.
Aspirin (Sigma, St Louis, USA) was prepared as a 0.5 m stock
solution in distilled water (final pH 7.0). Growth medium was
replaced with the respective low serum (0.5% FCS) medium and
cells were treated with aspirin at 1, 3, 5 and 10 mM for 24 h (or
72 h), or with carrier as a control.
Cell viability and determination of apoptosis
Adherent cells were harvested and viable cell number determined
by haemocytometric counts with nigrosin exclusion. IC50 values
for the CRC cell lines were calculated using the XL/if 3™ software.
Apoptosis was detected via its interaction with annexin V using an
Annexin V-FITC apoptosis detection kit (Oncogene Research
Products, Cambridge, MA, USA), as per the manufacturer's
instructions. Briefly, the medium from the flask of adherent cells
was transferred to a conical tube on ice to harvest any floating
cells. Cells were then washed with 2 ml of PBS, which was also
added to the tube to collect any cells dislodged during washing.
Cells were incubated with 1 ml of trypsin: versene (volume per
volume) just until the cells detached and then resuspended in the
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Table 1 Mutation status of cancer cell lines studied
Cell line APC /?-catenin p53 MMR
HRT-18 Mutant Wild type Mutant Deficient
SW480 Mutant Wild type Mutant Proficient
HT-29 Mutant Wild type Mutant Proficient
DLD-1 Mutant Wild type Mutant Deficient
LoVo Mutant Wild type Wild type Deficient
HCT-1 16 Wild type Mutant Wild type Deficient
MCF-7 Wild type Wild type Wild type Proficient
MDA-MB231 Wild type Wild type Mutant Not known
T47D Wild type Wild type Mutant Proficient
A2780 Wild type Wild type Wild type Proficient
HEC-l-A Not known Not known Not known Deficient
conical tube containing the media with the floating and washed
cells. Cells were counted using a haemocytometer and resuspended
in cold 1 x binding buffer to approximately 1 x 106 cellsml-1.
Media-binding reagent (10/rl) was added to 0.5ml of the cell
suspension, which was incubated with 1.25 /ul of annexin V-FITC
for 15min at room temperature in the dark. Annexin V was then
removed by centrifugation at lOOOg for 5min and the cells were
resuspended in 0.5ml of cold 1 x binding buffer and placed on ice.
The counting was done using a haemocytometer (two counting
grids) in duplicate and this was carried out immediately following
staining of cells, as apoptosis is an ongoing process and the FITC
signal may be lost after an hour.
Western blotting
Cells were washed with PBS, centrifuged (1200r.p.m., lOmin) and
cell pellets resuspended in lysis buffer (50 mM NaCl, 10mM HEPES,
500 mM sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM sper¬
mine, 0.2% Triton X-100) containing complete Protease Inhibitor
Cocktail and 100 mM Pefabloc (Roche Diagnostics, Manheim,
Germany). The cell suspension was centrifuged (6000r.p.m.,
15min, 4°C) and the supernatant containing cytoplasmic proteins
aliquoted. Protein content was measured by the method of
Bradford (BioRad, Hercules, California, USA). Cytoplasmic
proteins (30/tg) were separated on a 10% SDS-PAGE gel,
transferred to a polyvinylidine difluoride membrane (BioRad)
and blocked in 4% non-fat dry milk solution with 0.3% Tween20
(Sigma). Membranes were probed with a sheep polyclonal IkBo£
antibody (a gift from Professor R Hay, University of St Andrews,
UK), rabbit polyclonal p65 antibody (Santa Cruz, California, USA)
or mouse monoclonal COX-2 antibody (Cayman Chemicals,
Michigan, USA). COX-2 electrophoresis standard (Cayman Che¬
micals) was used to indicate the correct COX-2 band. Monoclonal
antibody to Cu/Zn SOD (The Binding Site, Birmingham, UK) and
to actin (Santa Cruz) was used as a control for protein loading.
Antigen-antibody complexes were visualised with chemilumines-
cence (Amersham ECL Reagents, UK).
Immunofluorescence analysis
Cells grown to 60-70% confluence on glass coverslips were treated
with carrier or 10 mM aspirin for 24 h (in the respective 0.5% FCS
medium). After treatment, cells were washed with PBS, fixed with
acetone:methanol (volume per volume) (—20°C, lOmin) and
blocked in 10% pre-immune donkey serum (Sigma) for 1 h. Rabbit
polyclonal antibody to NFkB p65 (Santa Cruz) was applied for 1 h,
followed by incubation with FITC-conjugated donkey anti-rabbit
IgG for 1 h. The nuclei were stained with DAPI and the coverslips
mounted with Vectashield (Vector Laboratories, Burlingame,
California, USA).
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RESULTS
Colorectal cancer cells are more susceptible to aspirin-
induced apoptosis than non-CRC cells
We studied the effect of aspirin on the growth of a panel of CRC
cell lines (HRT-18, SW480, HT-29, DLD-1, LoVo and HCT116) in
comparison to cell lines derived from other cancer types: breast
(MCF-7, MDA-MB-231, T47D), ovarian (A2780) and endometrial
(HEC-l-A). The non-CRC cell lines were chosen based on
epidemiological data, where there is some evidence to suggest a
protective effect in breast cancer and less so in ovarian and
endometrial cancer.
In triplicate dose-response experiments, cell lines were treated
for 24 h with aspirin at concentrations of 1, 3, 5 and lomm, and
viable cell number determined by haemocytometric counts. We
found a concentration-dependent decrease in viable cell number in
each of the six CRC cell lines studied (Figure 1A). In contrast, there
was no demonstrable effect of aspirin on the viability of the non-
CRC cell lines MCF-7, MDA-MB-231, A2780 and HEC-l-A
(Figure 1A). Interestingly, the T47D breast cancer cells did exhibit
a dose-dependent reduction in viability, although this effect was
not so pronounced as that seen in CRC cells at low aspirin
concentrations. The IC50 values were calculated from the growth
curves of the aspirin-treated CRC cell lines only, as there was no
consistent reduction in cell viability in the non-CRC cell lines
(Table 2). The mean IC50 value for the CRC cell lines was 2.38 mm
and the greatest incremental reduction in viability in these cells
was observed between 0 and 1 mm concentrations, which is
comparable to serum concentrations attainable in humans (Pach-
man et al, 1979).
We next wished to establish whether the reduction in viable cell
number that we observed in the CRC cell lines was due to
induction of apoptosis. Annexin-V binding of phosphatidylserine
residues externalised during apoptosis was used to determine the
proportion of cells undergoing programmed cell death in response
to increasing concentrations of aspirin. We found that aspirin
treatment induced a concentration-dependent increase in apopto¬
sis in all six of the CRC cell lines studied, confirming that
induction of apoptosis is responsible for the observed reduction in
cell viability (Figure IB). There was no dose-dependent increase in
apoptosis in the non-CRC cell lines following aspirin treatment,
which was consistent with the lack of effect on cell viability
(Figure 1A). Although the T47D breast cancer cells did exhibit a
reduction in viable cell count, this effect was less marked than that
seen in CRC cells and, furthermore, there was no increase in
apoptosis in this cell line. To confirm that the non-CRC cells were
less sensitive to apoptosis, we treated three non-CRC cell lines (two
breast and one ovarian) and one CRC cell line (SW480) with
aspirin for a longer time period of 72 h. Indeed, the non-CRC cell
lines were far less susceptible to apoptosis compared to the CRC
cell line despite treatment with aspirin for 72 h (Figure 1C). These
findings demonstrate that the anti-tumour activity of aspirin has a
substantial degree of specificity for CRC cells in vitro, reflecting the
epidemiological evidence for a greater protective effect against
CRC compared to other cancer types.
We also considered whether defects in genes commonly mutated
in CRC, and known to affect apoptotic pathways, might influence
such cell death. Mutation status for APC, /J-catenin, p53 and DNA
MMR genes (Table 1) does not appear to influence aspirin-induced
apoptosis in CRC lines, emphasising the relevance of the aspirin
NFfcB anti-tumour effect to CRC in general.
Differential sensitivity to the apoptotic effects of aspirin is
paralleled by differing responses of the NFkB pathway
Our previous work indicates that NFkB nuclear translocation is a
key component of aspirin-induced apoptosis in CRC cells. We
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therefore considered whether the variations in cell viability,
observed between CRC and non-CRC cell lines, were attributable
to differing responses of the NFkB pathway to aspirin. We first
investigated the effect of aspirin on cytoplasmic levels of the NFkB
inhibitor protein IkBx, using immunoblot analysis. We found that
aspirin treatment resulted in concentration-dependent degrada¬
tion of IkBx, as indicated by a reduction in cytoplasmic IkBx
protein levels (Figure 2A) in all CRC cell lines. Although the IkBx
degradation may be more obvious at the higher doses, there is
degradation at the lower doses of 1 and 3 mm aspirin (Figure 2A).
The IC50 values for the CRC cell lines range from 1.48 to 3.12 mm
aspirin, demonstrating differential sensitivity to aspirin with
respect to the concentration at which 50% of the cells are growth
inhibited (Table 2). The SW480 and HT-29 cell lines have IC50
values at the lower end of the range (1.48 and 1.98 mm,
respectively) and do undergo IkBx degradation at 1 mm, whereas
the HRT-18 and DLD-1 cell lines have IC50 values of 3.12 and
2.92 mm and also exhibit IkBk degradation at 3 mm. Hence, there is
a close relationship between IC50 values and iKBa degradation for
the individual CRC cell lines. In striking contrast, there was no
change in IkBx levels upon aspirin treatment in any of the non-
CRC cell lines even at the highest dose of 10mM (Figure 2B).
Since these findings suggested a cell-type specific NFkB
response to aspirin, we next determined whether the disparate
IkBx response was accompanied by a differential effect on NFkB
nuclear translocation in the CRC compared to the non-CRC cell
lines. Immunofluorescence analysis showed that p65, the tran¬
scriptionally active subunit of NFkB, was primarily located in the
cytoplasm in untreated cells as expected (Figure 2C, D, first panel).
Following aspirin treatment, there was nuclear accumulation of
p65 in all of the CRC cells (Figure 2C, second panel). However, in
keeping with our observation that there was no IkBx degradation
in the non-CRC cells, aspirin treatment did not induce nuclear
translocation of p65 in any of these cell lines (Figure 2D, second
panel). These data establish that the disparity in viability following
exposure to aspirin in CRC lines compared to lines derived from
other cancer types is associated with markedly differing responses
of the NFkB pathway to aspirin. This work suggests that the effect
of aspirin on NFkB signalling may be implicated in the differential
sensitivity of cancer types to aspirin-induced apoptosis.
Basal IkBoc and p65 protein levels and aspirin-induced
apoptosis in CRC cell lines
High basal NFkB activity and aberrant IkBk expression have been
observed in a number of cancers including CRC (Rayet and
Gelinas, 1999). In view of our findings of a cell-type specific NFkB
and death response to aspirin, we considered whether the basal
levels of IkBcc and p65 might determine increased sensitivity to
apoptosis, and so could be potential molecular markers of
response. We used immunoblot analysis of cytoplasmic extracts
to examine basal levels of IkBoi and p65 in both the CRC and non-
CRC cell lines (Figure 3). There was no difference in expression of
IkBx or p65 or their relative levels (analysed by densitometry, data
not shown) between colorectal and non-CRC cells that could
account for increased sensitivity to apoptosis. These results
indicate that sensitivity to aspirin-induced apoptosis is not related
to the cytoplasmic pool of either protein available for stimulation.
Basal COX-2 protein levels do not determine the NFkB
response to aspirin
Increased COX-2 expression has been observed both in premalig-
nant colonic lesions and CRCs (Eberhart et al, 1994), and COX-2
inhibition has been shown to play a role in aspirin-mediated cell
death (Boolbol et al, 1996). Hence, we considered whether COX-2
expression might explain the heterogeneity of the aspirin response
between the CRC and non-CRC cell lines. Immunoblot analysis of
383
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cytoplasmic proteins demonstrated considerable variation in basal
levels of COX-2 between the CRC cell lines (Figure 4). The CRC cell
lines SW480 and HCT116 do not express COX-2, whereas HT-29
and LoVo do express COX-2, and yet all underwent apoptosis
following aspirin treatment. In the non-CRC panel, the MCF-7 cell
line does not express COX-2 but the MDA-MB-231 cell line does
300 i
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Table 2 IC50 values for colorectal cancer cell lines
Cell line IC50
HRT-18 3.12 + 0.69
SW480 1.48 + 0.12
HT-29 1.98 + 0.68
DLD-I 2.92 + 0.58
LoVo 2.07+ 0.25
HCT-1 16 2.71+0.46
express COX-2, but neither undergoes aspirin-induced apoptosis.
Similarly, there was variability of COX-2 levels between the CRC
lines and the non-CRC lines (Figure 4). Thus, we found no
association between basal levels of COX-2 expression and
sensitivity to aspirin-induced apoptosis, providing further support
for the notion that COX-independent mechanisms play an
important role in the anti-tumour effect of NSAIDs.
DISCUSSION
The work presented here demonstrates a striking difference in the
response to aspirin between CRC cell lines and lines derived from
other cancer types, with respect to both cell viability and NFkB
signalling. We show that aspirin-induced apoptosis, associated
with IkBoc degradation and NFkB nuclear translocation, was
restricted to CRC cells. This relationship between aspirin-induced
apoptosis and the effect on NFkB signalling suggests a molecular
rationale for the particular sensitivity of CRC to NSAIDs compared
to other cancers. These findings also extend our previous
observations on the importance of the NFkB pathway as a key
NSAID target.
Epidemiological evidence indicates that NSAIDs impart greater
protection against CRC than other cancer types, but the molecular
basis for this effect is not known. Several previous reports,
including our own, have shown that aspirin induces apoptosis in
CRC cells (Hanif et al, 1996; Elder et al, 1997; Piazza et al, 1997;
Qiao et al, 1998; Castano et al, 1999; Stark et al, 2001). There is
little data directly comparing the anti-tumour effects of NSAIDs in
vitro between CRC cells and cancer cells of different tissue origin.
A recent study has demonstrated a tissue type-independent effect
in prostate, lung, colon, tongue and pancreatic cancer using nitric
oxide-donating NSAIDs and, although treatment with conven¬
tional NSAIDs did have a growth-inhibitory effect, it was observed
at concentrations in excess of the pharmacologically relevant range
after 48 h of treatment (Kashfi et al, 2002). Our findings
demonstrate that aspirin has a considerable degree of specificity
of apoptotic effect for CRC cells compared to other cell lines
studied, and this reflects the epidemiological observations in the
respective tumours. We show that aspirin induces apoptosis in a
panel of CRC cell lines, but has no consistent effect on viability and
apoptosis in cancer cell lines of non-colorectal origin. These results
contrast with some previous reports of NSAID-induced growth
inhibition and apoptosis in breast and endometrial cancer cells
(Noguchi et al, 1995; Planchon et al, 1995; Han et al, 1998; Arango
et al, 2001), but these differences are reconciled by considering
that these studies used NSAIDs other than aspirin (Noguchi et al,
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1995; Planchon et al, 1995; Han et al, 1998), while others only
observed apoptosis after long exposures (48-96h) to high
concentrations of salicylate out with the therapeutic range
(Sotiriou et al, 1999; Arango et al, 2001). The non-CRC cell lines
are susceptible to other apoptosis-inducing agents and NFkB
activators such as staurosporine and TNFa, respectively, indicating
that these cell lines are not generally resistant to apoptosis or NFkB
modulation (Mooney et al, 2002; Tang et al, 2002). The observation
that aspirin decreased cell viability in one of the three breast
cancer cell lines (T47D) is in keeping with epidemiological data
that suggest a lesser protective effect of NSAIDs against breast
cancer. One cohort epidemiological study showed that the effect of
aspirin use on CRC incidence was reduced in females (Schreine-
machers and Everson, 1994), raising the possibility that differential
protection may be related to gender. However, gender is unlikely
to impart a predominant protective effect, as it has not been borne
out by subsequent studies (Thun et al, 1993). Indeed, the HT-29
CRC cell line is derived from a female patient and is equally
susceptible to aspirin-mediated apoptosis and NFkB modulation
as the other CRC cell lines, which are male in origin. Our findings
clearly indicate important differences between CRC and other
cancer types with respect to aspirin effects on cell viability and
apoptosis.
We show that aspirin-induced apoptosis occurs following IkBc<
degradation and NFkB nuclear translocation, and that this effect is
common to all CRC cell lines studied. Notably, this effect on the
NFkB pathway was consistent between CRC cell lines despite
heterogeneity of the lines, with respect to the profile of mutations
in APC, /J-catenin, p53 and DNA MMR genes (see Table 1). In
contrast, aspirin treatment did not induce IkBcj degradation or
NFkB nuclear translocation in any cell lines derived from cancers
of other tissue types, paralleling the lack of consistent changes in
cell viability and apoptosis in these lines. We have previously
established that the observed effect of aspirin on IkBk and p65 is a
cause of rather than a consequence of apoptosis, based on the
findings that the IkBoc degradation was signal-specific and that
nuclear translocation of NFkB and apoptosis were blocked by a
dominant-negative super repressor ItcBa (Stark et al, 2001).
Furthermore, we showed that IkB degradation and NFkB nuclear
translocation occur at 2-5h after aspirin treatment and persists
thereafter to 24 h, whereas apoptosis is not observed to increase
until at least 16 h and continues to 24 h. Hence, the weight of
evidence presented here correlating IkBoc degradation and p65
nuclear translocation with apoptosis compared to the lack of
response in non-CRC cell lines provides considerable further
support for a causal role of the NFkB response as an important
component of aspirin-induced apoptosis.
Having shown a striking difference between the CRC and non-
CRC cell lines, with respect to aspirin effects on NFkB signalling
and apoptosis, we investigated potential factors that might
contribute to the ability of specific cell types to undergo apoptosis.
Increased NFkB activity has been observed in CRC (Hardwick et al,
2001) and relative resistance to apoptosis has been attributed to
high constitutive NFkB activity in other cancers (Bours et al, 1994;
Lind et al, 2001; Charalambous et al, 2003). However, we found no
evidence that the specificity of the aspirin-NFKB response is
related to differential expression of basal IkBo: or p65 proteins or
their relative expression. The SW480 and HT-29 CRC cell lines
undergo NFKB-mediated apoptosis, despite the considerable
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Figure I Differential effect of aspirin on cell viability and apoptosis in CRC and non-CRC cell lines. Aspirin treatment (0- IOmM) for 24 h induces a
concentration-dependent decrease in viable cell number (determined by haemocytometric counts) in all CRC cell lines, but there is no consistent change in
the non-colorectal cancer cell lines (A). Annexin V binding assay is used to determine whether all CRC cell lines undergo apoptosis after aspirin treatment
(0-5 mM) for 24 h, but there was no change in apoptosis in the non-CRC cell lines (B). Annexin V binding assay is used to determine whether the non-CRC
cell lines are less susceptible to aspirin-induced apoptosis compared to the CRC cell line SW480 following treatment for 72 h with aspirin (0-3 mM) (C).
The graphs represent three independent experiments and the bars on the graphs are standard error bars.
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Figure 2 Aspirin-induced kBa degradation and p65 nuclear translocation is restricted to CRC lines. Western blot analysis shows that aspirin treatment
(O-IOmM) for 24 h induces kBa degradation in a concentration-dependent manner in the CRC celi lines (A), but not in the non-CRC cell lines (B).
Following aspirin treatment, cytoplasmic extracts were made from untreated and treated cells and probed with sheep polyclonal kBa antibody. The western
blot shown is representative of at least three independent experiments, and Cu/Zn SOD was used as a control for protein loading. Micrographs ( x 63) of
immunocytochemically stained cells show that aspirin treatment (10 mM) for 24 h induces nuclear accumulation of p65 in the CRC cell lines (C), but not in
the non-CRC cell lines (D).










Colorectal cancer cell lines Non-colorectal cancer cell lines
Figure 3 Western blot analysis demonstrates basal expression levels of
cytoplasmic 1/cBa and p65 proteins in CRC and non-CRC cell lines in
untreated cells. Cytoplasmic extracts were made from untreated cells and
probed with sheep polyclonal IkBcx antibody and rabbit polyclonal p65
antibody. The western blot shown is representative of at least three








Colorectal cancer cell lines Non-colorectal cancer cell lines
Figure 4 Western blot analysis of basal expression levels of cytoplasmic
COX-2 protein in CRC and non-CRC cell lines. Cytoplasmic extracts were
made from untreated cells and probed with mouse monoclonal COX-2
antibody. A COX-2 electrophoresis standard (72 kDa monomer) is used to
indicate the COX-2 band. COX-2 is expressed in the HRT-18, HT-29,
LoVo and MDA-MB-231 cell lines. The Western blot shown is
representative of at least three independent experiments and actin was
used as a control for protein loading.
Aspirin effects on NFkB and apoptosis in cancer cells
FVN Din et al
to aspirin in any cell type. Furthermore, the fact that we observed
considerable variation in COX-2 expression within the CRC cell
lines, which were all susceptible to aspirin-induced apoptosis,
presents persuasive evidence that COX-2-independent as well as
COX-2-dependent mechanisms play a role in the anti-tumour
effects of NSAIDs (Rigas and Shiff, 2000).
Aspirin concentrations used here are relevant to pharmacolo¬
gical levels in clinical practice (1 -3 mm) (Insel, 1996). Nonetheless,
comparisons between cell culture concentrations and plasma levels
are somewhat artificial, because of the inability to accurately
mimic in vivo metabolism and tissue concentration of the agent in
epithelial or tumour cells. Decreased basal levels of apoptosis and
hyperproliferative mucosa have been observed in patients with
adenomas, suggesting the existence of a 'field defect' in the colonic
mucosa (Anti et al, 2001). Although we observed proportionally
less apoptosis at lower concentrations of aspirin, there is evidence
that low levels of apoptosis translate into significant tumour
regression over time in cell kinetics studies (Pritchard and
Watson, 1996). It remains to be determined whether aspirin
redresses the balance by inducing apoptosis de novo in newly
transformed colorectal epithelial cells destined to become
malignant clones. There is evidence of NFkB involvement in
colonic crypt differentiation and cell turnover in mouse colon,
where NFkB activity is greater in proliferating cells at the base of
crypts compared to mature cells at the surface (Inan et al, 2000).
Thus, it is also possible that the drug corrects deranged
mechanisms that permit escape from normal cellular turnover
and apoptosis.
In summary, the data presented here demonstrate that there are
substantial differences in the anti-tumour effects of aspirin and
modulation of NFkB signalling between cancer cells of different
tissue origin. The effect of aspirin on NFkB signalling and
apoptosis does not appear to be related to expression levels of
COX-2 or mutation status of APC, /?-catenin, p53 and DNA MMR
genes. This is important when considering translating these
findings to clinical studies aimed at defining the NFkB response
to aspirin in human colonic epithelium and tumours. The
molecular basis of NSAID anti-tumour activity is complex,
and our findings provide further evidence that the effects of
aspirin on NFkB signalling have particular relevance to CRC
chemoprevention.
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difference in basal NFkB activity previously reported between
these cell lines (Dejardin et al, 1999).
There is substantial rationale for investigating COX-2 as a
potential molecular determinant of response, in view of its role in
CRC development and as a pharmacological target for NSAIDs.
Additionally, it has been reported that the inconclusive nature of
epidemiological data in breast cancer might be related to the
observation that only a subset of breast cancers express COX-2
(Howe et al, 2001). In the work presented here, we did not detect a
relationship between COX-2 protein levels and apoptotic response
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Aspirin-induced nuclear translocation of NFtcB and apoptosis in
colorectal cancer is independent of p53 status and DNA
mismatch repair proficiency
FVN Din1, LA Stark1 and MG Dunlop*'1
Colon Cancer Genetics Group, Department of Oncology, Division ofClinical and Molecular Medicine and MRC Human Genetics Unit Western General
Hospital, University of Edinburgh, Crewe Rd, Edinburgh EH4 2XU, Scotland
Substantial evidence indicates nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC). However, the
molecular basis for this anti-tumour activity has not been fully elucidated. We previously reported that aspirin induces signal-specific
IrcBa degradation followed by NF;cB nuclear translocation in CRC cells, and that this mechanism contributes substantially to aspirin-
induced apoptosis. We have also reported the relative specificity of this aspirin-induced NFjcB-dependent apoptotic effect for CRC
cells, in comparison to other cancer cell types. It is now important to establish whether there is heterogeneity within CRC, with
respect to the effects of aspirin on the NFkB pathway and apoptosis. p53 signalling and DNA mismatch repair (MMR) are known to
be deranged in CRC and have been reported as potential molecular targets for the anti-tumour activity of NSAIDs. Furthermore,
both p53 and MMR dysfunction have been shown to confer resistance to chemotherapeutic agents. Here, we set out to determine
the p53 and hMLH I dependency of the effects of aspirin on NFkB signalling and apoptosis in CRC. We specifically compared the
effects of aspirin treatment on cell viability, apoptosis and NFkB signalling in an HCT-I 16 CRC cell line with the p53 gene
homozygously disrupted (HCT-I l6p53_/_) and an HCT-I 16 cell line rendered MMR proficient by chromosomal transfer (HCT-
I I 6+ch3), to the parental HCT-I I 6 CRC cell line. We found that aspirin treatment induced apoptosis following IkBoc degradation,
NFkB nuclear translocation and repression of NFKB-driven transcription, irrespective of p53 and DNA MMR status. These findings
are relevant for design of both novel chemopreventative agents and chemoprevention trials in CRC.
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Ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) has
been shown to be associated with a 40 - 50% reduction in relative
risk of colorectal cancer (CRC) (Thun et al, 1993). There is much
research effort focussed on the molecular mechanisms involved
in NSAID anti-tumour activity. Such understanding would
inform the rational design of novel agents both for chemopreven¬
tion and therapy.
We previously reported the pivotal involvement of the
transcription factor NFkB (p50-p65) in aspirin-mediated apopto¬
sis in CRC cells (Stark et al, 2001). NFkB is sequestered in the
cytoplasm, bound to a member of the IkB family of inhibitory
proteins. Stimulation by one of a range of signals results in
phosphorylation and ubiquitination of IkB followed by proteo-
some-mediated degradation. Dissociation from IkB results in
NFkB nuclear translocation and transcriptional regulation of
numerous target genes. NFkB has been shown to have both pro-
and anti-apoptotic effects (Barkett and Gilmore, 1999). Such
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disparate effects are due to differences in stimuli, NFkB composi¬
tion, cell type and distinct kB binding specificities of individual
complexes resulting in diverse target gene specificity (Epinat and
Gilmore, 1999). We have previously shown that aspirin-mediated
apoptosis in CRC cells involves IkBk degradation and NFkB
nuclear translocation (Stark et al, 2001). We also demonstrated
that aspirin-induced IkBx degradation was required for apoptosis
because cells constitutively expressing super-repressor IkBc< were
resistant to both aspirin-induced NFkB nuclear translocation and
apoptosis. More recently, we have reported the relative specificity
of this NFK'B-dependent apoptotic effect of aspirin for CRC cells,
when compared to other cancer cell types (Din et al, 2004).
Flowever, it is also important to determine whether there is
heterogeneity within CRC, with respect to the effects of aspirin on
the NFkB pathway and apoptosis.
It is now well established that genomic instability, by increasing
mutational load, promotes neoplastic progression in CRC. The p53
tumour suppressor gene is involved in cell cycle control, apoptosis
and maintenance of genomic stability and is frequently mutated in
colorectal tumours, heralding malignant transformation (Baker
et al, 1989, 1990; Honma et al, 2000). Another important
contributor to genomic instability is defective DNA mismatch
Aspirin effects on NFkB and apoptosis in colon cancer cells
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repair (MMR) resulting in microsatellite instability (MSI) (Veigl
et al, 1998). MSI is the hallmark of tumours arising in hereditary
nonpolyposis colorectal cancer (HNPCC) and is also found in 15%
of sporadic CRCs (Boland et al, 1998; Brown et al, 1998). The
majority of MSI tumours in familial cases are due to germline
mutations in hMLHl, hMLH2 and hMSH6 genes, and to hMLHl
promoter hypermethylation in sporadic cancers (Kuismanen et al,
2000). p53 dysfunction and DNA MMR deficiency are almost
wholly mutually exclusive (Cottu et al, 1996; Samowitz et al, 2001).
p53 signalling and DNA MMR have been identified as potential
molecular targets for NSAIDs (Ruschoff et al, 1998; Shao et al,
2000; Goel et al, 2003), suggesting that the anti-tumour effect may,
in part, involve countering the effects of genetic instability in CRC.
Such genetic aberrations in tumours have also been shown to be
involved in determining response to chemotherapeutic agents
(O'Connor et al, 1997; Weller, 1998; Ribic et al, 2003).
In light of the importance of p53 and MMR in CRC and that
genomic instability can influence response to chemotherapeutics,
we set out to determine the p53 and hMLHl dependency of the
effects of aspirin on NFkB signalling. Our findings suggest that the
NFfcB-apoptotic response to aspirin occurs irrespective of p53
status and MMR defects and shed further light on the chemopre-
ventive action of NSAIDs.
MATERIALS AND METHODS
Cell line culture and treatment
The CRC cell line HCT-116 (genotype p53 ( + / + ), hMLHl (—)), is
available from the American Type Culture Collection (ATCC). The
HCT-116 cell line has a hemizygous mutation in hMLHl resulting
in a truncated, nonfunctional protein. The HCT-116 subline where
hMLHl expression is restored by chromosome 3 transfer
(HCT116 + c 3, genotype p53 ( + / + ), hMLHl ( + )) was a gift
from Professor CR Boland and these cells are competent in DNA
MMR (Koi et al, 1994). The p53 null HCT-116 subline (HCT-
116p53-'-) was created by targeted homologous recombination
(Bunz et al, 1999) and was a gift from Professor B Vogelstein. All
three cell lines were grown in McCoy's 5A media and the HCT-
116+ch3 cell line was grown under selection with 0.4mgml~'
geneticin. All media were supplemented with 10% foetal calf serum
(FCS) and 1% penicillin/streptomycin (media supplied by Gibco
BRL, Paisley, UK) and cells were grown as monolayers (37°C in 5%
C02). Cells were plated (1 x 106 cells/50 ml flask) and grown until
60-70% confluent. Aspirin (Sigma, St Louis, USA) was prepared as
a 0.5 m stock solution in distilled water (final pH 7.0). Prior to
treatment for 16 h with aspirin (1, 3, 5 and 10mM) or carrier
control (at same concentrations as aspirin), the growth medium
was replaced with the respective low serum (0.5% FCS) medium.
Cell viability and determination of apoptosis
After aspirin treatment, adherent cells were harvested and viable
cell number determined by counting with a haemocytometer. Cell
surface phosphatidylserine is a marker for apoptosis and was
detected via its interaction with annexin V using the Annexin V-
FITC apoptosis detection kit (Oncogene Research Products,
Cambridge, MA, USA), as per the manufacturer's instructions.
Briefly, the media from the flask of adherent cells was transferred
to a conical tube on ice to harvest any floating cells. Cells were then
washed with 2 ml of PBS, which was also added to the tube to
collect any cells dislodged during washing. Cells were incubated
with 1ml of trypsin: versene (volume per volume) just until the
cells detached and then resuspended in the conical tube containing
the media with the floating and washed cells. Cells were counted
using a haemocytometer and resuspended in cold 1 x binding
buffer to approximately 1 x 10s cells ml-1. Media binding reagent
(10/d) was added to 0.5 ml of the cell suspension, which was
incubated with 1.25/d of annexin V-FITC for 15min at room
temperature in the dark. Annexin V was then removed by
centrifugation at 1000 x g for 5 min and the cells were resuspended
in 0.5 ml of cold 1 x binding buffer and placed on ice. The
counting was carried out using a haemocytometer (two counting
grids) in duplicate and this was carried out immediately following
staining of cells as apoptosis is an ongoing process and the FITC
signal may be lost after an hour.
Western blotting
After aspirin treatment, cells were washed with PBS, centrifuged
(1200r.p.m. for 10 min) and cell pellets were resuspended in lysis
buffer (50 mM NCI, 10 mM HEPES, 500 mM sucrose, ImM EDTA,
0.5 mM. spermidine, 0.15 mM spermine, 0.2% Triton X-100,
Complete Protease Inhibitor Cocktail (Roche Diagnostics, Man-
heim, Germany), 100 mM Pefabloc (Roche Diagnostics, Manheim,
Germany)). The cell suspension was centrifuged (6000r.p.m. for
15 min, 4°C) and the supernatant used as cytoplasmic extract.
Protein content was measured by the method of Bradford (BioRad,
Hercules, CA, USA).
Cytoplasmic proteins (30/(g) were separated on a 10% SDS-
PAGE gel, transferred to a polyvinylidine difluoride membrane
(BioRad) and blocked in 4% non-fat dry milk solution with 0.3%
Tween20 (Sigma). Membranes were probed with a sheep
polyclonal IjcBa antibody (a gift from Professor R Hay, University
of St Andrews, UK) and then with monoclonal antibody to
Cu/Zn SOD (The Binding Site, Birmingham, UK) as a control for
protein loading. Chemiluminescence was used to visualise the
antigen-antibody complexes (Amersham ECL Reagents, Little
Chalfont, UK).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were carried out by incubat¬
ing nuclear extracts from untreated cells (6//g) with binding
reaction mix (1 x binding buffer (50 mM KC1, 20 mM HEPES, 5%
glycerol, ImM EDTA, ImM DTT), 1/rg BSA, 1//g poly dl-dC,
25 fmol radioactively labelled oligo-DNA in a final volume of 20 /A)
for 30 min prior to analyses on a 4% native polyacrylamide gel.
Double-stranded oligonucleotides for NFkB were obtained from
Santa Cruz.
Immunofluorescence analysis
Cells grown to 60-70% confluence on glass coverslips were treated
with carrier or 10 mM aspirin for 16 h (in respective 0.5% FCS
medium). After treatment, cells were washed with PBS, fixed with
acetone: methanol (volume per volume) (—20°C, 10 min) and
blocked in 10% nonimmune donkey serum (Sigma) for 1 h. Rabbit
polyclonal antibody to NFkB p65 (Santa Cruz) was applied for 1 h
followed by incubation with FITC-conjugated donkey anti-rabbit
IgG for 1 h. The nuclei were stained with DAPI and the coverslips
mounted with Vectashield (Vector Laboratories, Burlingame,
California, USA).
Transfections and reporter assays
For transient transfection experiments, 50 ml flasks of cells were
grown to subconfluency then transfected with 6 /jg of luciferase
reporter plasmid and 3 /tg of /i-galactosidase control plasmid,
using Lipofectamine as described by the manufacturer's instruc¬
tions (Gibco BRL). Following transfection, cells were grown in low
serum (0.5% FCS) medium then treated with aspirin (0-10mM)
for 16 h. Luciferase activity was measured in cell extracts using a
luciferase reporter assay kit (Promega) and read using a
luminometer. Transfection efficiency and cell viability were
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monitored by cotransfection with a CMV-/i-galactosidase reporter
plasmid and /?-galactosidase activity was quantified with an assay
kit (Promega), as per the manufacturer's instructions. Relative
luciferase activity was calculated as unit of luciferase activity per
unit of /1-galactosidase activity.
RESULTS
Basal expression of Ik'Ba and p65 proteins in CRC cell lines
is independent of p53 and hMLHl expression
To investigate the relationship between p53 and MMR status and
the NFk'B-dependent apoptotic response to aspirin, we used the
following three CRC cell lines: parental HCT-116 cells (wild-type
p53, hMLHl deficient), HCT-116 + ch3 (wild-type p53, hMLHl
proficient) and HCT-116p53-/~ (p53 null, hMLHl deficient). The
presence of hMLHl in the HCT-116+ ch3 cell line and the absence
of p53 in the HCT-116p53~'~ cell line was verified by immunoblot
analysis (Figure 1A). Firstly, we considered whether p53 and
hMLHl mutation status might affect basal levels of IkB« and p65
proteins. Using immunoblot analysis of cytoplasmic extracts, we
found there were no significant differences in expression of IkB«
or p65, or their relative levels (data not shown), between the three
CRC cell lines (Figure IB). These results indicate that changes in

































cytoplasmic pool of either protein available for stimulation. We
next considered whether basal levels of NFkB DNA binding were
affected by changes in p53 or MMR status. Electrophoretic
mobility shift assays (EMSAs) performed on nuclear extracts of
untreated cells showed basal NFjcB DNA binding in the three CRC
cell lines (Figure 1C). The differences in basal levels of NFkB DNA
binding complexes in the HCT-116 + ch3 and HCT-116p53_/~ cell
lines compared to the parental HCT-116 cell line were marginal
(densitometry data not shown).
Aspirin induces apoptosis in CRC cell lines independent of
p53 and MMR status
To determine whether p53 and MMR status affects the aspirin-
mediated reduction in cell viability we have previously observed,
we compared the effects of aspirin treatment on the viability of
HCT-116 + ch3 and HCT-116p53~/_ cell lines to the parental HCT-
116 cell line. In triplicate dose-response experiments, all CRC cell
lines were treated for 16h with aspirin (1, 3, 5 and 10mM) and
viable cell number determined by haemocytometric counts.
Aspirin treatment resulted in a concentration-dependent decrease
in the number of viable cells in all three CRC cell lines (Figure 2A).
Furthermore, the cell lines showed proportionate decreases in cell
viability at each concentration increment, indicating a similar
sensitivity to aspirin, irrespective of p53 or MMR status
(Figure 2B). The IC50 values were calculated from the growth
curves of the aspirin-treated CRC cell lines (Table 1) and there
were no significant differences in levels of cell death with each
genetic background.
It is well established that aspirin induces apoptosis in CRC cell
lines (Piazza et al, 1995; Qiao et al, 1998; Stark et al, 2001; Din et al,
2004). We next confirmed that the reduction in viable cell number
in each of the cell lines was indeed due to apoptosis for all three
genotypes, and not simply a growth inhibitory effect. Following
aspirin treatment, cells were stained with Annexin V, which binds
phosphatidylserine residues that are externalised during apoptosis
and thus serves as a marker for programmed cell death. Consistent
with the reduction in cell viability, we found that aspirin induced a
concentration-dependent increase in the proportion of apoptotic
cells in all three CRC cell lines (Figure 2C). Furthermore, there was
no significant difference in apoptotic response between any of the
HCT-116, HCT-116 + ch3 and HCT-116p53_/~ cell lines. In addition
there was good correlation between the IC50 value and apoptotic
response; the lower the IC50 value, indicating greater sensitivity at
a lower aspirin concentration, the greater the fold increase in
apoptosis (r = —0.98). These data suggest that aspirin-mediated
apoptosis in CRC cells is independent of p53 and MMR status.
Aspirin induces IicBa degradation and NFkB nuclear












Figure I Basal expression of p53, hMLHl, kBa and p65 in untreated
colorectal cancer cell lines. Cytoplasmic extracts were made from
untreated cells and Western blots probed with p53 and hMLH I antibodies
to confirm the expression profile of the cell lines (A). Cytoplasmic extracts
were probed with sheep polyclonal IicBa and rabbit polyclonal p65
antibodies to examine the basal expression of proteins in the cell lines (B).
The Western blots shown are representative of at least three independent
experiments and Cu/Zn SOD was used as a control for protein loading.
Electrophoretic mobility shift assay using NFkB consensus oligonucleotide,
performed on nuclear extracts of untreated cells, demonstrated basal
NFkB DNA binding activity (C).
Having shown previously that p65 nuclear translocation is a
critical event in effecting the apoptotic response to aspirin (Stark
et al, 2001), we next studied the effect of aspirin on NFkB
signalling in each cell line. Since IkBcc sequesters NFkB in the
cytoplasm, we first investigated the effect of aspirin treatment on
the cytoplasmic levels of IkBs: in each cell line using immunoblot
analysis. We found that aspirin treatment induced degradation of
IkBoc in a similar concentration-dependent manner in each cell line
genotype (Figure 3A). We next determined whether the IkB«
degradation was accompanied by NFkB nuclear translocation in
the CRC cell lines. Immunofluorescence analysis showed that
following 16 h aspirin exposure, p65 translocated from the
cytoplasm to the nucleus in each cell line, irrespective of p53
and MMR status (Figure 3B). These findings indicate that aspirin-
induced apoptosis, due to modulation of the NFkB pathway,
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Figure 2 Effect of aspirin on cell viability and apoptosis in colorectal cancer (CRC) cell lines. Aspirin treatment (O-IOrnM) for 16 h induces a
concentration-dependent decrease in viable cell number (determined by haemocytometric counts) in all CRC cell lines (A). The decrease in cell viability is
proportionate at each concentration increment indicating a similar pattern of response following aspirin treatment in each cell line (B), Annexin V binding
assay used to determine that all CRC cell lines undergo apoptosis after aspirin treatment (0-5 mm) (C). The graphs represent three independent
experiments and the bars on the graphs are standard error bars.
occurs irrespective of derangements in p53 signalling and the
MMR system.
Aspirin-mediated repression of NF/cB-driven reporter
activity is unrelated to p53 and MMR status
We have previously demonstrated aspirin-induced nuclear trans¬
location of NFkB results in repression of NFkB transcriptional
activity in CRC cell lines (Stark et al, 2000). This was recently
substantiated by the finding that NFkB induced by some cytotoxic
stimuli acts as an active repressor of anti-apoptotic gene
expression (Campbell et al, 2004). The effect of aspirin on
NFKB-driven transcription was investigated to determine whether
p53 or MMR mutation status affects the ability of aspirin to induce
NFkB transcriptional repression in CRC cells. The cell lines were
transiently transfected with the 3enhancer-ConA NFK'B-dependent
luciferase reporter construct in which transcription of the firefly
luciferase gene is driven by three kB binding sites (Roff et al,
1996). A reporter plasmid with deleted kB sites served as control.
Following transfection, cells were exposed to aspirin for 16 h.
There was a substantial decrease in the basal levels of NFKB-driven
reporter activity following aspirin exposure and this was observed
in a concentration-dependent manner, irrespective of p53 or MMR
status (Figure 4). These findings show that aspirin-induced
repression ofNFkB transcriptional activity, and hence downstream
regulation of target genes, is independent of p53 signalling and
DNA MMR.
DISCUSSION
We previously reported that the effects of aspirin on NFkB
signalling are a centrally important mechanism of aspirin-
mediated apoptosis in CRC cells (Stark et al, 2001; Din et al,
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Table I IC50 values for colorectal cancer cell lines
Fold increase apoptosis
CRC cell line IC50 3 mM 5 mM
HCT-1 16 2.8 2.3 3.1
HCT-1 16+ch3 3.1 2.4 2.6
HCT-116p53-/_ 4.3 1.5 1.8
Cells were treated with aspirin (1,3,5,10 mM) for 16 h and cell numbers determined as
described in Materials and Methods. There is an inverse correlation between IC50
values and the fold increase in apoptosis at both 3 and 5 mM (r= —0.93 and —0.98).
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Figure 3 Aspirin induces Ix'Ba degradation and nuclear translocation of
p65 in colorectal cancer (CRC) lines. Following aspirin treatment,
cytoplasmic extracts were made from untreated and treated cells and
probed with sheep polyclonal licBa antibody. Western blot analysis shows
that aspirin treatment (0-l0mM) for 16 h induces l/cBa degradation in a
concentration-dependent manner in the HCT-II6, HCTI I6 + Ch3 and
HCT-1 16p53~'~ CRC cell lines (A). The Western blot shown is
representative of at least three independent experiments and Cu/Zn
SOD was used as a control for protein loading. Micrographs (63 x) of
immunocytochemically stained cells show that aspirin treatment (lOmM)
for 16 h induces nuclear accumulation of p65 in the HCT-1 16,
HCTI I6 + Ch3 and HCT-I I6p53_/" CRC cell lines (B).
2004). This work considerably extends these previous observations
since we have shown that the effect of aspirin on apoptosis and
NFkB signalling is independent of p53 and DNA MMR status.
Furthermore, we show that aspirin induces nuclear translocation
of p65 that is associated with repression of K'B-driven transcrip¬
tion, again independent of p53 or MMR status.
It is well established that aspirin has a chemopreventive effect
in CRC, but the mechanism of action has not been fully
characterised. It is apparent that inhibition of the cyclo-
oxygenase-2 enzyme (COX-2) plays a part in the anti-tumour
effect of NSAIDs in CRC (Marnett and DuBois, 2002). However, it
is also clear that there are other important mechanisms involved
since the growth inhibitory and apoptotic effects of NSAIDs occur
in CRC cell lines that do not express COX-2 (Hanif et al, 1996;
Elder et al, 1997). Furthermore, NSAIDs that lack COX-2 activity
are growth inhibitory and also induce apoptosis in CRC cells
(Piazza et al, 1995, 1997; Elder et al, 1997). It has also been
shown that NSAID concentrations required for growth inhibi¬
tion differ from those for COX-2 enzyme inhibition (Charalam-
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bous and O'Brien, 1996; Hanif et al, 1996). Taken together, such
evidence indicates that while COX-2 inhibition is important,
there are other essential mechanism(s) of action. p53 function and
DNA MMR have been proposed as potential targets responsible for
the anti-tumorigenic properties of NSAIDs (Ruschoff et al, 1998;
Shao et al, 2000).
The p53 signalling pathway is central to regulating cell growth
and death, and stabilisation of p53 by mutation is a key event
occurring late in colorectal tumorigenesis (Baker et al, 1990).
Several studies have shown an association between p53 mutation
status and sensitivity to chemotherapeutic drugs in colorectal and
other cancers (O'Connor et al, 1997; Weller, 1998). The p53
pathway has been postulated as a potential target since NSAIDs
have been shown to alter levels of p53 (Goldberg et al, 1996; Kralj
et al, 2001). Furthermore, there is evidence for regulatory
interdependence between p53 and NFkB involving competition
for common coactivators (Wu and Lozano, 1994; Webster and
Perkins, 1999). Indeed, wild-type p53 has been shown to suppress
constitutive NFkB activity and lead to apoptosis (Shao et al, 2000),
suggesting that tumours expressing wild-type p53 may be more
susceptible to aspirin-induced apoptosis.
Our previous work indicated that CRC cell lines expressing wild-
type p53 were not more sensitive to aspirin-induced apoptosis
mediated by NFkB signalling, but there are differences other than
p53 status between the cell lines studied (Din et al, 2004). In
this study, we specifically investigated the effects of p53 on the
NFKB-induced apoptotic response by use of HCT-116 cells with
the p53 gene homozygously disrupted by targeted homologous
recombination (Bunz et al, 1999). Using this approach, we have
shown that aspirin-induced apoptosis is independent of p53 in
CRC cells. Furthermore, p53 does not appear to play a role in
aspirin-induced effects on NFkB signalling or on the repression of
NFkB transcriptional activity. These findings are important in
terms of chemoprevention since p53 mutant CRCs have
been shown to differ in behaviour from those expressing
wild-type p53, with respect to response to chemotherapeutic
agents and prognosis.
Defective DNA MMR is characteristic of HNPCC and around
15% of sporadic CRCs also exhibit genetic instability, mainly due
to epigenetic silencing of hMLHl but also to somatic MMR gene
defects (Herman et al, 1998). The DNA MMR system has been
implicated as a potential pathway for modulation that may
contribute to NSAID anti-tumour activity (Ruschoff et al, 1998;
Goel et al, 2003). Our previous work suggested that MMR
proficient cells may be more sensitive to aspirin-induced apoptosis
since the MMR-deficient cell lines had greater IC50 values than
MMR-proficient cell lines (Din et al, 2004). Hence, we examined
whether MMR status influenced NFKB-dependent aspirin-induced
apoptosis, by comparing the MMR-deficient HCT-116 to its
proficient counterpart HCT116 + ch3. We observed a dose-depen¬
dent increase in apoptosis after treatment with aspirin following
IkBx degradation, NFkB nuclear translocation and repression
of NFx'B-driven transcription in both cell lines. The parental
HCT-116 cells, which are MMR deficient, did appear to have a
marginally lower IC50 value and show a greater fold increase
in apoptosis when compared to the MMR-proficient cell line,
but this was not significant (Table 1). Although we did not
detect any significant differences in the NFKB-dependent
apoptotic response to aspirin attributable to MMR status,
long-term in vitro aspirin exposure has been shown to select for
microsatellite stability in colorectal and gastric cancer cell lines
(Ruschoff et al, 1998; Yamamoto et al, 1999). It has also recently
been shown that aspirin treatment increased MMR protein
expression and apoptosis in CRC cell lines (Goel et al, 2003).
However, we found no evidence that MMR status influences the
NFKB-dependent apoptotic response, suggesting that the MMR
system is not the predominant pathway responsible for NSAID
anti-tumour activity.
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ConA NFkB 1' ConA ANFkB 1
Figure 4 Aspirin induces repression of NFrcB-driven transcription in colorectal cancer (CRC) lines. CRC cells were transfected with the ConA NFkB
dependent luciferase reporter construct, containing three kB binding sites, or the equivalent plasmid with kB consensus sites deleted (ConA AkB). All cells
were cotransfected with the control CMV-/J-ga!actosidase plasmid. Following 16 h treatment with 0- 10 mM aspirin, luciferase and /J-galactosidase assays
were performed on cell lysates and relative luciferase activity calculated. The graphs represent three independent experiments and the bars on the graphs
are standard error bars,
This work consolidates our previous findings that aspirin-
induced apoptosis occurs after IkB degradation, NFkB nuclear
translocation and repression of NFa'B-driven transcription. The
results presented here shed further light on the complex
mechanisms by which NSAIDs induce cell death in CRC.
Elucidation of the mechanism lies in defining the relative
contribution of putative targets to aspirin's anti-tumour activity.
We found no evidence for the involvement of p53 or DNA MMR
on inducing the NFkB pathway, nor on the ensuing apoptotic
response. Genomic instability due to p53 or MMR dysfunction has
been to shown to be associated with resistance to chemother-
apeutic agents. Hence, these findings may inform rational design
of novel therapeutics. In addition, since aspirin effects on NFkB
and apoptosis occur in cancers arising from different genetic
backgrounds, these findings are clinically relevant when consider¬
ing design of chemoprevention trials, both in genetically predis¬
posed individuals with defective MMR and in low and moderate
risk populations, since p53 mutational events are important during
development and progression of colorectal neoplasia.
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